!Series_title	"Methylation data from nine tissues from GTEx samples profiled with Infinium HumanMethylationEPIC BeadChip"
!Series_geo_accession	"GSE213478"
!Series_status	"Public on Sep 16 2022"
!Series_submission_date	"Sep 15 2022"
!Series_last_update_date	"Dec 16 2022"
!Series_pubmed_id	"36510025"
!Series_summary	"Genome wide DNA methylation profiling of tissue samples from GTEx donors. The Infinium HumanMethylationEPIC BeadChip was used to obtain DNA methylation profiles across approximately 850,000 CpGs sites from 1000 tissue samples."
!Series_overall_design	"Epigenome-wide DNAm was derived from 1,000 tissue samples from 9 unique tissue types - breast mammary tissue, colon transverse, kidney cortex, lung, muscle skeletal, ovary, prostate, testis and whole blood - obtained from 424 GTEx subjects, mostly (~83%) from European ancestry given available genotype data and the majority self-identified as white. DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA). All samples were then prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Infinium MethylationEPIC array (Illumina, San Diego, CA, USA); which was utilized to measure DNAm levels for 866,895 (867K) genomic locations, encompassing primarily CpG dinucleotides but also non-CpG sites."
!Series_overall_design	""
!Series_overall_design	">>>Submitter states: the IDAT files are currently available at AnVIL/dbGaP (phs000424.v9).  By GTEx consortium policy, IDAT files cannot be made publicly available as they could be used to re-identify GTEx samples <<<"
!Series_type	"Methylation profiling by array"
!Series_contributor	"Meritxell,,Oliva"
!Series_contributor	"Brandon,L,Pierce"
!Series_contributor	"Muhammad,G,Kibriya"
!Series_contributor	"Kristin,,Ardlie"
!Series_contributor	"Kathryn,,Demanelis"
!Series_sample_id	"GSM6586938 GSM6586939 GSM6586940 GSM6586941 GSM6586942 GSM6586943 GSM6586944 GSM6586945 GSM6586946 GSM6586947 GSM6586948 GSM6586949 GSM6586950 GSM6586951 GSM6586952 GSM6586953 GSM6586954 GSM6586955 GSM6586956 GSM6586957 GSM6586958 GSM6586959 GSM6586960 GSM6586961 GSM6586962 GSM6586963 GSM6586964 GSM6586965 GSM6586966 GSM6586967 GSM6586968 GSM6586969 GSM6586970 GSM6586971 GSM6586972 GSM6586973 GSM6586974 GSM6586975 GSM6586976 GSM6586977 GSM6586978 GSM6586979 GSM6586980 GSM6586981 GSM6586982 GSM6586983 GSM6586984 GSM6586985 GSM6586986 GSM6586987 GSM6586988 GSM6586989 GSM6586990 GSM6586991 GSM6586992 GSM6586993 GSM6586994 GSM6586995 GSM6586996 GSM6586997 GSM6586998 GSM6586999 GSM6587000 GSM6587001 GSM6587002 GSM6587003 GSM6587004 GSM6587005 GSM6587006 GSM6587007 GSM6587008 GSM6587009 GSM6587010 GSM6587011 GSM6587012 GSM6587013 GSM6587014 GSM6587015 GSM6587016 GSM6587017 GSM6587018 GSM6587019 GSM6587020 GSM6587021 GSM6587022 GSM6587023 GSM6587024 GSM6587025 GSM6587026 GSM6587027 GSM6587028 GSM6587029 GSM6587030 GSM6587031 GSM6587032 GSM6587033 GSM6587034 GSM6587035 GSM6587036 GSM6587037 GSM6587038 GSM6587039 GSM6587040 GSM6587041 GSM6587042 GSM6587043 GSM6587044 GSM6587045 GSM6587046 GSM6587047 GSM6587048 GSM6587049 GSM6587050 GSM6587051 GSM6587052 GSM6587053 GSM6587054 GSM6587055 GSM6587056 GSM6587057 GSM6587058 GSM6587059 GSM6587060 GSM6587061 GSM6587062 GSM6587063 GSM6587064 GSM6587065 GSM6587066 GSM6587067 GSM6587068 GSM6587069 GSM6587070 GSM6587071 GSM6587072 GSM6587073 GSM6587074 GSM6587075 GSM6587076 GSM6587077 GSM6587078 GSM6587079 GSM6587080 GSM6587081 GSM6587082 GSM6587083 GSM6587084 GSM6587085 GSM6587086 GSM6587087 GSM6587088 GSM6587089 GSM6587090 GSM6587091 GSM6587092 GSM6587093 GSM6587094 GSM6587095 GSM6587096 GSM6587097 GSM6587098 GSM6587099 GSM6587100 GSM6587101 GSM6587102 GSM6587103 GSM6587104 GSM6587105 GSM6587106 GSM6587107 GSM6587108 GSM6587109 GSM6587110 GSM6587111 GSM6587112 GSM6587113 GSM6587114 GSM6587115 GSM6587116 GSM6587117 GSM6587118 GSM6587119 GSM6587120 GSM6587121 GSM6587122 GSM6587123 GSM6587124 GSM6587125 GSM6587126 GSM6587127 GSM6587128 GSM6587129 GSM6587130 GSM6587131 GSM6587132 GSM6587133 GSM6587134 GSM6587135 GSM6587136 GSM6587137 GSM6587138 GSM6587139 GSM6587140 GSM6587141 GSM6587142 GSM6587143 GSM6587144 GSM6587145 GSM6587146 GSM6587147 GSM6587148 GSM6587149 GSM6587150 GSM6587151 GSM6587152 GSM6587153 GSM6587154 GSM6587155 GSM6587156 GSM6587157 GSM6587158 GSM6587159 GSM6587160 GSM6587161 GSM6587162 GSM6587163 GSM6587164 GSM6587165 GSM6587166 GSM6587167 GSM6587168 GSM6587169 GSM6587170 GSM6587171 GSM6587172 GSM6587173 GSM6587174 GSM6587175 GSM6587176 GSM6587177 GSM6587178 GSM6587179 GSM6587180 GSM6587181 GSM6587182 GSM6587183 GSM6587184 GSM6587185 GSM6587186 GSM6587187 GSM6587188 GSM6587189 GSM6587190 GSM6587191 GSM6587192 GSM6587193 GSM6587194 GSM6587195 GSM6587196 GSM6587197 GSM6587198 GSM6587199 GSM6587200 GSM6587201 GSM6587202 GSM6587203 GSM6587204 GSM6587205 GSM6587206 GSM6587207 GSM6587208 GSM6587209 GSM6587210 GSM6587211 GSM6587212 GSM6587213 GSM6587214 GSM6587215 GSM6587216 GSM6587217 GSM6587218 GSM6587219 GSM6587220 GSM6587221 GSM6587222 GSM6587223 GSM6587224 GSM6587225 GSM6587226 GSM6587227 GSM6587228 GSM6587229 GSM6587230 GSM6587231 GSM6587232 GSM6587233 GSM6587234 GSM6587235 GSM6587236 GSM6587237 GSM6587238 GSM6587239 GSM6587240 GSM6587241 GSM6587242 GSM6587243 GSM6587244 GSM6587245 GSM6587246 GSM6587247 GSM6587248 GSM6587249 GSM6587250 GSM6587251 GSM6587252 GSM6587253 GSM6587254 GSM6587255 GSM6587256 GSM6587257 GSM6587258 GSM6587259 GSM6587260 GSM6587261 GSM6587262 GSM6587263 GSM6587264 GSM6587265 GSM6587266 GSM6587267 GSM6587268 GSM6587269 GSM6587270 GSM6587271 GSM6587272 GSM6587273 GSM6587274 GSM6587275 GSM6587276 GSM6587277 GSM6587278 GSM6587279 GSM6587280 GSM6587281 GSM6587282 GSM6587283 GSM6587284 GSM6587285 GSM6587286 GSM6587287 GSM6587288 GSM6587289 GSM6587290 GSM6587291 GSM6587292 GSM6587293 GSM6587294 GSM6587295 GSM6587296 GSM6587297 GSM6587298 GSM6587299 GSM6587300 GSM6587301 GSM6587302 GSM6587303 GSM6587304 GSM6587305 GSM6587306 GSM6587307 GSM6587308 GSM6587309 GSM6587310 GSM6587311 GSM6587312 GSM6587313 GSM6587314 GSM6587315 GSM6587316 GSM6587317 GSM6587318 GSM6587319 GSM6587320 GSM6587321 GSM6587322 GSM6587323 GSM6587324 GSM6587325 GSM6587326 GSM6587327 GSM6587328 GSM6587329 GSM6587330 GSM6587331 GSM6587332 GSM6587333 GSM6587334 GSM6587335 GSM6587336 GSM6587337 GSM6587338 GSM6587339 GSM6587340 GSM6587341 GSM6587342 GSM6587343 GSM6587344 GSM6587345 GSM6587346 GSM6587347 GSM6587348 GSM6587349 GSM6587350 GSM6587351 GSM6587352 GSM6587353 GSM6587354 GSM6587355 GSM6587356 GSM6587357 GSM6587358 GSM6587359 GSM6587360 GSM6587361 GSM6587362 GSM6587363 GSM6587364 GSM6587365 GSM6587366 GSM6587367 GSM6587368 GSM6587369 GSM6587370 GSM6587371 GSM6587372 GSM6587373 GSM6587374 GSM6587375 GSM6587376 GSM6587377 GSM6587378 GSM6587379 GSM6587380 GSM6587381 GSM6587382 GSM6587383 GSM6587384 GSM6587385 GSM6587386 GSM6587387 GSM6587388 GSM6587389 GSM6587390 GSM6587391 GSM6587392 GSM6587393 GSM6587394 GSM6587395 GSM6587396 GSM6587397 GSM6587398 GSM6587399 GSM6587400 GSM6587401 GSM6587402 GSM6587403 GSM6587404 GSM6587405 GSM6587406 GSM6587407 GSM6587408 GSM6587409 GSM6587410 GSM6587411 GSM6587412 GSM6587413 GSM6587414 GSM6587415 GSM6587416 GSM6587417 GSM6587418 GSM6587419 GSM6587420 GSM6587421 GSM6587422 GSM6587423 GSM6587424 GSM6587425 GSM6587426 GSM6587427 GSM6587428 GSM6587429 GSM6587430 GSM6587431 GSM6587432 GSM6587433 GSM6587434 GSM6587435 GSM6587436 GSM6587437 GSM6587438 GSM6587439 GSM6587440 GSM6587441 GSM6587442 GSM6587443 GSM6587444 GSM6587445 GSM6587446 GSM6587447 GSM6587448 GSM6587449 GSM6587450 GSM6587451 GSM6587452 GSM6587453 GSM6587454 GSM6587455 GSM6587456 GSM6587457 GSM6587458 GSM6587459 GSM6587460 GSM6587461 GSM6587462 GSM6587463 GSM6587464 GSM6587465 GSM6587466 GSM6587467 GSM6587468 GSM6587469 GSM6587470 GSM6587471 GSM6587472 GSM6587473 GSM6587474 GSM6587475 GSM6587476 GSM6587477 GSM6587478 GSM6587479 GSM6587480 GSM6587481 GSM6587482 GSM6587483 GSM6587484 GSM6587485 GSM6587486 GSM6587487 GSM6587488 GSM6587489 GSM6587490 GSM6587491 GSM6587492 GSM6587493 GSM6587494 GSM6587495 GSM6587496 GSM6587497 GSM6587498 GSM6587499 GSM6587500 GSM6587501 GSM6587502 GSM6587503 GSM6587504 GSM6587505 GSM6587506 GSM6587507 GSM6587508 GSM6587509 GSM6587510 GSM6587511 GSM6587512 GSM6587513 GSM6587514 GSM6587515 GSM6587516 GSM6587517 GSM6587518 GSM6587519 GSM6587520 GSM6587521 GSM6587522 GSM6587523 GSM6587524 GSM6587525 GSM6587526 GSM6587527 GSM6587528 GSM6587529 GSM6587530 GSM6587531 GSM6587532 GSM6587533 GSM6587534 GSM6587535 GSM6587536 GSM6587537 GSM6587538 GSM6587539 GSM6587540 GSM6587541 GSM6587542 GSM6587543 GSM6587544 GSM6587545 GSM6587546 GSM6587547 GSM6587548 GSM6587549 GSM6587550 GSM6587551 GSM6587552 GSM6587553 GSM6587554 GSM6587555 GSM6587556 GSM6587557 GSM6587558 GSM6587559 GSM6587560 GSM6587561 GSM6587562 GSM6587563 GSM6587564 GSM6587565 GSM6587566 GSM6587567 GSM6587568 GSM6587569 GSM6587570 GSM6587571 GSM6587572 GSM6587573 GSM6587574 GSM6587575 GSM6587576 GSM6587577 GSM6587578 GSM6587579 GSM6587580 GSM6587581 GSM6587582 GSM6587583 GSM6587584 GSM6587585 GSM6587586 GSM6587587 GSM6587588 GSM6587589 GSM6587590 GSM6587591 GSM6587592 GSM6587593 GSM6587594 GSM6587595 GSM6587596 GSM6587597 GSM6587598 GSM6587599 GSM6587600 GSM6587601 GSM6587602 GSM6587603 GSM6587604 GSM6587605 GSM6587606 GSM6587607 GSM6587608 GSM6587609 GSM6587610 GSM6587611 GSM6587612 GSM6587613 GSM6587614 GSM6587615 GSM6587616 GSM6587617 GSM6587618 GSM6587619 GSM6587620 GSM6587621 GSM6587622 GSM6587623 GSM6587624 GSM6587625 GSM6587626 GSM6587627 GSM6587628 GSM6587629 GSM6587630 GSM6587631 GSM6587632 GSM6587633 GSM6587634 GSM6587635 GSM6587636 GSM6587637 GSM6587638 GSM6587639 GSM6587640 GSM6587641 GSM6587642 GSM6587643 GSM6587644 GSM6587645 GSM6587646 GSM6587647 GSM6587648 GSM6587649 GSM6587650 GSM6587651 GSM6587652 GSM6587653 GSM6587654 GSM6587655 GSM6587656 GSM6587657 GSM6587658 GSM6587659 GSM6587660 GSM6587661 GSM6587662 GSM6587663 GSM6587664 GSM6587665 GSM6587666 GSM6587667 GSM6587668 GSM6587669 GSM6587670 GSM6587671 GSM6587672 GSM6587673 GSM6587674 GSM6587675 GSM6587676 GSM6587677 GSM6587678 GSM6587679 GSM6587680 GSM6587681 GSM6587682 GSM6587683 GSM6587684 GSM6587685 GSM6587686 GSM6587687 GSM6587688 GSM6587689 GSM6587690 GSM6587691 GSM6587692 GSM6587693 GSM6587694 GSM6587695 GSM6587696 GSM6587697 GSM6587698 GSM6587699 GSM6587700 GSM6587701 GSM6587702 GSM6587703 GSM6587704 GSM6587705 GSM6587706 GSM6587707 GSM6587708 GSM6587709 GSM6587710 GSM6587711 GSM6587712 GSM6587713 GSM6587714 GSM6587715 GSM6587716 GSM6587717 GSM6587718 GSM6587719 GSM6587720 GSM6587721 GSM6587722 GSM6587723 GSM6587724 GSM6587725 GSM6587726 GSM6587727 GSM6587728 GSM6587729 GSM6587730 GSM6587731 GSM6587732 GSM6587733 GSM6587734 GSM6587735 GSM6587736 GSM6587737 GSM6587738 GSM6587739 GSM6587740 GSM6587741 GSM6587742 GSM6587743 GSM6587744 GSM6587745 GSM6587746 GSM6587747 GSM6587748 GSM6587749 GSM6587750 GSM6587751 GSM6587752 GSM6587753 GSM6587754 GSM6587755 GSM6587756 GSM6587757 GSM6587758 GSM6587759 GSM6587760 GSM6587761 GSM6587762 GSM6587763 GSM6587764 GSM6587765 GSM6587766 GSM6587767 GSM6587768 GSM6587769 GSM6587770 GSM6587771 GSM6587772 GSM6587773 GSM6587774 GSM6587775 GSM6587776 GSM6587777 GSM6587778 GSM6587779 GSM6587780 GSM6587781 GSM6587782 GSM6587783 GSM6587784 GSM6587785 GSM6587786 GSM6587787 GSM6587788 GSM6587789 GSM6587790 GSM6587791 GSM6587792 GSM6587793 GSM6587794 GSM6587795 GSM6587796 GSM6587797 GSM6587798 GSM6587799 GSM6587800 GSM6587801 GSM6587802 GSM6587803 GSM6587804 GSM6587805 GSM6587806 GSM6587807 GSM6587808 GSM6587809 GSM6587810 GSM6587811 GSM6587812 GSM6587813 GSM6587814 GSM6587815 GSM6587816 GSM6587817 GSM6587818 GSM6587819 GSM6587820 GSM6587821 GSM6587822 GSM6587823 GSM6587824 GSM6587825 GSM6587826 GSM6587827 GSM6587828 GSM6587829 GSM6587830 GSM6587831 GSM6587832 GSM6587833 GSM6587834 GSM6587835 GSM6587836 GSM6587837 GSM6587838 GSM6587839 GSM6587840 GSM6587841 GSM6587842 GSM6587843 GSM6587844 GSM6587845 GSM6587846 GSM6587847 GSM6587848 GSM6587849 GSM6587850 GSM6587851 GSM6587852 GSM6587853 GSM6587854 GSM6587855 GSM6587856 GSM6587857 GSM6587858 GSM6587859 GSM6587860 GSM6587861 GSM6587862 GSM6587863 GSM6587864 GSM6587865 GSM6587866 GSM6587867 GSM6587868 GSM6587869 GSM6587870 GSM6587871 GSM6587872 GSM6587873 GSM6587874 GSM6587875 GSM6587876 GSM6587877 GSM6587878 GSM6587879 GSM6587880 GSM6587881 GSM6587882 GSM6587883 GSM6587884 GSM6587885 GSM6587886 GSM6587887 GSM6587888 GSM6587889 GSM6587890 GSM6587891 GSM6587892 GSM6587893 GSM6587894 GSM6587895 GSM6587896 GSM6587897 GSM6587898 GSM6587899 GSM6587900 GSM6587901 GSM6587902 GSM6587903 GSM6587904 GSM6587905 GSM6587906 GSM6587907 GSM6587908 GSM6587909 GSM6587910 GSM6587911 GSM6587912 GSM6587913 GSM6587914 GSM6587915 GSM6587916 GSM6587917 GSM6587918 GSM6587919 GSM6587920 GSM6587921 GSM6587922 GSM6587923 GSM6587924 "
!Series_contact_name	"Meritxell,,Oliva"
!Series_contact_email	"meritxellop@gmail.com"
!Series_contact_laboratory	"Brandon Pierce & Lin Chen"
!Series_contact_department	"Public Health Sciences"
!Series_contact_institute	"University of Chicago"
!Series_contact_address	"5841 S. Maryland Ave"
!Series_contact_city	"Chicago"
!Series_contact_state	"Illinois"
!Series_contact_zip/postal_code	"60637"
!Series_contact_country	"USA"
!Series_supplementary_file	"ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE213nnn/GSE213478/suppl/GSE213478_RAW.tar"
!Series_supplementary_file	"ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE213nnn/GSE213478/suppl/GSE213478_methylation_DNAm_noob_final_BMIQ_all_tissues_987.txt.gz"
!Series_platform_id	"GPL21145"
!Series_platform_taxid	"9606"
!Series_sample_taxid	"9606"
!Series_relation	"BioProject: https://www.ncbi.nlm.nih.gov/bioproject/PRJNA880915"

!Sample_title	"GTEX-11EM3-1326-SM-GW24C"	"GTEX-11EMC-2026-SM-GW242"	"GTEX-11GSP-0926-SM-GW21X"	"GTEX-13D11-1026-SM-GW1D7"	"GTEX-13PL6-2926-SM-GW1SN"	"GTEX-147F3-1626-SM-GW1DU"	"GTEX-14BIL-2526-SM-GW1SZ"	"GTEX-14BIN-1826-SM-GW1X6"	"GTEX-14E6C-1326-SM-GW1D1"	"GTEX-14H4A-2526-SM-GW1GY"	"GTEX-14PHY-1926-SM-GW2A6"	"GTEX-14PJ6-2026-SM-GW1R5"	"GTEX-14PK6-1526-SM-GW21C"	"GTEX-15CHQ-0426-SM-GW1QF"	"GTEX-15CHR-1026-SM-GW218"	"GTEX-15DDE-0726-SM-GW1RC"	"GTEX-15ER7-1626-SM-GW1VP"	"GTEX-15EU6-2426-SM-GW1RL"	"GTEX-15SHU-0826-SM-GW21B"	"GTEX-16NGA-0826-SM-GW1UD"	"GTEX-17HG3-0126-SM-GW1R6"	"GTEX-18D9U-2326-SM-GW1S1"	"GTEX-18QFQ-0826-SM-GW1CA"	"GTEX-1AYD5-2526-SM-GW1DB"	"GTEX-1C6WA-2426-SM-GW1RG"	"GTEX-1F5PL-1026-SM-GW1AX"	"GTEX-1F88E-0326-SM-GW1CC"	"GTEX-1GMR3-2626-SM-GW1E8"	"GTEX-1GN1W-1926-SM-GW1DD"	"GTEX-1GPI6-0626-SM-GW1S3"	"GTEX-1GTWX-2826-SM-GW1E9"	"GTEX-1GZ2Q-2626-SM-GW1PZ"	"GTEX-1GZ4H-0326-SM-GW1RT"	"GTEX-1H3VE-2226-SM-GW1S4"	"GTEX-1IDJE-0826-SM-GW1GS"	"GTEX-1IKOH-2326-SM-GW1T3"	"GTEX-S341-1526-SM-GW24F"	"GTEX-S4P3-1326-SM-GW2AH"	"GTEX-SE5C-2126-SM-GW1G8"	"GTEX-T6MO-0326-SM-GW1ZU"	"GTEX-U3ZN-1926-SM-GW1U4"	"GTEX-UJHI-1426-SM-GW1SO"	"GTEX-WI4N-1426-SM-GW1FZ"	"GTEX-WRHU-0326-SM-GW1U1"	"GTEX-X15G-1626-SM-GW1D9"	"GTEX-X8HC-0826-SM-GW2B2"	"GTEX-XUW1-2326-SM-GW2AA"	"GTEX-XUZC-1626-SM-GW1CI"	"GTEX-XV7Q-2326-SM-GW1VQ"	"GTEX-YFC4-1426-SM-GW1SR"	"GTEX-ZC5H-2626-SM-GW1G6"	"GTEX-ZXES-0826-SM-GW2BT"	"GTEX-1117F-2726-SM-GW1F9"	"GTEX-111FC-2326-SM-GW2AK"	"GTEX-111VG-2226-SM-GW1XW"	"GTEX-111YS-1626-SM-GW23H"	"GTEX-113JC-1826-SM-GW29S"	"GTEX-1192W-1826-SM-GW248"	"GTEX-1192X-2626-SM-GW1EK"	"GTEX-11DXX-1826-SM-GW1UB"	"GTEX-11DXZ-1726-SM-GW1EW"	"GTEX-11EM3-1526-SM-GW249"	"GTEX-11EMC-1526-SM-GW23O"	"GTEX-11GS4-1926-SM-GW2CA"	"GTEX-11I78-1226-SM-GW192"	"GTEX-11ONC-2026-SM-GW1YJ"	"GTEX-11P82-1026-SM-GW1XX"	"GTEX-11TT1-1026-SM-GW1AF"	"GTEX-11TTK-2426-SM-GW24B"	"GTEX-11UD2-2426-SM-GW1BM"	"GTEX-11WQC-2126-SM-GW1Z4"	"GTEX-11ZTS-1726-SM-GW2BJ"	"GTEX-11ZTT-1326-SM-GW19N"	"GTEX-11ZU8-2226-SM-GW2B5"	"GTEX-11ZUS-2226-SM-GW1Z3"	"GTEX-1211K-1726-SM-GW1U8"	"GTEX-12584-2626-SM-GW1ZC"	"GTEX-12696-2126-SM-GW1BJ"	"GTEX-12KS4-2426-SM-GW1BA"	"GTEX-12WSE-2626-SM-GW1VB"	"GTEX-12WSF-2826-SM-GW1FS"	"GTEX-12WSI-1626-SM-GW1AC"	"GTEX-12ZZW-2526-SM-GW1AB"	"GTEX-12ZZX-2626-SM-GW2BU"	"GTEX-12ZZY-2826-SM-GW29L"	"GTEX-12ZZZ-2426-SM-GW24E"	"GTEX-13111-0726-SM-GW1Z8"	"GTEX-13112-1826-SM-GW1TV"	"GTEX-1399R-2226-SM-GW21Z"	"GTEX-139TT-2026-SM-GW1YB"	"GTEX-139YR-2126-SM-GW1G2"	"GTEX-13CF2-1926-SM-GW22O"	"GTEX-13N1W-2326-SM-GW1FV"	"GTEX-13NYS-2726-SM-GW1GE"	"GTEX-13NZB-1826-SM-GW1AH"	"GTEX-13O3P-2326-SM-GW19Y"	"GTEX-13OW5-2626-SM-GW1SS"	"GTEX-13OW7-2426-SM-GW1Z7"	"GTEX-13OW8-2626-SM-GW1R9"	"GTEX-13PL6-1826-SM-GW243"	"GTEX-13QIC-2726-SM-GW2B8"	"GTEX-13QJC-2026-SM-GW23U"	"GTEX-13SLW-2726-SM-GW1FX"	"GTEX-13SLX-2826-SM-GW1YI"	"GTEX-13X6I-2626-SM-GW1U3"	"GTEX-145MH-2526-SM-GW19X"	"GTEX-1477Z-1826-SM-GW1TG"	"GTEX-147GR-2726-SM-GW1TI"	"GTEX-14A5I-2626-SM-GW1R2"	"GTEX-14A6H-1826-SM-GW1RY"	"GTEX-14ABY-2426-SM-GW1UN"	"GTEX-14AS3-1126-SM-GW1UG"	"GTEX-14BIM-2426-SM-GW1QP"	"GTEX-14BIN-3026-SM-GW1QX"	"GTEX-14BMV-2426-SM-GW1RK"	"GTEX-14DAQ-2726-SM-GW1E6"	"GTEX-14DAR-1526-SM-GW1WG"	"GTEX-14E6D-2226-SM-GW1DI"	"GTEX-14E7W-2526-SM-GW1AR"	"GTEX-14H4A-1926-SM-GW1DE"	"GTEX-14LZ3-2726-SM-GW1WK"	"GTEX-14PJ4-1926-SM-GW1DO"	"GTEX-14PJM-2626-SM-GW1RJ"	"GTEX-14PK6-1726-SM-GW1WH"	"GTEX-14PN3-1826-SM-GW1UC"	"GTEX-15CHQ-2526-SM-GW1E3"	"GTEX-15CHR-1426-SM-GW22K"	"GTEX-15D79-2626-SM-GW1RH"	"GTEX-15DDE-2726-SM-GW1TP"	"GTEX-15DYW-2326-SM-GW1RO"	"GTEX-15EO6-2126-SM-GW1DH"	"GTEX-15EU6-1926-SM-GW1D3"	"GTEX-15RIE-1826-SM-GW1EB"	"GTEX-15SDE-1026-SM-GW1E5"	"GTEX-15SHU-2526-SM-GW1EC"	"GTEX-15SHV-1326-SM-GW1DY"	"GTEX-15SHW-2526-SM-GW1QY"	"GTEX-15SKB-2626-SM-GW1DC"	"GTEX-15SZO-2626-SM-GW1CT"	"GTEX-16AAH-1326-SM-GW22B"	"GTEX-16NPV-2626-SM-GW1R1"	"GTEX-16YQH-2526-SM-GW1DF"	"GTEX-17EVQ-1826-SM-GW1Q1"	"GTEX-17HGU-2426-SM-GW1GQ"	"GTEX-18A7A-2226-SM-GW1RX"	"GTEX-18D9B-2526-SM-GW22E"	"GTEX-18D9U-1926-SM-GW1D2"	"GTEX-19HZE-2626-SM-GW1BU"	"GTEX-1A32A-2426-SM-GW1GU"	"GTEX-1A3MV-1126-SM-GW1TJ"	"GTEX-1A3MX-2226-SM-GW1EF"	"GTEX-1AX9I-2626-SM-GW1RQ"	"GTEX-1AYD5-1726-SM-GW1UK"	"GTEX-1B8KE-1926-SM-GW1QT"	"GTEX-1B98T-2826-SM-GW1UE"	"GTEX-1BAJH-2326-SM-GW1RI"	"GTEX-1C4CL-2126-SM-GW21V"	"GTEX-1C64N-2326-SM-GW22X"	"GTEX-1C64O-2326-SM-GW22L"	"GTEX-1C6WA-2726-SM-GW1DK"	"GTEX-1CAMQ-1926-SM-GW1WS"	"GTEX-1CAV2-1826-SM-GW1EG"	"GTEX-1CB4H-2126-SM-GW1QJ"	"GTEX-1E2YA-2626-SM-GW1QZ"	"GTEX-1EN7A-2626-SM-GW1S2"	"GTEX-1F52S-2626-SM-GW1PV"	"GTEX-1F5PK-1926-SM-GW1AY"	"GTEX-1F5PL-2126-SM-GW1TK"	"GTEX-1F6I4-2626-SM-GW1WQ"	"GTEX-1F6IF-1226-SM-GW2A1"	"GTEX-1F6RS-2526-SM-GW1E4"	"GTEX-1F75A-2726-SM-GW1UL"	"GTEX-1F75W-2226-SM-GW1BY"	"GTEX-1F88E-2226-SM-GW1RS"	"GTEX-1GL5R-2426-SM-GW1TE"	"GTEX-1GMR2-1726-SM-GW1DS"	"GTEX-1GMR3-2826-SM-GW1RA"	"GTEX-1GTWX-2326-SM-GW1E2"	"GTEX-1GZ4I-2426-SM-GW1GO"	"GTEX-1GZHY-2626-SM-GW1WJ"	"GTEX-1H11D-2626-SM-GW1WM"	"GTEX-1H1DF-2526-SM-GW1PY"	"GTEX-1H1ZS-2326-SM-GW22W"	"GTEX-1H23P-2426-SM-GW1RE"	"GTEX-1H2FU-2726-SM-GW1TF"	"GTEX-1H3VE-2426-SM-GW1WI"	"GTEX-1H3VY-2426-SM-GW1DQ"	"GTEX-1HB9E-2426-SM-GW1TC"	"GTEX-1HCVE-2526-SM-GW1QI"	"GTEX-1HGF4-2126-SM-GW1GX"	"GTEX-1HSKV-2226-SM-GW1BW"	"GTEX-1I6K6-1826-SM-GW1PW"	"GTEX-1ICLY-2626-SM-GW1RB"	"GTEX-1IDJH-2726-SM-GW1X1"	"GTEX-1IDJI-2326-SM-GW1GZ"	"GTEX-1IDJU-2026-SM-GW1GM"	"GTEX-1IDJV-2726-SM-GW1WP"	"GTEX-1IGQW-2326-SM-GW29Y"	"GTEX-1IKJJ-2426-SM-GW1PX"	"GTEX-1IKK5-2726-SM-GW1C3"	"GTEX-1IY9M-2126-SM-GW1QM"	"GTEX-1J1OQ-2726-SM-GW1QH"	"GTEX-1J1R8-1126-SM-GW1T4"	"GTEX-1J8Q2-2426-SM-GW219"	"GTEX-1J8Q3-2326-SM-GW1BV"	"GTEX-1JK1U-1526-SM-GW2CH"	"GTEX-1JMOU-2426-SM-GW2CD"	"GTEX-1JMPZ-2426-SM-GW177"	"GTEX-1JMQJ-2826-SM-GW1EP"	"GTEX-1JN1M-2626-SM-GW1VZ"	"GTEX-1JN6P-1926-SM-GW1EO"	"GTEX-1JN76-1226-SM-GW211"	"GTEX-RUSQ-1226-SM-GW19J"	"GTEX-RVPU-1626-SM-GW1ZJ"	"GTEX-RVPV-2226-SM-GW23T"	"GTEX-S33H-2126-SM-GW1AJ"	"GTEX-S341-1426-SM-GW1XN"	"GTEX-S4Z8-1526-SM-GW1US"	"GTEX-S7SE-2226-SM-GW19R"	"GTEX-SIU8-2426-SM-GW2BZ"	"GTEX-SJXC-2226-SM-GW23Z"	"GTEX-SN8G-2726-SM-GW1YA"	"GTEX-T2IS-2726-SM-GW1ZR"	"GTEX-T2YK-2126-SM-GW193"	"GTEX-T8EM-1426-SM-GW19O"	"GTEX-TSE9-1826-SM-GW245"	"GTEX-U3ZH-1326-SM-GW1U2"	"GTEX-U3ZM-1126-SM-GW1YU"	"GTEX-U8T8-1326-SM-GW19F"	"GTEX-UJHI-1126-SM-GW1B7"	"GTEX-UPJH-2026-SM-GW1ZF"	"GTEX-UPK5-2226-SM-GW2AP"	"GTEX-UTHO-2526-SM-GW1B2"	"GTEX-W5X1-1726-SM-GW1ZH"	"GTEX-WFG8-1526-SM-GW2C7"	"GTEX-WH7G-1326-SM-GW1H6"	"GTEX-WK11-2326-SM-GW1BH"	"GTEX-WOFL-2626-SM-GW1FR"	"GTEX-WQUQ-2526-SM-GW1YS"	"GTEX-WRHU-2326-SM-GW1ZI"	"GTEX-WVLH-2426-SM-GW1ZT"	"GTEX-WWYW-2326-SM-GW1YR"	"GTEX-WXYG-1826-SM-GW1FQ"	"GTEX-WY7C-1626-SM-GW1WC"	"GTEX-WYBS-2326-SM-GW2AI"	"GTEX-X261-1826-SM-GW1ES"	"GTEX-X4EO-2526-SM-GW22T"	"GTEX-X4EP-2726-SM-GW2AY"	"GTEX-X4XX-2526-SM-GW1CH"	"GTEX-X4XY-2626-SM-GW23M"	"GTEX-X585-2626-SM-GW23A"	"GTEX-X5EB-0926-SM-GW22S"	"GTEX-X62O-2626-SM-GW2BO"	"GTEX-X8HC-2426-SM-GW1BF"	"GTEX-XBEC-2426-SM-GW1EU"	"GTEX-XBED-1526-SM-GW1XS"	"GTEX-XMD2-2526-SM-GW247"	"GTEX-XMK1-1726-SM-GW2AO"	"GTEX-XPT6-1126-SM-GW246"	"GTEX-XPVG-1826-SM-GW2BB"	"GTEX-XQ3S-2626-SM-GW1CK"	"GTEX-XUJ4-2026-SM-GW1WN"	"GTEX-XV7Q-2126-SM-GW1WA"	"GTEX-XYKS-2226-SM-GW1F7"	"GTEX-Y111-1426-SM-GW1YN"	"GTEX-YB5E-1626-SM-GW1B9"	"GTEX-YFCO-1426-SM-GW1A4"	"GTEX-YJ89-2426-SM-GW1Y9"	"GTEX-Z93S-2426-SM-GW1UT"	"GTEX-ZAB4-2226-SM-GW1GJ"	"GTEX-ZDTS-2526-SM-GW1GB"	"GTEX-ZDXO-1826-SM-GW229"	"GTEX-ZVZP-1926-SM-GW1XM"	"GTEX-ZVZQ-2526-SM-GW1UV"	"GTEX-ZYFG-1926-SM-GW23Q"	"GTEX-ZYY3-2026-SM-GW1GL"	"GTEX-117XS-1326-SM-GW22U"	"GTEX-117YW-1226-SM-GW1UU"	"GTEX-1192W-1326-SM-GW1BO"	"GTEX-1192X-2026-SM-GW1GI"	"GTEX-11EMC-1326-SM-GW1UW"	"GTEX-11NV4-1526-SM-GW1YO"	"GTEX-11UD2-2126-SM-GW1YM"	"GTEX-11WQC-1426-SM-GW1EM"	"GTEX-11WQK-1926-SM-GW29M"	"GTEX-11ZU8-1826-SM-GW1BE"	"GTEX-1212Z-1626-SM-GW2AS"	"GTEX-12696-0926-SM-GW2AJ"	"GTEX-12KS4-1826-SM-GW19V"	"GTEX-12WSA-2126-SM-GW23P"	"GTEX-12WSD-2226-SM-GW21W"	"GTEX-12WSF-2126-SM-GW2C8"	"GTEX-12WSI-1826-SM-GW1EH"	"GTEX-12ZZW-2126-SM-GW23V"	"GTEX-12ZZX-2226-SM-GW1BD"	"GTEX-12ZZY-2226-SM-GW1EI"	"GTEX-12ZZZ-1026-SM-GW1F4"	"GTEX-13112-2126-SM-GW2BK"	"GTEX-13N1W-2126-SM-GW1XQ"	"GTEX-13NYS-1426-SM-GW195"	"GTEX-13O3P-1926-SM-GW2C3"	"GTEX-13OW5-2026-SM-GW23Y"	"GTEX-13QJC-1226-SM-GW1H7"	"GTEX-13SLX-1526-SM-GW29U"	"GTEX-13W46-2326-SM-GW1ZG"	"GTEX-148VJ-1926-SM-GW22I"	"GTEX-14A5H-2526-SM-GW22F"	"GTEX-14C39-2126-SM-GW22J"	"GTEX-15DDE-2126-SM-GW1SW"	"GTEX-15SHU-2026-SM-GW22D"	"GTEX-1B98T-2526-SM-GW1SX"	"GTEX-1F6IF-1626-SM-GW1TL"	"GTEX-1GTWX-1826-SM-GW2A3"	"GTEX-1H1ZS-2026-SM-GW22H"	"GTEX-S33H-1426-SM-GW22P"	"GTEX-SIU8-1826-SM-GW1AO"	"GTEX-UTHO-2326-SM-GW1FP"	"GTEX-WOFL-1826-SM-GW1ZV"	"GTEX-WRHU-0526-SM-GW196"	"GTEX-WWYW-2226-SM-GW1YQ"	"GTEX-X261-1126-SM-GW1YZ"	"GTEX-X4EP-1926-SM-GW2AD"	"GTEX-X4XX-2326-SM-GW1CN"	"GTEX-X585-2126-SM-GW23B"	"GTEX-X62O-1926-SM-GW19P"	"GTEX-YFC4-1926-SM-GW244"	"GTEX-1117F-1026-SM-GW2CO"	"GTEX-113JC-1326-SM-GW1F2"	"GTEX-1192W-0626-SM-GW224"	"GTEX-1192X-1326-SM-GW191"	"GTEX-11DXZ-0726-SM-GW23R"	"GTEX-11DYG-0626-SM-GW1XU"	"GTEX-11GSP-0726-SM-GW2CL"	"GTEX-11I78-0126-SM-GW226"	"GTEX-11NV4-1126-SM-GW17Z"	"GTEX-11TTK-0926-SM-GW19B"	"GTEX-11WQK-1226-SM-GW2CV"	"GTEX-11XUK-0326-SM-GW19G"	"GTEX-11ZTS-1226-SM-GW1A7"	"GTEX-11ZUS-0126-SM-GW2BW"	"GTEX-1212Z-1026-SM-GW1UX"	"GTEX-12584-1426-SM-GW1UR"	"GTEX-12WSA-1026-SM-GW18E"	"GTEX-12WSD-0826-SM-GW21I"	"GTEX-12WSE-0826-SM-GW22V"	"GTEX-12ZZX-0926-SM-GW18L"	"GTEX-13111-0426-SM-GW1YH"	"GTEX-13112-0826-SM-GW1ST"	"GTEX-139TT-0726-SM-GW1XV"	"GTEX-139YR-0926-SM-GW1FL"	"GTEX-13CF2-0726-SM-GW1FT"	"GTEX-13FXS-0826-SM-GW2AX"	"GTEX-13IVO-1026-SM-GW1EL"	"GTEX-13NYS-1626-SM-GW1VT"	"GTEX-13NZA-1426-SM-GW1VS"	"GTEX-13O3P-1026-SM-GW1UY"	"GTEX-13OVK-0126-SM-GW1XG"	"GTEX-13OW5-0726-SM-GW1V7"	"GTEX-13OW8-1726-SM-GW1U6"	"GTEX-13PL6-2426-SM-GW1UQ"	"GTEX-13QIC-0326-SM-GW1TX"	"GTEX-13RTJ-1126-SM-GW18K"	"GTEX-13W46-1426-SM-GW1AA"	"GTEX-145MH-0626-SM-GW1ZB"	"GTEX-146FH-1226-SM-GW1RN"	"GTEX-14753-0826-SM-GW1E7"	"GTEX-1477Z-0626-SM-GW1RM"	"GTEX-14A5I-0926-SM-GW2DC"	"GTEX-14A6H-0526-SM-GW1DA"	"GTEX-14AS3-0926-SM-GW1X7"	"GTEX-14BIM-0726-SM-GW18T"	"GTEX-14BIN-0226-SM-GW188"	"GTEX-14BMV-0826-SM-GW1QQ"	"GTEX-14DAR-0226-SM-GW1WU"	"GTEX-14E6C-1426-SM-GW1CP"	"GTEX-14E7W-1326-SM-GW217"	"GTEX-14JFF-1126-SM-GW1CX"	"GTEX-14JG1-0926-SM-GW1CZ"	"GTEX-14JG6-0326-SM-GW1ED"	"GTEX-14LZ3-0726-SM-GW18U"	"GTEX-14PJ4-0626-SM-GW1QR"	"GTEX-14PJ6-0426-SM-GW1C8"	"GTEX-14PJM-0926-SM-GW2CR"	"GTEX-14PJO-0926-SM-GW1RZ"	"GTEX-14PK6-0326-SM-GW1C7"	"GTEX-14PN3-0926-SM-GW1DX"	"GTEX-15CHR-0726-SM-GW1RR"	"GTEX-15D1Q-0526-SM-GW2DA"	"GTEX-15D79-1026-SM-GW1CY"	"GTEX-15DDE-0826-SM-GW21H"	"GTEX-15EO6-0326-SM-GW1T5"	"GTEX-15EU6-1226-SM-GW17S"	"GTEX-15G1A-0426-SM-GW1BS"	"GTEX-15RIE-0326-SM-GW1GV"	"GTEX-15RJE-1026-SM-GW2CM"	"GTEX-15SDE-0226-SM-GW1S7"	"GTEX-15SHV-0326-SM-GW1QS"	"GTEX-15SHW-0926-SM-GW1RW"	"GTEX-15SKB-0826-SM-GW1S9"	"GTEX-15SZO-0926-SM-GW2DF"	"GTEX-15UF6-1226-SM-GW1WV"	"GTEX-15UKP-1926-SM-GW22M"	"GTEX-16AAH-0426-SM-GW1DR"	"GTEX-16NPV-0726-SM-GW2DE"	"GTEX-16YQH-1626-SM-GW17E"	"GTEX-17EVQ-1526-SM-GW1R3"	"GTEX-17HG3-0326-SM-GW231"	"GTEX-18465-0626-SM-GW1C9"	"GTEX-18A66-0926-SM-GW29X"	"GTEX-18D9B-1026-SM-GW1QG"	"GTEX-18D9U-0526-SM-GW1XD"	"GTEX-19HZE-0526-SM-GW1RP"	"GTEX-1A3MV-0526-SM-GW2DB"	"GTEX-1A3MX-0726-SM-GW1DP"	"GTEX-1AX9I-0826-SM-GW1R7"	"GTEX-1AYD5-1226-SM-GW1EA"	"GTEX-1B98T-1226-SM-GW1S5"	"GTEX-1BAJH-1326-SM-GW1FE"	"GTEX-1C4CL-0826-SM-GW1D4"	"GTEX-1C64N-1126-SM-GW1CB"	"GTEX-1C64O-1226-SM-GW1TA"	"GTEX-1CAMQ-1026-SM-GW1QU"	"GTEX-1CAV2-0626-SM-GW29Z"	"GTEX-1E1VI-0926-SM-GW1DZ"	"GTEX-1EN7A-0826-SM-GW1R8"	"GTEX-1F52S-0726-SM-GW1QO"	"GTEX-1F5PK-0526-SM-GW189"	"GTEX-1F6I4-1026-SM-GW1WX"	"GTEX-1F6IF-1826-SM-GW1EE"	"GTEX-1F75B-1026-SM-GW2D8"	"GTEX-1F75W-0626-SM-GW2D9"	"GTEX-1F88E-0226-SM-GW1TM"	"GTEX-1GL5R-0526-SM-GW1DT"	"GTEX-1GMR2-0126-SM-GW1WR"	"GTEX-1GMR3-0226-SM-GW1C2"	"GTEX-1GN1W-1026-SM-GW17F"	"GTEX-1GPI6-0726-SM-GW2D7"	"GTEX-1GTWX-0626-SM-GW1S8"	"GTEX-1GZHY-0826-SM-GW1RD"	"GTEX-1H11D-0726-SM-GW1XA"	"GTEX-1H1DF-1226-SM-GW1D5"	"GTEX-1H23P-1026-SM-GW1WW"	"GTEX-1H3VE-1026-SM-GW2CS"	"GTEX-1H3VY-1426-SM-GW2CN"	"GTEX-1HB9E-0726-SM-GW1XB"	"GTEX-1HCVE-0626-SM-GW1CF"	"GTEX-1HR9M-0826-SM-GW18A"	"GTEX-1I6K6-0926-SM-GW2CT"	"GTEX-1IDJI-0626-SM-GW1WO"	"GTEX-1IDJU-0226-SM-GW1T6"	"GTEX-1IGQW-0726-SM-GW1CE"	"GTEX-1IKJJ-0926-SM-GW1DJ"	"GTEX-1IKK5-1926-SM-GW1QN"	"GTEX-1IL2U-0926-SM-GW1DV"	"GTEX-1J1OQ-0926-SM-GW21Y"	"GTEX-1J1R8-0226-SM-GW1C1"	"GTEX-1J8JJ-1126-SM-GW1Q2"	"GTEX-1J8Q3-0826-SM-GW1TO"	"GTEX-1JK1U-1126-SM-GW1VL"	"GTEX-1JMOU-0526-SM-GW2CI"	"GTEX-1JMQJ-2126-SM-GW2D5"	"GTEX-1JN76-0826-SM-GW1SB"	"GTEX-1KXAM-0426-SM-GW2CW"	"GTEX-1L5NE-0726-SM-GW17C"	"GTEX-1LC47-1126-SM-GW2CJ"	"GTEX-1LG7Y-0826-SM-GW2D2"	"GTEX-1LSNL-1126-SM-GW2D6"	"GTEX-1LSVX-0626-SM-GW2CX"	"GTEX-1LVA9-1126-SM-GW2D1"	"GTEX-1LVAO-1226-SM-GW2D4"	"GTEX-1MCC2-0726-SM-GW2CC"	"GTEX-1MGNQ-0826-SM-GW2D3"	"GTEX-1MJK2-1126-SM-GW179"	"GTEX-1N2EE-1626-SM-GW17A"	"GTEX-1N5O9-1226-SM-GW17M"	"GTEX-1N7R6-0726-SM-GW1W9"	"GTEX-1NHNU-0426-SM-GW1ZY"	"GTEX-1NUQO-1026-SM-GW2CK"	"GTEX-1O97I-1526-SM-GW2CY"	"GTEX-1OFPY-0226-SM-GW2CZ"	"GTEX-1OJC3-0726-SM-GW1W7"	"GTEX-1OZHM-0826-SM-GW18Y"	"GTEX-1PBJJ-1326-SM-GW1VU"	"GTEX-1QCLY-1026-SM-GW2CF"	"GTEX-1QMI2-0926-SM-GW178"	"GTEX-1R46S-1226-SM-GW2CU"	"GTEX-1RAZR-0726-SM-GW1VY"	"GTEX-RUSQ-0626-SM-GW19E"	"GTEX-RVPU-0526-SM-GW19H"	"GTEX-RVPV-1726-SM-GW1XI"	"GTEX-S33H-0626-SM-GW1ZK"	"GTEX-S341-0326-SM-GW23W"	"GTEX-S4Z8-0426-SM-GW2DD"	"GTEX-S7SE-0926-SM-GW181"	"GTEX-SIU8-0926-SM-GW2A7"	"GTEX-SN8G-0926-SM-GW23D"	"GTEX-SNOS-0426-SM-GW1SU"	"GTEX-T2YK-0826-SM-GW1A9"	"GTEX-T6MO-0426-SM-GW1GH"	"GTEX-T8EM-0326-SM-GW1ZN"	"GTEX-TSE9-0726-SM-GW1WE"	"GTEX-U3ZH-0526-SM-GW19I"	"GTEX-U3ZM-0426-SM-GW2BF"	"GTEX-U8T8-2226-SM-GW17X"	"GTEX-U8XE-1426-SM-GW1VC"	"GTEX-UJHI-0726-SM-GW1W5"	"GTEX-UPJH-0826-SM-GW19D"	"GTEX-UPK5-1126-SM-GW2BY"	"GTEX-W5X1-0526-SM-GW241"	"GTEX-WFG8-0926-SM-GW18N"	"GTEX-WH7G-0726-SM-GW18W"	"GTEX-WHWD-0626-SM-GW1B4"	"GTEX-WK11-0526-SM-GW18G"	"GTEX-WOFL-1126-SM-GW29K"	"GTEX-WQUQ-1126-SM-GW184"	"GTEX-WRHU-0226-SM-GW18F"	"GTEX-WVLH-0826-SM-GW182"	"GTEX-WWYW-0926-SM-GW186"	"GTEX-WXYG-0726-SM-GW18D"	"GTEX-WY7C-0426-SM-GW1VR"	"GTEX-WYBS-1126-SM-GW1Z1"	"GTEX-WZTO-0426-SM-GW1TS"	"GTEX-X261-1026-SM-GW18Q"	"GTEX-X4EO-0926-SM-GW1Z5"	"GTEX-X4EP-0526-SM-GW18O"	"GTEX-X4XY-1026-SM-GW18J"	"GTEX-X5EB-0426-SM-GW18S"	"GTEX-X62O-0726-SM-GW1ER"	"GTEX-X8HC-0926-SM-GW183"	"GTEX-XBEC-1026-SM-GW18I"	"GTEX-XBED-0826-SM-GW17W"	"GTEX-XMD1-1026-SM-GW1VA"	"GTEX-XPT6-1226-SM-GW2AZ"	"GTEX-XPVG-1026-SM-GW1B6"	"GTEX-XQ3S-0926-SM-GW1CL"	"GTEX-XUJ4-1426-SM-GW22Z"	"GTEX-XV7Q-0426-SM-GW1TT"	"GTEX-XYKS-0526-SM-GW18H"	"GTEX-YB5E-0726-SM-GW2CQ"	"GTEX-YEC3-0226-SM-GW17H"	"GTEX-YFC4-1126-SM-GW2BS"	"GTEX-YFCO-0426-SM-GW1FK"	"GTEX-YJ89-0826-SM-GW1FD"	"GTEX-Z93S-0626-SM-GW18C"	"GTEX-ZAB4-0626-SM-GW1G5"	"GTEX-ZDTS-1026-SM-GW23S"	"GTEX-ZDXO-1326-SM-GW21U"	"GTEX-ZYFG-0226-SM-GW1G9"	"GTEX-ZYY3-0926-SM-GW1XT"	"GTEX-11XUK-2226-SM-GW2AB"	"GTEX-12584-0526-SM-GW1W4"	"GTEX-12WSF-0926-SM-GW2AE"	"GTEX-13RTJ-2726-SM-GW22R"	"GTEX-13SLX-0326-SM-GW1V9"	"GTEX-13X6I-0526-SM-GW1GF"	"GTEX-13X6K-0326-SM-GW1AG"	"GTEX-14753-0526-SM-GW1QL"	"GTEX-147GR-0126-SM-GW1T2"	"GTEX-148VJ-0326-SM-GW1GP"	"GTEX-14A5H-0326-SM-GW1T1"	"GTEX-14B4R-1726-SM-GW1AZ"	"GTEX-15D1Q-0926-SM-GW1S6"	"GTEX-15DCD-0626-SM-GW1R4"	"GTEX-15SHU-0626-SM-GW1RF"	"GTEX-1F6IF-0226-SM-GW1QW"	"GTEX-1F75B-0526-SM-GW1CD"	"GTEX-1F88E-1826-SM-GW1QK"	"GTEX-1GPI6-0326-SM-GW1QV"	"GTEX-1H1ZS-0626-SM-GW1DG"	"GTEX-1H3NZ-0326-SM-GW1D6"	"GTEX-1H3O1-0626-SM-GW1RV"	"GTEX-1IKOE-0326-SM-GW1E1"	"GTEX-1J8QM-2226-SM-GW1GN"	"GTEX-SNOS-1526-SM-GW24A"	"GTEX-T6MO-1826-SM-GW1Y2"	"GTEX-T8EM-1326-SM-GW2BQ"	"GTEX-U3ZH-1926-SM-GW1XZ"	"GTEX-W5WG-1926-SM-GW2AV"	"GTEX-W5X1-2726-SM-GW19S"	"GTEX-WOFL-0626-SM-GW1G1"	"GTEX-WWYW-0526-SM-GW194"	"GTEX-WYBS-0526-SM-GW1Y3"	"GTEX-X4EO-0526-SM-GW1XH"	"GTEX-X4EP-0926-SM-GW1XJ"	"GTEX-X4XY-0626-SM-GW1XO"	"GTEX-X585-0626-SM-GW227"	"GTEX-X5EB-2326-SM-GW1TW"	"GTEX-X62O-1226-SM-GW1ZE"	"GTEX-XMD1-0626-SM-GW19T"	"GTEX-XMD2-0526-SM-GW1Y1"	"GTEX-XMK1-2326-SM-GW1SM"	"GTEX-XV7Q-2926-SM-GW1TR"	"GTEX-XYKS-2426-SM-GW1W1"	"GTEX-Y111-0326-SM-GW1Z6"	"GTEX-ZVZP-2526-SM-GW1EJ"	"GTEX-ZVZQ-0526-SM-GW2A9"	"GTEX-11EM3-1726-SM-GW199"	"GTEX-11EMC-1726-SM-GW2AF"	"GTEX-11GSP-0226-SM-GW1Q3"	"GTEX-11I78-1926-SM-GW2BI"	"GTEX-11VI4-1026-SM-GW223"	"GTEX-11XUK-1626-SM-GW1YD"	"GTEX-11ZTS-1926-SM-GW1GA"	"GTEX-11ZTT-1826-SM-GW1BG"	"GTEX-12WSD-2726-SM-GW1UA"	"GTEX-12WSG-1426-SM-GW1FC"	"GTEX-12WSJ-1226-SM-GW2BN"	"GTEX-12WSK-1926-SM-GW1AP"	"GTEX-12ZZX-2026-SM-GW222"	"GTEX-133LE-1226-SM-GW1A3"	"GTEX-1399U-1726-SM-GW1CW"	"GTEX-13FTY-1826-SM-GW23X"	"GTEX-13N11-0526-SM-GW1A6"	"GTEX-13O3O-2726-SM-GW29N"	"GTEX-13OVJ-2426-SM-GW2BA"	"GTEX-13PL7-2326-SM-GW1Z9"	"GTEX-13QBU-1526-SM-GW1YG"	"GTEX-13QIC-1526-SM-GW1D8"	"GTEX-13QJC-1526-SM-GW29O"	"GTEX-13SLX-2426-SM-GW1EY"	"GTEX-13VXT-1526-SM-GW1ZA"	"GTEX-13X6H-1026-SM-GW24H"	"GTEX-145LS-2326-SM-GW16E"	"GTEX-145ME-1226-SM-GW1CQ"	"GTEX-146FH-2526-SM-GW1H1"	"GTEX-14AS3-1326-SM-GW16Q"	"GTEX-14BIM-2026-SM-GW16J"	"GTEX-14BIN-1426-SM-GW234"	"GTEX-14BMU-1726-SM-GW16P"	"GTEX-14DAQ-2226-SM-GW21P"	"GTEX-14H4A-2226-SM-GW16W"	"GTEX-14JG6-0626-SM-GW16R"	"GTEX-14LZ3-2326-SM-GW1VH"	"GTEX-14PHW-2226-SM-GW16D"	"GTEX-14PHY-1626-SM-GW237"	"GTEX-14PJ6-1426-SM-GW16N"	"GTEX-14PJM-2426-SM-GW174"	"GTEX-14PKU-1226-SM-GW233"	"GTEX-14PN3-1526-SM-GW1UZ"	"GTEX-14PQA-2626-SM-GW16M"	"GTEX-15DCD-2126-SM-GW16C"	"GTEX-15DDE-2326-SM-GW1VI"	"GTEX-15DYW-2626-SM-GW16A"	"GTEX-15EOM-1526-SM-GW16Z"	"GTEX-15ER7-2326-SM-GW1VO"	"GTEX-15ETS-1426-SM-GW175"	"GTEX-15FZZ-0826-SM-GW1VD"	"GTEX-15SDE-0926-SM-GW16H"	"GTEX-15SHU-2726-SM-GW16S"	"GTEX-15UF6-2026-SM-GW21M"	"GTEX-16MT8-2226-SM-GW21N"	"GTEX-16NGA-0426-SM-GW16O"	"GTEX-16NPV-2326-SM-GW1V1"	"GTEX-17F9Y-2226-SM-GW239"	"GTEX-17HG3-1826-SM-GW238"	"GTEX-17JCI-2326-SM-GW232"	"GTEX-183WM-1926-SM-GW16G"	"GTEX-18A7A-2626-SM-GW16T"	"GTEX-18D9A-0826-SM-GW171"	"GTEX-19HZE-2226-SM-GW16V"	"GTEX-1A32A-2726-SM-GW1V2"	"GTEX-1A3MW-2726-SM-GW172"	"GTEX-1AMEY-0926-SM-GW16U"	"GTEX-1AMFI-1426-SM-GW173"	"GTEX-1C475-0426-SM-GW176"	"GTEX-1CAMS-2126-SM-GW21Q"	"GTEX-1CAV2-1526-SM-GW1VG"	"GTEX-1CB4H-2526-SM-GW1GW"	"GTEX-1EWIQ-2226-SM-GW16Y"	"GTEX-1F48J-2326-SM-GW16X"	"GTEX-1F52S-2226-SM-GW1QC"	"GTEX-1F5PL-1626-SM-GW1QA"	"GTEX-1F6RS-2726-SM-GW1QD"	"GTEX-1GN1W-1426-SM-GW1Q9"	"GTEX-1GZHY-2426-SM-GW1Q8"	"GTEX-1H1CY-1926-SM-GW1Q5"	"GTEX-1H1DF-2326-SM-GW1C6"	"GTEX-1H2FU-2326-SM-GW1QE"	"GTEX-1HBPH-2726-SM-GW169"	"GTEX-1HCU6-2226-SM-GW236"	"GTEX-1HCU8-2126-SM-GW1EN"	"GTEX-1HCUA-1326-SM-GW235"	"GTEX-1HSGN-2426-SM-GW1Q6"	"GTEX-1IDJE-1126-SM-GW1QB"	"GTEX-1IDJI-1526-SM-GW1Q4"	"GTEX-1IDJU-1126-SM-GW1VJ"	"GTEX-1IKOE-2326-SM-GW21T"	"GTEX-1J1OQ-1626-SM-GW1Q7"	"GTEX-1J8JJ-0826-SM-GW16I"	"GTEX-1J8QM-1326-SM-GW21O"	"GTEX-1JMOU-1626-SM-GW1W6"	"GTEX-1JN1M-2126-SM-GW212"	"GTEX-1JN76-1426-SM-GW215"	"GTEX-1K9T9-2426-SM-GW1SD"	"GTEX-1KANC-1026-SM-GW1SK"	"GTEX-1LGOU-1026-SM-GW1SC"	"GTEX-1LKK1-1626-SM-GW1SI"	"GTEX-1LVAM-1826-SM-GW1SL"	"GTEX-1MCC2-1026-SM-GW1SA"	"GTEX-1MCYP-1426-SM-GW1SJ"	"GTEX-1N7R6-1826-SM-GW1VV"	"GTEX-1NUQO-1726-SM-GW1SE"	"GTEX-1NV5F-1626-SM-GW2CG"	"GTEX-1PBJI-2026-SM-GW1SF"	"GTEX-1PIEJ-1626-SM-GW1VX"	"GTEX-1QEPI-2726-SM-GW216"	"GTEX-1QP28-1326-SM-GW1W8"	"GTEX-1QP67-1526-SM-GW2CB"	"GTEX-1QPFJ-1726-SM-GW213"	"GTEX-1R46S-1826-SM-GW2CE"	"GTEX-1R9JW-1226-SM-GW214"	"GTEX-1R9PN-0626-SM-GW1SG"	"GTEX-1RDX4-0826-SM-GW1VW"	"GTEX-1RNTQ-1726-SM-GW1SH"	"GTEX-1S5ZU-2326-SM-GW1ZZ"	"GTEX-P4PP-2426-SM-GW23I"	"GTEX-POMQ-1426-SM-GW1ZQ"	"GTEX-R55G-1526-SM-GW1Y7"	"GTEX-RWS6-1026-SM-GW1A1"	"GTEX-S341-0726-SM-GW1Y6"	"GTEX-S4P3-0926-SM-GW1YV"	"GTEX-S4UY-1026-SM-GW23C"	"GTEX-S7SF-1326-SM-GW2BM"	"GTEX-SE5C-0826-SM-GW1GG"	"GTEX-SN8G-2426-SM-GW1GD"	"GTEX-T2IS-2026-SM-GW1ZS"	"GTEX-T5JW-0426-SM-GW1BB"	"GTEX-T6MO-1126-SM-GW18Z"	"GTEX-TML8-0926-SM-GW2AN"	"GTEX-TMMY-1726-SM-GW2C9"	"GTEX-TSE9-2226-SM-GW1VN"	"GTEX-U3ZN-1026-SM-GW1U5"	"GTEX-UJHI-1226-SM-GW1ZL"	"GTEX-W5WG-0926-SM-GW1YX"	"GTEX-WEY5-0626-SM-GW1FH"	"GTEX-WI4N-2526-SM-GW1AM"	"GTEX-WRHU-2026-SM-GW2BC"	"GTEX-WWYW-2726-SM-GW1BC"	"GTEX-WXYG-1426-SM-GW1H5"	"GTEX-WYVS-1526-SM-GW1VM"	"GTEX-X15G-1726-SM-GW1F5"	"GTEX-X4EP-2426-SM-GW23J"	"GTEX-X8HC-2726-SM-GW2AL"	"GTEX-XMD2-2726-SM-GW1ET"	"GTEX-XOT4-2726-SM-GW2B4"	"GTEX-XUJ4-1326-SM-GW1U9"	"GTEX-XUW1-0126-SM-GW29T"	"GTEX-XUZC-1026-SM-GW1CO"	"GTEX-XYKS-1726-SM-GW1Y5"	"GTEX-Y114-1726-SM-GW2BE"	"GTEX-YFC4-2726-SM-GW2C1"	"GTEX-ZAJG-2726-SM-GW1Z2"	"GTEX-ZLWG-0926-SM-GW1GK"	"GTEX-ZP4G-0626-SM-GW1H3"	"GTEX-ZPIC-1426-SM-GW2B6"	"GTEX-ZVT2-0326-SM-GW1B8"	"GTEX-ZVT3-2626-SM-GW1FA"	"GTEX-ZYFG-1726-SM-GW29P"	"GTEX-ZYWO-1926-SM-GW1BL"	"GTEX-ZZPU-2126-SM-GW1YK"	"GTEX-111FC-2026-SM-GW2C2"	"GTEX-117YW-1426-SM-GW24I"	"GTEX-1192X-2126-SM-GW1EQ"	"GTEX-11DYG-2526-SM-GW197"	"GTEX-11NV4-1826-SM-GW29Q"	"GTEX-11ONC-0626-SM-GW1BN"	"GTEX-11TT1-2026-SM-GW1A8"	"GTEX-11UD2-2626-SM-GW2BV"	"GTEX-11WQC-1926-SM-GW1FO"	"GTEX-11WQK-2726-SM-GW1XL"	"GTEX-11ZU8-0526-SM-GW1AE"	"GTEX-11ZUS-2126-SM-GW1ZD"	"GTEX-12696-2226-SM-GW2AG"	"GTEX-12KS4-2526-SM-GW1AD"	"GTEX-12WSA-2426-SM-GW1XF"	"GTEX-12WSE-2526-SM-GW1B5"	"GTEX-12WSF-2526-SM-GW2AW"	"GTEX-12ZZW-2626-SM-GW1A2"	"GTEX-12ZZY-2526-SM-GW1ZO"	"GTEX-13111-1326-SM-GW1V5"	"GTEX-13112-2226-SM-GW1FY"	"GTEX-139TT-1726-SM-GW1G3"	"GTEX-139YR-1326-SM-GW1XY"	"GTEX-13FHP-2726-SM-GW2A8"	"GTEX-13FTW-1226-SM-GW21A"	"GTEX-13IVO-1326-SM-GW19W"	"GTEX-13N1W-2526-SM-GW1FU"	"GTEX-13NYS-1026-SM-GW19Z"	"GTEX-13NZA-2226-SM-GW1FG"	"GTEX-13OW5-2426-SM-GW1AL"	"GTEX-13W46-2826-SM-GW19U"	"GTEX-13X6I-2226-SM-GW2AR"	"GTEX-147GR-2526-SM-GW1AW"	"GTEX-14BMV-2326-SM-GW1T8"	"GTEX-14C39-2226-SM-GW1T7"	"GTEX-14JG1-2426-SM-GW22A"	"GTEX-14PJO-2826-SM-GW1BR"	"GTEX-15CHQ-2826-SM-GW1AQ"	"GTEX-15CHR-1226-SM-GW1AU"	"GTEX-15G1A-1326-SM-GW1TB"	"GTEX-15SKB-2226-SM-GW1BT"	"GTEX-15SZO-2126-SM-GW1AS"	"GTEX-15UKP-0626-SM-GW1SV"	"GTEX-16YQH-2326-SM-GW1UM"	"GTEX-17EVQ-2626-SM-GW1WT"	"GTEX-17HGU-2226-SM-GW22C"	"GTEX-1A3MV-0826-SM-GW1X5"	"GTEX-1B8KE-1026-SM-GW1UF"	"GTEX-1B98T-2626-SM-GW29W"	"GTEX-1CAMQ-2226-SM-GW1T9"	"GTEX-1E2YA-2226-SM-GW1XE"	"GTEX-1F5PK-1126-SM-GW2A4"	"GTEX-1F6IF-0326-SM-GW1BZ"	"GTEX-1F75A-2226-SM-GW1WY"	"GTEX-1F75W-2526-SM-GW1UO"	"GTEX-1GL5R-1226-SM-GW1X2"	"GTEX-1GMR3-1826-SM-GW1BX"	"GTEX-1GN73-1626-SM-GW22G"	"GTEX-1GTWX-2126-SM-GW2A5"	"GTEX-1GZ2Q-2426-SM-GW1WZ"	"GTEX-1H11D-1726-SM-GW24G"	"GTEX-1H1ZS-2226-SM-GW1TQ"	"GTEX-1H3NZ-2826-SM-GW1WL"	"GTEX-1H3VE-2126-SM-GW1UI"	"GTEX-1HR9M-2026-SM-GW1X8"	"GTEX-1HSKV-1726-SM-GW1X4"	"GTEX-1I6K6-2126-SM-GW1X3"	"GTEX-1ICLY-2826-SM-GW1UJ"	"GTEX-1IDJH-2426-SM-GW1AV"	"GTEX-1IGQW-2226-SM-GW1TH"	"GTEX-1IKJJ-2026-SM-GW1TD"	"GTEX-1IKK5-2326-SM-GW2A2"	"GTEX-1IL2U-2826-SM-GW1TN"	"GTEX-1IY9M-2426-SM-GW22N"	"GTEX-1J1R8-0726-SM-GW1UH"	"GTEX-1J8Q3-0926-SM-GW1X9"	"GTEX-RUSQ-1426-SM-GW1YP"	"GTEX-RVPU-1826-SM-GW1XP"	"GTEX-RWSA-2026-SM-GW2BR"	"GTEX-S33H-1826-SM-GW1Y8"	"GTEX-S3XE-1326-SM-GW1W3"	"GTEX-S4Q7-1026-SM-GW1YE"	"GTEX-S7PM-2426-SM-GW29V"	"GTEX-S7SE-2426-SM-GW2BP"	"GTEX-S95S-1026-SM-GW1A5"	"GTEX-SIU8-2226-SM-GW1BI"	"GTEX-SJXC-2026-SM-GW19M"	"GTEX-SNMC-0926-SM-GW1EX"	"GTEX-SNOS-1026-SM-GW22Q"	"GTEX-SUCS-1126-SM-GW1SP"	"GTEX-T8EM-1826-SM-GW2BH"	"GTEX-U3ZH-0926-SM-GW1TY"	"GTEX-U3ZM-0926-SM-GW1ZM"	"GTEX-U412-2026-SM-GW1AI"	"GTEX-U8T8-2126-SM-GW2C6"	"GTEX-UPK5-2526-SM-GW2C4"	"GTEX-UTHO-2726-SM-GW1B3"	"GTEX-WFG8-1826-SM-GW2B1"	"GTEX-WHSE-2826-SM-GW1CM"	"GTEX-WL46-2126-SM-GW1GC"	"GTEX-WOFL-2126-SM-GW1H4"	"GTEX-WQUQ-2726-SM-GW1YT"	"GTEX-WVLH-2826-SM-GW19C"	"GTEX-WY7C-2026-SM-GW1WF"	"GTEX-WYJK-0626-SM-GW1WD"	"GTEX-WZTO-0926-SM-GW1WB"	"GTEX-X261-2226-SM-GW1F6"	"GTEX-X3Y1-1026-SM-GW1UP"	"GTEX-X4XY-2826-SM-GW1FB"	"GTEX-X585-2726-SM-GW19Q"	"GTEX-X62O-2726-SM-GW1EV"	"GTEX-XBED-1826-SM-GW1F8"	"GTEX-XBEW-2226-SM-GW2BG"	"GTEX-XGQ4-1826-SM-GW1BK"	"GTEX-XMD1-2626-SM-GW2BD"	"GTEX-XMK1-1026-SM-GW1G4"	"GTEX-XPT6-1526-SM-GW1W2"	"GTEX-XPVG-2026-SM-GW2AQ"	"GTEX-XQ3S-2526-SM-GW1CJ"	"GTEX-Y111-2326-SM-GW1FN"	"GTEX-YB5E-1826-SM-GW2AC"	"GTEX-YEC3-2226-SM-GW2B9"	"GTEX-YJ89-2726-SM-GW198"	"GTEX-111FC-1926-SM-GW23G"	"GTEX-1192W-2326-SM-GW2AU"	"GTEX-11NV4-1726-SM-GW1ZP"	"GTEX-11TT1-2226-SM-GW2BX"	"GTEX-11UD2-2826-SM-GW23F"	"GTEX-11ZUS-2726-SM-GW1TZ"	"GTEX-1212Z-0326-SM-GW2C5"	"GTEX-12696-0226-SM-GW1XR"	"GTEX-12KS4-0226-SM-GW2AT"	"GTEX-12WSA-0126-SM-GW1YY"	"GTEX-12WSE-0126-SM-GW23K"	"GTEX-12ZZW-0626-SM-GW1F1"	"GTEX-12ZZY-0126-SM-GW1SQ"	"GTEX-13112-0226-SM-GW2AM"	"GTEX-1399R-1626-SM-GW1U7"	"GTEX-139YR-1426-SM-GW1XK"	"GTEX-13FTW-1326-SM-GW1RU"	"GTEX-13NYS-1126-SM-GW1Y4"	"GTEX-13NZA-2526-SM-GW23E"	"GTEX-13O3P-2526-SM-GW1V8"	"GTEX-13OW5-2526-SM-GW19A"	"GTEX-13W46-0126-SM-GW1AN"	"GTEX-147GR-0626-SM-GW1CU"	"GTEX-148VJ-2526-SM-GW1VF"	"GTEX-14C39-0526-SM-GW16B"	"GTEX-14E6D-1226-SM-GW1CS"	"GTEX-15CHQ-2726-SM-GW1VK"	"GTEX-15D1Q-2326-SM-GW21J"	"GTEX-15EU6-2326-SM-GW16L"	"GTEX-15G1A-1526-SM-GW21L"	"GTEX-18465-1526-SM-GW1GT"	"GTEX-1A3MV-0726-SM-GW1V4"	"GTEX-1B98T-0626-SM-GW21S"	"GTEX-1C64N-2826-SM-GW21K"	"GTEX-1CAMQ-2326-SM-GW21R"	"GTEX-1F5PK-1226-SM-GW1V3"	"GTEX-1F6IF-0526-SM-GW1C5"	"GTEX-1GL5R-0826-SM-GW1H2"	"GTEX-1GTWX-2226-SM-GW16F"	"GTEX-1H1ZS-2826-SM-GW1VE"	"GTEX-S33H-0126-SM-GW1ZW"	"GTEX-SIU8-2326-SM-GW1FW"	"GTEX-SNOS-1126-SM-GW1TU"	"GTEX-T8EM-0126-SM-GW23L"	"GTEX-U3ZH-1526-SM-GW1YW"	"GTEX-WOFL-0526-SM-GW221"	"GTEX-X261-2326-SM-GW24K"	"GTEX-X4XX-0726-SM-GW1CG"	"GTEX-X585-0126-SM-GW1EZ"	"GTEX-X62O-0326-SM-GW228"	"GTEX-117YW-0003-SM-GW185"	"GTEX-11DYG-0004-SM-GW225"	"GTEX-11EMC-0004-SM-GW1YF"	"GTEX-11TT1-0001-SM-GW21F"	"GTEX-11ZU8-0002-SM-GW18V"	"GTEX-11ZUS-0003-SM-GW1V6"	"GTEX-12KS4-0003-SM-GW1BP"	"GTEX-12WSA-0001-SM-GW187"	"GTEX-12WSE-0002-SM-GW19L"	"GTEX-12WSI-0004-SM-GW2CP"	"GTEX-12ZZW-0003-SM-GW18R"	"GTEX-12ZZY-0004-SM-GW19K"	"GTEX-139YR-0004-SM-GW1DM"	"GTEX-13NYS-0003-SM-GW1FJ"	"GTEX-13NZA-0003-SM-GW1F3"	"GTEX-13OW5-0003-SM-GW2B3"	"GTEX-13QIC-0004-SM-GW2BL"	"GTEX-13SLX-0003-SM-GW18M"	"GTEX-14A6H-0003-SM-GW21E"	"GTEX-14C39-0004-SM-GW17K"	"GTEX-14E6D-0002-SM-GW17I"	"GTEX-15CHQ-0002-SM-GW21D"	"GTEX-15D1Q-0004-SM-GW17J"	"GTEX-15DDE-0001-SM-GW17D"	"GTEX-15EU6-0003-SM-GW17V"	"GTEX-15SHU-0001-SM-GW17T"	"GTEX-1A3MV-0002-SM-GW17U"	"GTEX-1B98T-0003-SM-GW1CR"	"GTEX-1C64N-0003-SM-GW1CV"	"GTEX-1CAMQ-0003-SM-GW1ZX"	"GTEX-1GMR3-0001-SM-GW1BQ"	"GTEX-1GTWX-0001-SM-GW1GR"	"GTEX-1H1ZS-0002-SM-GW1AK"	"GTEX-1H3VE-0001-SM-GW18P"	"GTEX-1I6K6-0004-SM-GW1DL"	"GTEX-1J1R8-0004-SM-GW22Y"	"GTEX-SNOS-0004-SM-GW1FF"	"GTEX-U3ZH-0003-SM-GW1FM"	"GTEX-U3ZM-0004-SM-GW1C4"	"GTEX-U8XE-0004-SM-GW1FI"	"GTEX-WFG8-0004-SM-GW21G"	"GTEX-WH7G-0004-SM-GW17G"	"GTEX-WRHU-0003-SM-GW18B"	"GTEX-WWYW-0004-SM-GW17Q"	"GTEX-X261-0002-SM-GW17B"	"GTEX-X4EP-0002-SM-GW17R"	"GTEX-X4XX-0004-SM-GW17N"	"GTEX-X585-0003-SM-GW17P"	"GTEX-X5EB-0001-SM-GW17Y"	"GTEX-XMK1-0003-SM-GW2B7"	"GTEX-XPT6-0004-SM-GW1DN"	"GTEX-YFC4-0001-SM-GW1YL"	"GTEX-YFCO-0001-SM-GW29R"	"GTEX-ZAB4-0001-SM-GW24D"
!Sample_geo_accession	"GSM6586938"	"GSM6586939"	"GSM6586940"	"GSM6586941"	"GSM6586942"	"GSM6586943"	"GSM6586944"	"GSM6586945"	"GSM6586946"	"GSM6586947"	"GSM6586948"	"GSM6586949"	"GSM6586950"	"GSM6586951"	"GSM6586952"	"GSM6586953"	"GSM6586954"	"GSM6586955"	"GSM6586956"	"GSM6586957"	"GSM6586958"	"GSM6586959"	"GSM6586960"	"GSM6586961"	"GSM6586962"	"GSM6586963"	"GSM6586964"	"GSM6586965"	"GSM6586966"	"GSM6586967"	"GSM6586968"	"GSM6586969"	"GSM6586970"	"GSM6586971"	"GSM6586972"	"GSM6586973"	"GSM6586974"	"GSM6586975"	"GSM6586976"	"GSM6586977"	"GSM6586978"	"GSM6586979"	"GSM6586980"	"GSM6586981"	"GSM6586982"	"GSM6586983"	"GSM6586984"	"GSM6586985"	"GSM6586986"	"GSM6586987"	"GSM6586988"	"GSM6586989"	"GSM6586990"	"GSM6586991"	"GSM6586992"	"GSM6586993"	"GSM6586994"	"GSM6586995"	"GSM6586996"	"GSM6586997"	"GSM6586998"	"GSM6586999"	"GSM6587000"	"GSM6587001"	"GSM6587002"	"GSM6587003"	"GSM6587004"	"GSM6587005"	"GSM6587006"	"GSM6587007"	"GSM6587008"	"GSM6587009"	"GSM6587010"	"GSM6587011"	"GSM6587012"	"GSM6587013"	"GSM6587014"	"GSM6587015"	"GSM6587016"	"GSM6587017"	"GSM6587018"	"GSM6587019"	"GSM6587020"	"GSM6587021"	"GSM6587022"	"GSM6587023"	"GSM6587024"	"GSM6587025"	"GSM6587026"	"GSM6587027"	"GSM6587028"	"GSM6587029"	"GSM6587030"	"GSM6587031"	"GSM6587032"	"GSM6587033"	"GSM6587034"	"GSM6587035"	"GSM6587036"	"GSM6587037"	"GSM6587038"	"GSM6587039"	"GSM6587040"	"GSM6587041"	"GSM6587042"	"GSM6587043"	"GSM6587044"	"GSM6587045"	"GSM6587046"	"GSM6587047"	"GSM6587048"	"GSM6587049"	"GSM6587050"	"GSM6587051"	"GSM6587052"	"GSM6587053"	"GSM6587054"	"GSM6587055"	"GSM6587056"	"GSM6587057"	"GSM6587058"	"GSM6587059"	"GSM6587060"	"GSM6587061"	"GSM6587062"	"GSM6587063"	"GSM6587064"	"GSM6587065"	"GSM6587066"	"GSM6587067"	"GSM6587068"	"GSM6587069"	"GSM6587070"	"GSM6587071"	"GSM6587072"	"GSM6587073"	"GSM6587074"	"GSM6587075"	"GSM6587076"	"GSM6587077"	"GSM6587078"	"GSM6587079"	"GSM6587080"	"GSM6587081"	"GSM6587082"	"GSM6587083"	"GSM6587084"	"GSM6587085"	"GSM6587086"	"GSM6587087"	"GSM6587088"	"GSM6587089"	"GSM6587090"	"GSM6587091"	"GSM6587092"	"GSM6587093"	"GSM6587094"	"GSM6587095"	"GSM6587096"	"GSM6587097"	"GSM6587098"	"GSM6587099"	"GSM6587100"	"GSM6587101"	"GSM6587102"	"GSM6587103"	"GSM6587104"	"GSM6587105"	"GSM6587106"	"GSM6587107"	"GSM6587108"	"GSM6587109"	"GSM6587110"	"GSM6587111"	"GSM6587112"	"GSM6587113"	"GSM6587114"	"GSM6587115"	"GSM6587116"	"GSM6587117"	"GSM6587118"	"GSM6587119"	"GSM6587120"	"GSM6587121"	"GSM6587122"	"GSM6587123"	"GSM6587124"	"GSM6587125"	"GSM6587126"	"GSM6587127"	"GSM6587128"	"GSM6587129"	"GSM6587130"	"GSM6587131"	"GSM6587132"	"GSM6587133"	"GSM6587134"	"GSM6587135"	"GSM6587136"	"GSM6587137"	"GSM6587138"	"GSM6587139"	"GSM6587140"	"GSM6587141"	"GSM6587142"	"GSM6587143"	"GSM6587144"	"GSM6587145"	"GSM6587146"	"GSM6587147"	"GSM6587148"	"GSM6587149"	"GSM6587150"	"GSM6587151"	"GSM6587152"	"GSM6587153"	"GSM6587154"	"GSM6587155"	"GSM6587156"	"GSM6587157"	"GSM6587158"	"GSM6587159"	"GSM6587160"	"GSM6587161"	"GSM6587162"	"GSM6587163"	"GSM6587164"	"GSM6587165"	"GSM6587166"	"GSM6587167"	"GSM6587168"	"GSM6587169"	"GSM6587170"	"GSM6587171"	"GSM6587172"	"GSM6587173"	"GSM6587174"	"GSM6587175"	"GSM6587176"	"GSM6587177"	"GSM6587178"	"GSM6587179"	"GSM6587180"	"GSM6587181"	"GSM6587182"	"GSM6587183"	"GSM6587184"	"GSM6587185"	"GSM6587186"	"GSM6587187"	"GSM6587188"	"GSM6587189"	"GSM6587190"	"GSM6587191"	"GSM6587192"	"GSM6587193"	"GSM6587194"	"GSM6587195"	"GSM6587196"	"GSM6587197"	"GSM6587198"	"GSM6587199"	"GSM6587200"	"GSM6587201"	"GSM6587202"	"GSM6587203"	"GSM6587204"	"GSM6587205"	"GSM6587206"	"GSM6587207"	"GSM6587208"	"GSM6587209"	"GSM6587210"	"GSM6587211"	"GSM6587212"	"GSM6587213"	"GSM6587214"	"GSM6587215"	"GSM6587216"	"GSM6587217"	"GSM6587218"	"GSM6587219"	"GSM6587220"	"GSM6587221"	"GSM6587222"	"GSM6587223"	"GSM6587224"	"GSM6587225"	"GSM6587226"	"GSM6587227"	"GSM6587228"	"GSM6587229"	"GSM6587230"	"GSM6587231"	"GSM6587232"	"GSM6587233"	"GSM6587234"	"GSM6587235"	"GSM6587236"	"GSM6587237"	"GSM6587238"	"GSM6587239"	"GSM6587240"	"GSM6587241"	"GSM6587242"	"GSM6587243"	"GSM6587244"	"GSM6587245"	"GSM6587246"	"GSM6587247"	"GSM6587248"	"GSM6587249"	"GSM6587250"	"GSM6587251"	"GSM6587252"	"GSM6587253"	"GSM6587254"	"GSM6587255"	"GSM6587256"	"GSM6587257"	"GSM6587258"	"GSM6587259"	"GSM6587260"	"GSM6587261"	"GSM6587262"	"GSM6587263"	"GSM6587264"	"GSM6587265"	"GSM6587266"	"GSM6587267"	"GSM6587268"	"GSM6587269"	"GSM6587270"	"GSM6587271"	"GSM6587272"	"GSM6587273"	"GSM6587274"	"GSM6587275"	"GSM6587276"	"GSM6587277"	"GSM6587278"	"GSM6587279"	"GSM6587280"	"GSM6587281"	"GSM6587282"	"GSM6587283"	"GSM6587284"	"GSM6587285"	"GSM6587286"	"GSM6587287"	"GSM6587288"	"GSM6587289"	"GSM6587290"	"GSM6587291"	"GSM6587292"	"GSM6587293"	"GSM6587294"	"GSM6587295"	"GSM6587296"	"GSM6587297"	"GSM6587298"	"GSM6587299"	"GSM6587300"	"GSM6587301"	"GSM6587302"	"GSM6587303"	"GSM6587304"	"GSM6587305"	"GSM6587306"	"GSM6587307"	"GSM6587308"	"GSM6587309"	"GSM6587310"	"GSM6587311"	"GSM6587312"	"GSM6587313"	"GSM6587314"	"GSM6587315"	"GSM6587316"	"GSM6587317"	"GSM6587318"	"GSM6587319"	"GSM6587320"	"GSM6587321"	"GSM6587322"	"GSM6587323"	"GSM6587324"	"GSM6587325"	"GSM6587326"	"GSM6587327"	"GSM6587328"	"GSM6587329"	"GSM6587330"	"GSM6587331"	"GSM6587332"	"GSM6587333"	"GSM6587334"	"GSM6587335"	"GSM6587336"	"GSM6587337"	"GSM6587338"	"GSM6587339"	"GSM6587340"	"GSM6587341"	"GSM6587342"	"GSM6587343"	"GSM6587344"	"GSM6587345"	"GSM6587346"	"GSM6587347"	"GSM6587348"	"GSM6587349"	"GSM6587350"	"GSM6587351"	"GSM6587352"	"GSM6587353"	"GSM6587354"	"GSM6587355"	"GSM6587356"	"GSM6587357"	"GSM6587358"	"GSM6587359"	"GSM6587360"	"GSM6587361"	"GSM6587362"	"GSM6587363"	"GSM6587364"	"GSM6587365"	"GSM6587366"	"GSM6587367"	"GSM6587368"	"GSM6587369"	"GSM6587370"	"GSM6587371"	"GSM6587372"	"GSM6587373"	"GSM6587374"	"GSM6587375"	"GSM6587376"	"GSM6587377"	"GSM6587378"	"GSM6587379"	"GSM6587380"	"GSM6587381"	"GSM6587382"	"GSM6587383"	"GSM6587384"	"GSM6587385"	"GSM6587386"	"GSM6587387"	"GSM6587388"	"GSM6587389"	"GSM6587390"	"GSM6587391"	"GSM6587392"	"GSM6587393"	"GSM6587394"	"GSM6587395"	"GSM6587396"	"GSM6587397"	"GSM6587398"	"GSM6587399"	"GSM6587400"	"GSM6587401"	"GSM6587402"	"GSM6587403"	"GSM6587404"	"GSM6587405"	"GSM6587406"	"GSM6587407"	"GSM6587408"	"GSM6587409"	"GSM6587410"	"GSM6587411"	"GSM6587412"	"GSM6587413"	"GSM6587414"	"GSM6587415"	"GSM6587416"	"GSM6587417"	"GSM6587418"	"GSM6587419"	"GSM6587420"	"GSM6587421"	"GSM6587422"	"GSM6587423"	"GSM6587424"	"GSM6587425"	"GSM6587426"	"GSM6587427"	"GSM6587428"	"GSM6587429"	"GSM6587430"	"GSM6587431"	"GSM6587432"	"GSM6587433"	"GSM6587434"	"GSM6587435"	"GSM6587436"	"GSM6587437"	"GSM6587438"	"GSM6587439"	"GSM6587440"	"GSM6587441"	"GSM6587442"	"GSM6587443"	"GSM6587444"	"GSM6587445"	"GSM6587446"	"GSM6587447"	"GSM6587448"	"GSM6587449"	"GSM6587450"	"GSM6587451"	"GSM6587452"	"GSM6587453"	"GSM6587454"	"GSM6587455"	"GSM6587456"	"GSM6587457"	"GSM6587458"	"GSM6587459"	"GSM6587460"	"GSM6587461"	"GSM6587462"	"GSM6587463"	"GSM6587464"	"GSM6587465"	"GSM6587466"	"GSM6587467"	"GSM6587468"	"GSM6587469"	"GSM6587470"	"GSM6587471"	"GSM6587472"	"GSM6587473"	"GSM6587474"	"GSM6587475"	"GSM6587476"	"GSM6587477"	"GSM6587478"	"GSM6587479"	"GSM6587480"	"GSM6587481"	"GSM6587482"	"GSM6587483"	"GSM6587484"	"GSM6587485"	"GSM6587486"	"GSM6587487"	"GSM6587488"	"GSM6587489"	"GSM6587490"	"GSM6587491"	"GSM6587492"	"GSM6587493"	"GSM6587494"	"GSM6587495"	"GSM6587496"	"GSM6587497"	"GSM6587498"	"GSM6587499"	"GSM6587500"	"GSM6587501"	"GSM6587502"	"GSM6587503"	"GSM6587504"	"GSM6587505"	"GSM6587506"	"GSM6587507"	"GSM6587508"	"GSM6587509"	"GSM6587510"	"GSM6587511"	"GSM6587512"	"GSM6587513"	"GSM6587514"	"GSM6587515"	"GSM6587516"	"GSM6587517"	"GSM6587518"	"GSM6587519"	"GSM6587520"	"GSM6587521"	"GSM6587522"	"GSM6587523"	"GSM6587524"	"GSM6587525"	"GSM6587526"	"GSM6587527"	"GSM6587528"	"GSM6587529"	"GSM6587530"	"GSM6587531"	"GSM6587532"	"GSM6587533"	"GSM6587534"	"GSM6587535"	"GSM6587536"	"GSM6587537"	"GSM6587538"	"GSM6587539"	"GSM6587540"	"GSM6587541"	"GSM6587542"	"GSM6587543"	"GSM6587544"	"GSM6587545"	"GSM6587546"	"GSM6587547"	"GSM6587548"	"GSM6587549"	"GSM6587550"	"GSM6587551"	"GSM6587552"	"GSM6587553"	"GSM6587554"	"GSM6587555"	"GSM6587556"	"GSM6587557"	"GSM6587558"	"GSM6587559"	"GSM6587560"	"GSM6587561"	"GSM6587562"	"GSM6587563"	"GSM6587564"	"GSM6587565"	"GSM6587566"	"GSM6587567"	"GSM6587568"	"GSM6587569"	"GSM6587570"	"GSM6587571"	"GSM6587572"	"GSM6587573"	"GSM6587574"	"GSM6587575"	"GSM6587576"	"GSM6587577"	"GSM6587578"	"GSM6587579"	"GSM6587580"	"GSM6587581"	"GSM6587582"	"GSM6587583"	"GSM6587584"	"GSM6587585"	"GSM6587586"	"GSM6587587"	"GSM6587588"	"GSM6587589"	"GSM6587590"	"GSM6587591"	"GSM6587592"	"GSM6587593"	"GSM6587594"	"GSM6587595"	"GSM6587596"	"GSM6587597"	"GSM6587598"	"GSM6587599"	"GSM6587600"	"GSM6587601"	"GSM6587602"	"GSM6587603"	"GSM6587604"	"GSM6587605"	"GSM6587606"	"GSM6587607"	"GSM6587608"	"GSM6587609"	"GSM6587610"	"GSM6587611"	"GSM6587612"	"GSM6587613"	"GSM6587614"	"GSM6587615"	"GSM6587616"	"GSM6587617"	"GSM6587618"	"GSM6587619"	"GSM6587620"	"GSM6587621"	"GSM6587622"	"GSM6587623"	"GSM6587624"	"GSM6587625"	"GSM6587626"	"GSM6587627"	"GSM6587628"	"GSM6587629"	"GSM6587630"	"GSM6587631"	"GSM6587632"	"GSM6587633"	"GSM6587634"	"GSM6587635"	"GSM6587636"	"GSM6587637"	"GSM6587638"	"GSM6587639"	"GSM6587640"	"GSM6587641"	"GSM6587642"	"GSM6587643"	"GSM6587644"	"GSM6587645"	"GSM6587646"	"GSM6587647"	"GSM6587648"	"GSM6587649"	"GSM6587650"	"GSM6587651"	"GSM6587652"	"GSM6587653"	"GSM6587654"	"GSM6587655"	"GSM6587656"	"GSM6587657"	"GSM6587658"	"GSM6587659"	"GSM6587660"	"GSM6587661"	"GSM6587662"	"GSM6587663"	"GSM6587664"	"GSM6587665"	"GSM6587666"	"GSM6587667"	"GSM6587668"	"GSM6587669"	"GSM6587670"	"GSM6587671"	"GSM6587672"	"GSM6587673"	"GSM6587674"	"GSM6587675"	"GSM6587676"	"GSM6587677"	"GSM6587678"	"GSM6587679"	"GSM6587680"	"GSM6587681"	"GSM6587682"	"GSM6587683"	"GSM6587684"	"GSM6587685"	"GSM6587686"	"GSM6587687"	"GSM6587688"	"GSM6587689"	"GSM6587690"	"GSM6587691"	"GSM6587692"	"GSM6587693"	"GSM6587694"	"GSM6587695"	"GSM6587696"	"GSM6587697"	"GSM6587698"	"GSM6587699"	"GSM6587700"	"GSM6587701"	"GSM6587702"	"GSM6587703"	"GSM6587704"	"GSM6587705"	"GSM6587706"	"GSM6587707"	"GSM6587708"	"GSM6587709"	"GSM6587710"	"GSM6587711"	"GSM6587712"	"GSM6587713"	"GSM6587714"	"GSM6587715"	"GSM6587716"	"GSM6587717"	"GSM6587718"	"GSM6587719"	"GSM6587720"	"GSM6587721"	"GSM6587722"	"GSM6587723"	"GSM6587724"	"GSM6587725"	"GSM6587726"	"GSM6587727"	"GSM6587728"	"GSM6587729"	"GSM6587730"	"GSM6587731"	"GSM6587732"	"GSM6587733"	"GSM6587734"	"GSM6587735"	"GSM6587736"	"GSM6587737"	"GSM6587738"	"GSM6587739"	"GSM6587740"	"GSM6587741"	"GSM6587742"	"GSM6587743"	"GSM6587744"	"GSM6587745"	"GSM6587746"	"GSM6587747"	"GSM6587748"	"GSM6587749"	"GSM6587750"	"GSM6587751"	"GSM6587752"	"GSM6587753"	"GSM6587754"	"GSM6587755"	"GSM6587756"	"GSM6587757"	"GSM6587758"	"GSM6587759"	"GSM6587760"	"GSM6587761"	"GSM6587762"	"GSM6587763"	"GSM6587764"	"GSM6587765"	"GSM6587766"	"GSM6587767"	"GSM6587768"	"GSM6587769"	"GSM6587770"	"GSM6587771"	"GSM6587772"	"GSM6587773"	"GSM6587774"	"GSM6587775"	"GSM6587776"	"GSM6587777"	"GSM6587778"	"GSM6587779"	"GSM6587780"	"GSM6587781"	"GSM6587782"	"GSM6587783"	"GSM6587784"	"GSM6587785"	"GSM6587786"	"GSM6587787"	"GSM6587788"	"GSM6587789"	"GSM6587790"	"GSM6587791"	"GSM6587792"	"GSM6587793"	"GSM6587794"	"GSM6587795"	"GSM6587796"	"GSM6587797"	"GSM6587798"	"GSM6587799"	"GSM6587800"	"GSM6587801"	"GSM6587802"	"GSM6587803"	"GSM6587804"	"GSM6587805"	"GSM6587806"	"GSM6587807"	"GSM6587808"	"GSM6587809"	"GSM6587810"	"GSM6587811"	"GSM6587812"	"GSM6587813"	"GSM6587814"	"GSM6587815"	"GSM6587816"	"GSM6587817"	"GSM6587818"	"GSM6587819"	"GSM6587820"	"GSM6587821"	"GSM6587822"	"GSM6587823"	"GSM6587824"	"GSM6587825"	"GSM6587826"	"GSM6587827"	"GSM6587828"	"GSM6587829"	"GSM6587830"	"GSM6587831"	"GSM6587832"	"GSM6587833"	"GSM6587834"	"GSM6587835"	"GSM6587836"	"GSM6587837"	"GSM6587838"	"GSM6587839"	"GSM6587840"	"GSM6587841"	"GSM6587842"	"GSM6587843"	"GSM6587844"	"GSM6587845"	"GSM6587846"	"GSM6587847"	"GSM6587848"	"GSM6587849"	"GSM6587850"	"GSM6587851"	"GSM6587852"	"GSM6587853"	"GSM6587854"	"GSM6587855"	"GSM6587856"	"GSM6587857"	"GSM6587858"	"GSM6587859"	"GSM6587860"	"GSM6587861"	"GSM6587862"	"GSM6587863"	"GSM6587864"	"GSM6587865"	"GSM6587866"	"GSM6587867"	"GSM6587868"	"GSM6587869"	"GSM6587870"	"GSM6587871"	"GSM6587872"	"GSM6587873"	"GSM6587874"	"GSM6587875"	"GSM6587876"	"GSM6587877"	"GSM6587878"	"GSM6587879"	"GSM6587880"	"GSM6587881"	"GSM6587882"	"GSM6587883"	"GSM6587884"	"GSM6587885"	"GSM6587886"	"GSM6587887"	"GSM6587888"	"GSM6587889"	"GSM6587890"	"GSM6587891"	"GSM6587892"	"GSM6587893"	"GSM6587894"	"GSM6587895"	"GSM6587896"	"GSM6587897"	"GSM6587898"	"GSM6587899"	"GSM6587900"	"GSM6587901"	"GSM6587902"	"GSM6587903"	"GSM6587904"	"GSM6587905"	"GSM6587906"	"GSM6587907"	"GSM6587908"	"GSM6587909"	"GSM6587910"	"GSM6587911"	"GSM6587912"	"GSM6587913"	"GSM6587914"	"GSM6587915"	"GSM6587916"	"GSM6587917"	"GSM6587918"	"GSM6587919"	"GSM6587920"	"GSM6587921"	"GSM6587922"	"GSM6587923"	"GSM6587924"
!Sample_status	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"	"Public on Sep 16 2022"
!Sample_submission_date	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"	"Sep 15 2022"
!Sample_last_update_date	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"	"Sep 16 2022"
!Sample_type	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"	"genomic"
!Sample_channel_count	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"	"1"
!Sample_source_name_ch1	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Breast - Mammary Tissue"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Colon - Transverse"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Kidney - Cortex"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Lung"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Muscle - Skeletal"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Ovary"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Prostate"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Testis"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"	"Whole Blood"
!Sample_organism_ch1	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"	"Homo sapiens"
!Sample_characteristics_ch1	"sample_plate: CO-25654826"	"sample_plate: CO-25654826"	"sample_plate: CO-25654826"	"sample_plate: CO-25654153"	"sample_plate: CO-25654823"	"sample_plate: CO-25654153"	"sample_plate: CO-25654823"	"sample_plate: CO-25654824"	"sample_plate: CO-25654153"	"sample_plate: CO-25654154"	"sample_plate: CO-25655788"	"sample_plate: CO-25654822"	"sample_plate: CO-25654825"	"sample_plate: CO-25654822"	"sample_plate: CO-25654825"	"sample_plate: CO-25654822"	"sample_plate: CO-25654824"	"sample_plate: CO-25654822"	"sample_plate: CO-25654825"	"sample_plate: CO-25654823"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654153"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654152"	"sample_plate: CO-25654153"	"sample_plate: CO-25654153"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654154"	"sample_plate: CO-25654823"	"sample_plate: CO-25654826"	"sample_plate: CO-25655788"	"sample_plate: CO-25654154"	"sample_plate: CO-25654825"	"sample_plate: CO-25654823"	"sample_plate: CO-25654823"	"sample_plate: CO-25654154"	"sample_plate: CO-25654823"	"sample_plate: CO-25654153"	"sample_plate: CO-25655788"	"sample_plate: CO-25655788"	"sample_plate: CO-25654153"	"sample_plate: CO-25654824"	"sample_plate: CO-25654823"	"sample_plate: CO-25654154"	"sample_plate: CO-25655788"	"sample_plate: CO-25654154"	"sample_plate: CO-25655788"	"sample_plate: CO-25654824"	"sample_plate: CO-25654826"	"sample_plate: CO-25655788"	"sample_plate: CO-25654826"	"sample_plate: CO-25654154"	"sample_plate: CO-25654823"	"sample_plate: CO-25654154"	"sample_plate: CO-25654826"	"sample_plate: CO-25654826"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25654825"	"sample_plate: CO-25654824"	"sample_plate: CO-25654152"	"sample_plate: CO-25654826"	"sample_plate: CO-25654152"	"sample_plate: CO-25654825"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25654825"	"sample_plate: CO-25654823"	"sample_plate: CO-25654825"	"sample_plate: CO-25654152"	"sample_plate: CO-25654152"	"sample_plate: CO-25654823"	"sample_plate: CO-25654154"	"sample_plate: CO-25654152"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25655788"	"sample_plate: CO-25654826"	"sample_plate: CO-25654825"	"sample_plate: CO-25654823"	"sample_plate: CO-25654826"	"sample_plate: CO-25654825"	"sample_plate: CO-25654154"	"sample_plate: CO-25654826"	"sample_plate: CO-25654154"	"sample_plate: CO-25654154"	"sample_plate: CO-25654152"	"sample_plate: CO-25654152"	"sample_plate: CO-25654823"	"sample_plate: CO-25654825"	"sample_plate: CO-25654822"	"sample_plate: CO-25654826"	"sample_plate: CO-25655788"	"sample_plate: CO-25654826"	"sample_plate: CO-25654154"	"sample_plate: CO-25654825"	"sample_plate: CO-25654823"	"sample_plate: CO-25654152"	"sample_plate: CO-25654823"	"sample_plate: CO-25654823"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654823"	"sample_plate: CO-25654823"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654153"	"sample_plate: CO-25654824"	"sample_plate: CO-25654153"	"sample_plate: CO-25654152"	"sample_plate: CO-25654153"	"sample_plate: CO-25654824"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654824"	"sample_plate: CO-25654823"	"sample_plate: CO-25654153"	"sample_plate: CO-25654826"	"sample_plate: CO-25654822"	"sample_plate: CO-25654823"	"sample_plate: CO-25654822"	"sample_plate: CO-25654153"	"sample_plate: CO-25654153"	"sample_plate: CO-25654153"	"sample_plate: CO-25654153"	"sample_plate: CO-25654153"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654153"	"sample_plate: CO-25654153"	"sample_plate: CO-25654826"	"sample_plate: CO-25654822"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654154"	"sample_plate: CO-25654822"	"sample_plate: CO-25654826"	"sample_plate: CO-25654153"	"sample_plate: CO-25654153"	"sample_plate: CO-25654154"	"sample_plate: CO-25654823"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654823"	"sample_plate: CO-25654822"	"sample_plate: CO-25654823"	"sample_plate: CO-25654822"	"sample_plate: CO-25654826"	"sample_plate: CO-25654826"	"sample_plate: CO-25654826"	"sample_plate: CO-25654153"	"sample_plate: CO-25654824"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654152"	"sample_plate: CO-25654823"	"sample_plate: CO-25654824"	"sample_plate: CO-25655788"	"sample_plate: CO-25654153"	"sample_plate: CO-25654823"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654823"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654153"	"sample_plate: CO-25654154"	"sample_plate: CO-25654824"	"sample_plate: CO-25654824"	"sample_plate: CO-25654822"	"sample_plate: CO-25654826"	"sample_plate: CO-25654822"	"sample_plate: CO-25654823"	"sample_plate: CO-25654824"	"sample_plate: CO-25654153"	"sample_plate: CO-25654823"	"sample_plate: CO-25654822"	"sample_plate: CO-25654154"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654824"	"sample_plate: CO-25654154"	"sample_plate: CO-25654154"	"sample_plate: CO-25654824"	"sample_plate: CO-25655788"	"sample_plate: CO-25654822"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654823"	"sample_plate: CO-25654825"	"sample_plate: CO-25654153"	"sample_plate: CO-25655789"	"sample_plate: CO-25655789"	"sample_plate: CO-25654151"	"sample_plate: CO-25654154"	"sample_plate: CO-25654824"	"sample_plate: CO-25654154"	"sample_plate: CO-25654825"	"sample_plate: CO-25654152"	"sample_plate: CO-25654825"	"sample_plate: CO-25654826"	"sample_plate: CO-25654152"	"sample_plate: CO-25654824"	"sample_plate: CO-25654823"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25654826"	"sample_plate: CO-25654825"	"sample_plate: CO-25654825"	"sample_plate: CO-25654152"	"sample_plate: CO-25654152"	"sample_plate: CO-25654826"	"sample_plate: CO-25654823"	"sample_plate: CO-25654825"	"sample_plate: CO-25654152"	"sample_plate: CO-25654152"	"sample_plate: CO-25654825"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25654825"	"sample_plate: CO-25655788"	"sample_plate: CO-25654154"	"sample_plate: CO-25654152"	"sample_plate: CO-25654154"	"sample_plate: CO-25654825"	"sample_plate: CO-25654825"	"sample_plate: CO-25654825"	"sample_plate: CO-25654825"	"sample_plate: CO-25654154"	"sample_plate: CO-25654824"	"sample_plate: CO-25655788"	"sample_plate: CO-25654154"	"sample_plate: CO-25654826"	"sample_plate: CO-25655788"	"sample_plate: CO-25654153"	"sample_plate: CO-25654826"	"sample_plate: CO-25654826"	"sample_plate: CO-25654826"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25654154"	"sample_plate: CO-25654824"	"sample_plate: CO-25654826"	"sample_plate: CO-25655788"	"sample_plate: CO-25654826"	"sample_plate: CO-25655788"	"sample_plate: CO-25654153"	"sample_plate: CO-25654824"	"sample_plate: CO-25654824"	"sample_plate: CO-25654154"	"sample_plate: CO-25654825"	"sample_plate: CO-25654152"	"sample_plate: CO-25654152"	"sample_plate: CO-25654825"	"sample_plate: CO-25654823"	"sample_plate: CO-25654154"	"sample_plate: CO-25654154"	"sample_plate: CO-25654826"	"sample_plate: CO-25654824"	"sample_plate: CO-25654823"	"sample_plate: CO-25654826"	"sample_plate: CO-25654154"	"sample_plate: CO-25654826"	"sample_plate: CO-25654823"	"sample_plate: CO-25654152"	"sample_plate: CO-25654154"	"sample_plate: CO-25654823"	"sample_plate: CO-25654825"	"sample_plate: CO-25654825"	"sample_plate: CO-25654154"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25654826"	"sample_plate: CO-25654826"	"sample_plate: CO-25655788"	"sample_plate: CO-25654154"	"sample_plate: CO-25654826"	"sample_plate: CO-25654152"	"sample_plate: CO-25654154"	"sample_plate: CO-25654154"	"sample_plate: CO-25655788"	"sample_plate: CO-25654824"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25654826"	"sample_plate: CO-25654154"	"sample_plate: CO-25655788"	"sample_plate: CO-25654825"	"sample_plate: CO-25654826"	"sample_plate: CO-25654826"	"sample_plate: CO-25654826"	"sample_plate: CO-25654823"	"sample_plate: CO-25654826"	"sample_plate: CO-25654823"	"sample_plate: CO-25654823"	"sample_plate: CO-25655788"	"sample_plate: CO-25654826"	"sample_plate: CO-25654826"	"sample_plate: CO-25654152"	"sample_plate: CO-25654154"	"sample_plate: CO-25654825"	"sample_plate: CO-25654152"	"sample_plate: CO-25654825"	"sample_plate: CO-25654825"	"sample_plate: CO-25655788"	"sample_plate: CO-25654153"	"sample_plate: CO-25654826"	"sample_plate: CO-25654152"	"sample_plate: CO-25654826"	"sample_plate: CO-25655789"	"sample_plate: CO-25654154"	"sample_plate: CO-25654826"	"sample_plate: CO-25654152"	"sample_plate: CO-25654826"	"sample_plate: CO-25654824"	"sample_plate: CO-25655789"	"sample_plate: CO-25654826"	"sample_plate: CO-25654151"	"sample_plate: CO-25654152"	"sample_plate: CO-25655789"	"sample_plate: CO-25654152"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25654823"	"sample_plate: CO-25654823"	"sample_plate: CO-25654151"	"sample_plate: CO-25654825"	"sample_plate: CO-25654826"	"sample_plate: CO-25654151"	"sample_plate: CO-25654825"	"sample_plate: CO-25654823"	"sample_plate: CO-25654824"	"sample_plate: CO-25654154"	"sample_plate: CO-25654154"	"sample_plate: CO-25655788"	"sample_plate: CO-25654154"	"sample_plate: CO-25654824"	"sample_plate: CO-25654824"	"sample_plate: CO-25654823"	"sample_plate: CO-25654824"	"sample_plate: CO-25654823"	"sample_plate: CO-25654823"	"sample_plate: CO-25654823"	"sample_plate: CO-25654823"	"sample_plate: CO-25654151"	"sample_plate: CO-25654152"	"sample_plate: CO-25654825"	"sample_plate: CO-25654822"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25655789"	"sample_plate: CO-25654153"	"sample_plate: CO-25654824"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654822"	"sample_plate: CO-25654824"	"sample_plate: CO-25654153"	"sample_plate: CO-25654825"	"sample_plate: CO-25654153"	"sample_plate: CO-25654153"	"sample_plate: CO-25654153"	"sample_plate: CO-25654151"	"sample_plate: CO-25654822"	"sample_plate: CO-25654153"	"sample_plate: CO-25655789"	"sample_plate: CO-25654822"	"sample_plate: CO-25654153"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25655789"	"sample_plate: CO-25654153"	"sample_plate: CO-25654825"	"sample_plate: CO-25654823"	"sample_plate: CO-25654151"	"sample_plate: CO-25654153"	"sample_plate: CO-25654154"	"sample_plate: CO-25655789"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25655789"	"sample_plate: CO-25654824"	"sample_plate: CO-25654826"	"sample_plate: CO-25654153"	"sample_plate: CO-25655789"	"sample_plate: CO-25654151"	"sample_plate: CO-25654822"	"sample_plate: CO-25654826"	"sample_plate: CO-25654153"	"sample_plate: CO-25655788"	"sample_plate: CO-25654822"	"sample_plate: CO-25654824"	"sample_plate: CO-25654822"	"sample_plate: CO-25655789"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654154"	"sample_plate: CO-25654153"	"sample_plate: CO-25654153"	"sample_plate: CO-25654823"	"sample_plate: CO-25654822"	"sample_plate: CO-25655788"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654151"	"sample_plate: CO-25654824"	"sample_plate: CO-25654153"	"sample_plate: CO-25655789"	"sample_plate: CO-25655789"	"sample_plate: CO-25654823"	"sample_plate: CO-25654153"	"sample_plate: CO-25654824"	"sample_plate: CO-25654153"	"sample_plate: CO-25654151"	"sample_plate: CO-25655789"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654824"	"sample_plate: CO-25654153"	"sample_plate: CO-25654824"	"sample_plate: CO-25655789"	"sample_plate: CO-25655789"	"sample_plate: CO-25654824"	"sample_plate: CO-25654153"	"sample_plate: CO-25654151"	"sample_plate: CO-25655789"	"sample_plate: CO-25654824"	"sample_plate: CO-25654823"	"sample_plate: CO-25654153"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654153"	"sample_plate: CO-25654826"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654823"	"sample_plate: CO-25654824"	"sample_plate: CO-25655789"	"sample_plate: CO-25655789"	"sample_plate: CO-25654822"	"sample_plate: CO-25655789"	"sample_plate: CO-25654151"	"sample_plate: CO-25655789"	"sample_plate: CO-25655789"	"sample_plate: CO-25655789"	"sample_plate: CO-25655789"	"sample_plate: CO-25655789"	"sample_plate: CO-25655789"	"sample_plate: CO-25655789"	"sample_plate: CO-25655789"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654824"	"sample_plate: CO-25654825"	"sample_plate: CO-25655789"	"sample_plate: CO-25655789"	"sample_plate: CO-25655789"	"sample_plate: CO-25654824"	"sample_plate: CO-25654151"	"sample_plate: CO-25654824"	"sample_plate: CO-25655789"	"sample_plate: CO-25654151"	"sample_plate: CO-25655789"	"sample_plate: CO-25654824"	"sample_plate: CO-25654152"	"sample_plate: CO-25654152"	"sample_plate: CO-25654824"	"sample_plate: CO-25654825"	"sample_plate: CO-25654826"	"sample_plate: CO-25655789"	"sample_plate: CO-25654151"	"sample_plate: CO-25655788"	"sample_plate: CO-25654826"	"sample_plate: CO-25654823"	"sample_plate: CO-25654152"	"sample_plate: CO-25654154"	"sample_plate: CO-25654825"	"sample_plate: CO-25654824"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25654151"	"sample_plate: CO-25654823"	"sample_plate: CO-25654824"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25654826"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654152"	"sample_plate: CO-25654151"	"sample_plate: CO-25655788"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654824"	"sample_plate: CO-25654825"	"sample_plate: CO-25654823"	"sample_plate: CO-25654151"	"sample_plate: CO-25654825"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654154"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654823"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25654153"	"sample_plate: CO-25654826"	"sample_plate: CO-25654823"	"sample_plate: CO-25654151"	"sample_plate: CO-25655789"	"sample_plate: CO-25654151"	"sample_plate: CO-25655788"	"sample_plate: CO-25654154"	"sample_plate: CO-25654154"	"sample_plate: CO-25654151"	"sample_plate: CO-25654154"	"sample_plate: CO-25654826"	"sample_plate: CO-25654826"	"sample_plate: CO-25654154"	"sample_plate: CO-25654824"	"sample_plate: CO-25655788"	"sample_plate: CO-25654824"	"sample_plate: CO-25655788"	"sample_plate: CO-25654826"	"sample_plate: CO-25654823"	"sample_plate: CO-25654154"	"sample_plate: CO-25654152"	"sample_plate: CO-25654822"	"sample_plate: CO-25654823"	"sample_plate: CO-25654154"	"sample_plate: CO-25654823"	"sample_plate: CO-25654152"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654153"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654153"	"sample_plate: CO-25654154"	"sample_plate: CO-25654826"	"sample_plate: CO-25654824"	"sample_plate: CO-25655788"	"sample_plate: CO-25654824"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25654154"	"sample_plate: CO-25654152"	"sample_plate: CO-25654824"	"sample_plate: CO-25654824"	"sample_plate: CO-25654824"	"sample_plate: CO-25654824"	"sample_plate: CO-25654826"	"sample_plate: CO-25654823"	"sample_plate: CO-25654825"	"sample_plate: CO-25654152"	"sample_plate: CO-25654824"	"sample_plate: CO-25654823"	"sample_plate: CO-25654823"	"sample_plate: CO-25654824"	"sample_plate: CO-25654825"	"sample_plate: CO-25654154"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25654822"	"sample_plate: CO-25655788"	"sample_plate: CO-25654826"	"sample_plate: CO-25654825"	"sample_plate: CO-25654154"	"sample_plate: CO-25654152"	"sample_plate: CO-25654823"	"sample_plate: CO-25654154"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25654826"	"sample_plate: CO-25654152"	"sample_plate: CO-25654153"	"sample_plate: CO-25654826"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25655788"	"sample_plate: CO-25654825"	"sample_plate: CO-25654825"	"sample_plate: CO-25654153"	"sample_plate: CO-25655788"	"sample_plate: CO-25654154"	"sample_plate: CO-25654825"	"sample_plate: CO-25654826"	"sample_plate: CO-25654151"	"sample_plate: CO-25654153"	"sample_plate: CO-25654154"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654826"	"sample_plate: CO-25654151"	"sample_plate: CO-25654825"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654824"	"sample_plate: CO-25654151"	"sample_plate: CO-25654826"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654826"	"sample_plate: CO-25654823"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654824"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654824"	"sample_plate: CO-25654151"	"sample_plate: CO-25654824"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654825"	"sample_plate: CO-25654825"	"sample_plate: CO-25654151"	"sample_plate: CO-25654823"	"sample_plate: CO-25654826"	"sample_plate: CO-25654826"	"sample_plate: CO-25654826"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654823"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654825"	"sample_plate: CO-25654824"	"sample_plate: CO-25654154"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654153"	"sample_plate: CO-25654822"	"sample_plate: CO-25654151"	"sample_plate: CO-25654826"	"sample_plate: CO-25654154"	"sample_plate: CO-25654826"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654824"	"sample_plate: CO-25654825"	"sample_plate: CO-25654822"	"sample_plate: CO-25654151"	"sample_plate: CO-25654825"	"sample_plate: CO-25654824"	"sample_plate: CO-25654825"	"sample_plate: CO-25654825"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654822"	"sample_plate: CO-25654824"	"sample_plate: CO-25654822"	"sample_plate: CO-25655789"	"sample_plate: CO-25654822"	"sample_plate: CO-25654824"	"sample_plate: CO-25654825"	"sample_plate: CO-25654824"	"sample_plate: CO-25655789"	"sample_plate: CO-25654825"	"sample_plate: CO-25655789"	"sample_plate: CO-25654825"	"sample_plate: CO-25654822"	"sample_plate: CO-25654824"	"sample_plate: CO-25654822"	"sample_plate: CO-25654825"	"sample_plate: CO-25654826"	"sample_plate: CO-25654825"	"sample_plate: CO-25654825"	"sample_plate: CO-25654152"	"sample_plate: CO-25654825"	"sample_plate: CO-25654825"	"sample_plate: CO-25654826"	"sample_plate: CO-25655788"	"sample_plate: CO-25654154"	"sample_plate: CO-25654154"	"sample_plate: CO-25654825"	"sample_plate: CO-25654152"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25655788"	"sample_plate: CO-25654824"	"sample_plate: CO-25654823"	"sample_plate: CO-25654825"	"sample_plate: CO-25654825"	"sample_plate: CO-25654154"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25654154"	"sample_plate: CO-25654824"	"sample_plate: CO-25654154"	"sample_plate: CO-25654826"	"sample_plate: CO-25655788"	"sample_plate: CO-25654154"	"sample_plate: CO-25655788"	"sample_plate: CO-25654823"	"sample_plate: CO-25655788"	"sample_plate: CO-25654153"	"sample_plate: CO-25654825"	"sample_plate: CO-25655788"	"sample_plate: CO-25655788"	"sample_plate: CO-25654825"	"sample_plate: CO-25654154"	"sample_plate: CO-25654154"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25654154"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25654825"	"sample_plate: CO-25655788"	"sample_plate: CO-25654826"	"sample_plate: CO-25654154"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25654154"	"sample_plate: CO-25654824"	"sample_plate: CO-25654152"	"sample_plate: CO-25654825"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25654824"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25654825"	"sample_plate: CO-25654823"	"sample_plate: CO-25654154"	"sample_plate: CO-25654154"	"sample_plate: CO-25654824"	"sample_plate: CO-25655788"	"sample_plate: CO-25654825"	"sample_plate: CO-25654152"	"sample_plate: CO-25654154"	"sample_plate: CO-25654152"	"sample_plate: CO-25654154"	"sample_plate: CO-25654152"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25654823"	"sample_plate: CO-25654823"	"sample_plate: CO-25654826"	"sample_plate: CO-25654153"	"sample_plate: CO-25654152"	"sample_plate: CO-25654152"	"sample_plate: CO-25654823"	"sample_plate: CO-25654153"	"sample_plate: CO-25654152"	"sample_plate: CO-25654823"	"sample_plate: CO-25654823"	"sample_plate: CO-25654824"	"sample_plate: CO-25654826"	"sample_plate: CO-25654824"	"sample_plate: CO-25654823"	"sample_plate: CO-25655788"	"sample_plate: CO-25654823"	"sample_plate: CO-25654824"	"sample_plate: CO-25655788"	"sample_plate: CO-25654153"	"sample_plate: CO-25654824"	"sample_plate: CO-25654823"	"sample_plate: CO-25654824"	"sample_plate: CO-25654153"	"sample_plate: CO-25654826"	"sample_plate: CO-25655788"	"sample_plate: CO-25654824"	"sample_plate: CO-25654826"	"sample_plate: CO-25654823"	"sample_plate: CO-25654824"	"sample_plate: CO-25654823"	"sample_plate: CO-25654824"	"sample_plate: CO-25654824"	"sample_plate: CO-25654824"	"sample_plate: CO-25654823"	"sample_plate: CO-25654152"	"sample_plate: CO-25654823"	"sample_plate: CO-25654823"	"sample_plate: CO-25655788"	"sample_plate: CO-25654823"	"sample_plate: CO-25654826"	"sample_plate: CO-25654823"	"sample_plate: CO-25654824"	"sample_plate: CO-25654825"	"sample_plate: CO-25654824"	"sample_plate: CO-25655788"	"sample_plate: CO-25654825"	"sample_plate: CO-25654824"	"sample_plate: CO-25654825"	"sample_plate: CO-25655788"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25654152"	"sample_plate: CO-25654152"	"sample_plate: CO-25654154"	"sample_plate: CO-25654826"	"sample_plate: CO-25654823"	"sample_plate: CO-25655788"	"sample_plate: CO-25654823"	"sample_plate: CO-25654825"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25654153"	"sample_plate: CO-25654154"	"sample_plate: CO-25654154"	"sample_plate: CO-25654825"	"sample_plate: CO-25654152"	"sample_plate: CO-25654824"	"sample_plate: CO-25654824"	"sample_plate: CO-25654824"	"sample_plate: CO-25654154"	"sample_plate: CO-25654823"	"sample_plate: CO-25654154"	"sample_plate: CO-25654152"	"sample_plate: CO-25654154"	"sample_plate: CO-25654154"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25655788"	"sample_plate: CO-25654154"	"sample_plate: CO-25654824"	"sample_plate: CO-25655788"	"sample_plate: CO-25654153"	"sample_plate: CO-25654154"	"sample_plate: CO-25655788"	"sample_plate: CO-25655788"	"sample_plate: CO-25654152"	"sample_plate: CO-25654826"	"sample_plate: CO-25655788"	"sample_plate: CO-25654825"	"sample_plate: CO-25655788"	"sample_plate: CO-25654826"	"sample_plate: CO-25654823"	"sample_plate: CO-25655788"	"sample_plate: CO-25654824"	"sample_plate: CO-25655788"	"sample_plate: CO-25654825"	"sample_plate: CO-25654826"	"sample_plate: CO-25654154"	"sample_plate: CO-25654823"	"sample_plate: CO-25655788"	"sample_plate: CO-25654823"	"sample_plate: CO-25654824"	"sample_plate: CO-25654822"	"sample_plate: CO-25654825"	"sample_plate: CO-25654826"	"sample_plate: CO-25654823"	"sample_plate: CO-25654152"	"sample_plate: CO-25654152"	"sample_plate: CO-25654153"	"sample_plate: CO-25654824"	"sample_plate: CO-25654151"	"sample_plate: CO-25654153"	"sample_plate: CO-25654824"	"sample_plate: CO-25654825"	"sample_plate: CO-25654151"	"sample_plate: CO-25654825"	"sample_plate: CO-25654154"	"sample_plate: CO-25654823"	"sample_plate: CO-25654825"	"sample_plate: CO-25654825"	"sample_plate: CO-25654825"	"sample_plate: CO-25654823"	"sample_plate: CO-25654153"	"sample_plate: CO-25654154"	"sample_plate: CO-25654151"	"sample_plate: CO-25654824"	"sample_plate: CO-25654825"	"sample_plate: CO-25654154"	"sample_plate: CO-25654823"	"sample_plate: CO-25654826"	"sample_plate: CO-25654825"	"sample_plate: CO-25654826"	"sample_plate: CO-25654826"	"sample_plate: CO-25654153"	"sample_plate: CO-25654154"	"sample_plate: CO-25654826"	"sample_plate: CO-25654151"	"sample_plate: CO-25654826"	"sample_plate: CO-25654825"	"sample_plate: CO-25654825"	"sample_plate: CO-25654151"	"sample_plate: CO-25654823"	"sample_plate: CO-25654152"	"sample_plate: CO-25654151"	"sample_plate: CO-25654152"	"sample_plate: CO-25655789"	"sample_plate: CO-25654151"	"sample_plate: CO-25654152"	"sample_plate: CO-25654153"	"sample_plate: CO-25654154"	"sample_plate: CO-25654154"	"sample_plate: CO-25655788"	"sample_plate: CO-25655788"	"sample_plate: CO-25654151"	"sample_plate: CO-25654825"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654825"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654153"	"sample_plate: CO-25654153"	"sample_plate: CO-25654825"	"sample_plate: CO-25654153"	"sample_plate: CO-25654154"	"sample_plate: CO-25654152"	"sample_plate: CO-25654151"	"sample_plate: CO-25654153"	"sample_plate: CO-25654826"	"sample_plate: CO-25654154"	"sample_plate: CO-25654154"	"sample_plate: CO-25654153"	"sample_plate: CO-25654154"	"sample_plate: CO-25654825"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25654151"	"sample_plate: CO-25655788"	"sample_plate: CO-25654153"	"sample_plate: CO-25654825"	"sample_plate: CO-25655788"	"sample_plate: CO-25654826"
!Sample_characteristics_ch1	"sample_plate_position: H04"	"sample_plate_position: G06"	"sample_plate_position: A04"	"sample_plate_position: E04"	"sample_plate_position: A02"	"sample_plate_position: G03"	"sample_plate_position: B02"	"sample_plate_position: F04"	"sample_plate_position: D10"	"sample_plate_position: H04"	"sample_plate_position: B10"	"sample_plate_position: D09"	"sample_plate_position: G07"	"sample_plate_position: B08"	"sample_plate_position: G03"	"sample_plate_position: E04"	"sample_plate_position: B01"	"sample_plate_position: F01"	"sample_plate_position: G06"	"sample_plate_position: F02"	"sample_plate_position: D10"	"sample_plate_position: G04"	"sample_plate_position: B08"	"sample_plate_position: E08"	"sample_plate_position: E08"	"sample_plate_position: F09"	"sample_plate_position: B10"	"sample_plate_position: H04"	"sample_plate_position: E10"	"sample_plate_position: G06"	"sample_plate_position: H05"	"sample_plate_position: A05"	"sample_plate_position: F09"	"sample_plate_position: G07"	"sample_plate_position: G10"	"sample_plate_position: B05"	"sample_plate_position: H07"	"sample_plate_position: C09"	"sample_plate_position: F02"	"sample_plate_position: F02"	"sample_plate_position: E05"	"sample_plate_position: A03"	"sample_plate_position: E06"	"sample_plate_position: E02"	"sample_plate_position: E06"	"sample_plate_position: E05"	"sample_plate_position: C02"	"sample_plate_position: C04"	"sample_plate_position: B02"	"sample_plate_position: A06"	"sample_plate_position: E12"	"sample_plate_position: G08"	"sample_plate_position: C04"	"sample_plate_position: C12"	"sample_plate_position: H06"	"sample_plate_position: E10"	"sample_plate_position: A09"	"sample_plate_position: G12"	"sample_plate_position: A04"	"sample_plate_position: E12"	"sample_plate_position: B04"	"sample_plate_position: H01"	"sample_plate_position: F05"	"sample_plate_position: H12"	"sample_plate_position: A03"	"sample_plate_position: B04"	"sample_plate_position: H07"	"sample_plate_position: E03"	"sample_plate_position: H03"	"sample_plate_position: H09"	"sample_plate_position: C12"	"sample_plate_position: F10"	"sample_plate_position: B12"	"sample_plate_position: E08"	"sample_plate_position: C11"	"sample_plate_position: E09"	"sample_plate_position: D08"	"sample_plate_position: H06"	"sample_plate_position: G09"	"sample_plate_position: H11"	"sample_plate_position: D11"	"sample_plate_position: D12"	"sample_plate_position: D11"	"sample_plate_position: G09"	"sample_plate_position: A02"	"sample_plate_position: H06"	"sample_plate_position: D04"	"sample_plate_position: D09"	"sample_plate_position: A06"	"sample_plate_position: A08"	"sample_plate_position: E08"	"sample_plate_position: C06"	"sample_plate_position: E02"	"sample_plate_position: F08"	"sample_plate_position: E05"	"sample_plate_position: C11"	"sample_plate_position: A07"	"sample_plate_position: D03"	"sample_plate_position: E01"	"sample_plate_position: G07"	"sample_plate_position: E11"	"sample_plate_position: F11"	"sample_plate_position: E04"	"sample_plate_position: B03"	"sample_plate_position: E04"	"sample_plate_position: C10"	"sample_plate_position: C06"	"sample_plate_position: C08"	"sample_plate_position: D06"	"sample_plate_position: G02"	"sample_plate_position: F12"	"sample_plate_position: F05"	"sample_plate_position: C06"	"sample_plate_position: D02"	"sample_plate_position: E12"	"sample_plate_position: H02"	"sample_plate_position: D03"	"sample_plate_position: F03"	"sample_plate_position: F03"	"sample_plate_position: E11"	"sample_plate_position: D07"	"sample_plate_position: F09"	"sample_plate_position: E11"	"sample_plate_position: D04"	"sample_plate_position: F01"	"sample_plate_position: G11"	"sample_plate_position: C02"	"sample_plate_position: E09"	"sample_plate_position: D03"	"sample_plate_position: F04"	"sample_plate_position: F02"	"sample_plate_position: D12"	"sample_plate_position: H07"	"sample_plate_position: H01"	"sample_plate_position: H08"	"sample_plate_position: G07"	"sample_plate_position: D03"	"sample_plate_position: E09"	"sample_plate_position: D03"	"sample_plate_position: B05"	"sample_plate_position: D05"	"sample_plate_position: E12"	"sample_plate_position: A06"	"sample_plate_position: G08"	"sample_plate_position: G01"	"sample_plate_position: B08"	"sample_plate_position: D11"	"sample_plate_position: A05"	"sample_plate_position: G12"	"sample_plate_position: C09"	"sample_plate_position: H11"	"sample_plate_position: F06"	"sample_plate_position: F09"	"sample_plate_position: C10"	"sample_plate_position: F03"	"sample_plate_position: E10"	"sample_plate_position: A02"	"sample_plate_position: D03"	"sample_plate_position: C03"	"sample_plate_position: F05"	"sample_plate_position: E03"	"sample_plate_position: H12"	"sample_plate_position: B12"	"sample_plate_position: D04"	"sample_plate_position: G05"	"sample_plate_position: A01"	"sample_plate_position: F10"	"sample_plate_position: C10"	"sample_plate_position: E01"	"sample_plate_position: B05"	"sample_plate_position: G12"	"sample_plate_position: F10"	"sample_plate_position: A09"	"sample_plate_position: F08"	"sample_plate_position: C04"	"sample_plate_position: G01"	"sample_plate_position: E02"	"sample_plate_position: G10"	"sample_plate_position: G06"	"sample_plate_position: D06"	"sample_plate_position: D09"	"sample_plate_position: A04"	"sample_plate_position: D02"	"sample_plate_position: E06"	"sample_plate_position: C05"	"sample_plate_position: D05"	"sample_plate_position: F11"	"sample_plate_position: C02"	"sample_plate_position: B11"	"sample_plate_position: H03"	"sample_plate_position: A07"	"sample_plate_position: A02"	"sample_plate_position: E03"	"sample_plate_position: E11"	"sample_plate_position: H05"	"sample_plate_position: G04"	"sample_plate_position: D12"	"sample_plate_position: B03"	"sample_plate_position: A03"	"sample_plate_position: B01"	"sample_plate_position: C03"	"sample_plate_position: B10"	"sample_plate_position: B06"	"sample_plate_position: G04"	"sample_plate_position: A06"	"sample_plate_position: A07"	"sample_plate_position: A03"	"sample_plate_position: C10"	"sample_plate_position: A09"	"sample_plate_position: B11"	"sample_plate_position: A08"	"sample_plate_position: F08"	"sample_plate_position: B08"	"sample_plate_position: E03"	"sample_plate_position: F10"	"sample_plate_position: E07"	"sample_plate_position: G09"	"sample_plate_position: G05"	"sample_plate_position: C04"	"sample_plate_position: H02"	"sample_plate_position: G04"	"sample_plate_position: A07"	"sample_plate_position: E11"	"sample_plate_position: A04"	"sample_plate_position: C01"	"sample_plate_position: G09"	"sample_plate_position: E03"	"sample_plate_position: C03"	"sample_plate_position: B04"	"sample_plate_position: G06"	"sample_plate_position: D11"	"sample_plate_position: D05"	"sample_plate_position: G01"	"sample_plate_position: E01"	"sample_plate_position: H09"	"sample_plate_position: H11"	"sample_plate_position: H04"	"sample_plate_position: D10"	"sample_plate_position: C01"	"sample_plate_position: E02"	"sample_plate_position: F01"	"sample_plate_position: B12"	"sample_plate_position: D09"	"sample_plate_position: C11"	"sample_plate_position: C10"	"sample_plate_position: A12"	"sample_plate_position: C11"	"sample_plate_position: E02"	"sample_plate_position: C03"	"sample_plate_position: F03"	"sample_plate_position: E03"	"sample_plate_position: C10"	"sample_plate_position: G03"	"sample_plate_position: H02"	"sample_plate_position: B02"	"sample_plate_position: H02"	"sample_plate_position: G11"	"sample_plate_position: D04"	"sample_plate_position: G10"	"sample_plate_position: F02"	"sample_plate_position: C06"	"sample_plate_position: D10"	"sample_plate_position: C09"	"sample_plate_position: C02"	"sample_plate_position: B08"	"sample_plate_position: G08"	"sample_plate_position: D04"	"sample_plate_position: A06"	"sample_plate_position: G06"	"sample_plate_position: G01"	"sample_plate_position: F05"	"sample_plate_position: B03"	"sample_plate_position: G08"	"sample_plate_position: G08"	"sample_plate_position: F07"	"sample_plate_position: G03"	"sample_plate_position: C12"	"sample_plate_position: G07"	"sample_plate_position: H11"	"sample_plate_position: F12"	"sample_plate_position: G09"	"sample_plate_position: B09"	"sample_plate_position: B07"	"sample_plate_position: A06"	"sample_plate_position: A03"	"sample_plate_position: H01"	"sample_plate_position: D08"	"sample_plate_position: C11"	"sample_plate_position: C08"	"sample_plate_position: F06"	"sample_plate_position: A03"	"sample_plate_position: H10"	"sample_plate_position: A01"	"sample_plate_position: F12"	"sample_plate_position: G12"	"sample_plate_position: A02"	"sample_plate_position: B11"	"sample_plate_position: F11"	"sample_plate_position: G12"	"sample_plate_position: A06"	"sample_plate_position: H05"	"sample_plate_position: G03"	"sample_plate_position: H12"	"sample_plate_position: A11"	"sample_plate_position: D12"	"sample_plate_position: B12"	"sample_plate_position: B09"	"sample_plate_position: C01"	"sample_plate_position: A11"	"sample_plate_position: B07"	"sample_plate_position: A12"	"sample_plate_position: C11"	"sample_plate_position: B07"	"sample_plate_position: B11"	"sample_plate_position: C07"	"sample_plate_position: E12"	"sample_plate_position: D08"	"sample_plate_position: F03"	"sample_plate_position: A07"	"sample_plate_position: B11"	"sample_plate_position: C08"	"sample_plate_position: C05"	"sample_plate_position: C09"	"sample_plate_position: E04"	"sample_plate_position: C02"	"sample_plate_position: G08"	"sample_plate_position: B02"	"sample_plate_position: B09"	"sample_plate_position: A10"	"sample_plate_position: A02"	"sample_plate_position: F08"	"sample_plate_position: H04"	"sample_plate_position: A11"	"sample_plate_position: A12"	"sample_plate_position: F02"	"sample_plate_position: A12"	"sample_plate_position: B09"	"sample_plate_position: B05"	"sample_plate_position: D07"	"sample_plate_position: G11"	"sample_plate_position: G10"	"sample_plate_position: G04"	"sample_plate_position: G04"	"sample_plate_position: H01"	"sample_plate_position: D01"	"sample_plate_position: G11"	"sample_plate_position: B02"	"sample_plate_position: A08"	"sample_plate_position: H05"	"sample_plate_position: D04"	"sample_plate_position: D12"	"sample_plate_position: E01"	"sample_plate_position: A05"	"sample_plate_position: B05"	"sample_plate_position: B04"	"sample_plate_position: G11"	"sample_plate_position: G02"	"sample_plate_position: H07"	"sample_plate_position: E07"	"sample_plate_position: G03"	"sample_plate_position: D11"	"sample_plate_position: G10"	"sample_plate_position: D10"	"sample_plate_position: D07"	"sample_plate_position: F03"	"sample_plate_position: H03"	"sample_plate_position: F02"	"sample_plate_position: D01"	"sample_plate_position: E07"	"sample_plate_position: F05"	"sample_plate_position: H07"	"sample_plate_position: F10"	"sample_plate_position: C07"	"sample_plate_position: E05"	"sample_plate_position: C11"	"sample_plate_position: G02"	"sample_plate_position: D07"	"sample_plate_position: D09"	"sample_plate_position: H09"	"sample_plate_position: H08"	"sample_plate_position: C08"	"sample_plate_position: B06"	"sample_plate_position: B05"	"sample_plate_position: G03"	"sample_plate_position: B05"	"sample_plate_position: G06"	"sample_plate_position: F07"	"sample_plate_position: C11"	"sample_plate_position: D08"	"sample_plate_position: G12"	"sample_plate_position: B07"	"sample_plate_position: E07"	"sample_plate_position: A03"	"sample_plate_position: H01"	"sample_plate_position: A12"	"sample_plate_position: G10"	"sample_plate_position: C09"	"sample_plate_position: F12"	"sample_plate_position: G12"	"sample_plate_position: D04"	"sample_plate_position: E06"	"sample_plate_position: C04"	"sample_plate_position: F12"	"sample_plate_position: D03"	"sample_plate_position: D05"	"sample_plate_position: D07"	"sample_plate_position: D06"	"sample_plate_position: B07"	"sample_plate_position: B02"	"sample_plate_position: B09"	"sample_plate_position: F11"	"sample_plate_position: F05"	"sample_plate_position: C12"	"sample_plate_position: F10"	"sample_plate_position: D11"	"sample_plate_position: H06"	"sample_plate_position: G08"	"sample_plate_position: C09"	"sample_plate_position: E01"	"sample_plate_position: B09"	"sample_plate_position: B12"	"sample_plate_position: C11"	"sample_plate_position: B04"	"sample_plate_position: G08"	"sample_plate_position: D12"	"sample_plate_position: C05"	"sample_plate_position: F11"	"sample_plate_position: E08"	"sample_plate_position: H10"	"sample_plate_position: C09"	"sample_plate_position: C10"	"sample_plate_position: C12"	"sample_plate_position: G02"	"sample_plate_position: E02"	"sample_plate_position: A12"	"sample_plate_position: D06"	"sample_plate_position: C08"	"sample_plate_position: G11"	"sample_plate_position: E05"	"sample_plate_position: F08"	"sample_plate_position: E02"	"sample_plate_position: E07"	"sample_plate_position: B06"	"sample_plate_position: B01"	"sample_plate_position: F09"	"sample_plate_position: C01"	"sample_plate_position: F12"	"sample_plate_position: B07"	"sample_plate_position: D11"	"sample_plate_position: B08"	"sample_plate_position: B12"	"sample_plate_position: F04"	"sample_plate_position: C04"	"sample_plate_position: G04"	"sample_plate_position: A05"	"sample_plate_position: A11"	"sample_plate_position: A07"	"sample_plate_position: D02"	"sample_plate_position: A09"	"sample_plate_position: A08"	"sample_plate_position: C06"	"sample_plate_position: H02"	"sample_plate_position: B10"	"sample_plate_position: D03"	"sample_plate_position: A09"	"sample_plate_position: C03"	"sample_plate_position: C07"	"sample_plate_position: B11"	"sample_plate_position: C02"	"sample_plate_position: C05"	"sample_plate_position: A02"	"sample_plate_position: C04"	"sample_plate_position: C12"	"sample_plate_position: D01"	"sample_plate_position: E01"	"sample_plate_position: C08"	"sample_plate_position: F06"	"sample_plate_position: A10"	"sample_plate_position: B12"	"sample_plate_position: C01"	"sample_plate_position: C06"	"sample_plate_position: H12"	"sample_plate_position: B06"	"sample_plate_position: A05"	"sample_plate_position: C11"	"sample_plate_position: B08"	"sample_plate_position: B10"	"sample_plate_position: B03"	"sample_plate_position: B06"	"sample_plate_position: G04"	"sample_plate_position: E04"	"sample_plate_position: G01"	"sample_plate_position: D02"	"sample_plate_position: F03"	"sample_plate_position: B11"	"sample_plate_position: E06"	"sample_plate_position: A09"	"sample_plate_position: D09"	"sample_plate_position: F11"	"sample_plate_position: E07"	"sample_plate_position: D01"	"sample_plate_position: B07"	"sample_plate_position: F06"	"sample_plate_position: E12"	"sample_plate_position: H12"	"sample_plate_position: C04"	"sample_plate_position: B02"	"sample_plate_position: H01"	"sample_plate_position: G05"	"sample_plate_position: H01"	"sample_plate_position: H10"	"sample_plate_position: G03"	"sample_plate_position: G06"	"sample_plate_position: A01"	"sample_plate_position: F06"	"sample_plate_position: G05"	"sample_plate_position: F04"	"sample_plate_position: F08"	"sample_plate_position: G03"	"sample_plate_position: B03"	"sample_plate_position: C09"	"sample_plate_position: D06"	"sample_plate_position: H04"	"sample_plate_position: D01"	"sample_plate_position: H02"	"sample_plate_position: G09"	"sample_plate_position: H06"	"sample_plate_position: A11"	"sample_plate_position: F05"	"sample_plate_position: G08"	"sample_plate_position: E11"	"sample_plate_position: H10"	"sample_plate_position: E03"	"sample_plate_position: G05"	"sample_plate_position: C07"	"sample_plate_position: D05"	"sample_plate_position: D07"	"sample_plate_position: G07"	"sample_plate_position: B04"	"sample_plate_position: D08"	"sample_plate_position: G07"	"sample_plate_position: D03"	"sample_plate_position: C08"	"sample_plate_position: G02"	"sample_plate_position: E11"	"sample_plate_position: F09"	"sample_plate_position: A01"	"sample_plate_position: F03"	"sample_plate_position: H03"	"sample_plate_position: C03"	"sample_plate_position: C03"	"sample_plate_position: C06"	"sample_plate_position: C09"	"sample_plate_position: H09"	"sample_plate_position: F09"	"sample_plate_position: E04"	"sample_plate_position: C02"	"sample_plate_position: B04"	"sample_plate_position: G07"	"sample_plate_position: B03"	"sample_plate_position: F11"	"sample_plate_position: G09"	"sample_plate_position: D08"	"sample_plate_position: E07"	"sample_plate_position: D01"	"sample_plate_position: B11"	"sample_plate_position: C01"	"sample_plate_position: C12"	"sample_plate_position: F01"	"sample_plate_position: E03"	"sample_plate_position: F11"	"sample_plate_position: G09"	"sample_plate_position: G05"	"sample_plate_position: H02"	"sample_plate_position: H11"	"sample_plate_position: G05"	"sample_plate_position: H09"	"sample_plate_position: D11"	"sample_plate_position: C05"	"sample_plate_position: E07"	"sample_plate_position: A05"	"sample_plate_position: H12"	"sample_plate_position: G03"	"sample_plate_position: G05"	"sample_plate_position: G10"	"sample_plate_position: B01"	"sample_plate_position: D10"	"sample_plate_position: D10"	"sample_plate_position: C06"	"sample_plate_position: H10"	"sample_plate_position: A01"	"sample_plate_position: D05"	"sample_plate_position: B12"	"sample_plate_position: D02"	"sample_plate_position: A03"	"sample_plate_position: C01"	"sample_plate_position: A10"	"sample_plate_position: C07"	"sample_plate_position: A08"	"sample_plate_position: F09"	"sample_plate_position: A09"	"sample_plate_position: A10"	"sample_plate_position: F04"	"sample_plate_position: H03"	"sample_plate_position: E11"	"sample_plate_position: C07"	"sample_plate_position: G02"	"sample_plate_position: F01"	"sample_plate_position: A08"	"sample_plate_position: D03"	"sample_plate_position: D06"	"sample_plate_position: G02"	"sample_plate_position: D06"	"sample_plate_position: A04"	"sample_plate_position: F01"	"sample_plate_position: D05"	"sample_plate_position: B01"	"sample_plate_position: E05"	"sample_plate_position: A05"	"sample_plate_position: B06"	"sample_plate_position: D06"	"sample_plate_position: H09"	"sample_plate_position: A06"	"sample_plate_position: C12"	"sample_plate_position: H06"	"sample_plate_position: B06"	"sample_plate_position: A11"	"sample_plate_position: D09"	"sample_plate_position: B05"	"sample_plate_position: H08"	"sample_plate_position: B12"	"sample_plate_position: B07"	"sample_plate_position: A05"	"sample_plate_position: A05"	"sample_plate_position: D12"	"sample_plate_position: B03"	"sample_plate_position: C07"	"sample_plate_position: D08"	"sample_plate_position: G12"	"sample_plate_position: B02"	"sample_plate_position: A04"	"sample_plate_position: A06"	"sample_plate_position: A02"	"sample_plate_position: C03"	"sample_plate_position: A12"	"sample_plate_position: C08"	"sample_plate_position: A01"	"sample_plate_position: A09"	"sample_plate_position: B08"	"sample_plate_position: H05"	"sample_plate_position: H06"	"sample_plate_position: B04"	"sample_plate_position: H01"	"sample_plate_position: E02"	"sample_plate_position: E01"	"sample_plate_position: D07"	"sample_plate_position: A08"	"sample_plate_position: B09"	"sample_plate_position: C04"	"sample_plate_position: B11"	"sample_plate_position: H02"	"sample_plate_position: C05"	"sample_plate_position: B10"	"sample_plate_position: C06"	"sample_plate_position: C09"	"sample_plate_position: H09"	"sample_plate_position: A04"	"sample_plate_position: H02"	"sample_plate_position: C02"	"sample_plate_position: C01"	"sample_plate_position: B05"	"sample_plate_position: B03"	"sample_plate_position: B06"	"sample_plate_position: B02"	"sample_plate_position: B01"	"sample_plate_position: A10"	"sample_plate_position: B04"	"sample_plate_position: B07"	"sample_plate_position: A01"	"sample_plate_position: D11"	"sample_plate_position: A07"	"sample_plate_position: D10"	"sample_plate_position: A11"	"sample_plate_position: B04"	"sample_plate_position: A09"	"sample_plate_position: A07"	"sample_plate_position: H12"	"sample_plate_position: A12"	"sample_plate_position: A10"	"sample_plate_position: H07"	"sample_plate_position: C05"	"sample_plate_position: F09"	"sample_plate_position: F12"	"sample_plate_position: H04"	"sample_plate_position: H11"	"sample_plate_position: H03"	"sample_plate_position: H09"	"sample_plate_position: H12"	"sample_plate_position: H01"	"sample_plate_position: H10"	"sample_plate_position: B07"	"sample_plate_position: H05"	"sample_plate_position: A06"	"sample_plate_position: H06"	"sample_plate_position: B09"	"sample_plate_position: G01"	"sample_plate_position: C07"	"sample_plate_position: A01"	"sample_plate_position: F10"	"sample_plate_position: A04"	"sample_plate_position: F11"	"sample_plate_position: H07"	"sample_plate_position: B08"	"sample_plate_position: H08"	"sample_plate_position: F07"	"sample_plate_position: E11"	"sample_plate_position: E10"	"sample_plate_position: A04"	"sample_plate_position: D01"	"sample_plate_position: A03"	"sample_plate_position: C04"	"sample_plate_position: E05"	"sample_plate_position: G01"	"sample_plate_position: F10"	"sample_plate_position: F07"	"sample_plate_position: E12"	"sample_plate_position: G10"	"sample_plate_position: A01"	"sample_plate_position: D03"	"sample_plate_position: H11"	"sample_plate_position: A11"	"sample_plate_position: E06"	"sample_plate_position: E05"	"sample_plate_position: C06"	"sample_plate_position: C12"	"sample_plate_position: E10"	"sample_plate_position: F03"	"sample_plate_position: G11"	"sample_plate_position: H10"	"sample_plate_position: A10"	"sample_plate_position: B12"	"sample_plate_position: E12"	"sample_plate_position: D01"	"sample_plate_position: B01"	"sample_plate_position: E07"	"sample_plate_position: E10"	"sample_plate_position: A10"	"sample_plate_position: C10"	"sample_plate_position: A02"	"sample_plate_position: F05"	"sample_plate_position: H03"	"sample_plate_position: C10"	"sample_plate_position: G02"	"sample_plate_position: H08"	"sample_plate_position: E09"	"sample_plate_position: G07"	"sample_plate_position: C05"	"sample_plate_position: A06"	"sample_plate_position: H08"	"sample_plate_position: B05"	"sample_plate_position: H04"	"sample_plate_position: H10"	"sample_plate_position: A10"	"sample_plate_position: A08"	"sample_plate_position: A07"	"sample_plate_position: H10"	"sample_plate_position: D08"	"sample_plate_position: G10"	"sample_plate_position: D07"	"sample_plate_position: G07"	"sample_plate_position: E02"	"sample_plate_position: D09"	"sample_plate_position: C08"	"sample_plate_position: E01"	"sample_plate_position: G01"	"sample_plate_position: G04"	"sample_plate_position: D12"	"sample_plate_position: D02"	"sample_plate_position: E08"	"sample_plate_position: H05"	"sample_plate_position: E05"	"sample_plate_position: E09"	"sample_plate_position: H08"	"sample_plate_position: B12"	"sample_plate_position: G05"	"sample_plate_position: C09"	"sample_plate_position: E01"	"sample_plate_position: C12"	"sample_plate_position: C11"	"sample_plate_position: E09"	"sample_plate_position: C07"	"sample_plate_position: D07"	"sample_plate_position: F08"	"sample_plate_position: B10"	"sample_plate_position: B09"	"sample_plate_position: B04"	"sample_plate_position: A02"	"sample_plate_position: F02"	"sample_plate_position: F06"	"sample_plate_position: C01"	"sample_plate_position: A04"	"sample_plate_position: F04"	"sample_plate_position: A10"	"sample_plate_position: F11"	"sample_plate_position: E04"	"sample_plate_position: B06"	"sample_plate_position: F03"	"sample_plate_position: F04"	"sample_plate_position: B01"	"sample_plate_position: B11"	"sample_plate_position: F12"	"sample_plate_position: B08"	"sample_plate_position: A10"	"sample_plate_position: E09"	"sample_plate_position: G01"	"sample_plate_position: E12"	"sample_plate_position: A08"	"sample_plate_position: B10"	"sample_plate_position: B09"	"sample_plate_position: E10"	"sample_plate_position: H08"	"sample_plate_position: D04"	"sample_plate_position: D08"	"sample_plate_position: F07"	"sample_plate_position: F06"	"sample_plate_position: F02"	"sample_plate_position: F01"	"sample_plate_position: F08"	"sample_plate_position: F07"	"sample_plate_position: C07"	"sample_plate_position: C03"	"sample_plate_position: B06"	"sample_plate_position: D01"	"sample_plate_position: C05"	"sample_plate_position: F06"	"sample_plate_position: F07"	"sample_plate_position: B10"	"sample_plate_position: G11"	"sample_plate_position: G06"	"sample_plate_position: A05"	"sample_plate_position: C02"	"sample_plate_position: A11"	"sample_plate_position: A12"	"sample_plate_position: G04"	"sample_plate_position: D05"	"sample_plate_position: H05"	"sample_plate_position: B11"	"sample_plate_position: B05"	"sample_plate_position: C08"	"sample_plate_position: A04"	"sample_plate_position: F08"	"sample_plate_position: D12"	"sample_plate_position: E06"	"sample_plate_position: E06"	"sample_plate_position: H08"	"sample_plate_position: H06"	"sample_plate_position: G02"	"sample_plate_position: E04"	"sample_plate_position: C08"	"sample_plate_position: F06"	"sample_plate_position: H09"	"sample_plate_position: C02"	"sample_plate_position: B01"	"sample_plate_position: D02"	"sample_plate_position: C12"	"sample_plate_position: C10"	"sample_plate_position: C01"	"sample_plate_position: G02"	"sample_plate_position: C06"	"sample_plate_position: C03"	"sample_plate_position: B03"	"sample_plate_position: C03"	"sample_plate_position: F07"	"sample_plate_position: H07"	"sample_plate_position: F04"	"sample_plate_position: E10"	"sample_plate_position: C01"	"sample_plate_position: D06"	"sample_plate_position: C05"	"sample_plate_position: D06"	"sample_plate_position: C04"	"sample_plate_position: E12"	"sample_plate_position: A09"	"sample_plate_position: E09"	"sample_plate_position: D10"	"sample_plate_position: E09"	"sample_plate_position: G12"	"sample_plate_position: E08"	"sample_plate_position: E01"	"sample_plate_position: H07"	"sample_plate_position: H01"	"sample_plate_position: D09"	"sample_plate_position: C07"	"sample_plate_position: F01"	"sample_plate_position: B08"	"sample_plate_position: A05"	"sample_plate_position: D02"	"sample_plate_position: E08"	"sample_plate_position: G06"	"sample_plate_position: F10"	"sample_plate_position: A01"	"sample_plate_position: E07"	"sample_plate_position: H08"	"sample_plate_position: A11"	"sample_plate_position: E11"	"sample_plate_position: D04"	"sample_plate_position: A03"	"sample_plate_position: A03"	"sample_plate_position: D02"	"sample_plate_position: A08"	"sample_plate_position: H02"	"sample_plate_position: B01"	"sample_plate_position: H04"	"sample_plate_position: G11"	"sample_plate_position: H04"	"sample_plate_position: H11"	"sample_plate_position: H03"	"sample_plate_position: H10"	"sample_plate_position: H03"	"sample_plate_position: B03"	"sample_plate_position: H07"	"sample_plate_position: A07"	"sample_plate_position: A02"	"sample_plate_position: F04"	"sample_plate_position: E03"	"sample_plate_position: D08"	"sample_plate_position: F02"	"sample_plate_position: C05"	"sample_plate_position: A07"	"sample_plate_position: H12"	"sample_plate_position: C02"	"sample_plate_position: B07"	"sample_plate_position: B02"	"sample_plate_position: F07"	"sample_plate_position: A11"	"sample_plate_position: A12"	"sample_plate_position: G10"	"sample_plate_position: H09"	"sample_plate_position: H06"	"sample_plate_position: H12"	"sample_plate_position: F09"	"sample_plate_position: B10"	"sample_plate_position: B03"	"sample_plate_position: H05"	"sample_plate_position: B09"	"sample_plate_position: F07"	"sample_plate_position: D02"	"sample_plate_position: B10"	"sample_plate_position: E06"	"sample_plate_position: F12"	"sample_plate_position: G12"	"sample_plate_position: G09"	"sample_plate_position: D11"	"sample_plate_position: D09"	"sample_plate_position: G08"	"sample_plate_position: D10"	"sample_plate_position: D04"	"sample_plate_position: E10"	"sample_plate_position: E08"	"sample_plate_position: E09"	"sample_plate_position: D01"	"sample_plate_position: D05"	"sample_plate_position: F05"	"sample_plate_position: A01"	"sample_plate_position: G09"	"sample_plate_position: E08"	"sample_plate_position: H03"	"sample_plate_position: F06"	"sample_plate_position: D04"	"sample_plate_position: C10"	"sample_plate_position: D05"	"sample_plate_position: B02"	"sample_plate_position: D01"	"sample_plate_position: G11"	"sample_plate_position: D07"	"sample_plate_position: G01"	"sample_plate_position: E05"	"sample_plate_position: D02"	"sample_plate_position: E06"	"sample_plate_position: E02"	"sample_plate_position: E04"	"sample_plate_position: F01"	"sample_plate_position: E10"	"sample_plate_position: F08"	"sample_plate_position: B06"	"sample_plate_position: A08"	"sample_plate_position: H05"
!Sample_characteristics_ch1	"sentrix_id: 202242400165"	"sentrix_id: 202242400179"	"sentrix_id: 202242400165"	"sentrix_id: 202242410037"	"sentrix_id: 202242400020"	"sentrix_id: 202242400081"	"sentrix_id: 202242400020"	"sentrix_id: 202242400063"	"sentrix_id: 202259350124"	"sentrix_id: 202242400017"	"sentrix_id: 202250800019"	"sentrix_id: 202259340003"	"sentrix_id: 202242400080"	"sentrix_id: 202242410128"	"sentrix_id: 202232360119"	"sentrix_id: 202242400220"	"sentrix_id: 202242400014"	"sentrix_id: 202242400067"	"sentrix_id: 202242400075"	"sentrix_id: 202242400020"	"sentrix_id: 202259340017"	"sentrix_id: 202242400220"	"sentrix_id: 202259350096"	"sentrix_id: 202259350096"	"sentrix_id: 202242410128"	"sentrix_id: 202242400224"	"sentrix_id: 202259350124"	"sentrix_id: 202242410037"	"sentrix_id: 202259350124"	"sentrix_id: 202242410075"	"sentrix_id: 202259340021"	"sentrix_id: 202242410048"	"sentrix_id: 202259340003"	"sentrix_id: 202242410095"	"sentrix_id: 202259350058"	"sentrix_id: 202242400078"	"sentrix_id: 202242400194"	"sentrix_id: 202250790199"	"sentrix_id: 202232360060"	"sentrix_id: 202232360076"	"sentrix_id: 202242400078"	"sentrix_id: 202242400053"	"sentrix_id: 202242400156"	"sentrix_id: 202242400020"	"sentrix_id: 202259340092"	"sentrix_id: 202250790041"	"sentrix_id: 202234390006"	"sentrix_id: 202242410037"	"sentrix_id: 202242400015"	"sentrix_id: 202242400086"	"sentrix_id: 202259350123"	"sentrix_id: 202250790166"	"sentrix_id: 202242400017"	"sentrix_id: 202250800035"	"sentrix_id: 202242410039"	"sentrix_id: 202242410136"	"sentrix_id: 202250790199"	"sentrix_id: 202242410214"	"sentrix_id: 202242400017"	"sentrix_id: 202250790142"	"sentrix_id: 202242400017"	"sentrix_id: 202242400021"	"sentrix_id: 202242400167"	"sentrix_id: 202250800035"	"sentrix_id: 202242400091"	"sentrix_id: 202242400007"	"sentrix_id: 202242410054"	"sentrix_id: 202242400091"	"sentrix_id: 202242400161"	"sentrix_id: 202242400224"	"sentrix_id: 202242410030"	"sentrix_id: 202250800019"	"sentrix_id: 202242410217"	"sentrix_id: 202250790166"	"sentrix_id: 202242400213"	"sentrix_id: 202250790019"	"sentrix_id: 202242400108"	"sentrix_id: 202242400162"	"sentrix_id: 202242400224"	"sentrix_id: 202250790071"	"sentrix_id: 202259350119"	"sentrix_id: 202242410217"	"sentrix_id: 202242410083"	"sentrix_id: 202250790199"	"sentrix_id: 202234390006"	"sentrix_id: 202242400179"	"sentrix_id: 202242400007"	"sentrix_id: 202250790019"	"sentrix_id: 202242400179"	"sentrix_id: 202242400108"	"sentrix_id: 202242410047"	"sentrix_id: 202242400179"	"sentrix_id: 202232360060"	"sentrix_id: 202242410047"	"sentrix_id: 202242400138"	"sentrix_id: 202242410083"	"sentrix_id: 202242400134"	"sentrix_id: 202232360119"	"sentrix_id: 202242400067"	"sentrix_id: 202242400194"	"sentrix_id: 202250800031"	"sentrix_id: 202242410162"	"sentrix_id: 202242400017"	"sentrix_id: 202232360119"	"sentrix_id: 202242400073"	"sentrix_id: 202242410028"	"sentrix_id: 202242400086"	"sentrix_id: 202242410198"	"sentrix_id: 202242410075"	"sentrix_id: 202242400089"	"sentrix_id: 202250790142"	"sentrix_id: 202242400078"	"sentrix_id: 202242410075"	"sentrix_id: 202242400089"	"sentrix_id: 202259350141"	"sentrix_id: 202242400076"	"sentrix_id: 202242400019"	"sentrix_id: 202242400081"	"sentrix_id: 202242400091"	"sentrix_id: 202259350150"	"sentrix_id: 202242410054"	"sentrix_id: 202259350108"	"sentrix_id: 202259350003"	"sentrix_id: 202242400063"	"sentrix_id: 202242400010"	"sentrix_id: 202259350150"	"sentrix_id: 202242400110"	"sentrix_id: 202259340003"	"sentrix_id: 202242400053"	"sentrix_id: 202242400220"	"sentrix_id: 202242400076"	"sentrix_id: 202259350191"	"sentrix_id: 202259350094"	"sentrix_id: 202242400066"	"sentrix_id: 202259350096"	"sentrix_id: 202259350094"	"sentrix_id: 202242400199"	"sentrix_id: 202259350108"	"sentrix_id: 202242400081"	"sentrix_id: 202242400167"	"sentrix_id: 202242410048"	"sentrix_id: 202259350191"	"sentrix_id: 202242410075"	"sentrix_id: 202242410047"	"sentrix_id: 202242400067"	"sentrix_id: 202242400196"	"sentrix_id: 202259350150"	"sentrix_id: 202259340021"	"sentrix_id: 202259350123"	"sentrix_id: 202250790019"	"sentrix_id: 202259350150"	"sentrix_id: 202242410075"	"sentrix_id: 202250790019"	"sentrix_id: 202259340017"	"sentrix_id: 202242400053"	"sentrix_id: 202259340017"	"sentrix_id: 202242400110"	"sentrix_id: 202242400161"	"sentrix_id: 202242400161"	"sentrix_id: 202259340021"	"sentrix_id: 202242400019"	"sentrix_id: 202259350191"	"sentrix_id: 202259350141"	"sentrix_id: 202242400220"	"sentrix_id: 202242410048"	"sentrix_id: 202242400067"	"sentrix_id: 202242410028"	"sentrix_id: 202250790020"	"sentrix_id: 202242400014"	"sentrix_id: 202250790041"	"sentrix_id: 202259350191"	"sentrix_id: 202250790020"	"sentrix_id: 202259350108"	"sentrix_id: 202242410128"	"sentrix_id: 202242400073"	"sentrix_id: 202242400066"	"sentrix_id: 202242400089"	"sentrix_id: 202259350124"	"sentrix_id: 202242400156"	"sentrix_id: 202242410039"	"sentrix_id: 202250790012"	"sentrix_id: 202242400220"	"sentrix_id: 202242400110"	"sentrix_id: 202242410075"	"sentrix_id: 202242400078"	"sentrix_id: 202242400064"	"sentrix_id: 202259350150"	"sentrix_id: 202242400020"	"sentrix_id: 202259350003"	"sentrix_id: 202242400011"	"sentrix_id: 202259350094"	"sentrix_id: 202242400089"	"sentrix_id: 202242400199"	"sentrix_id: 202250790168"	"sentrix_id: 202242400029"	"sentrix_id: 202242400017"	"sentrix_id: 202250800034"	"sentrix_id: 202234390009"	"sentrix_id: 202242400199"	"sentrix_id: 202242400066"	"sentrix_id: 202242400199"	"sentrix_id: 202259340017"	"sentrix_id: 202242400086"	"sentrix_id: 202242400007"	"sentrix_id: 202259340092"	"sentrix_id: 202250790052"	"sentrix_id: 202250790052"	"sentrix_id: 202250790129"	"sentrix_id: 202259340144"	"sentrix_id: 202250790168"	"sentrix_id: 202242410047"	"sentrix_id: 202242400108"	"sentrix_id: 202242400223"	"sentrix_id: 202232360119"	"sentrix_id: 202242410136"	"sentrix_id: 202242400210"	"sentrix_id: 202250790012"	"sentrix_id: 202242400078"	"sentrix_id: 202242400104"	"sentrix_id: 202234390006"	"sentrix_id: 202242400165"	"sentrix_id: 202242400080"	"sentrix_id: 202242400213"	"sentrix_id: 202242400104"	"sentrix_id: 202242400016"	"sentrix_id: 202242410041"	"sentrix_id: 202242400053"	"sentrix_id: 202232360119"	"sentrix_id: 202242400104"	"sentrix_id: 202242400162"	"sentrix_id: 202242400213"	"sentrix_id: 202250790041"	"sentrix_id: 202242400016"	"sentrix_id: 202232290016"	"sentrix_id: 202250790199"	"sentrix_id: 202259350119"	"sentrix_id: 202242400104"	"sentrix_id: 202259350058"	"sentrix_id: 202232290016"	"sentrix_id: 202232360076"	"sentrix_id: 202232290016"	"sentrix_id: 202242410030"	"sentrix_id: 202259340144"	"sentrix_id: 202250790168"	"sentrix_id: 202250800019"	"sentrix_id: 202259350123"	"sentrix_id: 202242410162"	"sentrix_id: 202234390006"	"sentrix_id: 202242400081"	"sentrix_id: 202242400161"	"sentrix_id: 202242400161"	"sentrix_id: 202242410136"	"sentrix_id: 202234390009"	"sentrix_id: 202242400077"	"sentrix_id: 202232360060"	"sentrix_id: 202242400015"	"sentrix_id: 202242410162"	"sentrix_id: 202234390052"	"sentrix_id: 202242410136"	"sentrix_id: 202234390006"	"sentrix_id: 202259340092"	"sentrix_id: 202250790125"	"sentrix_id: 202250790012"	"sentrix_id: 202232360060"	"sentrix_id: 202242400108"	"sentrix_id: 202242400223"	"sentrix_id: 202242400104"	"sentrix_id: 202242400075"	"sentrix_id: 202242400086"	"sentrix_id: 202232360054"	"sentrix_id: 202242400029"	"sentrix_id: 202242400161"	"sentrix_id: 202242410102"	"sentrix_id: 202242410198"	"sentrix_id: 202242400194"	"sentrix_id: 202242400011"	"sentrix_id: 202242410214"	"sentrix_id: 202242400134"	"sentrix_id: 202242410083"	"sentrix_id: 202259350123"	"sentrix_id: 202250790019"	"sentrix_id: 202242400137"	"sentrix_id: 202242400080"	"sentrix_id: 202242400156"	"sentrix_id: 202234390009"	"sentrix_id: 202242400016"	"sentrix_id: 202250790166"	"sentrix_id: 202250800031"	"sentrix_id: 202242400223"	"sentrix_id: 202242400179"	"sentrix_id: 202242400161"	"sentrix_id: 202250800019"	"sentrix_id: 202232360054"	"sentrix_id: 202242410214"	"sentrix_id: 202242410217"	"sentrix_id: 202232360060"	"sentrix_id: 202259350119"	"sentrix_id: 202250800031"	"sentrix_id: 202250800034"	"sentrix_id: 202242400162"	"sentrix_id: 202250790041"	"sentrix_id: 202242400161"	"sentrix_id: 202259350123"	"sentrix_id: 202250800031"	"sentrix_id: 202242410030"	"sentrix_id: 202242410214"	"sentrix_id: 202242410041"	"sentrix_id: 202242400021"	"sentrix_id: 202250790071"	"sentrix_id: 202242400194"	"sentrix_id: 202250790142"	"sentrix_id: 202250790071"	"sentrix_id: 202250790139"	"sentrix_id: 202242410162"	"sentrix_id: 202242400194"	"sentrix_id: 202242410217"	"sentrix_id: 202242410047"	"sentrix_id: 202232360119"	"sentrix_id: 202242400210"	"sentrix_id: 202242400213"	"sentrix_id: 202242400108"	"sentrix_id: 202250790041"	"sentrix_id: 202259350108"	"sentrix_id: 202242400165"	"sentrix_id: 202242400077"	"sentrix_id: 202242400196"	"sentrix_id: 202250790053"	"sentrix_id: 202259340144"	"sentrix_id: 202242410136"	"sentrix_id: 202242400077"	"sentrix_id: 202242400196"	"sentrix_id: 202242400063"	"sentrix_id: 202250790053"	"sentrix_id: 202242410214"	"sentrix_id: 202242410053"	"sentrix_id: 202242410217"	"sentrix_id: 202250790095"	"sentrix_id: 202242400138"	"sentrix_id: 202242400210"	"sentrix_id: 202250800031"	"sentrix_id: 202250790020"	"sentrix_id: 202242400073"	"sentrix_id: 202242400209"	"sentrix_id: 202232290016"	"sentrix_id: 202242400021"	"sentrix_id: 202250790132"	"sentrix_id: 202232360076"	"sentrix_id: 202242410198"	"sentrix_id: 202242400064"	"sentrix_id: 202242400017"	"sentrix_id: 202259350123"	"sentrix_id: 202234390005"	"sentrix_id: 202242400029"	"sentrix_id: 202242400064"	"sentrix_id: 202242400063"	"sentrix_id: 202250790071"	"sentrix_id: 202242400015"	"sentrix_id: 202242400134"	"sentrix_id: 202242400134"	"sentrix_id: 202242400053"	"sentrix_id: 202250790071"	"sentrix_id: 202250790129"	"sentrix_id: 202242410028"	"sentrix_id: 202242400080"	"sentrix_id: 202242400199"	"sentrix_id: 202242400081"	"sentrix_id: 202242400089"	"sentrix_id: 202259340084"	"sentrix_id: 202259350094"	"sentrix_id: 202242400064"	"sentrix_id: 202250790014"	"sentrix_id: 202250790129"	"sentrix_id: 202242410095"	"sentrix_id: 202242400064"	"sentrix_id: 202259350150"	"sentrix_id: 202232360076"	"sentrix_id: 202259350094"	"sentrix_id: 202259350108"	"sentrix_id: 202259350108"	"sentrix_id: 202250790021"	"sentrix_id: 202242410128"	"sentrix_id: 202259340092"	"sentrix_id: 202250790095"	"sentrix_id: 202242400199"	"sentrix_id: 202259340021"	"sentrix_id: 202259340092"	"sentrix_id: 202242410095"	"sentrix_id: 202259340084"	"sentrix_id: 202259350096"	"sentrix_id: 202242410030"	"sentrix_id: 202242400134"	"sentrix_id: 202250790014"	"sentrix_id: 202242400081"	"sentrix_id: 202232360054"	"sentrix_id: 202250790053"	"sentrix_id: 202259340017"	"sentrix_id: 202259340003"	"sentrix_id: 202259350141"	"sentrix_id: 202259350141"	"sentrix_id: 202259340084"	"sentrix_id: 202242410039"	"sentrix_id: 202242400165"	"sentrix_id: 202259350191"	"sentrix_id: 202259340084"	"sentrix_id: 202250790002"	"sentrix_id: 202242410095"	"sentrix_id: 202242400179"	"sentrix_id: 202259350094"	"sentrix_id: 202234390006"	"sentrix_id: 202259340003"	"sentrix_id: 202250790168"	"sentrix_id: 202242410048"	"sentrix_id: 202259340084"	"sentrix_id: 202259350124"	"sentrix_id: 202259350003"	"sentrix_id: 202259340092"	"sentrix_id: 202242410128"	"sentrix_id: 202259340144"	"sentrix_id: 202242400066"	"sentrix_id: 202259350108"	"sentrix_id: 202250790142"	"sentrix_id: 202259350003"	"sentrix_id: 202234390052"	"sentrix_id: 202259350096"	"sentrix_id: 202259350141"	"sentrix_id: 202242410048"	"sentrix_id: 202250790132"	"sentrix_id: 202242410102"	"sentrix_id: 202259350124"	"sentrix_id: 202259340084"	"sentrix_id: 202259340084"	"sentrix_id: 202250790142"	"sentrix_id: 202242400076"	"sentrix_id: 202242400015"	"sentrix_id: 202259350191"	"sentrix_id: 202250790006"	"sentrix_id: 202250790133"	"sentrix_id: 202259350003"	"sentrix_id: 202242410048"	"sentrix_id: 202242410102"	"sentrix_id: 202242400076"	"sentrix_id: 202242410054"	"sentrix_id: 202250790095"	"sentrix_id: 202250790053"	"sentrix_id: 202250790012"	"sentrix_id: 202242400066"	"sentrix_id: 202250800020"	"sentrix_id: 202250790095"	"sentrix_id: 202250790168"	"sentrix_id: 202242410198"	"sentrix_id: 202259350191"	"sentrix_id: 202242410037"	"sentrix_id: 202242400220"	"sentrix_id: 202242410037"	"sentrix_id: 202242400167"	"sentrix_id: 202259350150"	"sentrix_id: 202242410095"	"sentrix_id: 202242400020"	"sentrix_id: 202250790012"	"sentrix_id: 202250790052"	"sentrix_id: 202250790133"	"sentrix_id: 202242400089"	"sentrix_id: 202250790095"	"sentrix_id: 202242400092"	"sentrix_id: 202250790053"	"sentrix_id: 202250790133"	"sentrix_id: 202250790133"	"sentrix_id: 202250790095"	"sentrix_id: 202250790133"	"sentrix_id: 202250790133"	"sentrix_id: 202250790052"	"sentrix_id: 202250790133"	"sentrix_id: 202250800020"	"sentrix_id: 202242400004"	"sentrix_id: 202242400004"	"sentrix_id: 202242410102"	"sentrix_id: 202242400075"	"sentrix_id: 202250790053"	"sentrix_id: 202250790095"	"sentrix_id: 202250790133"	"sentrix_id: 202242410039"	"sentrix_id: 202250800020"	"sentrix_id: 202242410039"	"sentrix_id: 202250790052"	"sentrix_id: 202250790132"	"sentrix_id: 202250790095"	"sentrix_id: 202250790125"	"sentrix_id: 202242400091"	"sentrix_id: 202242400162"	"sentrix_id: 202242400063"	"sentrix_id: 202242400007"	"sentrix_id: 202242400021"	"sentrix_id: 202259340084"	"sentrix_id: 202242400092"	"sentrix_id: 202250800031"	"sentrix_id: 202242400179"	"sentrix_id: 202250790019"	"sentrix_id: 202242400224"	"sentrix_id: 202259350119"	"sentrix_id: 202242400080"	"sentrix_id: 202242400014"	"sentrix_id: 202242400210"	"sentrix_id: 202250790097"	"sentrix_id: 202250800020"	"sentrix_id: 202250790142"	"sentrix_id: 202242400063"	"sentrix_id: 202242400077"	"sentrix_id: 202234390005"	"sentrix_id: 202242400167"	"sentrix_id: 202242400004"	"sentrix_id: 202250790129"	"sentrix_id: 202242400091"	"sentrix_id: 202250790006"	"sentrix_id: 202234390005"	"sentrix_id: 202250790006"	"sentrix_id: 202250790002"	"sentrix_id: 202242400209"	"sentrix_id: 202250790021"	"sentrix_id: 202242400092"	"sentrix_id: 202242400019"	"sentrix_id: 202242400137"	"sentrix_id: 202242400086"	"sentrix_id: 202242400209"	"sentrix_id: 202232290016"	"sentrix_id: 202242410053"	"sentrix_id: 202250790060"	"sentrix_id: 202250790006"	"sentrix_id: 202259350119"	"sentrix_id: 202250790002"	"sentrix_id: 202250790021"	"sentrix_id: 202250790132"	"sentrix_id: 202250790020"	"sentrix_id: 202234390009"	"sentrix_id: 202242400138"	"sentrix_id: 202259350094"	"sentrix_id: 202242400167"	"sentrix_id: 202242400134"	"sentrix_id: 202250790014"	"sentrix_id: 202250790053"	"sentrix_id: 202250790021"	"sentrix_id: 202250790139"	"sentrix_id: 202242400011"	"sentrix_id: 202242410047"	"sentrix_id: 202242410053"	"sentrix_id: 202259350119"	"sentrix_id: 202242410041"	"sentrix_id: 202242400021"	"sentrix_id: 202242400011"	"sentrix_id: 202242400019"	"sentrix_id: 202234390009"	"sentrix_id: 202242400019"	"sentrix_id: 202250790097"	"sentrix_id: 202242410041"	"sentrix_id: 202250790019"	"sentrix_id: 202259340144"	"sentrix_id: 202242400104"	"sentrix_id: 202242400089"	"sentrix_id: 202242400073"	"sentrix_id: 202242400204"	"sentrix_id: 202242400053"	"sentrix_id: 202242410083"	"sentrix_id: 202259340003"	"sentrix_id: 202242410128"	"sentrix_id: 202242410095"	"sentrix_id: 202242400067"	"sentrix_id: 202259350150"	"sentrix_id: 202242400067"	"sentrix_id: 202259350141"	"sentrix_id: 202242400066"	"sentrix_id: 202242400081"	"sentrix_id: 202259350003"	"sentrix_id: 202259350108"	"sentrix_id: 202242400029"	"sentrix_id: 202242400110"	"sentrix_id: 202250790168"	"sentrix_id: 202250790041"	"sentrix_id: 202250790012"	"sentrix_id: 202250800031"	"sentrix_id: 202242400138"	"sentrix_id: 202242400204"	"sentrix_id: 202242400138"	"sentrix_id: 202250800034"	"sentrix_id: 202242400019"	"sentrix_id: 202242400064"	"sentrix_id: 202250790125"	"sentrix_id: 202242400021"	"sentrix_id: 202250790020"	"sentrix_id: 202242400146"	"sentrix_id: 202242400162"	"sentrix_id: 202250790125"	"sentrix_id: 202242400010"	"sentrix_id: 202242400078"	"sentrix_id: 202250800034"	"sentrix_id: 202232360076"	"sentrix_id: 202242400011"	"sentrix_id: 202234390005"	"sentrix_id: 202242410028"	"sentrix_id: 202250790139"	"sentrix_id: 202242410128"	"sentrix_id: 202250790199"	"sentrix_id: 202242410041"	"sentrix_id: 202242400146"	"sentrix_id: 202242400017"	"sentrix_id: 202242400091"	"sentrix_id: 202250790071"	"sentrix_id: 202242400204"	"sentrix_id: 202234390006"	"sentrix_id: 202242400016"	"sentrix_id: 202242400196"	"sentrix_id: 202242400091"	"sentrix_id: 202259340092"	"sentrix_id: 202242400110"	"sentrix_id: 202242400162"	"sentrix_id: 202234390052"	"sentrix_id: 202234390005"	"sentrix_id: 202242400065"	"sentrix_id: 202232290016"	"sentrix_id: 202259340021"	"sentrix_id: 202250790041"	"sentrix_id: 202242400156"	"sentrix_id: 202242400075"	"sentrix_id: 202242410041"	"sentrix_id: 202250790006"	"sentrix_id: 202259350191"	"sentrix_id: 202242400156"	"sentrix_id: 202250790006"	"sentrix_id: 202250790132"	"sentrix_id: 202242410041"	"sentrix_id: 202250790002"	"sentrix_id: 202242400108"	"sentrix_id: 202250800020"	"sentrix_id: 202250790014"	"sentrix_id: 202242400064"	"sentrix_id: 202250790002"	"sentrix_id: 202242410214"	"sentrix_id: 202242400092"	"sentrix_id: 202250790014"	"sentrix_id: 202242400196"	"sentrix_id: 202250790142"	"sentrix_id: 202242410053"	"sentrix_id: 202242400209"	"sentrix_id: 202242410039"	"sentrix_id: 202242410053"	"sentrix_id: 202242400092"	"sentrix_id: 202250800034"	"sentrix_id: 202250790021"	"sentrix_id: 202242400014"	"sentrix_id: 202250790060"	"sentrix_id: 202250790021"	"sentrix_id: 202242400065"	"sentrix_id: 202242400075"	"sentrix_id: 202242400209"	"sentrix_id: 202242400010"	"sentrix_id: 202242400110"	"sentrix_id: 202242400021"	"sentrix_id: 202242400194"	"sentrix_id: 202250790021"	"sentrix_id: 202250790060"	"sentrix_id: 202242400209"	"sentrix_id: 202250790132"	"sentrix_id: 202242400020"	"sentrix_id: 202250790002"	"sentrix_id: 202250790129"	"sentrix_id: 202250790006"	"sentrix_id: 202250790060"	"sentrix_id: 202242400137"	"sentrix_id: 202242400063"	"sentrix_id: 202232360060"	"sentrix_id: 202242410053"	"sentrix_id: 202242400004"	"sentrix_id: 202242410048"	"sentrix_id: 202242400199"	"sentrix_id: 202242410075"	"sentrix_id: 202242400089"	"sentrix_id: 202242400067"	"sentrix_id: 202259340017"	"sentrix_id: 202242410037"	"sentrix_id: 202242410095"	"sentrix_id: 202242400004"	"sentrix_id: 202242410162"	"sentrix_id: 202242400204"	"sentrix_id: 202242410136"	"sentrix_id: 202259350003"	"sentrix_id: 202242400220"	"sentrix_id: 202259340003"	"sentrix_id: 202242410054"	"sentrix_id: 202242410030"	"sentrix_id: 202259350141"	"sentrix_id: 202250790129"	"sentrix_id: 202242400080"	"sentrix_id: 202242400064"	"sentrix_id: 202242400137"	"sentrix_id: 202242410030"	"sentrix_id: 202242400220"	"sentrix_id: 202259350003"	"sentrix_id: 202242400199"	"sentrix_id: 202259340003"	"sentrix_id: 202259350141"	"sentrix_id: 202242400067"	"sentrix_id: 202259340017"	"sentrix_id: 202242410054"	"sentrix_id: 202242410048"	"sentrix_id: 202250790052"	"sentrix_id: 202242410075"	"sentrix_id: 202250790012"	"sentrix_id: 202232290016"	"sentrix_id: 202242410054"	"sentrix_id: 202250790052"	"sentrix_id: 202242400146"	"sentrix_id: 202250790052"	"sentrix_id: 202242400213"	"sentrix_id: 202242410095"	"sentrix_id: 202242410102"	"sentrix_id: 202242410128"	"sentrix_id: 202242400080"	"sentrix_id: 202242410162"	"sentrix_id: 202242400146"	"sentrix_id: 202242400007"	"sentrix_id: 202242400016"	"sentrix_id: 202232360119"	"sentrix_id: 202242400007"	"sentrix_id: 202242400167"	"sentrix_id: 202234390005"	"sentrix_id: 202259350058"	"sentrix_id: 202242400204"	"sentrix_id: 202242410030"	"sentrix_id: 202242410028"	"sentrix_id: 202242400016"	"sentrix_id: 202234390009"	"sentrix_id: 202250800031"	"sentrix_id: 202250790168"	"sentrix_id: 202242400086"	"sentrix_id: 202242400065"	"sentrix_id: 202242400075"	"sentrix_id: 202259350123"	"sentrix_id: 202242410028"	"sentrix_id: 202234390009"	"sentrix_id: 202242410083"	"sentrix_id: 202259350058"	"sentrix_id: 202250790125"	"sentrix_id: 202259350123"	"sentrix_id: 202242410214"	"sentrix_id: 202234390005"	"sentrix_id: 202232360054"	"sentrix_id: 202250790139"	"sentrix_id: 202250790020"	"sentrix_id: 202250800019"	"sentrix_id: 202259350124"	"sentrix_id: 202232360076"	"sentrix_id: 202250790041"	"sentrix_id: 202234390009"	"sentrix_id: 202242400146"	"sentrix_id: 202232360060"	"sentrix_id: 202242410047"	"sentrix_id: 202250790199"	"sentrix_id: 202242400210"	"sentrix_id: 202242400029"	"sentrix_id: 202250790097"	"sentrix_id: 202242400223"	"sentrix_id: 202242400065"	"sentrix_id: 202234390052"	"sentrix_id: 202242410136"	"sentrix_id: 202259350058"	"sentrix_id: 202242400223"	"sentrix_id: 202250790139"	"sentrix_id: 202242410028"	"sentrix_id: 202242400223"	"sentrix_id: 202250800019"	"sentrix_id: 202242400204"	"sentrix_id: 202242410054"	"sentrix_id: 202242400077"	"sentrix_id: 202242400137"	"sentrix_id: 202250790166"	"sentrix_id: 202242400016"	"sentrix_id: 202242400014"	"sentrix_id: 202242400104"	"sentrix_id: 202250800035"	"sentrix_id: 202242400077"	"sentrix_id: 202242400108"	"sentrix_id: 202242400078"	"sentrix_id: 202242400029"	"sentrix_id: 202259340144"	"sentrix_id: 202242410102"	"sentrix_id: 202250800035"	"sentrix_id: 202242400065"	"sentrix_id: 202242400224"	"sentrix_id: 202232360054"	"sentrix_id: 202242410217"	"sentrix_id: 202259350119"	"sentrix_id: 202242400224"	"sentrix_id: 202242400210"	"sentrix_id: 202250790139"	"sentrix_id: 202242400223"	"sentrix_id: 202250790020"	"sentrix_id: 202250790019"	"sentrix_id: 202242400165"	"sentrix_id: 202242400076"	"sentrix_id: 202242400077"	"sentrix_id: 202242400162"	"sentrix_id: 202242400010"	"sentrix_id: 202242410037"	"sentrix_id: 202242400104"	"sentrix_id: 202250790020"	"sentrix_id: 202250790071"	"sentrix_id: 202242400063"	"sentrix_id: 202242400179"	"sentrix_id: 202242400019"	"sentrix_id: 202242400073"	"sentrix_id: 202234390005"	"sentrix_id: 202250790071"	"sentrix_id: 202250800034"	"sentrix_id: 202250790166"	"sentrix_id: 202259350124"	"sentrix_id: 202250790012"	"sentrix_id: 202242400010"	"sentrix_id: 202250800034"	"sentrix_id: 202259350096"	"sentrix_id: 202242410136"	"sentrix_id: 202250790199"	"sentrix_id: 202250790125"	"sentrix_id: 202242400196"	"sentrix_id: 202242400073"	"sentrix_id: 202242410102"	"sentrix_id: 202242400134"	"sentrix_id: 202242410039"	"sentrix_id: 202242400015"	"sentrix_id: 202242400014"	"sentrix_id: 202242410198"	"sentrix_id: 202242400210"	"sentrix_id: 202242400134"	"sentrix_id: 202242400053"	"sentrix_id: 202250790097"	"sentrix_id: 202242400010"	"sentrix_id: 202242400167"	"sentrix_id: 202242400086"	"sentrix_id: 202242410054"	"sentrix_id: 202242400146"	"sentrix_id: 202250790168"	"sentrix_id: 202250790097"	"sentrix_id: 202242400065"	"sentrix_id: 202242400015"	"sentrix_id: 202242400213"	"sentrix_id: 202250800035"	"sentrix_id: 202234390052"	"sentrix_id: 202242400138"	"sentrix_id: 202242400138"	"sentrix_id: 202242410083"	"sentrix_id: 202242400029"	"sentrix_id: 202242400196"	"sentrix_id: 202242400073"	"sentrix_id: 202250790166"	"sentrix_id: 202250790142"	"sentrix_id: 202242400075"	"sentrix_id: 202242400162"	"sentrix_id: 202250790166"	"sentrix_id: 202250790097"	"sentrix_id: 202242400077"	"sentrix_id: 202234390052"	"sentrix_id: 202259350096"	"sentrix_id: 202242400156"	"sentrix_id: 202259340144"	"sentrix_id: 202232360076"	"sentrix_id: 202242400016"	"sentrix_id: 202242400015"	"sentrix_id: 202250800034"	"sentrix_id: 202250790125"	"sentrix_id: 202232360054"	"sentrix_id: 202242400020"	"sentrix_id: 202242400156"	"sentrix_id: 202242400091"	"sentrix_id: 202242400011"	"sentrix_id: 202242400011"	"sentrix_id: 202250790139"	"sentrix_id: 202242400210"	"sentrix_id: 202234390052"	"sentrix_id: 202259350058"	"sentrix_id: 202242400014"	"sentrix_id: 202250790097"	"sentrix_id: 202259340021"	"sentrix_id: 202242400156"	"sentrix_id: 202234390052"	"sentrix_id: 202250800035"	"sentrix_id: 202242400224"	"sentrix_id: 202242410041"	"sentrix_id: 202250800019"	"sentrix_id: 202242400137"	"sentrix_id: 202250800035"	"sentrix_id: 202242400196"	"sentrix_id: 202242400010"	"sentrix_id: 202250790139"	"sentrix_id: 202242400014"	"sentrix_id: 202250790199"	"sentrix_id: 202242400080"	"sentrix_id: 202242400021"	"sentrix_id: 202242410047"	"sentrix_id: 202242400078"	"sentrix_id: 202234390006"	"sentrix_id: 202242410198"	"sentrix_id: 202242410039"	"sentrix_id: 202259340017"	"sentrix_id: 202232290016"	"sentrix_id: 202242400194"	"sentrix_id: 202242410198"	"sentrix_id: 202242410083"	"sentrix_id: 202242410083"	"sentrix_id: 202242410037"	"sentrix_id: 202242400019"	"sentrix_id: 202242400092"	"sentrix_id: 202242400076"	"sentrix_id: 202242410102"	"sentrix_id: 202232360076"	"sentrix_id: 202242400004"	"sentrix_id: 202242400007"	"sentrix_id: 202259350119"	"sentrix_id: 202242400073"	"sentrix_id: 202242400213"	"sentrix_id: 202232360119"	"sentrix_id: 202242400146"	"sentrix_id: 202242400053"	"sentrix_id: 202242400081"	"sentrix_id: 202242400204"	"sentrix_id: 202250790014"	"sentrix_id: 202242400015"	"sentrix_id: 202242400007"	"sentrix_id: 202242400011"	"sentrix_id: 202242410198"	"sentrix_id: 202242400110"	"sentrix_id: 202242400065"	"sentrix_id: 202242400194"	"sentrix_id: 202242410214"	"sentrix_id: 202242400076"	"sentrix_id: 202242400204"	"sentrix_id: 202242400110"	"sentrix_id: 202250790014"	"sentrix_id: 202242410162"	"sentrix_id: 202242410030"	"sentrix_id: 202242400146"	"sentrix_id: 202250790060"	"sentrix_id: 202242400086"	"sentrix_id: 202242410217"	"sentrix_id: 202250790060"	"sentrix_id: 202242410028"	"sentrix_id: 202250790053"	"sentrix_id: 202250790002"	"sentrix_id: 202242400224"	"sentrix_id: 202259350094"	"sentrix_id: 202232360060"	"sentrix_id: 202259350058"	"sentrix_id: 202250790097"	"sentrix_id: 202250800035"	"sentrix_id: 202250800020"	"sentrix_id: 202242400137"	"sentrix_id: 202250790132"	"sentrix_id: 202250790060"	"sentrix_id: 202242400108"	"sentrix_id: 202250790129"	"sentrix_id: 202242400209"	"sentrix_id: 202250790129"	"sentrix_id: 202250790021"	"sentrix_id: 202250790060"	"sentrix_id: 202242400066"	"sentrix_id: 202259340021"	"sentrix_id: 202242400065"	"sentrix_id: 202242400066"	"sentrix_id: 202259340144"	"sentrix_id: 202242400223"	"sentrix_id: 202242400092"	"sentrix_id: 202259340092"	"sentrix_id: 202242400165"	"sentrix_id: 202259350058"	"sentrix_id: 202242400029"	"sentrix_id: 202242400076"	"sentrix_id: 202232360054"	"sentrix_id: 202242400213"	"sentrix_id: 202250790014"	"sentrix_id: 202242400004"	"sentrix_id: 202250790002"	"sentrix_id: 202242410053"	"sentrix_id: 202250790006"	"sentrix_id: 202242410053"	"sentrix_id: 202242400209"	"sentrix_id: 202242400004"	"sentrix_id: 202250800019"	"sentrix_id: 202259350096"	"sentrix_id: 202242400075"	"sentrix_id: 202250790166"	"sentrix_id: 202242400167"
!Sample_characteristics_ch1	"sentrix_position: R08C01"	"sentrix_position: R07C01"	"sentrix_position: R01C01"	"sentrix_position: R05C01"	"sentrix_position: R01C01"	"sentrix_position: R07C01"	"sentrix_position: R02C01"	"sentrix_position: R06C01"	"sentrix_position: R04C01"	"sentrix_position: R08C01"	"sentrix_position: R02C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R02C01"	"sentrix_position: R07C01"	"sentrix_position: R05C01"	"sentrix_position: R02C01"	"sentrix_position: R06C01"	"sentrix_position: R07C01"	"sentrix_position: R06C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R02C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R06C01"	"sentrix_position: R02C01"	"sentrix_position: R08C01"	"sentrix_position: R05C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R02C01"	"sentrix_position: R08C01"	"sentrix_position: R03C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R01C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R05C01"	"sentrix_position: R07C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R08C01"	"sentrix_position: R05C01"	"sentrix_position: R01C01"	"sentrix_position: R07C01"	"sentrix_position: R01C01"	"sentrix_position: R05C01"	"sentrix_position: R02C01"	"sentrix_position: R08C01"	"sentrix_position: R06C01"	"sentrix_position: R08C01"	"sentrix_position: R01C01"	"sentrix_position: R02C01"	"sentrix_position: R08C01"	"sentrix_position: R05C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R03C01"	"sentrix_position: R06C01"	"sentrix_position: R02C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R05C01"	"sentrix_position: R04C01"	"sentrix_position: R08C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R01C01"	"sentrix_position: R08C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R05C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R01C01"	"sentrix_position: R04C01"	"sentrix_position: R05C01"	"sentrix_position: R07C01"	"sentrix_position: R05C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R02C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R03C01"	"sentrix_position: R04C01"	"sentrix_position: R05C01"	"sentrix_position: R08C01"	"sentrix_position: R04C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R04C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R04C01"	"sentrix_position: R06C01"	"sentrix_position: R07C01"	"sentrix_position: R03C01"	"sentrix_position: R05C01"	"sentrix_position: R04C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R04C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R05C01"	"sentrix_position: R04C01"	"sentrix_position: R02C01"	"sentrix_position: R04C01"	"sentrix_position: R05C01"	"sentrix_position: R01C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R02C01"	"sentrix_position: R04C01"	"sentrix_position: R01C01"	"sentrix_position: R07C01"	"sentrix_position: R03C01"	"sentrix_position: R08C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R03C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R01C01"	"sentrix_position: R04C01"	"sentrix_position: R03C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R08C01"	"sentrix_position: R02C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R03C01"	"sentrix_position: R05C01"	"sentrix_position: R02C01"	"sentrix_position: R07C01"	"sentrix_position: R06C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R03C01"	"sentrix_position: R07C01"	"sentrix_position: R05C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R01C01"	"sentrix_position: R04C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R04C01"	"sentrix_position: R06C01"	"sentrix_position: R03C01"	"sentrix_position: R02C01"	"sentrix_position: R08C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R08C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R02C01"	"sentrix_position: R03C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R07C01"	"sentrix_position: R01C01"	"sentrix_position: R07C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R01C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R02C01"	"sentrix_position: R05C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R03C01"	"sentrix_position: R08C01"	"sentrix_position: R07C01"	"sentrix_position: R01C01"	"sentrix_position: R05C01"	"sentrix_position: R01C01"	"sentrix_position: R03C01"	"sentrix_position: R07C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R02C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R05C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R04C01"	"sentrix_position: R03C01"	"sentrix_position: R05C01"	"sentrix_position: R06C01"	"sentrix_position: R02C01"	"sentrix_position: R04C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R01C01"	"sentrix_position: R03C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R02C01"	"sentrix_position: R08C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R06C01"	"sentrix_position: R03C01"	"sentrix_position: R04C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R02C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R01C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R06C01"	"sentrix_position: R02C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R06C01"	"sentrix_position: R07C01"	"sentrix_position: R03C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R06C01"	"sentrix_position: R07C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R08C01"	"sentrix_position: R04C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R06C01"	"sentrix_position: R01C01"	"sentrix_position: R08C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R07C01"	"sentrix_position: R01C01"	"sentrix_position: R02C01"	"sentrix_position: R06C01"	"sentrix_position: R07C01"	"sentrix_position: R01C01"	"sentrix_position: R08C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R01C01"	"sentrix_position: R04C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R03C01"	"sentrix_position: R01C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R03C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R03C01"	"sentrix_position: R05C01"	"sentrix_position: R04C01"	"sentrix_position: R06C01"	"sentrix_position: R01C01"	"sentrix_position: R02C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R07C01"	"sentrix_position: R06C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R08C01"	"sentrix_position: R03C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R01C01"	"sentrix_position: R05C01"	"sentrix_position: R02C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R08C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R05C01"	"sentrix_position: R01C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R05C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R06C01"	"sentrix_position: R08C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R06C01"	"sentrix_position: R08C01"	"sentrix_position: R06C01"	"sentrix_position: R03C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R03C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R07C01"	"sentrix_position: R02C01"	"sentrix_position: R07C01"	"sentrix_position: R06C01"	"sentrix_position: R03C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R02C01"	"sentrix_position: R05C01"	"sentrix_position: R01C01"	"sentrix_position: R08C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R03C01"	"sentrix_position: R06C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R06C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R04C01"	"sentrix_position: R06C01"	"sentrix_position: R04C01"	"sentrix_position: R08C01"	"sentrix_position: R07C01"	"sentrix_position: R03C01"	"sentrix_position: R05C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R03C01"	"sentrix_position: R02C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R03C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R08C01"	"sentrix_position: R01C01"	"sentrix_position: R02C01"	"sentrix_position: R03C01"	"sentrix_position: R07C01"	"sentrix_position: R05C01"	"sentrix_position: R01C01"	"sentrix_position: R04C01"	"sentrix_position: R08C01"	"sentrix_position: R07C01"	"sentrix_position: R05C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R02C01"	"sentrix_position: R05C01"	"sentrix_position: R06C01"	"sentrix_position: R03C01"	"sentrix_position: R06C01"	"sentrix_position: R03C01"	"sentrix_position: R04C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R06C01"	"sentrix_position: R03C01"	"sentrix_position: R07C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R04C01"	"sentrix_position: R01C01"	"sentrix_position: R08C01"	"sentrix_position: R06C01"	"sentrix_position: R08C01"	"sentrix_position: R06C01"	"sentrix_position: R04C01"	"sentrix_position: R01C01"	"sentrix_position: R03C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R02C01"	"sentrix_position: R05C01"	"sentrix_position: R02C01"	"sentrix_position: R04C01"	"sentrix_position: R03C01"	"sentrix_position: R04C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R06C01"	"sentrix_position: R02C01"	"sentrix_position: R08C01"	"sentrix_position: R01C01"	"sentrix_position: R03C01"	"sentrix_position: R08C01"	"sentrix_position: R02C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R04C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R07C01"	"sentrix_position: R05C01"	"sentrix_position: R07C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R02C01"	"sentrix_position: R05C01"	"sentrix_position: R01C01"	"sentrix_position: R04C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R04C01"	"sentrix_position: R02C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R08C01"	"sentrix_position: R03C01"	"sentrix_position: R02C01"	"sentrix_position: R08C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R07C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R07C01"	"sentrix_position: R02C01"	"sentrix_position: R03C01"	"sentrix_position: R04C01"	"sentrix_position: R08C01"	"sentrix_position: R04C01"	"sentrix_position: R08C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R07C01"	"sentrix_position: R05C01"	"sentrix_position: R08C01"	"sentrix_position: R05C01"	"sentrix_position: R07C01"	"sentrix_position: R03C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R03C01"	"sentrix_position: R07C01"	"sentrix_position: R05C01"	"sentrix_position: R06C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R08C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R08C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R02C01"	"sentrix_position: R07C01"	"sentrix_position: R02C01"	"sentrix_position: R06C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R05C01"	"sentrix_position: R04C01"	"sentrix_position: R02C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R06C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R04C01"	"sentrix_position: R03C01"	"sentrix_position: R05C01"	"sentrix_position: R01C01"	"sentrix_position: R08C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R02C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R03C01"	"sentrix_position: R08C01"	"sentrix_position: R01C01"	"sentrix_position: R04C01"	"sentrix_position: R02C01"	"sentrix_position: R04C01"	"sentrix_position: R01C01"	"sentrix_position: R03C01"	"sentrix_position: R01C01"	"sentrix_position: R03C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R08C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R07C01"	"sentrix_position: R06C01"	"sentrix_position: R01C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R04C01"	"sentrix_position: R02C01"	"sentrix_position: R05C01"	"sentrix_position: R01C01"	"sentrix_position: R02C01"	"sentrix_position: R04C01"	"sentrix_position: R08C01"	"sentrix_position: R01C01"	"sentrix_position: R03C01"	"sentrix_position: R08C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R04C01"	"sentrix_position: R02C01"	"sentrix_position: R08C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R04C01"	"sentrix_position: R02C01"	"sentrix_position: R03C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R03C01"	"sentrix_position: R01C01"	"sentrix_position: R03C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R02C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R02C01"	"sentrix_position: R08C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R04C01"	"sentrix_position: R01C01"	"sentrix_position: R02C01"	"sentrix_position: R03C01"	"sentrix_position: R02C01"	"sentrix_position: R08C01"	"sentrix_position: R03C01"	"sentrix_position: R02C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R08C01"	"sentrix_position: R01C01"	"sentrix_position: R08C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R04C01"	"sentrix_position: R01C01"	"sentrix_position: R04C01"	"sentrix_position: R01C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R08C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R08C01"	"sentrix_position: R03C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R02C01"	"sentrix_position: R08C01"	"sentrix_position: R06C01"	"sentrix_position: R08C01"	"sentrix_position: R02C01"	"sentrix_position: R07C01"	"sentrix_position: R03C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R04C01"	"sentrix_position: R06C01"	"sentrix_position: R08C01"	"sentrix_position: R02C01"	"sentrix_position: R08C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R01C01"	"sentrix_position: R04C01"	"sentrix_position: R01C01"	"sentrix_position: R03C01"	"sentrix_position: R05C01"	"sentrix_position: R07C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R07C01"	"sentrix_position: R01C01"	"sentrix_position: R04C01"	"sentrix_position: R08C01"	"sentrix_position: R01C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R05C01"	"sentrix_position: R06C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R01C01"	"sentrix_position: R02C01"	"sentrix_position: R05C01"	"sentrix_position: R04C01"	"sentrix_position: R02C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R01C01"	"sentrix_position: R03C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R08C01"	"sentrix_position: R03C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R05C01"	"sentrix_position: R07C01"	"sentrix_position: R03C01"	"sentrix_position: R01C01"	"sentrix_position: R08C01"	"sentrix_position: R02C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R08C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R05C01"	"sentrix_position: R04C01"	"sentrix_position: R03C01"	"sentrix_position: R05C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R05C01"	"sentrix_position: R08C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R08C01"	"sentrix_position: R02C01"	"sentrix_position: R07C01"	"sentrix_position: R03C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R04C01"	"sentrix_position: R06C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R03C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R02C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R06C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R05C01"	"sentrix_position: R07C01"	"sentrix_position: R05C01"	"sentrix_position: R01C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R05C01"	"sentrix_position: R08C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R02C01"	"sentrix_position: R04C01"	"sentrix_position: R03C01"	"sentrix_position: R06C01"	"sentrix_position: R06C01"	"sentrix_position: R02C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R01C01"	"sentrix_position: R03C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R08C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R03C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R04C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R07C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R06C01"	"sentrix_position: R08C01"	"sentrix_position: R03C01"	"sentrix_position: R02C01"	"sentrix_position: R04C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R07C01"	"sentrix_position: R03C01"	"sentrix_position: R03C01"	"sentrix_position: R02C01"	"sentrix_position: R03C01"	"sentrix_position: R06C01"	"sentrix_position: R08C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R03C01"	"sentrix_position: R04C01"	"sentrix_position: R03C01"	"sentrix_position: R04C01"	"sentrix_position: R03C01"	"sentrix_position: R05C01"	"sentrix_position: R01C01"	"sentrix_position: R05C01"	"sentrix_position: R04C01"	"sentrix_position: R05C01"	"sentrix_position: R07C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R04C01"	"sentrix_position: R03C01"	"sentrix_position: R06C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R04C01"	"sentrix_position: R05C01"	"sentrix_position: R07C01"	"sentrix_position: R06C01"	"sentrix_position: R01C01"	"sentrix_position: R05C01"	"sentrix_position: R08C01"	"sentrix_position: R01C01"	"sentrix_position: R05C01"	"sentrix_position: R04C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R04C01"	"sentrix_position: R01C01"	"sentrix_position: R08C01"	"sentrix_position: R02C01"	"sentrix_position: R08C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R02C01"	"sentrix_position: R08C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R04C01"	"sentrix_position: R06C01"	"sentrix_position: R03C01"	"sentrix_position: R01C01"	"sentrix_position: R08C01"	"sentrix_position: R03C01"	"sentrix_position: R02C01"	"sentrix_position: R02C01"	"sentrix_position: R06C01"	"sentrix_position: R01C01"	"sentrix_position: R01C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R08C01"	"sentrix_position: R06C01"	"sentrix_position: R02C01"	"sentrix_position: R07C01"	"sentrix_position: R08C01"	"sentrix_position: R02C01"	"sentrix_position: R06C01"	"sentrix_position: R04C01"	"sentrix_position: R02C01"	"sentrix_position: R05C01"	"sentrix_position: R06C01"	"sentrix_position: R07C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R04C01"	"sentrix_position: R04C01"	"sentrix_position: R06C01"	"sentrix_position: R01C01"	"sentrix_position: R07C01"	"sentrix_position: R05C01"	"sentrix_position: R08C01"	"sentrix_position: R06C01"	"sentrix_position: R04C01"	"sentrix_position: R03C01"	"sentrix_position: R04C01"	"sentrix_position: R02C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R04C01"	"sentrix_position: R07C01"	"sentrix_position: R05C01"	"sentrix_position: R04C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R05C01"	"sentrix_position: R06C01"	"sentrix_position: R05C01"	"sentrix_position: R06C01"	"sentrix_position: R02C01"	"sentrix_position: R01C01"	"sentrix_position: R08C01"
!Sample_characteristics_ch1	"participant_id: PT-11EM3"	"participant_id: PT-11EMC"	"participant_id: PT-11GSP"	"participant_id: PT-13D11"	"participant_id: PT-13PL6"	"participant_id: PT-147F3"	"participant_id: PT-14BIL"	"participant_id: PT-14BIN"	"participant_id: PT-14E6C"	"participant_id: PT-14H4A"	"participant_id: PT-14PHY"	"participant_id: PT-14PJ6"	"participant_id: PT-14PK6"	"participant_id: PT-15CHQ"	"participant_id: PT-15CHR"	"participant_id: PT-15DDE"	"participant_id: PT-15ER7"	"participant_id: PT-15EU6"	"participant_id: PT-15SHU"	"participant_id: PT-16NGA"	"participant_id: PT-17HG3"	"participant_id: PT-18D9U"	"participant_id: PT-18QFQ"	"participant_id: PT-1AYD5"	"participant_id: PT-1C6WA"	"participant_id: PT-1F5PL"	"participant_id: PT-1F88E"	"participant_id: PT-1GMR3"	"participant_id: PT-1GN1W"	"participant_id: PT-1GPI6"	"participant_id: PT-1GTWX"	"participant_id: PT-1GZ2Q"	"participant_id: PT-1GZ4H"	"participant_id: PT-1H3VE"	"participant_id: PT-1IDJE"	"participant_id: PT-1IKOH"	"participant_id: PT-S341"	"participant_id: PT-S4P3"	"participant_id: PT-SE5C"	"participant_id: PT-T6MO"	"participant_id: PT-U3ZN"	"participant_id: PT-UJHI"	"participant_id: PT-WI4N"	"participant_id: PT-WRHU"	"participant_id: PT-X15G"	"participant_id: PT-X8HC"	"participant_id: PT-XUW1"	"participant_id: PT-XUZC"	"participant_id: PT-XV7Q"	"participant_id: PT-YFC4"	"participant_id: PT-ZC5H"	"participant_id: PT-ZXES"	"participant_id: PT-1117F"	"participant_id: PT-111FC"	"participant_id: PT-111VG"	"participant_id: PT-111YS"	"participant_id: PT-113JC"	"participant_id: PT-1192W"	"participant_id: PT-1192X"	"participant_id: PT-11DXX"	"participant_id: PT-11DXZ"	"participant_id: PT-11EM3"	"participant_id: PT-11EMC"	"participant_id: PT-11GS4"	"participant_id: PT-11I78"	"participant_id: PT-11ONC"	"participant_id: PT-11P82"	"participant_id: PT-11TT1"	"participant_id: PT-11TTK"	"participant_id: PT-11UD2"	"participant_id: PT-11WQC"	"participant_id: PT-11ZTS"	"participant_id: PT-11ZTT"	"participant_id: PT-11ZU8"	"participant_id: PT-11ZUS"	"participant_id: PT-1211K"	"participant_id: PT-12584"	"participant_id: PT-12696"	"participant_id: PT-12KS4"	"participant_id: PT-12WSE"	"participant_id: PT-12WSF"	"participant_id: PT-12WSI"	"participant_id: PT-12ZZW"	"participant_id: PT-12ZZX"	"participant_id: PT-12ZZY"	"participant_id: PT-12ZZZ"	"participant_id: PT-13111"	"participant_id: PT-13112"	"participant_id: PT-1399R"	"participant_id: PT-139TT"	"participant_id: PT-139YR"	"participant_id: PT-13CF2"	"participant_id: PT-13N1W"	"participant_id: PT-13NYS"	"participant_id: PT-13NZB"	"participant_id: PT-13O3P"	"participant_id: PT-13OW5"	"participant_id: PT-13OW7"	"participant_id: PT-13OW8"	"participant_id: PT-13PL6"	"participant_id: PT-13QIC"	"participant_id: PT-13QJC"	"participant_id: PT-13SLW"	"participant_id: PT-13SLX"	"participant_id: PT-13X6I"	"participant_id: PT-145MH"	"participant_id: PT-1477Z"	"participant_id: PT-147GR"	"participant_id: PT-14A5I"	"participant_id: PT-14A6H"	"participant_id: PT-14ABY"	"participant_id: PT-14AS3"	"participant_id: PT-14BIM"	"participant_id: PT-14BIN"	"participant_id: PT-14BMV"	"participant_id: PT-14DAQ"	"participant_id: PT-14DAR"	"participant_id: PT-14E6D"	"participant_id: PT-14E7W"	"participant_id: PT-14H4A"	"participant_id: PT-14LZ3"	"participant_id: PT-14PJ4"	"participant_id: PT-14PJM"	"participant_id: PT-14PK6"	"participant_id: PT-14PN3"	"participant_id: PT-15CHQ"	"participant_id: PT-15CHR"	"participant_id: PT-15D79"	"participant_id: PT-15DDE"	"participant_id: PT-15DYW"	"participant_id: PT-15EO6"	"participant_id: PT-15EU6"	"participant_id: PT-15RIE"	"participant_id: PT-15SDE"	"participant_id: PT-15SHU"	"participant_id: PT-15SHV"	"participant_id: PT-15SHW"	"participant_id: PT-15SKB"	"participant_id: PT-15SZO"	"participant_id: PT-16AAH"	"participant_id: PT-16NPV"	"participant_id: PT-16YQH"	"participant_id: PT-17EVQ"	"participant_id: PT-17HGU"	"participant_id: PT-18A7A"	"participant_id: PT-18D9B"	"participant_id: PT-18D9U"	"participant_id: PT-19HZE"	"participant_id: PT-1A32A"	"participant_id: PT-1A3MV"	"participant_id: PT-1A3MX"	"participant_id: PT-1AX9I"	"participant_id: PT-1AYD5"	"participant_id: PT-1B8KE"	"participant_id: PT-1B98T"	"participant_id: PT-1BAJH"	"participant_id: PT-1C4CL"	"participant_id: PT-1C64N"	"participant_id: PT-1C64O"	"participant_id: PT-1C6WA"	"participant_id: PT-1CAMQ"	"participant_id: PT-1CAV2"	"participant_id: PT-1CB4H"	"participant_id: PT-1E2YA"	"participant_id: PT-1EN7A"	"participant_id: PT-1F52S"	"participant_id: PT-1F5PK"	"participant_id: PT-1F5PL"	"participant_id: PT-1F6I4"	"participant_id: PT-1F6IF"	"participant_id: PT-1F6RS"	"participant_id: PT-1F75A"	"participant_id: PT-1F75W"	"participant_id: PT-1F88E"	"participant_id: PT-1GL5R"	"participant_id: PT-1GMR2"	"participant_id: PT-1GMR3"	"participant_id: PT-1GTWX"	"participant_id: PT-1GZ4I"	"participant_id: PT-1GZHY"	"participant_id: PT-1H11D"	"participant_id: PT-1H1DF"	"participant_id: PT-1H1ZS"	"participant_id: PT-1H23P"	"participant_id: PT-1H2FU"	"participant_id: PT-1H3VE"	"participant_id: PT-1H3VY"	"participant_id: PT-1HB9E"	"participant_id: PT-1HCVE"	"participant_id: PT-1HGF4"	"participant_id: PT-1HSKV"	"participant_id: PT-1I6K6"	"participant_id: PT-1ICLY"	"participant_id: PT-1IDJH"	"participant_id: PT-1IDJI"	"participant_id: PT-1IDJU"	"participant_id: PT-1IDJV"	"participant_id: PT-1IGQW"	"participant_id: PT-1IKJJ"	"participant_id: PT-1IKK5"	"participant_id: PT-1IY9M"	"participant_id: PT-1J1OQ"	"participant_id: PT-1J1R8"	"participant_id: PT-1J8Q2"	"participant_id: PT-1J8Q3"	"participant_id: PT-1JK1U"	"participant_id: PT-1JMOU"	"participant_id: PT-1JMPZ"	"participant_id: PT-1JMQJ"	"participant_id: PT-1JN1M"	"participant_id: PT-1JN6P"	"participant_id: PT-1JN76"	"participant_id: PT-RUSQ"	"participant_id: PT-RVPU"	"participant_id: PT-RVPV"	"participant_id: PT-S33H"	"participant_id: PT-S341"	"participant_id: PT-S4Z8"	"participant_id: PT-S7SE"	"participant_id: PT-SIU8"	"participant_id: PT-SJXC"	"participant_id: PT-SN8G"	"participant_id: PT-T2IS"	"participant_id: PT-T2YK"	"participant_id: PT-T8EM"	"participant_id: PT-TSE9"	"participant_id: PT-U3ZH"	"participant_id: PT-U3ZM"	"participant_id: PT-U8T8"	"participant_id: PT-UJHI"	"participant_id: PT-UPJH"	"participant_id: PT-UPK5"	"participant_id: PT-UTHO"	"participant_id: PT-W5X1"	"participant_id: PT-WFG8"	"participant_id: PT-WH7G"	"participant_id: PT-WK11"	"participant_id: PT-WOFL"	"participant_id: PT-WQUQ"	"participant_id: PT-WRHU"	"participant_id: PT-WVLH"	"participant_id: PT-WWYW"	"participant_id: PT-WXYG"	"participant_id: PT-WY7C"	"participant_id: PT-WYBS"	"participant_id: PT-X261"	"participant_id: PT-X4EO"	"participant_id: PT-X4EP"	"participant_id: PT-X4XX"	"participant_id: PT-X4XY"	"participant_id: PT-X585"	"participant_id: PT-X5EB"	"participant_id: PT-X62O"	"participant_id: PT-X8HC"	"participant_id: PT-XBEC"	"participant_id: PT-XBED"	"participant_id: PT-XMD2"	"participant_id: PT-XMK1"	"participant_id: PT-XPT6"	"participant_id: PT-XPVG"	"participant_id: PT-XQ3S"	"participant_id: PT-XUJ4"	"participant_id: PT-XV7Q"	"participant_id: PT-XYKS"	"participant_id: PT-Y111"	"participant_id: PT-YB5E"	"participant_id: PT-YFCO"	"participant_id: PT-YJ89"	"participant_id: PT-Z93S"	"participant_id: PT-ZAB4"	"participant_id: PT-ZDTS"	"participant_id: PT-ZDXO"	"participant_id: PT-ZVZP"	"participant_id: PT-ZVZQ"	"participant_id: PT-ZYFG"	"participant_id: PT-ZYY3"	"participant_id: PT-117XS"	"participant_id: PT-117YW"	"participant_id: PT-1192W"	"participant_id: PT-1192X"	"participant_id: PT-11EMC"	"participant_id: PT-11NV4"	"participant_id: PT-11UD2"	"participant_id: PT-11WQC"	"participant_id: PT-11WQK"	"participant_id: PT-11ZU8"	"participant_id: PT-1212Z"	"participant_id: PT-12696"	"participant_id: PT-12KS4"	"participant_id: PT-12WSA"	"participant_id: PT-12WSD"	"participant_id: PT-12WSF"	"participant_id: PT-12WSI"	"participant_id: PT-12ZZW"	"participant_id: PT-12ZZX"	"participant_id: PT-12ZZY"	"participant_id: PT-12ZZZ"	"participant_id: PT-13112"	"participant_id: PT-13N1W"	"participant_id: PT-13NYS"	"participant_id: PT-13O3P"	"participant_id: PT-13OW5"	"participant_id: PT-13QJC"	"participant_id: PT-13SLX"	"participant_id: PT-13W46"	"participant_id: PT-148VJ"	"participant_id: PT-14A5H"	"participant_id: PT-14C39"	"participant_id: PT-15DDE"	"participant_id: PT-15SHU"	"participant_id: PT-1B98T"	"participant_id: PT-1F6IF"	"participant_id: PT-1GTWX"	"participant_id: PT-1H1ZS"	"participant_id: PT-S33H"	"participant_id: PT-SIU8"	"participant_id: PT-UTHO"	"participant_id: PT-WOFL"	"participant_id: PT-WRHU"	"participant_id: PT-WWYW"	"participant_id: PT-X261"	"participant_id: PT-X4EP"	"participant_id: PT-X4XX"	"participant_id: PT-X585"	"participant_id: PT-X62O"	"participant_id: PT-YFC4"	"participant_id: PT-1117F"	"participant_id: PT-113JC"	"participant_id: PT-1192W"	"participant_id: PT-1192X"	"participant_id: PT-11DXZ"	"participant_id: PT-11DYG"	"participant_id: PT-11GSP"	"participant_id: PT-11I78"	"participant_id: PT-11NV4"	"participant_id: PT-11TTK"	"participant_id: PT-11WQK"	"participant_id: PT-11XUK"	"participant_id: PT-11ZTS"	"participant_id: PT-11ZUS"	"participant_id: PT-1212Z"	"participant_id: PT-12584"	"participant_id: PT-12WSA"	"participant_id: PT-12WSD"	"participant_id: PT-12WSE"	"participant_id: PT-12ZZX"	"participant_id: PT-13111"	"participant_id: PT-13112"	"participant_id: PT-139TT"	"participant_id: PT-139YR"	"participant_id: PT-13CF2"	"participant_id: PT-13FXS"	"participant_id: PT-13IVO"	"participant_id: PT-13NYS"	"participant_id: PT-13NZA"	"participant_id: PT-13O3P"	"participant_id: PT-13OVK"	"participant_id: PT-13OW5"	"participant_id: PT-13OW8"	"participant_id: PT-13PL6"	"participant_id: PT-13QIC"	"participant_id: PT-13RTJ"	"participant_id: PT-13W46"	"participant_id: PT-145MH"	"participant_id: PT-146FH"	"participant_id: PT-14753"	"participant_id: PT-1477Z"	"participant_id: PT-14A5I"	"participant_id: PT-14A6H"	"participant_id: PT-14AS3"	"participant_id: PT-14BIM"	"participant_id: PT-14BIN"	"participant_id: PT-14BMV"	"participant_id: PT-14DAR"	"participant_id: PT-14E6C"	"participant_id: PT-14E7W"	"participant_id: PT-14JFF"	"participant_id: PT-14JG1"	"participant_id: PT-14JG6"	"participant_id: PT-14LZ3"	"participant_id: PT-14PJ4"	"participant_id: PT-14PJ6"	"participant_id: PT-14PJM"	"participant_id: PT-14PJO"	"participant_id: PT-14PK6"	"participant_id: PT-14PN3"	"participant_id: PT-15CHR"	"participant_id: PT-15D1Q"	"participant_id: PT-15D79"	"participant_id: PT-15DDE"	"participant_id: PT-15EO6"	"participant_id: PT-15EU6"	"participant_id: PT-15G1A"	"participant_id: PT-15RIE"	"participant_id: PT-15RJE"	"participant_id: PT-15SDE"	"participant_id: PT-15SHV"	"participant_id: PT-15SHW"	"participant_id: PT-15SKB"	"participant_id: PT-15SZO"	"participant_id: PT-15UF6"	"participant_id: PT-15UKP"	"participant_id: PT-16AAH"	"participant_id: PT-16NPV"	"participant_id: PT-16YQH"	"participant_id: PT-17EVQ"	"participant_id: PT-17HG3"	"participant_id: PT-18465"	"participant_id: PT-18A66"	"participant_id: PT-18D9B"	"participant_id: PT-18D9U"	"participant_id: PT-19HZE"	"participant_id: PT-1A3MV"	"participant_id: PT-1A3MX"	"participant_id: PT-1AX9I"	"participant_id: PT-1AYD5"	"participant_id: PT-1B98T"	"participant_id: PT-1BAJH"	"participant_id: PT-1C4CL"	"participant_id: PT-1C64N"	"participant_id: PT-1C64O"	"participant_id: PT-1CAMQ"	"participant_id: PT-1CAV2"	"participant_id: PT-1E1VI"	"participant_id: PT-1EN7A"	"participant_id: PT-1F52S"	"participant_id: PT-1F5PK"	"participant_id: PT-1F6I4"	"participant_id: PT-1F6IF"	"participant_id: PT-1F75B"	"participant_id: PT-1F75W"	"participant_id: PT-1F88E"	"participant_id: PT-1GL5R"	"participant_id: PT-1GMR2"	"participant_id: PT-1GMR3"	"participant_id: PT-1GN1W"	"participant_id: PT-1GPI6"	"participant_id: PT-1GTWX"	"participant_id: PT-1GZHY"	"participant_id: PT-1H11D"	"participant_id: PT-1H1DF"	"participant_id: PT-1H23P"	"participant_id: PT-1H3VE"	"participant_id: PT-1H3VY"	"participant_id: PT-1HB9E"	"participant_id: PT-1HCVE"	"participant_id: PT-1HR9M"	"participant_id: PT-1I6K6"	"participant_id: PT-1IDJI"	"participant_id: PT-1IDJU"	"participant_id: PT-1IGQW"	"participant_id: PT-1IKJJ"	"participant_id: PT-1IKK5"	"participant_id: PT-1IL2U"	"participant_id: PT-1J1OQ"	"participant_id: PT-1J1R8"	"participant_id: PT-1J8JJ"	"participant_id: PT-1J8Q3"	"participant_id: PT-1JK1U"	"participant_id: PT-1JMOU"	"participant_id: PT-1JMQJ"	"participant_id: PT-1JN76"	"participant_id: PT-1KXAM"	"participant_id: PT-1L5NE"	"participant_id: PT-1LC47"	"participant_id: PT-1LG7Y"	"participant_id: PT-1LSNL"	"participant_id: PT-1LSVX"	"participant_id: PT-1LVA9"	"participant_id: PT-1LVAO"	"participant_id: PT-1MCC2"	"participant_id: PT-1MGNQ"	"participant_id: PT-1MJK2"	"participant_id: PT-1N2EE"	"participant_id: PT-1N5O9"	"participant_id: PT-1N7R6"	"participant_id: PT-1NHNU"	"participant_id: PT-1NUQO"	"participant_id: PT-1O97I"	"participant_id: PT-1OFPY"	"participant_id: PT-1OJC3"	"participant_id: PT-1OZHM"	"participant_id: PT-1PBJJ"	"participant_id: PT-1QCLY"	"participant_id: PT-1QMI2"	"participant_id: PT-1R46S"	"participant_id: PT-1RAZR"	"participant_id: PT-RUSQ"	"participant_id: PT-RVPU"	"participant_id: PT-RVPV"	"participant_id: PT-S33H"	"participant_id: PT-S341"	"participant_id: PT-S4Z8"	"participant_id: PT-S7SE"	"participant_id: PT-SIU8"	"participant_id: PT-SN8G"	"participant_id: PT-SNOS"	"participant_id: PT-T2YK"	"participant_id: PT-T6MO"	"participant_id: PT-T8EM"	"participant_id: PT-TSE9"	"participant_id: PT-U3ZH"	"participant_id: PT-U3ZM"	"participant_id: PT-U8T8"	"participant_id: PT-U8XE"	"participant_id: PT-UJHI"	"participant_id: PT-UPJH"	"participant_id: PT-UPK5"	"participant_id: PT-W5X1"	"participant_id: PT-WFG8"	"participant_id: PT-WH7G"	"participant_id: PT-WHWD"	"participant_id: PT-WK11"	"participant_id: PT-WOFL"	"participant_id: PT-WQUQ"	"participant_id: PT-WRHU"	"participant_id: PT-WVLH"	"participant_id: PT-WWYW"	"participant_id: PT-WXYG"	"participant_id: PT-WY7C"	"participant_id: PT-WYBS"	"participant_id: PT-WZTO"	"participant_id: PT-X261"	"participant_id: PT-X4EO"	"participant_id: PT-X4EP"	"participant_id: PT-X4XY"	"participant_id: PT-X5EB"	"participant_id: PT-X62O"	"participant_id: PT-X8HC"	"participant_id: PT-XBEC"	"participant_id: PT-XBED"	"participant_id: PT-XMD1"	"participant_id: PT-XPT6"	"participant_id: PT-XPVG"	"participant_id: PT-XQ3S"	"participant_id: PT-XUJ4"	"participant_id: PT-XV7Q"	"participant_id: PT-XYKS"	"participant_id: PT-YB5E"	"participant_id: PT-YEC3"	"participant_id: PT-YFC4"	"participant_id: PT-YFCO"	"participant_id: PT-YJ89"	"participant_id: PT-Z93S"	"participant_id: PT-ZAB4"	"participant_id: PT-ZDTS"	"participant_id: PT-ZDXO"	"participant_id: PT-ZYFG"	"participant_id: PT-ZYY3"	"participant_id: PT-11XUK"	"participant_id: PT-12584"	"participant_id: PT-12WSF"	"participant_id: PT-13RTJ"	"participant_id: PT-13SLX"	"participant_id: PT-13X6I"	"participant_id: PT-13X6K"	"participant_id: PT-14753"	"participant_id: PT-147GR"	"participant_id: PT-148VJ"	"participant_id: PT-14A5H"	"participant_id: PT-14B4R"	"participant_id: PT-15D1Q"	"participant_id: PT-15DCD"	"participant_id: PT-15SHU"	"participant_id: PT-1F6IF"	"participant_id: PT-1F75B"	"participant_id: PT-1F88E"	"participant_id: PT-1GPI6"	"participant_id: PT-1H1ZS"	"participant_id: PT-1H3NZ"	"participant_id: PT-1H3O1"	"participant_id: PT-1IKOE"	"participant_id: PT-1J8QM"	"participant_id: PT-SNOS"	"participant_id: PT-T6MO"	"participant_id: PT-T8EM"	"participant_id: PT-U3ZH"	"participant_id: PT-W5WG"	"participant_id: PT-W5X1"	"participant_id: PT-WOFL"	"participant_id: PT-WWYW"	"participant_id: PT-WYBS"	"participant_id: PT-X4EO"	"participant_id: PT-X4EP"	"participant_id: PT-X4XY"	"participant_id: PT-X585"	"participant_id: PT-X5EB"	"participant_id: PT-X62O"	"participant_id: PT-XMD1"	"participant_id: PT-XMD2"	"participant_id: PT-XMK1"	"participant_id: PT-XV7Q"	"participant_id: PT-XYKS"	"participant_id: PT-Y111"	"participant_id: PT-ZVZP"	"participant_id: PT-ZVZQ"	"participant_id: PT-11EM3"	"participant_id: PT-11EMC"	"participant_id: PT-11GSP"	"participant_id: PT-11I78"	"participant_id: PT-11VI4"	"participant_id: PT-11XUK"	"participant_id: PT-11ZTS"	"participant_id: PT-11ZTT"	"participant_id: PT-12WSD"	"participant_id: PT-12WSG"	"participant_id: PT-12WSJ"	"participant_id: PT-12WSK"	"participant_id: PT-12ZZX"	"participant_id: PT-133LE"	"participant_id: PT-1399U"	"participant_id: PT-13FTY"	"participant_id: PT-13N11"	"participant_id: PT-13O3O"	"participant_id: PT-13OVJ"	"participant_id: PT-13PL7"	"participant_id: PT-13QBU"	"participant_id: PT-13QIC"	"participant_id: PT-13QJC"	"participant_id: PT-13SLX"	"participant_id: PT-13VXT"	"participant_id: PT-13X6H"	"participant_id: PT-145LS"	"participant_id: PT-145ME"	"participant_id: PT-146FH"	"participant_id: PT-14AS3"	"participant_id: PT-14BIM"	"participant_id: PT-14BIN"	"participant_id: PT-14BMU"	"participant_id: PT-14DAQ"	"participant_id: PT-14H4A"	"participant_id: PT-14JG6"	"participant_id: PT-14LZ3"	"participant_id: PT-14PHW"	"participant_id: PT-14PHY"	"participant_id: PT-14PJ6"	"participant_id: PT-14PJM"	"participant_id: PT-14PKU"	"participant_id: PT-14PN3"	"participant_id: PT-14PQA"	"participant_id: PT-15DCD"	"participant_id: PT-15DDE"	"participant_id: PT-15DYW"	"participant_id: PT-15EOM"	"participant_id: PT-15ER7"	"participant_id: PT-15ETS"	"participant_id: PT-15FZZ"	"participant_id: PT-15SDE"	"participant_id: PT-15SHU"	"participant_id: PT-15UF6"	"participant_id: PT-16MT8"	"participant_id: PT-16NGA"	"participant_id: PT-16NPV"	"participant_id: PT-17F9Y"	"participant_id: PT-17HG3"	"participant_id: PT-17JCI"	"participant_id: PT-183WM"	"participant_id: PT-18A7A"	"participant_id: PT-18D9A"	"participant_id: PT-19HZE"	"participant_id: PT-1A32A"	"participant_id: PT-1A3MW"	"participant_id: PT-1AMEY"	"participant_id: PT-1AMFI"	"participant_id: PT-1C475"	"participant_id: PT-1CAMS"	"participant_id: PT-1CAV2"	"participant_id: PT-1CB4H"	"participant_id: PT-1EWIQ"	"participant_id: PT-1F48J"	"participant_id: PT-1F52S"	"participant_id: PT-1F5PL"	"participant_id: PT-1F6RS"	"participant_id: PT-1GN1W"	"participant_id: PT-1GZHY"	"participant_id: PT-1H1CY"	"participant_id: PT-1H1DF"	"participant_id: PT-1H2FU"	"participant_id: PT-1HBPH"	"participant_id: PT-1HCU6"	"participant_id: PT-1HCU8"	"participant_id: PT-1HCUA"	"participant_id: PT-1HSGN"	"participant_id: PT-1IDJE"	"participant_id: PT-1IDJI"	"participant_id: PT-1IDJU"	"participant_id: PT-1IKOE"	"participant_id: PT-1J1OQ"	"participant_id: PT-1J8JJ"	"participant_id: PT-1J8QM"	"participant_id: PT-1JMOU"	"participant_id: PT-1JN1M"	"participant_id: PT-1JN76"	"participant_id: PT-1K9T9"	"participant_id: PT-1KANC"	"participant_id: PT-1LGOU"	"participant_id: PT-1LKK1"	"participant_id: PT-1LVAM"	"participant_id: PT-1MCC2"	"participant_id: PT-1MCYP"	"participant_id: PT-1N7R6"	"participant_id: PT-1NUQO"	"participant_id: PT-1NV5F"	"participant_id: PT-1PBJI"	"participant_id: PT-1PIEJ"	"participant_id: PT-1QEPI"	"participant_id: PT-1QP28"	"participant_id: PT-1QP67"	"participant_id: PT-1QPFJ"	"participant_id: PT-1R46S"	"participant_id: PT-1R9JW"	"participant_id: PT-1R9PN"	"participant_id: PT-1RDX4"	"participant_id: PT-1RNTQ"	"participant_id: PT-1S5ZU"	"participant_id: PT-P4PP"	"participant_id: PT-POMQ"	"participant_id: PT-R55G"	"participant_id: PT-RWS6"	"participant_id: PT-S341"	"participant_id: PT-S4P3"	"participant_id: PT-S4UY"	"participant_id: PT-S7SF"	"participant_id: PT-SE5C"	"participant_id: PT-SN8G"	"participant_id: PT-T2IS"	"participant_id: PT-T5JW"	"participant_id: PT-T6MO"	"participant_id: PT-TML8"	"participant_id: PT-TMMY"	"participant_id: PT-TSE9"	"participant_id: PT-U3ZN"	"participant_id: PT-UJHI"	"participant_id: PT-W5WG"	"participant_id: PT-WEY5"	"participant_id: PT-WI4N"	"participant_id: PT-WRHU"	"participant_id: PT-WWYW"	"participant_id: PT-WXYG"	"participant_id: PT-WYVS"	"participant_id: PT-X15G"	"participant_id: PT-X4EP"	"participant_id: PT-X8HC"	"participant_id: PT-XMD2"	"participant_id: PT-XOT4"	"participant_id: PT-XUJ4"	"participant_id: PT-XUW1"	"participant_id: PT-XUZC"	"participant_id: PT-XYKS"	"participant_id: PT-Y114"	"participant_id: PT-YFC4"	"participant_id: PT-ZAJG"	"participant_id: PT-ZLWG"	"participant_id: PT-ZP4G"	"participant_id: PT-ZPIC"	"participant_id: PT-ZVT2"	"participant_id: PT-ZVT3"	"participant_id: PT-ZYFG"	"participant_id: PT-ZYWO"	"participant_id: PT-ZZPU"	"participant_id: PT-111FC"	"participant_id: PT-117YW"	"participant_id: PT-1192X"	"participant_id: PT-11DYG"	"participant_id: PT-11NV4"	"participant_id: PT-11ONC"	"participant_id: PT-11TT1"	"participant_id: PT-11UD2"	"participant_id: PT-11WQC"	"participant_id: PT-11WQK"	"participant_id: PT-11ZU8"	"participant_id: PT-11ZUS"	"participant_id: PT-12696"	"participant_id: PT-12KS4"	"participant_id: PT-12WSA"	"participant_id: PT-12WSE"	"participant_id: PT-12WSF"	"participant_id: PT-12ZZW"	"participant_id: PT-12ZZY"	"participant_id: PT-13111"	"participant_id: PT-13112"	"participant_id: PT-139TT"	"participant_id: PT-139YR"	"participant_id: PT-13FHP"	"participant_id: PT-13FTW"	"participant_id: PT-13IVO"	"participant_id: PT-13N1W"	"participant_id: PT-13NYS"	"participant_id: PT-13NZA"	"participant_id: PT-13OW5"	"participant_id: PT-13W46"	"participant_id: PT-13X6I"	"participant_id: PT-147GR"	"participant_id: PT-14BMV"	"participant_id: PT-14C39"	"participant_id: PT-14JG1"	"participant_id: PT-14PJO"	"participant_id: PT-15CHQ"	"participant_id: PT-15CHR"	"participant_id: PT-15G1A"	"participant_id: PT-15SKB"	"participant_id: PT-15SZO"	"participant_id: PT-15UKP"	"participant_id: PT-16YQH"	"participant_id: PT-17EVQ"	"participant_id: PT-17HGU"	"participant_id: PT-1A3MV"	"participant_id: PT-1B8KE"	"participant_id: PT-1B98T"	"participant_id: PT-1CAMQ"	"participant_id: PT-1E2YA"	"participant_id: PT-1F5PK"	"participant_id: PT-1F6IF"	"participant_id: PT-1F75A"	"participant_id: PT-1F75W"	"participant_id: PT-1GL5R"	"participant_id: PT-1GMR3"	"participant_id: PT-1GN73"	"participant_id: PT-1GTWX"	"participant_id: PT-1GZ2Q"	"participant_id: PT-1H11D"	"participant_id: PT-1H1ZS"	"participant_id: PT-1H3NZ"	"participant_id: PT-1H3VE"	"participant_id: PT-1HR9M"	"participant_id: PT-1HSKV"	"participant_id: PT-1I6K6"	"participant_id: PT-1ICLY"	"participant_id: PT-1IDJH"	"participant_id: PT-1IGQW"	"participant_id: PT-1IKJJ"	"participant_id: PT-1IKK5"	"participant_id: PT-1IL2U"	"participant_id: PT-1IY9M"	"participant_id: PT-1J1R8"	"participant_id: PT-1J8Q3"	"participant_id: PT-RUSQ"	"participant_id: PT-RVPU"	"participant_id: PT-RWSA"	"participant_id: PT-S33H"	"participant_id: PT-S3XE"	"participant_id: PT-S4Q7"	"participant_id: PT-S7PM"	"participant_id: PT-S7SE"	"participant_id: PT-S95S"	"participant_id: PT-SIU8"	"participant_id: PT-SJXC"	"participant_id: PT-SNMC"	"participant_id: PT-SNOS"	"participant_id: PT-SUCS"	"participant_id: PT-T8EM"	"participant_id: PT-U3ZH"	"participant_id: PT-U3ZM"	"participant_id: PT-U412"	"participant_id: PT-U8T8"	"participant_id: PT-UPK5"	"participant_id: PT-UTHO"	"participant_id: PT-WFG8"	"participant_id: PT-WHSE"	"participant_id: PT-WL46"	"participant_id: PT-WOFL"	"participant_id: PT-WQUQ"	"participant_id: PT-WVLH"	"participant_id: PT-WY7C"	"participant_id: PT-WYJK"	"participant_id: PT-WZTO"	"participant_id: PT-X261"	"participant_id: PT-X3Y1"	"participant_id: PT-X4XY"	"participant_id: PT-X585"	"participant_id: PT-X62O"	"participant_id: PT-XBED"	"participant_id: PT-XBEW"	"participant_id: PT-XGQ4"	"participant_id: PT-XMD1"	"participant_id: PT-XMK1"	"participant_id: PT-XPT6"	"participant_id: PT-XPVG"	"participant_id: PT-XQ3S"	"participant_id: PT-Y111"	"participant_id: PT-YB5E"	"participant_id: PT-YEC3"	"participant_id: PT-YJ89"	"participant_id: PT-111FC"	"participant_id: PT-1192W"	"participant_id: PT-11NV4"	"participant_id: PT-11TT1"	"participant_id: PT-11UD2"	"participant_id: PT-11ZUS"	"participant_id: PT-1212Z"	"participant_id: PT-12696"	"participant_id: PT-12KS4"	"participant_id: PT-12WSA"	"participant_id: PT-12WSE"	"participant_id: PT-12ZZW"	"participant_id: PT-12ZZY"	"participant_id: PT-13112"	"participant_id: PT-1399R"	"participant_id: PT-139YR"	"participant_id: PT-13FTW"	"participant_id: PT-13NYS"	"participant_id: PT-13NZA"	"participant_id: PT-13O3P"	"participant_id: PT-13OW5"	"participant_id: PT-13W46"	"participant_id: PT-147GR"	"participant_id: PT-148VJ"	"participant_id: PT-14C39"	"participant_id: PT-14E6D"	"participant_id: PT-15CHQ"	"participant_id: PT-15D1Q"	"participant_id: PT-15EU6"	"participant_id: PT-15G1A"	"participant_id: PT-18465"	"participant_id: PT-1A3MV"	"participant_id: PT-1B98T"	"participant_id: PT-1C64N"	"participant_id: PT-1CAMQ"	"participant_id: PT-1F5PK"	"participant_id: PT-1F6IF"	"participant_id: PT-1GL5R"	"participant_id: PT-1GTWX"	"participant_id: PT-1H1ZS"	"participant_id: PT-S33H"	"participant_id: PT-SIU8"	"participant_id: PT-SNOS"	"participant_id: PT-T8EM"	"participant_id: PT-U3ZH"	"participant_id: PT-WOFL"	"participant_id: PT-X261"	"participant_id: PT-X4XX"	"participant_id: PT-X585"	"participant_id: PT-X62O"	"participant_id: PT-117YW"	"participant_id: PT-11DYG"	"participant_id: PT-11EMC"	"participant_id: PT-11TT1"	"participant_id: PT-11ZU8"	"participant_id: PT-11ZUS"	"participant_id: PT-12KS4"	"participant_id: PT-12WSA"	"participant_id: PT-12WSE"	"participant_id: PT-12WSI"	"participant_id: PT-12ZZW"	"participant_id: PT-12ZZY"	"participant_id: PT-139YR"	"participant_id: PT-13NYS"	"participant_id: PT-13NZA"	"participant_id: PT-13OW5"	"participant_id: PT-13QIC"	"participant_id: PT-13SLX"	"participant_id: PT-14A6H"	"participant_id: PT-14C39"	"participant_id: PT-14E6D"	"participant_id: PT-15CHQ"	"participant_id: PT-15D1Q"	"participant_id: PT-15DDE"	"participant_id: PT-15EU6"	"participant_id: PT-15SHU"	"participant_id: PT-1A3MV"	"participant_id: PT-1B98T"	"participant_id: PT-1C64N"	"participant_id: PT-1CAMQ"	"participant_id: PT-1GMR3"	"participant_id: PT-1GTWX"	"participant_id: PT-1H1ZS"	"participant_id: PT-1H3VE"	"participant_id: PT-1I6K6"	"participant_id: PT-1J1R8"	"participant_id: PT-SNOS"	"participant_id: PT-U3ZH"	"participant_id: PT-U3ZM"	"participant_id: PT-U8XE"	"participant_id: PT-WFG8"	"participant_id: PT-WH7G"	"participant_id: PT-WRHU"	"participant_id: PT-WWYW"	"participant_id: PT-X261"	"participant_id: PT-X4EP"	"participant_id: PT-X4XX"	"participant_id: PT-X585"	"participant_id: PT-X5EB"	"participant_id: PT-XMK1"	"participant_id: PT-XPT6"	"participant_id: PT-YFC4"	"participant_id: PT-YFCO"	"participant_id: PT-ZAB4"
!Sample_characteristics_ch1	"sample_id: SM-GW24C"	"sample_id: SM-GW242"	"sample_id: SM-GW21X"	"sample_id: SM-GW1D7"	"sample_id: SM-GW1SN"	"sample_id: SM-GW1DU"	"sample_id: SM-GW1SZ"	"sample_id: SM-GW1X6"	"sample_id: SM-GW1D1"	"sample_id: SM-GW1GY"	"sample_id: SM-GW2A6"	"sample_id: SM-GW1R5"	"sample_id: SM-GW21C"	"sample_id: SM-GW1QF"	"sample_id: SM-GW218"	"sample_id: SM-GW1RC"	"sample_id: SM-GW1VP"	"sample_id: SM-GW1RL"	"sample_id: SM-GW21B"	"sample_id: SM-GW1UD"	"sample_id: SM-GW1R6"	"sample_id: SM-GW1S1"	"sample_id: SM-GW1CA"	"sample_id: SM-GW1DB"	"sample_id: SM-GW1RG"	"sample_id: SM-GW1AX"	"sample_id: SM-GW1CC"	"sample_id: SM-GW1E8"	"sample_id: SM-GW1DD"	"sample_id: SM-GW1S3"	"sample_id: SM-GW1E9"	"sample_id: SM-GW1PZ"	"sample_id: SM-GW1RT"	"sample_id: SM-GW1S4"	"sample_id: SM-GW1GS"	"sample_id: SM-GW1T3"	"sample_id: SM-GW24F"	"sample_id: SM-GW2AH"	"sample_id: SM-GW1G8"	"sample_id: SM-GW1ZU"	"sample_id: SM-GW1U4"	"sample_id: SM-GW1SO"	"sample_id: SM-GW1FZ"	"sample_id: SM-GW1U1"	"sample_id: SM-GW1D9"	"sample_id: SM-GW2B2"	"sample_id: SM-GW2AA"	"sample_id: SM-GW1CI"	"sample_id: SM-GW1VQ"	"sample_id: SM-GW1SR"	"sample_id: SM-GW1G6"	"sample_id: SM-GW2BT"	"sample_id: SM-GW1F9"	"sample_id: SM-GW2AK"	"sample_id: SM-GW1XW"	"sample_id: SM-GW23H"	"sample_id: SM-GW29S"	"sample_id: SM-GW248"	"sample_id: SM-GW1EK"	"sample_id: SM-GW1UB"	"sample_id: SM-GW1EW"	"sample_id: SM-GW249"	"sample_id: SM-GW23O"	"sample_id: SM-GW2CA"	"sample_id: SM-GW192"	"sample_id: SM-GW1YJ"	"sample_id: SM-GW1XX"	"sample_id: SM-GW1AF"	"sample_id: SM-GW24B"	"sample_id: SM-GW1BM"	"sample_id: SM-GW1Z4"	"sample_id: SM-GW2BJ"	"sample_id: SM-GW19N"	"sample_id: SM-GW2B5"	"sample_id: SM-GW1Z3"	"sample_id: SM-GW1U8"	"sample_id: SM-GW1ZC"	"sample_id: SM-GW1BJ"	"sample_id: SM-GW1BA"	"sample_id: SM-GW1VB"	"sample_id: SM-GW1FS"	"sample_id: SM-GW1AC"	"sample_id: SM-GW1AB"	"sample_id: SM-GW2BU"	"sample_id: SM-GW29L"	"sample_id: SM-GW24E"	"sample_id: SM-GW1Z8"	"sample_id: SM-GW1TV"	"sample_id: SM-GW21Z"	"sample_id: SM-GW1YB"	"sample_id: SM-GW1G2"	"sample_id: SM-GW22O"	"sample_id: SM-GW1FV"	"sample_id: SM-GW1GE"	"sample_id: SM-GW1AH"	"sample_id: SM-GW19Y"	"sample_id: SM-GW1SS"	"sample_id: SM-GW1Z7"	"sample_id: SM-GW1R9"	"sample_id: SM-GW243"	"sample_id: SM-GW2B8"	"sample_id: SM-GW23U"	"sample_id: SM-GW1FX"	"sample_id: SM-GW1YI"	"sample_id: SM-GW1U3"	"sample_id: SM-GW19X"	"sample_id: SM-GW1TG"	"sample_id: SM-GW1TI"	"sample_id: SM-GW1R2"	"sample_id: SM-GW1RY"	"sample_id: SM-GW1UN"	"sample_id: SM-GW1UG"	"sample_id: SM-GW1QP"	"sample_id: SM-GW1QX"	"sample_id: SM-GW1RK"	"sample_id: SM-GW1E6"	"sample_id: SM-GW1WG"	"sample_id: SM-GW1DI"	"sample_id: SM-GW1AR"	"sample_id: SM-GW1DE"	"sample_id: SM-GW1WK"	"sample_id: SM-GW1DO"	"sample_id: SM-GW1RJ"	"sample_id: SM-GW1WH"	"sample_id: SM-GW1UC"	"sample_id: SM-GW1E3"	"sample_id: SM-GW22K"	"sample_id: SM-GW1RH"	"sample_id: SM-GW1TP"	"sample_id: SM-GW1RO"	"sample_id: SM-GW1DH"	"sample_id: SM-GW1D3"	"sample_id: SM-GW1EB"	"sample_id: SM-GW1E5"	"sample_id: SM-GW1EC"	"sample_id: SM-GW1DY"	"sample_id: SM-GW1QY"	"sample_id: SM-GW1DC"	"sample_id: SM-GW1CT"	"sample_id: SM-GW22B"	"sample_id: SM-GW1R1"	"sample_id: SM-GW1DF"	"sample_id: SM-GW1Q1"	"sample_id: SM-GW1GQ"	"sample_id: SM-GW1RX"	"sample_id: SM-GW22E"	"sample_id: SM-GW1D2"	"sample_id: SM-GW1BU"	"sample_id: SM-GW1GU"	"sample_id: SM-GW1TJ"	"sample_id: SM-GW1EF"	"sample_id: SM-GW1RQ"	"sample_id: SM-GW1UK"	"sample_id: SM-GW1QT"	"sample_id: SM-GW1UE"	"sample_id: SM-GW1RI"	"sample_id: SM-GW21V"	"sample_id: SM-GW22X"	"sample_id: SM-GW22L"	"sample_id: SM-GW1DK"	"sample_id: SM-GW1WS"	"sample_id: SM-GW1EG"	"sample_id: SM-GW1QJ"	"sample_id: SM-GW1QZ"	"sample_id: SM-GW1S2"	"sample_id: SM-GW1PV"	"sample_id: SM-GW1AY"	"sample_id: SM-GW1TK"	"sample_id: SM-GW1WQ"	"sample_id: SM-GW2A1"	"sample_id: SM-GW1E4"	"sample_id: SM-GW1UL"	"sample_id: SM-GW1BY"	"sample_id: SM-GW1RS"	"sample_id: SM-GW1TE"	"sample_id: SM-GW1DS"	"sample_id: SM-GW1RA"	"sample_id: SM-GW1E2"	"sample_id: SM-GW1GO"	"sample_id: SM-GW1WJ"	"sample_id: SM-GW1WM"	"sample_id: SM-GW1PY"	"sample_id: SM-GW22W"	"sample_id: SM-GW1RE"	"sample_id: SM-GW1TF"	"sample_id: SM-GW1WI"	"sample_id: SM-GW1DQ"	"sample_id: SM-GW1TC"	"sample_id: SM-GW1QI"	"sample_id: SM-GW1GX"	"sample_id: SM-GW1BW"	"sample_id: SM-GW1PW"	"sample_id: SM-GW1RB"	"sample_id: SM-GW1X1"	"sample_id: SM-GW1GZ"	"sample_id: SM-GW1GM"	"sample_id: SM-GW1WP"	"sample_id: SM-GW29Y"	"sample_id: SM-GW1PX"	"sample_id: SM-GW1C3"	"sample_id: SM-GW1QM"	"sample_id: SM-GW1QH"	"sample_id: SM-GW1T4"	"sample_id: SM-GW219"	"sample_id: SM-GW1BV"	"sample_id: SM-GW2CH"	"sample_id: SM-GW2CD"	"sample_id: SM-GW177"	"sample_id: SM-GW1EP"	"sample_id: SM-GW1VZ"	"sample_id: SM-GW1EO"	"sample_id: SM-GW211"	"sample_id: SM-GW19J"	"sample_id: SM-GW1ZJ"	"sample_id: SM-GW23T"	"sample_id: SM-GW1AJ"	"sample_id: SM-GW1XN"	"sample_id: SM-GW1US"	"sample_id: SM-GW19R"	"sample_id: SM-GW2BZ"	"sample_id: SM-GW23Z"	"sample_id: SM-GW1YA"	"sample_id: SM-GW1ZR"	"sample_id: SM-GW193"	"sample_id: SM-GW19O"	"sample_id: SM-GW245"	"sample_id: SM-GW1U2"	"sample_id: SM-GW1YU"	"sample_id: SM-GW19F"	"sample_id: SM-GW1B7"	"sample_id: SM-GW1ZF"	"sample_id: SM-GW2AP"	"sample_id: SM-GW1B2"	"sample_id: SM-GW1ZH"	"sample_id: SM-GW2C7"	"sample_id: SM-GW1H6"	"sample_id: SM-GW1BH"	"sample_id: SM-GW1FR"	"sample_id: SM-GW1YS"	"sample_id: SM-GW1ZI"	"sample_id: SM-GW1ZT"	"sample_id: SM-GW1YR"	"sample_id: SM-GW1FQ"	"sample_id: SM-GW1WC"	"sample_id: SM-GW2AI"	"sample_id: SM-GW1ES"	"sample_id: SM-GW22T"	"sample_id: SM-GW2AY"	"sample_id: SM-GW1CH"	"sample_id: SM-GW23M"	"sample_id: SM-GW23A"	"sample_id: SM-GW22S"	"sample_id: SM-GW2BO"	"sample_id: SM-GW1BF"	"sample_id: SM-GW1EU"	"sample_id: SM-GW1XS"	"sample_id: SM-GW247"	"sample_id: SM-GW2AO"	"sample_id: SM-GW246"	"sample_id: SM-GW2BB"	"sample_id: SM-GW1CK"	"sample_id: SM-GW1WN"	"sample_id: SM-GW1WA"	"sample_id: SM-GW1F7"	"sample_id: SM-GW1YN"	"sample_id: SM-GW1B9"	"sample_id: SM-GW1A4"	"sample_id: SM-GW1Y9"	"sample_id: SM-GW1UT"	"sample_id: SM-GW1GJ"	"sample_id: SM-GW1GB"	"sample_id: SM-GW229"	"sample_id: SM-GW1XM"	"sample_id: SM-GW1UV"	"sample_id: SM-GW23Q"	"sample_id: SM-GW1GL"	"sample_id: SM-GW22U"	"sample_id: SM-GW1UU"	"sample_id: SM-GW1BO"	"sample_id: SM-GW1GI"	"sample_id: SM-GW1UW"	"sample_id: SM-GW1YO"	"sample_id: SM-GW1YM"	"sample_id: SM-GW1EM"	"sample_id: SM-GW29M"	"sample_id: SM-GW1BE"	"sample_id: SM-GW2AS"	"sample_id: SM-GW2AJ"	"sample_id: SM-GW19V"	"sample_id: SM-GW23P"	"sample_id: SM-GW21W"	"sample_id: SM-GW2C8"	"sample_id: SM-GW1EH"	"sample_id: SM-GW23V"	"sample_id: SM-GW1BD"	"sample_id: SM-GW1EI"	"sample_id: SM-GW1F4"	"sample_id: SM-GW2BK"	"sample_id: SM-GW1XQ"	"sample_id: SM-GW195"	"sample_id: SM-GW2C3"	"sample_id: SM-GW23Y"	"sample_id: SM-GW1H7"	"sample_id: SM-GW29U"	"sample_id: SM-GW1ZG"	"sample_id: SM-GW22I"	"sample_id: SM-GW22F"	"sample_id: SM-GW22J"	"sample_id: SM-GW1SW"	"sample_id: SM-GW22D"	"sample_id: SM-GW1SX"	"sample_id: SM-GW1TL"	"sample_id: SM-GW2A3"	"sample_id: SM-GW22H"	"sample_id: SM-GW22P"	"sample_id: SM-GW1AO"	"sample_id: SM-GW1FP"	"sample_id: SM-GW1ZV"	"sample_id: SM-GW196"	"sample_id: SM-GW1YQ"	"sample_id: SM-GW1YZ"	"sample_id: SM-GW2AD"	"sample_id: SM-GW1CN"	"sample_id: SM-GW23B"	"sample_id: SM-GW19P"	"sample_id: SM-GW244"	"sample_id: SM-GW2CO"	"sample_id: SM-GW1F2"	"sample_id: SM-GW224"	"sample_id: SM-GW191"	"sample_id: SM-GW23R"	"sample_id: SM-GW1XU"	"sample_id: SM-GW2CL"	"sample_id: SM-GW226"	"sample_id: SM-GW17Z"	"sample_id: SM-GW19B"	"sample_id: SM-GW2CV"	"sample_id: SM-GW19G"	"sample_id: SM-GW1A7"	"sample_id: SM-GW2BW"	"sample_id: SM-GW1UX"	"sample_id: SM-GW1UR"	"sample_id: SM-GW18E"	"sample_id: SM-GW21I"	"sample_id: SM-GW22V"	"sample_id: SM-GW18L"	"sample_id: SM-GW1YH"	"sample_id: SM-GW1ST"	"sample_id: SM-GW1XV"	"sample_id: SM-GW1FL"	"sample_id: SM-GW1FT"	"sample_id: SM-GW2AX"	"sample_id: SM-GW1EL"	"sample_id: SM-GW1VT"	"sample_id: SM-GW1VS"	"sample_id: SM-GW1UY"	"sample_id: SM-GW1XG"	"sample_id: SM-GW1V7"	"sample_id: SM-GW1U6"	"sample_id: SM-GW1UQ"	"sample_id: SM-GW1TX"	"sample_id: SM-GW18K"	"sample_id: SM-GW1AA"	"sample_id: SM-GW1ZB"	"sample_id: SM-GW1RN"	"sample_id: SM-GW1E7"	"sample_id: SM-GW1RM"	"sample_id: SM-GW2DC"	"sample_id: SM-GW1DA"	"sample_id: SM-GW1X7"	"sample_id: SM-GW18T"	"sample_id: SM-GW188"	"sample_id: SM-GW1QQ"	"sample_id: SM-GW1WU"	"sample_id: SM-GW1CP"	"sample_id: SM-GW217"	"sample_id: SM-GW1CX"	"sample_id: SM-GW1CZ"	"sample_id: SM-GW1ED"	"sample_id: SM-GW18U"	"sample_id: SM-GW1QR"	"sample_id: SM-GW1C8"	"sample_id: SM-GW2CR"	"sample_id: SM-GW1RZ"	"sample_id: SM-GW1C7"	"sample_id: SM-GW1DX"	"sample_id: SM-GW1RR"	"sample_id: SM-GW2DA"	"sample_id: SM-GW1CY"	"sample_id: SM-GW21H"	"sample_id: SM-GW1T5"	"sample_id: SM-GW17S"	"sample_id: SM-GW1BS"	"sample_id: SM-GW1GV"	"sample_id: SM-GW2CM"	"sample_id: SM-GW1S7"	"sample_id: SM-GW1QS"	"sample_id: SM-GW1RW"	"sample_id: SM-GW1S9"	"sample_id: SM-GW2DF"	"sample_id: SM-GW1WV"	"sample_id: SM-GW22M"	"sample_id: SM-GW1DR"	"sample_id: SM-GW2DE"	"sample_id: SM-GW17E"	"sample_id: SM-GW1R3"	"sample_id: SM-GW231"	"sample_id: SM-GW1C9"	"sample_id: SM-GW29X"	"sample_id: SM-GW1QG"	"sample_id: SM-GW1XD"	"sample_id: SM-GW1RP"	"sample_id: SM-GW2DB"	"sample_id: SM-GW1DP"	"sample_id: SM-GW1R7"	"sample_id: SM-GW1EA"	"sample_id: SM-GW1S5"	"sample_id: SM-GW1FE"	"sample_id: SM-GW1D4"	"sample_id: SM-GW1CB"	"sample_id: SM-GW1TA"	"sample_id: SM-GW1QU"	"sample_id: SM-GW29Z"	"sample_id: SM-GW1DZ"	"sample_id: SM-GW1R8"	"sample_id: SM-GW1QO"	"sample_id: SM-GW189"	"sample_id: SM-GW1WX"	"sample_id: SM-GW1EE"	"sample_id: SM-GW2D8"	"sample_id: SM-GW2D9"	"sample_id: SM-GW1TM"	"sample_id: SM-GW1DT"	"sample_id: SM-GW1WR"	"sample_id: SM-GW1C2"	"sample_id: SM-GW17F"	"sample_id: SM-GW2D7"	"sample_id: SM-GW1S8"	"sample_id: SM-GW1RD"	"sample_id: SM-GW1XA"	"sample_id: SM-GW1D5"	"sample_id: SM-GW1WW"	"sample_id: SM-GW2CS"	"sample_id: SM-GW2CN"	"sample_id: SM-GW1XB"	"sample_id: SM-GW1CF"	"sample_id: SM-GW18A"	"sample_id: SM-GW2CT"	"sample_id: SM-GW1WO"	"sample_id: SM-GW1T6"	"sample_id: SM-GW1CE"	"sample_id: SM-GW1DJ"	"sample_id: SM-GW1QN"	"sample_id: SM-GW1DV"	"sample_id: SM-GW21Y"	"sample_id: SM-GW1C1"	"sample_id: SM-GW1Q2"	"sample_id: SM-GW1TO"	"sample_id: SM-GW1VL"	"sample_id: SM-GW2CI"	"sample_id: SM-GW2D5"	"sample_id: SM-GW1SB"	"sample_id: SM-GW2CW"	"sample_id: SM-GW17C"	"sample_id: SM-GW2CJ"	"sample_id: SM-GW2D2"	"sample_id: SM-GW2D6"	"sample_id: SM-GW2CX"	"sample_id: SM-GW2D1"	"sample_id: SM-GW2D4"	"sample_id: SM-GW2CC"	"sample_id: SM-GW2D3"	"sample_id: SM-GW179"	"sample_id: SM-GW17A"	"sample_id: SM-GW17M"	"sample_id: SM-GW1W9"	"sample_id: SM-GW1ZY"	"sample_id: SM-GW2CK"	"sample_id: SM-GW2CY"	"sample_id: SM-GW2CZ"	"sample_id: SM-GW1W7"	"sample_id: SM-GW18Y"	"sample_id: SM-GW1VU"	"sample_id: SM-GW2CF"	"sample_id: SM-GW178"	"sample_id: SM-GW2CU"	"sample_id: SM-GW1VY"	"sample_id: SM-GW19E"	"sample_id: SM-GW19H"	"sample_id: SM-GW1XI"	"sample_id: SM-GW1ZK"	"sample_id: SM-GW23W"	"sample_id: SM-GW2DD"	"sample_id: SM-GW181"	"sample_id: SM-GW2A7"	"sample_id: SM-GW23D"	"sample_id: SM-GW1SU"	"sample_id: SM-GW1A9"	"sample_id: SM-GW1GH"	"sample_id: SM-GW1ZN"	"sample_id: SM-GW1WE"	"sample_id: SM-GW19I"	"sample_id: SM-GW2BF"	"sample_id: SM-GW17X"	"sample_id: SM-GW1VC"	"sample_id: SM-GW1W5"	"sample_id: SM-GW19D"	"sample_id: SM-GW2BY"	"sample_id: SM-GW241"	"sample_id: SM-GW18N"	"sample_id: SM-GW18W"	"sample_id: SM-GW1B4"	"sample_id: SM-GW18G"	"sample_id: SM-GW29K"	"sample_id: SM-GW184"	"sample_id: SM-GW18F"	"sample_id: SM-GW182"	"sample_id: SM-GW186"	"sample_id: SM-GW18D"	"sample_id: SM-GW1VR"	"sample_id: SM-GW1Z1"	"sample_id: SM-GW1TS"	"sample_id: SM-GW18Q"	"sample_id: SM-GW1Z5"	"sample_id: SM-GW18O"	"sample_id: SM-GW18J"	"sample_id: SM-GW18S"	"sample_id: SM-GW1ER"	"sample_id: SM-GW183"	"sample_id: SM-GW18I"	"sample_id: SM-GW17W"	"sample_id: SM-GW1VA"	"sample_id: SM-GW2AZ"	"sample_id: SM-GW1B6"	"sample_id: SM-GW1CL"	"sample_id: SM-GW22Z"	"sample_id: SM-GW1TT"	"sample_id: SM-GW18H"	"sample_id: SM-GW2CQ"	"sample_id: SM-GW17H"	"sample_id: SM-GW2BS"	"sample_id: SM-GW1FK"	"sample_id: SM-GW1FD"	"sample_id: SM-GW18C"	"sample_id: SM-GW1G5"	"sample_id: SM-GW23S"	"sample_id: SM-GW21U"	"sample_id: SM-GW1G9"	"sample_id: SM-GW1XT"	"sample_id: SM-GW2AB"	"sample_id: SM-GW1W4"	"sample_id: SM-GW2AE"	"sample_id: SM-GW22R"	"sample_id: SM-GW1V9"	"sample_id: SM-GW1GF"	"sample_id: SM-GW1AG"	"sample_id: SM-GW1QL"	"sample_id: SM-GW1T2"	"sample_id: SM-GW1GP"	"sample_id: SM-GW1T1"	"sample_id: SM-GW1AZ"	"sample_id: SM-GW1S6"	"sample_id: SM-GW1R4"	"sample_id: SM-GW1RF"	"sample_id: SM-GW1QW"	"sample_id: SM-GW1CD"	"sample_id: SM-GW1QK"	"sample_id: SM-GW1QV"	"sample_id: SM-GW1DG"	"sample_id: SM-GW1D6"	"sample_id: SM-GW1RV"	"sample_id: SM-GW1E1"	"sample_id: SM-GW1GN"	"sample_id: SM-GW24A"	"sample_id: SM-GW1Y2"	"sample_id: SM-GW2BQ"	"sample_id: SM-GW1XZ"	"sample_id: SM-GW2AV"	"sample_id: SM-GW19S"	"sample_id: SM-GW1G1"	"sample_id: SM-GW194"	"sample_id: SM-GW1Y3"	"sample_id: SM-GW1XH"	"sample_id: SM-GW1XJ"	"sample_id: SM-GW1XO"	"sample_id: SM-GW227"	"sample_id: SM-GW1TW"	"sample_id: SM-GW1ZE"	"sample_id: SM-GW19T"	"sample_id: SM-GW1Y1"	"sample_id: SM-GW1SM"	"sample_id: SM-GW1TR"	"sample_id: SM-GW1W1"	"sample_id: SM-GW1Z6"	"sample_id: SM-GW1EJ"	"sample_id: SM-GW2A9"	"sample_id: SM-GW199"	"sample_id: SM-GW2AF"	"sample_id: SM-GW1Q3"	"sample_id: SM-GW2BI"	"sample_id: SM-GW223"	"sample_id: SM-GW1YD"	"sample_id: SM-GW1GA"	"sample_id: SM-GW1BG"	"sample_id: SM-GW1UA"	"sample_id: SM-GW1FC"	"sample_id: SM-GW2BN"	"sample_id: SM-GW1AP"	"sample_id: SM-GW222"	"sample_id: SM-GW1A3"	"sample_id: SM-GW1CW"	"sample_id: SM-GW23X"	"sample_id: SM-GW1A6"	"sample_id: SM-GW29N"	"sample_id: SM-GW2BA"	"sample_id: SM-GW1Z9"	"sample_id: SM-GW1YG"	"sample_id: SM-GW1D8"	"sample_id: SM-GW29O"	"sample_id: SM-GW1EY"	"sample_id: SM-GW1ZA"	"sample_id: SM-GW24H"	"sample_id: SM-GW16E"	"sample_id: SM-GW1CQ"	"sample_id: SM-GW1H1"	"sample_id: SM-GW16Q"	"sample_id: SM-GW16J"	"sample_id: SM-GW234"	"sample_id: SM-GW16P"	"sample_id: SM-GW21P"	"sample_id: SM-GW16W"	"sample_id: SM-GW16R"	"sample_id: SM-GW1VH"	"sample_id: SM-GW16D"	"sample_id: SM-GW237"	"sample_id: SM-GW16N"	"sample_id: SM-GW174"	"sample_id: SM-GW233"	"sample_id: SM-GW1UZ"	"sample_id: SM-GW16M"	"sample_id: SM-GW16C"	"sample_id: SM-GW1VI"	"sample_id: SM-GW16A"	"sample_id: SM-GW16Z"	"sample_id: SM-GW1VO"	"sample_id: SM-GW175"	"sample_id: SM-GW1VD"	"sample_id: SM-GW16H"	"sample_id: SM-GW16S"	"sample_id: SM-GW21M"	"sample_id: SM-GW21N"	"sample_id: SM-GW16O"	"sample_id: SM-GW1V1"	"sample_id: SM-GW239"	"sample_id: SM-GW238"	"sample_id: SM-GW232"	"sample_id: SM-GW16G"	"sample_id: SM-GW16T"	"sample_id: SM-GW171"	"sample_id: SM-GW16V"	"sample_id: SM-GW1V2"	"sample_id: SM-GW172"	"sample_id: SM-GW16U"	"sample_id: SM-GW173"	"sample_id: SM-GW176"	"sample_id: SM-GW21Q"	"sample_id: SM-GW1VG"	"sample_id: SM-GW1GW"	"sample_id: SM-GW16Y"	"sample_id: SM-GW16X"	"sample_id: SM-GW1QC"	"sample_id: SM-GW1QA"	"sample_id: SM-GW1QD"	"sample_id: SM-GW1Q9"	"sample_id: SM-GW1Q8"	"sample_id: SM-GW1Q5"	"sample_id: SM-GW1C6"	"sample_id: SM-GW1QE"	"sample_id: SM-GW169"	"sample_id: SM-GW236"	"sample_id: SM-GW1EN"	"sample_id: SM-GW235"	"sample_id: SM-GW1Q6"	"sample_id: SM-GW1QB"	"sample_id: SM-GW1Q4"	"sample_id: SM-GW1VJ"	"sample_id: SM-GW21T"	"sample_id: SM-GW1Q7"	"sample_id: SM-GW16I"	"sample_id: SM-GW21O"	"sample_id: SM-GW1W6"	"sample_id: SM-GW212"	"sample_id: SM-GW215"	"sample_id: SM-GW1SD"	"sample_id: SM-GW1SK"	"sample_id: SM-GW1SC"	"sample_id: SM-GW1SI"	"sample_id: SM-GW1SL"	"sample_id: SM-GW1SA"	"sample_id: SM-GW1SJ"	"sample_id: SM-GW1VV"	"sample_id: SM-GW1SE"	"sample_id: SM-GW2CG"	"sample_id: SM-GW1SF"	"sample_id: SM-GW1VX"	"sample_id: SM-GW216"	"sample_id: SM-GW1W8"	"sample_id: SM-GW2CB"	"sample_id: SM-GW213"	"sample_id: SM-GW2CE"	"sample_id: SM-GW214"	"sample_id: SM-GW1SG"	"sample_id: SM-GW1VW"	"sample_id: SM-GW1SH"	"sample_id: SM-GW1ZZ"	"sample_id: SM-GW23I"	"sample_id: SM-GW1ZQ"	"sample_id: SM-GW1Y7"	"sample_id: SM-GW1A1"	"sample_id: SM-GW1Y6"	"sample_id: SM-GW1YV"	"sample_id: SM-GW23C"	"sample_id: SM-GW2BM"	"sample_id: SM-GW1GG"	"sample_id: SM-GW1GD"	"sample_id: SM-GW1ZS"	"sample_id: SM-GW1BB"	"sample_id: SM-GW18Z"	"sample_id: SM-GW2AN"	"sample_id: SM-GW2C9"	"sample_id: SM-GW1VN"	"sample_id: SM-GW1U5"	"sample_id: SM-GW1ZL"	"sample_id: SM-GW1YX"	"sample_id: SM-GW1FH"	"sample_id: SM-GW1AM"	"sample_id: SM-GW2BC"	"sample_id: SM-GW1BC"	"sample_id: SM-GW1H5"	"sample_id: SM-GW1VM"	"sample_id: SM-GW1F5"	"sample_id: SM-GW23J"	"sample_id: SM-GW2AL"	"sample_id: SM-GW1ET"	"sample_id: SM-GW2B4"	"sample_id: SM-GW1U9"	"sample_id: SM-GW29T"	"sample_id: SM-GW1CO"	"sample_id: SM-GW1Y5"	"sample_id: SM-GW2BE"	"sample_id: SM-GW2C1"	"sample_id: SM-GW1Z2"	"sample_id: SM-GW1GK"	"sample_id: SM-GW1H3"	"sample_id: SM-GW2B6"	"sample_id: SM-GW1B8"	"sample_id: SM-GW1FA"	"sample_id: SM-GW29P"	"sample_id: SM-GW1BL"	"sample_id: SM-GW1YK"	"sample_id: SM-GW2C2"	"sample_id: SM-GW24I"	"sample_id: SM-GW1EQ"	"sample_id: SM-GW197"	"sample_id: SM-GW29Q"	"sample_id: SM-GW1BN"	"sample_id: SM-GW1A8"	"sample_id: SM-GW2BV"	"sample_id: SM-GW1FO"	"sample_id: SM-GW1XL"	"sample_id: SM-GW1AE"	"sample_id: SM-GW1ZD"	"sample_id: SM-GW2AG"	"sample_id: SM-GW1AD"	"sample_id: SM-GW1XF"	"sample_id: SM-GW1B5"	"sample_id: SM-GW2AW"	"sample_id: SM-GW1A2"	"sample_id: SM-GW1ZO"	"sample_id: SM-GW1V5"	"sample_id: SM-GW1FY"	"sample_id: SM-GW1G3"	"sample_id: SM-GW1XY"	"sample_id: SM-GW2A8"	"sample_id: SM-GW21A"	"sample_id: SM-GW19W"	"sample_id: SM-GW1FU"	"sample_id: SM-GW19Z"	"sample_id: SM-GW1FG"	"sample_id: SM-GW1AL"	"sample_id: SM-GW19U"	"sample_id: SM-GW2AR"	"sample_id: SM-GW1AW"	"sample_id: SM-GW1T8"	"sample_id: SM-GW1T7"	"sample_id: SM-GW22A"	"sample_id: SM-GW1BR"	"sample_id: SM-GW1AQ"	"sample_id: SM-GW1AU"	"sample_id: SM-GW1TB"	"sample_id: SM-GW1BT"	"sample_id: SM-GW1AS"	"sample_id: SM-GW1SV"	"sample_id: SM-GW1UM"	"sample_id: SM-GW1WT"	"sample_id: SM-GW22C"	"sample_id: SM-GW1X5"	"sample_id: SM-GW1UF"	"sample_id: SM-GW29W"	"sample_id: SM-GW1T9"	"sample_id: SM-GW1XE"	"sample_id: SM-GW2A4"	"sample_id: SM-GW1BZ"	"sample_id: SM-GW1WY"	"sample_id: SM-GW1UO"	"sample_id: SM-GW1X2"	"sample_id: SM-GW1BX"	"sample_id: SM-GW22G"	"sample_id: SM-GW2A5"	"sample_id: SM-GW1WZ"	"sample_id: SM-GW24G"	"sample_id: SM-GW1TQ"	"sample_id: SM-GW1WL"	"sample_id: SM-GW1UI"	"sample_id: SM-GW1X8"	"sample_id: SM-GW1X4"	"sample_id: SM-GW1X3"	"sample_id: SM-GW1UJ"	"sample_id: SM-GW1AV"	"sample_id: SM-GW1TH"	"sample_id: SM-GW1TD"	"sample_id: SM-GW2A2"	"sample_id: SM-GW1TN"	"sample_id: SM-GW22N"	"sample_id: SM-GW1UH"	"sample_id: SM-GW1X9"	"sample_id: SM-GW1YP"	"sample_id: SM-GW1XP"	"sample_id: SM-GW2BR"	"sample_id: SM-GW1Y8"	"sample_id: SM-GW1W3"	"sample_id: SM-GW1YE"	"sample_id: SM-GW29V"	"sample_id: SM-GW2BP"	"sample_id: SM-GW1A5"	"sample_id: SM-GW1BI"	"sample_id: SM-GW19M"	"sample_id: SM-GW1EX"	"sample_id: SM-GW22Q"	"sample_id: SM-GW1SP"	"sample_id: SM-GW2BH"	"sample_id: SM-GW1TY"	"sample_id: SM-GW1ZM"	"sample_id: SM-GW1AI"	"sample_id: SM-GW2C6"	"sample_id: SM-GW2C4"	"sample_id: SM-GW1B3"	"sample_id: SM-GW2B1"	"sample_id: SM-GW1CM"	"sample_id: SM-GW1GC"	"sample_id: SM-GW1H4"	"sample_id: SM-GW1YT"	"sample_id: SM-GW19C"	"sample_id: SM-GW1WF"	"sample_id: SM-GW1WD"	"sample_id: SM-GW1WB"	"sample_id: SM-GW1F6"	"sample_id: SM-GW1UP"	"sample_id: SM-GW1FB"	"sample_id: SM-GW19Q"	"sample_id: SM-GW1EV"	"sample_id: SM-GW1F8"	"sample_id: SM-GW2BG"	"sample_id: SM-GW1BK"	"sample_id: SM-GW2BD"	"sample_id: SM-GW1G4"	"sample_id: SM-GW1W2"	"sample_id: SM-GW2AQ"	"sample_id: SM-GW1CJ"	"sample_id: SM-GW1FN"	"sample_id: SM-GW2AC"	"sample_id: SM-GW2B9"	"sample_id: SM-GW198"	"sample_id: SM-GW23G"	"sample_id: SM-GW2AU"	"sample_id: SM-GW1ZP"	"sample_id: SM-GW2BX"	"sample_id: SM-GW23F"	"sample_id: SM-GW1TZ"	"sample_id: SM-GW2C5"	"sample_id: SM-GW1XR"	"sample_id: SM-GW2AT"	"sample_id: SM-GW1YY"	"sample_id: SM-GW23K"	"sample_id: SM-GW1F1"	"sample_id: SM-GW1SQ"	"sample_id: SM-GW2AM"	"sample_id: SM-GW1U7"	"sample_id: SM-GW1XK"	"sample_id: SM-GW1RU"	"sample_id: SM-GW1Y4"	"sample_id: SM-GW23E"	"sample_id: SM-GW1V8"	"sample_id: SM-GW19A"	"sample_id: SM-GW1AN"	"sample_id: SM-GW1CU"	"sample_id: SM-GW1VF"	"sample_id: SM-GW16B"	"sample_id: SM-GW1CS"	"sample_id: SM-GW1VK"	"sample_id: SM-GW21J"	"sample_id: SM-GW16L"	"sample_id: SM-GW21L"	"sample_id: SM-GW1GT"	"sample_id: SM-GW1V4"	"sample_id: SM-GW21S"	"sample_id: SM-GW21K"	"sample_id: SM-GW21R"	"sample_id: SM-GW1V3"	"sample_id: SM-GW1C5"	"sample_id: SM-GW1H2"	"sample_id: SM-GW16F"	"sample_id: SM-GW1VE"	"sample_id: SM-GW1ZW"	"sample_id: SM-GW1FW"	"sample_id: SM-GW1TU"	"sample_id: SM-GW23L"	"sample_id: SM-GW1YW"	"sample_id: SM-GW221"	"sample_id: SM-GW24K"	"sample_id: SM-GW1CG"	"sample_id: SM-GW1EZ"	"sample_id: SM-GW228"	"sample_id: SM-GW185"	"sample_id: SM-GW225"	"sample_id: SM-GW1YF"	"sample_id: SM-GW21F"	"sample_id: SM-GW18V"	"sample_id: SM-GW1V6"	"sample_id: SM-GW1BP"	"sample_id: SM-GW187"	"sample_id: SM-GW19L"	"sample_id: SM-GW2CP"	"sample_id: SM-GW18R"	"sample_id: SM-GW19K"	"sample_id: SM-GW1DM"	"sample_id: SM-GW1FJ"	"sample_id: SM-GW1F3"	"sample_id: SM-GW2B3"	"sample_id: SM-GW2BL"	"sample_id: SM-GW18M"	"sample_id: SM-GW21E"	"sample_id: SM-GW17K"	"sample_id: SM-GW17I"	"sample_id: SM-GW21D"	"sample_id: SM-GW17J"	"sample_id: SM-GW17D"	"sample_id: SM-GW17V"	"sample_id: SM-GW17T"	"sample_id: SM-GW17U"	"sample_id: SM-GW1CR"	"sample_id: SM-GW1CV"	"sample_id: SM-GW1ZX"	"sample_id: SM-GW1BQ"	"sample_id: SM-GW1GR"	"sample_id: SM-GW1AK"	"sample_id: SM-GW18P"	"sample_id: SM-GW1DL"	"sample_id: SM-GW22Y"	"sample_id: SM-GW1FF"	"sample_id: SM-GW1FM"	"sample_id: SM-GW1C4"	"sample_id: SM-GW1FI"	"sample_id: SM-GW21G"	"sample_id: SM-GW17G"	"sample_id: SM-GW18B"	"sample_id: SM-GW17Q"	"sample_id: SM-GW17B"	"sample_id: SM-GW17R"	"sample_id: SM-GW17N"	"sample_id: SM-GW17P"	"sample_id: SM-GW17Y"	"sample_id: SM-GW2B7"	"sample_id: SM-GW1DN"	"sample_id: SM-GW1YL"	"sample_id: SM-GW29R"	"sample_id: SM-GW24D"
!Sample_characteristics_ch1	"collaborator_participant_id: GTEX-11EM3"	"collaborator_participant_id: GTEX-11EMC"	"collaborator_participant_id: GTEX-11GSP"	"collaborator_participant_id: GTEX-13D11"	"collaborator_participant_id: GTEX-13PL6"	"collaborator_participant_id: GTEX-147F3"	"collaborator_participant_id: GTEX-14BIL"	"collaborator_participant_id: GTEX-14BIN"	"collaborator_participant_id: GTEX-14E6C"	"collaborator_participant_id: GTEX-14H4A"	"collaborator_participant_id: GTEX-14PHY"	"collaborator_participant_id: GTEX-14PJ6"	"collaborator_participant_id: GTEX-14PK6"	"collaborator_participant_id: GTEX-15CHQ"	"collaborator_participant_id: GTEX-15CHR"	"collaborator_participant_id: GTEX-15DDE"	"collaborator_participant_id: GTEX-15ER7"	"collaborator_participant_id: GTEX-15EU6"	"collaborator_participant_id: GTEX-15SHU"	"collaborator_participant_id: GTEX-16NGA"	"collaborator_participant_id: GTEX-17HG3"	"collaborator_participant_id: GTEX-18D9U"	"collaborator_participant_id: GTEX-18QFQ"	"collaborator_participant_id: GTEX-1AYD5"	"collaborator_participant_id: GTEX-1C6WA"	"collaborator_participant_id: GTEX-1F5PL"	"collaborator_participant_id: GTEX-1F88E"	"collaborator_participant_id: GTEX-1GMR3"	"collaborator_participant_id: GTEX-1GN1W"	"collaborator_participant_id: GTEX-1GPI6"	"collaborator_participant_id: GTEX-1GTWX"	"collaborator_participant_id: GTEX-1GZ2Q"	"collaborator_participant_id: GTEX-1GZ4H"	"collaborator_participant_id: GTEX-1H3VE"	"collaborator_participant_id: GTEX-1IDJE"	"collaborator_participant_id: GTEX-1IKOH"	"collaborator_participant_id: GTEX-S341"	"collaborator_participant_id: GTEX-S4P3"	"collaborator_participant_id: GTEX-SE5C"	"collaborator_participant_id: GTEX-T6MO"	"collaborator_participant_id: GTEX-U3ZN"	"collaborator_participant_id: GTEX-UJHI"	"collaborator_participant_id: GTEX-WI4N"	"collaborator_participant_id: GTEX-WRHU"	"collaborator_participant_id: GTEX-X15G"	"collaborator_participant_id: GTEX-X8HC"	"collaborator_participant_id: GTEX-XUW1"	"collaborator_participant_id: GTEX-XUZC"	"collaborator_participant_id: GTEX-XV7Q"	"collaborator_participant_id: GTEX-YFC4"	"collaborator_participant_id: GTEX-ZC5H"	"collaborator_participant_id: GTEX-ZXES"	"collaborator_participant_id: GTEX-1117F"	"collaborator_participant_id: GTEX-111FC"	"collaborator_participant_id: GTEX-111VG"	"collaborator_participant_id: GTEX-111YS"	"collaborator_participant_id: GTEX-113JC"	"collaborator_participant_id: GTEX-1192W"	"collaborator_participant_id: GTEX-1192X"	"collaborator_participant_id: GTEX-11DXX"	"collaborator_participant_id: GTEX-11DXZ"	"collaborator_participant_id: GTEX-11EM3"	"collaborator_participant_id: GTEX-11EMC"	"collaborator_participant_id: GTEX-11GS4"	"collaborator_participant_id: GTEX-11I78"	"collaborator_participant_id: GTEX-11ONC"	"collaborator_participant_id: GTEX-11P82"	"collaborator_participant_id: GTEX-11TT1"	"collaborator_participant_id: GTEX-11TTK"	"collaborator_participant_id: GTEX-11UD2"	"collaborator_participant_id: GTEX-11WQC"	"collaborator_participant_id: GTEX-11ZTS"	"collaborator_participant_id: GTEX-11ZTT"	"collaborator_participant_id: GTEX-11ZU8"	"collaborator_participant_id: GTEX-11ZUS"	"collaborator_participant_id: GTEX-1211K"	"collaborator_participant_id: GTEX-12584"	"collaborator_participant_id: GTEX-12696"	"collaborator_participant_id: GTEX-12KS4"	"collaborator_participant_id: GTEX-12WSE"	"collaborator_participant_id: GTEX-12WSF"	"collaborator_participant_id: GTEX-12WSI"	"collaborator_participant_id: GTEX-12ZZW"	"collaborator_participant_id: GTEX-12ZZX"	"collaborator_participant_id: GTEX-12ZZY"	"collaborator_participant_id: GTEX-12ZZZ"	"collaborator_participant_id: GTEX-13111"	"collaborator_participant_id: GTEX-13112"	"collaborator_participant_id: GTEX-1399R"	"collaborator_participant_id: GTEX-139TT"	"collaborator_participant_id: GTEX-139YR"	"collaborator_participant_id: GTEX-13CF2"	"collaborator_participant_id: GTEX-13N1W"	"collaborator_participant_id: GTEX-13NYS"	"collaborator_participant_id: GTEX-13NZB"	"collaborator_participant_id: GTEX-13O3P"	"collaborator_participant_id: GTEX-13OW5"	"collaborator_participant_id: GTEX-13OW7"	"collaborator_participant_id: GTEX-13OW8"	"collaborator_participant_id: GTEX-13PL6"	"collaborator_participant_id: GTEX-13QIC"	"collaborator_participant_id: GTEX-13QJC"	"collaborator_participant_id: GTEX-13SLW"	"collaborator_participant_id: GTEX-13SLX"	"collaborator_participant_id: GTEX-13X6I"	"collaborator_participant_id: GTEX-145MH"	"collaborator_participant_id: GTEX-1477Z"	"collaborator_participant_id: GTEX-147GR"	"collaborator_participant_id: GTEX-14A5I"	"collaborator_participant_id: GTEX-14A6H"	"collaborator_participant_id: GTEX-14ABY"	"collaborator_participant_id: GTEX-14AS3"	"collaborator_participant_id: GTEX-14BIM"	"collaborator_participant_id: GTEX-14BIN"	"collaborator_participant_id: GTEX-14BMV"	"collaborator_participant_id: GTEX-14DAQ"	"collaborator_participant_id: GTEX-14DAR"	"collaborator_participant_id: GTEX-14E6D"	"collaborator_participant_id: GTEX-14E7W"	"collaborator_participant_id: GTEX-14H4A"	"collaborator_participant_id: GTEX-14LZ3"	"collaborator_participant_id: GTEX-14PJ4"	"collaborator_participant_id: GTEX-14PJM"	"collaborator_participant_id: GTEX-14PK6"	"collaborator_participant_id: GTEX-14PN3"	"collaborator_participant_id: GTEX-15CHQ"	"collaborator_participant_id: GTEX-15CHR"	"collaborator_participant_id: GTEX-15D79"	"collaborator_participant_id: GTEX-15DDE"	"collaborator_participant_id: GTEX-15DYW"	"collaborator_participant_id: GTEX-15EO6"	"collaborator_participant_id: GTEX-15EU6"	"collaborator_participant_id: GTEX-15RIE"	"collaborator_participant_id: GTEX-15SDE"	"collaborator_participant_id: GTEX-15SHU"	"collaborator_participant_id: GTEX-15SHV"	"collaborator_participant_id: GTEX-15SHW"	"collaborator_participant_id: GTEX-15SKB"	"collaborator_participant_id: GTEX-15SZO"	"collaborator_participant_id: GTEX-16AAH"	"collaborator_participant_id: GTEX-16NPV"	"collaborator_participant_id: GTEX-16YQH"	"collaborator_participant_id: GTEX-17EVQ"	"collaborator_participant_id: GTEX-17HGU"	"collaborator_participant_id: GTEX-18A7A"	"collaborator_participant_id: GTEX-18D9B"	"collaborator_participant_id: GTEX-18D9U"	"collaborator_participant_id: GTEX-19HZE"	"collaborator_participant_id: GTEX-1A32A"	"collaborator_participant_id: GTEX-1A3MV"	"collaborator_participant_id: GTEX-1A3MX"	"collaborator_participant_id: GTEX-1AX9I"	"collaborator_participant_id: GTEX-1AYD5"	"collaborator_participant_id: GTEX-1B8KE"	"collaborator_participant_id: GTEX-1B98T"	"collaborator_participant_id: GTEX-1BAJH"	"collaborator_participant_id: GTEX-1C4CL"	"collaborator_participant_id: GTEX-1C64N"	"collaborator_participant_id: GTEX-1C64O"	"collaborator_participant_id: GTEX-1C6WA"	"collaborator_participant_id: GTEX-1CAMQ"	"collaborator_participant_id: GTEX-1CAV2"	"collaborator_participant_id: GTEX-1CB4H"	"collaborator_participant_id: GTEX-1E2YA"	"collaborator_participant_id: GTEX-1EN7A"	"collaborator_participant_id: GTEX-1F52S"	"collaborator_participant_id: GTEX-1F5PK"	"collaborator_participant_id: GTEX-1F5PL"	"collaborator_participant_id: GTEX-1F6I4"	"collaborator_participant_id: GTEX-1F6IF"	"collaborator_participant_id: GTEX-1F6RS"	"collaborator_participant_id: GTEX-1F75A"	"collaborator_participant_id: GTEX-1F75W"	"collaborator_participant_id: GTEX-1F88E"	"collaborator_participant_id: GTEX-1GL5R"	"collaborator_participant_id: GTEX-1GMR2"	"collaborator_participant_id: GTEX-1GMR3"	"collaborator_participant_id: GTEX-1GTWX"	"collaborator_participant_id: GTEX-1GZ4I"	"collaborator_participant_id: GTEX-1GZHY"	"collaborator_participant_id: GTEX-1H11D"	"collaborator_participant_id: GTEX-1H1DF"	"collaborator_participant_id: GTEX-1H1ZS"	"collaborator_participant_id: GTEX-1H23P"	"collaborator_participant_id: GTEX-1H2FU"	"collaborator_participant_id: GTEX-1H3VE"	"collaborator_participant_id: GTEX-1H3VY"	"collaborator_participant_id: GTEX-1HB9E"	"collaborator_participant_id: GTEX-1HCVE"	"collaborator_participant_id: GTEX-1HGF4"	"collaborator_participant_id: GTEX-1HSKV"	"collaborator_participant_id: GTEX-1I6K6"	"collaborator_participant_id: GTEX-1ICLY"	"collaborator_participant_id: GTEX-1IDJH"	"collaborator_participant_id: GTEX-1IDJI"	"collaborator_participant_id: GTEX-1IDJU"	"collaborator_participant_id: GTEX-1IDJV"	"collaborator_participant_id: GTEX-1IGQW"	"collaborator_participant_id: GTEX-1IKJJ"	"collaborator_participant_id: GTEX-1IKK5"	"collaborator_participant_id: GTEX-1IY9M"	"collaborator_participant_id: GTEX-1J1OQ"	"collaborator_participant_id: GTEX-1J1R8"	"collaborator_participant_id: GTEX-1J8Q2"	"collaborator_participant_id: GTEX-1J8Q3"	"collaborator_participant_id: GTEX-1JK1U"	"collaborator_participant_id: GTEX-1JMOU"	"collaborator_participant_id: GTEX-1JMPZ"	"collaborator_participant_id: GTEX-1JMQJ"	"collaborator_participant_id: GTEX-1JN1M"	"collaborator_participant_id: GTEX-1JN6P"	"collaborator_participant_id: GTEX-1JN76"	"collaborator_participant_id: GTEX-RUSQ"	"collaborator_participant_id: GTEX-RVPU"	"collaborator_participant_id: GTEX-RVPV"	"collaborator_participant_id: GTEX-S33H"	"collaborator_participant_id: GTEX-S341"	"collaborator_participant_id: GTEX-S4Z8"	"collaborator_participant_id: GTEX-S7SE"	"collaborator_participant_id: GTEX-SIU8"	"collaborator_participant_id: GTEX-SJXC"	"collaborator_participant_id: GTEX-SN8G"	"collaborator_participant_id: GTEX-T2IS"	"collaborator_participant_id: GTEX-T2YK"	"collaborator_participant_id: GTEX-T8EM"	"collaborator_participant_id: GTEX-TSE9"	"collaborator_participant_id: GTEX-U3ZH"	"collaborator_participant_id: GTEX-U3ZM"	"collaborator_participant_id: GTEX-U8T8"	"collaborator_participant_id: GTEX-UJHI"	"collaborator_participant_id: GTEX-UPJH"	"collaborator_participant_id: GTEX-UPK5"	"collaborator_participant_id: GTEX-UTHO"	"collaborator_participant_id: GTEX-W5X1"	"collaborator_participant_id: GTEX-WFG8"	"collaborator_participant_id: GTEX-WH7G"	"collaborator_participant_id: GTEX-WK11"	"collaborator_participant_id: GTEX-WOFL"	"collaborator_participant_id: GTEX-WQUQ"	"collaborator_participant_id: GTEX-WRHU"	"collaborator_participant_id: GTEX-WVLH"	"collaborator_participant_id: GTEX-WWYW"	"collaborator_participant_id: GTEX-WXYG"	"collaborator_participant_id: GTEX-WY7C"	"collaborator_participant_id: GTEX-WYBS"	"collaborator_participant_id: GTEX-X261"	"collaborator_participant_id: GTEX-X4EO"	"collaborator_participant_id: GTEX-X4EP"	"collaborator_participant_id: GTEX-X4XX"	"collaborator_participant_id: GTEX-X4XY"	"collaborator_participant_id: GTEX-X585"	"collaborator_participant_id: GTEX-X5EB"	"collaborator_participant_id: GTEX-X62O"	"collaborator_participant_id: GTEX-X8HC"	"collaborator_participant_id: GTEX-XBEC"	"collaborator_participant_id: GTEX-XBED"	"collaborator_participant_id: GTEX-XMD2"	"collaborator_participant_id: GTEX-XMK1"	"collaborator_participant_id: GTEX-XPT6"	"collaborator_participant_id: GTEX-XPVG"	"collaborator_participant_id: GTEX-XQ3S"	"collaborator_participant_id: GTEX-XUJ4"	"collaborator_participant_id: GTEX-XV7Q"	"collaborator_participant_id: GTEX-XYKS"	"collaborator_participant_id: GTEX-Y111"	"collaborator_participant_id: GTEX-YB5E"	"collaborator_participant_id: GTEX-YFCO"	"collaborator_participant_id: GTEX-YJ89"	"collaborator_participant_id: GTEX-Z93S"	"collaborator_participant_id: GTEX-ZAB4"	"collaborator_participant_id: GTEX-ZDTS"	"collaborator_participant_id: GTEX-ZDXO"	"collaborator_participant_id: GTEX-ZVZP"	"collaborator_participant_id: GTEX-ZVZQ"	"collaborator_participant_id: GTEX-ZYFG"	"collaborator_participant_id: GTEX-ZYY3"	"collaborator_participant_id: GTEX-117XS"	"collaborator_participant_id: GTEX-117YW"	"collaborator_participant_id: GTEX-1192W"	"collaborator_participant_id: GTEX-1192X"	"collaborator_participant_id: GTEX-11EMC"	"collaborator_participant_id: GTEX-11NV4"	"collaborator_participant_id: GTEX-11UD2"	"collaborator_participant_id: GTEX-11WQC"	"collaborator_participant_id: GTEX-11WQK"	"collaborator_participant_id: GTEX-11ZU8"	"collaborator_participant_id: GTEX-1212Z"	"collaborator_participant_id: GTEX-12696"	"collaborator_participant_id: GTEX-12KS4"	"collaborator_participant_id: GTEX-12WSA"	"collaborator_participant_id: GTEX-12WSD"	"collaborator_participant_id: GTEX-12WSF"	"collaborator_participant_id: GTEX-12WSI"	"collaborator_participant_id: GTEX-12ZZW"	"collaborator_participant_id: GTEX-12ZZX"	"collaborator_participant_id: GTEX-12ZZY"	"collaborator_participant_id: GTEX-12ZZZ"	"collaborator_participant_id: GTEX-13112"	"collaborator_participant_id: GTEX-13N1W"	"collaborator_participant_id: GTEX-13NYS"	"collaborator_participant_id: GTEX-13O3P"	"collaborator_participant_id: GTEX-13OW5"	"collaborator_participant_id: GTEX-13QJC"	"collaborator_participant_id: GTEX-13SLX"	"collaborator_participant_id: GTEX-13W46"	"collaborator_participant_id: GTEX-148VJ"	"collaborator_participant_id: GTEX-14A5H"	"collaborator_participant_id: GTEX-14C39"	"collaborator_participant_id: GTEX-15DDE"	"collaborator_participant_id: GTEX-15SHU"	"collaborator_participant_id: GTEX-1B98T"	"collaborator_participant_id: GTEX-1F6IF"	"collaborator_participant_id: GTEX-1GTWX"	"collaborator_participant_id: GTEX-1H1ZS"	"collaborator_participant_id: GTEX-S33H"	"collaborator_participant_id: GTEX-SIU8"	"collaborator_participant_id: GTEX-UTHO"	"collaborator_participant_id: GTEX-WOFL"	"collaborator_participant_id: GTEX-WRHU"	"collaborator_participant_id: GTEX-WWYW"	"collaborator_participant_id: GTEX-X261"	"collaborator_participant_id: GTEX-X4EP"	"collaborator_participant_id: GTEX-X4XX"	"collaborator_participant_id: GTEX-X585"	"collaborator_participant_id: GTEX-X62O"	"collaborator_participant_id: GTEX-YFC4"	"collaborator_participant_id: GTEX-1117F"	"collaborator_participant_id: GTEX-113JC"	"collaborator_participant_id: GTEX-1192W"	"collaborator_participant_id: GTEX-1192X"	"collaborator_participant_id: GTEX-11DXZ"	"collaborator_participant_id: GTEX-11DYG"	"collaborator_participant_id: GTEX-11GSP"	"collaborator_participant_id: GTEX-11I78"	"collaborator_participant_id: GTEX-11NV4"	"collaborator_participant_id: GTEX-11TTK"	"collaborator_participant_id: GTEX-11WQK"	"collaborator_participant_id: GTEX-11XUK"	"collaborator_participant_id: GTEX-11ZTS"	"collaborator_participant_id: GTEX-11ZUS"	"collaborator_participant_id: GTEX-1212Z"	"collaborator_participant_id: GTEX-12584"	"collaborator_participant_id: GTEX-12WSA"	"collaborator_participant_id: GTEX-12WSD"	"collaborator_participant_id: GTEX-12WSE"	"collaborator_participant_id: GTEX-12ZZX"	"collaborator_participant_id: GTEX-13111"	"collaborator_participant_id: GTEX-13112"	"collaborator_participant_id: GTEX-139TT"	"collaborator_participant_id: GTEX-139YR"	"collaborator_participant_id: GTEX-13CF2"	"collaborator_participant_id: GTEX-13FXS"	"collaborator_participant_id: GTEX-13IVO"	"collaborator_participant_id: GTEX-13NYS"	"collaborator_participant_id: GTEX-13NZA"	"collaborator_participant_id: GTEX-13O3P"	"collaborator_participant_id: GTEX-13OVK"	"collaborator_participant_id: GTEX-13OW5"	"collaborator_participant_id: GTEX-13OW8"	"collaborator_participant_id: GTEX-13PL6"	"collaborator_participant_id: GTEX-13QIC"	"collaborator_participant_id: GTEX-13RTJ"	"collaborator_participant_id: GTEX-13W46"	"collaborator_participant_id: GTEX-145MH"	"collaborator_participant_id: GTEX-146FH"	"collaborator_participant_id: GTEX-14753"	"collaborator_participant_id: GTEX-1477Z"	"collaborator_participant_id: GTEX-14A5I"	"collaborator_participant_id: GTEX-14A6H"	"collaborator_participant_id: GTEX-14AS3"	"collaborator_participant_id: GTEX-14BIM"	"collaborator_participant_id: GTEX-14BIN"	"collaborator_participant_id: GTEX-14BMV"	"collaborator_participant_id: GTEX-14DAR"	"collaborator_participant_id: GTEX-14E6C"	"collaborator_participant_id: GTEX-14E7W"	"collaborator_participant_id: GTEX-14JFF"	"collaborator_participant_id: GTEX-14JG1"	"collaborator_participant_id: GTEX-14JG6"	"collaborator_participant_id: GTEX-14LZ3"	"collaborator_participant_id: GTEX-14PJ4"	"collaborator_participant_id: GTEX-14PJ6"	"collaborator_participant_id: GTEX-14PJM"	"collaborator_participant_id: GTEX-14PJO"	"collaborator_participant_id: GTEX-14PK6"	"collaborator_participant_id: GTEX-14PN3"	"collaborator_participant_id: GTEX-15CHR"	"collaborator_participant_id: GTEX-15D1Q"	"collaborator_participant_id: GTEX-15D79"	"collaborator_participant_id: GTEX-15DDE"	"collaborator_participant_id: GTEX-15EO6"	"collaborator_participant_id: GTEX-15EU6"	"collaborator_participant_id: GTEX-15G1A"	"collaborator_participant_id: GTEX-15RIE"	"collaborator_participant_id: GTEX-15RJE"	"collaborator_participant_id: GTEX-15SDE"	"collaborator_participant_id: GTEX-15SHV"	"collaborator_participant_id: GTEX-15SHW"	"collaborator_participant_id: GTEX-15SKB"	"collaborator_participant_id: GTEX-15SZO"	"collaborator_participant_id: GTEX-15UF6"	"collaborator_participant_id: GTEX-15UKP"	"collaborator_participant_id: GTEX-16AAH"	"collaborator_participant_id: GTEX-16NPV"	"collaborator_participant_id: GTEX-16YQH"	"collaborator_participant_id: GTEX-17EVQ"	"collaborator_participant_id: GTEX-17HG3"	"collaborator_participant_id: GTEX-18465"	"collaborator_participant_id: GTEX-18A66"	"collaborator_participant_id: GTEX-18D9B"	"collaborator_participant_id: GTEX-18D9U"	"collaborator_participant_id: GTEX-19HZE"	"collaborator_participant_id: GTEX-1A3MV"	"collaborator_participant_id: GTEX-1A3MX"	"collaborator_participant_id: GTEX-1AX9I"	"collaborator_participant_id: GTEX-1AYD5"	"collaborator_participant_id: GTEX-1B98T"	"collaborator_participant_id: GTEX-1BAJH"	"collaborator_participant_id: GTEX-1C4CL"	"collaborator_participant_id: GTEX-1C64N"	"collaborator_participant_id: GTEX-1C64O"	"collaborator_participant_id: GTEX-1CAMQ"	"collaborator_participant_id: GTEX-1CAV2"	"collaborator_participant_id: GTEX-1E1VI"	"collaborator_participant_id: GTEX-1EN7A"	"collaborator_participant_id: GTEX-1F52S"	"collaborator_participant_id: GTEX-1F5PK"	"collaborator_participant_id: GTEX-1F6I4"	"collaborator_participant_id: GTEX-1F6IF"	"collaborator_participant_id: GTEX-1F75B"	"collaborator_participant_id: GTEX-1F75W"	"collaborator_participant_id: GTEX-1F88E"	"collaborator_participant_id: GTEX-1GL5R"	"collaborator_participant_id: GTEX-1GMR2"	"collaborator_participant_id: GTEX-1GMR3"	"collaborator_participant_id: GTEX-1GN1W"	"collaborator_participant_id: GTEX-1GPI6"	"collaborator_participant_id: GTEX-1GTWX"	"collaborator_participant_id: GTEX-1GZHY"	"collaborator_participant_id: GTEX-1H11D"	"collaborator_participant_id: GTEX-1H1DF"	"collaborator_participant_id: GTEX-1H23P"	"collaborator_participant_id: GTEX-1H3VE"	"collaborator_participant_id: GTEX-1H3VY"	"collaborator_participant_id: GTEX-1HB9E"	"collaborator_participant_id: GTEX-1HCVE"	"collaborator_participant_id: GTEX-1HR9M"	"collaborator_participant_id: GTEX-1I6K6"	"collaborator_participant_id: GTEX-1IDJI"	"collaborator_participant_id: GTEX-1IDJU"	"collaborator_participant_id: GTEX-1IGQW"	"collaborator_participant_id: GTEX-1IKJJ"	"collaborator_participant_id: GTEX-1IKK5"	"collaborator_participant_id: GTEX-1IL2U"	"collaborator_participant_id: GTEX-1J1OQ"	"collaborator_participant_id: GTEX-1J1R8"	"collaborator_participant_id: GTEX-1J8JJ"	"collaborator_participant_id: GTEX-1J8Q3"	"collaborator_participant_id: GTEX-1JK1U"	"collaborator_participant_id: GTEX-1JMOU"	"collaborator_participant_id: GTEX-1JMQJ"	"collaborator_participant_id: GTEX-1JN76"	"collaborator_participant_id: GTEX-1KXAM"	"collaborator_participant_id: GTEX-1L5NE"	"collaborator_participant_id: GTEX-1LC47"	"collaborator_participant_id: GTEX-1LG7Y"	"collaborator_participant_id: GTEX-1LSNL"	"collaborator_participant_id: GTEX-1LSVX"	"collaborator_participant_id: GTEX-1LVA9"	"collaborator_participant_id: GTEX-1LVAO"	"collaborator_participant_id: GTEX-1MCC2"	"collaborator_participant_id: GTEX-1MGNQ"	"collaborator_participant_id: GTEX-1MJK2"	"collaborator_participant_id: GTEX-1N2EE"	"collaborator_participant_id: GTEX-1N5O9"	"collaborator_participant_id: GTEX-1N7R6"	"collaborator_participant_id: GTEX-1NHNU"	"collaborator_participant_id: GTEX-1NUQO"	"collaborator_participant_id: GTEX-1O97I"	"collaborator_participant_id: GTEX-1OFPY"	"collaborator_participant_id: GTEX-1OJC3"	"collaborator_participant_id: GTEX-1OZHM"	"collaborator_participant_id: GTEX-1PBJJ"	"collaborator_participant_id: GTEX-1QCLY"	"collaborator_participant_id: GTEX-1QMI2"	"collaborator_participant_id: GTEX-1R46S"	"collaborator_participant_id: GTEX-1RAZR"	"collaborator_participant_id: GTEX-RUSQ"	"collaborator_participant_id: GTEX-RVPU"	"collaborator_participant_id: GTEX-RVPV"	"collaborator_participant_id: GTEX-S33H"	"collaborator_participant_id: GTEX-S341"	"collaborator_participant_id: GTEX-S4Z8"	"collaborator_participant_id: GTEX-S7SE"	"collaborator_participant_id: GTEX-SIU8"	"collaborator_participant_id: GTEX-SN8G"	"collaborator_participant_id: GTEX-SNOS"	"collaborator_participant_id: GTEX-T2YK"	"collaborator_participant_id: GTEX-T6MO"	"collaborator_participant_id: GTEX-T8EM"	"collaborator_participant_id: GTEX-TSE9"	"collaborator_participant_id: GTEX-U3ZH"	"collaborator_participant_id: GTEX-U3ZM"	"collaborator_participant_id: GTEX-U8T8"	"collaborator_participant_id: GTEX-U8XE"	"collaborator_participant_id: GTEX-UJHI"	"collaborator_participant_id: GTEX-UPJH"	"collaborator_participant_id: GTEX-UPK5"	"collaborator_participant_id: GTEX-W5X1"	"collaborator_participant_id: GTEX-WFG8"	"collaborator_participant_id: GTEX-WH7G"	"collaborator_participant_id: GTEX-WHWD"	"collaborator_participant_id: GTEX-WK11"	"collaborator_participant_id: GTEX-WOFL"	"collaborator_participant_id: GTEX-WQUQ"	"collaborator_participant_id: GTEX-WRHU"	"collaborator_participant_id: GTEX-WVLH"	"collaborator_participant_id: GTEX-WWYW"	"collaborator_participant_id: GTEX-WXYG"	"collaborator_participant_id: GTEX-WY7C"	"collaborator_participant_id: GTEX-WYBS"	"collaborator_participant_id: GTEX-WZTO"	"collaborator_participant_id: GTEX-X261"	"collaborator_participant_id: GTEX-X4EO"	"collaborator_participant_id: GTEX-X4EP"	"collaborator_participant_id: GTEX-X4XY"	"collaborator_participant_id: GTEX-X5EB"	"collaborator_participant_id: GTEX-X62O"	"collaborator_participant_id: GTEX-X8HC"	"collaborator_participant_id: GTEX-XBEC"	"collaborator_participant_id: GTEX-XBED"	"collaborator_participant_id: GTEX-XMD1"	"collaborator_participant_id: GTEX-XPT6"	"collaborator_participant_id: GTEX-XPVG"	"collaborator_participant_id: GTEX-XQ3S"	"collaborator_participant_id: GTEX-XUJ4"	"collaborator_participant_id: GTEX-XV7Q"	"collaborator_participant_id: GTEX-XYKS"	"collaborator_participant_id: GTEX-YB5E"	"collaborator_participant_id: GTEX-YEC3"	"collaborator_participant_id: GTEX-YFC4"	"collaborator_participant_id: GTEX-YFCO"	"collaborator_participant_id: GTEX-YJ89"	"collaborator_participant_id: GTEX-Z93S"	"collaborator_participant_id: GTEX-ZAB4"	"collaborator_participant_id: GTEX-ZDTS"	"collaborator_participant_id: GTEX-ZDXO"	"collaborator_participant_id: GTEX-ZYFG"	"collaborator_participant_id: GTEX-ZYY3"	"collaborator_participant_id: GTEX-11XUK"	"collaborator_participant_id: GTEX-12584"	"collaborator_participant_id: GTEX-12WSF"	"collaborator_participant_id: GTEX-13RTJ"	"collaborator_participant_id: GTEX-13SLX"	"collaborator_participant_id: GTEX-13X6I"	"collaborator_participant_id: GTEX-13X6K"	"collaborator_participant_id: GTEX-14753"	"collaborator_participant_id: GTEX-147GR"	"collaborator_participant_id: GTEX-148VJ"	"collaborator_participant_id: GTEX-14A5H"	"collaborator_participant_id: GTEX-14B4R"	"collaborator_participant_id: GTEX-15D1Q"	"collaborator_participant_id: GTEX-15DCD"	"collaborator_participant_id: GTEX-15SHU"	"collaborator_participant_id: GTEX-1F6IF"	"collaborator_participant_id: GTEX-1F75B"	"collaborator_participant_id: GTEX-1F88E"	"collaborator_participant_id: GTEX-1GPI6"	"collaborator_participant_id: GTEX-1H1ZS"	"collaborator_participant_id: GTEX-1H3NZ"	"collaborator_participant_id: GTEX-1H3O1"	"collaborator_participant_id: GTEX-1IKOE"	"collaborator_participant_id: GTEX-1J8QM"	"collaborator_participant_id: GTEX-SNOS"	"collaborator_participant_id: GTEX-T6MO"	"collaborator_participant_id: GTEX-T8EM"	"collaborator_participant_id: GTEX-U3ZH"	"collaborator_participant_id: GTEX-W5WG"	"collaborator_participant_id: GTEX-W5X1"	"collaborator_participant_id: GTEX-WOFL"	"collaborator_participant_id: GTEX-WWYW"	"collaborator_participant_id: GTEX-WYBS"	"collaborator_participant_id: GTEX-X4EO"	"collaborator_participant_id: GTEX-X4EP"	"collaborator_participant_id: GTEX-X4XY"	"collaborator_participant_id: GTEX-X585"	"collaborator_participant_id: GTEX-X5EB"	"collaborator_participant_id: GTEX-X62O"	"collaborator_participant_id: GTEX-XMD1"	"collaborator_participant_id: GTEX-XMD2"	"collaborator_participant_id: GTEX-XMK1"	"collaborator_participant_id: GTEX-XV7Q"	"collaborator_participant_id: GTEX-XYKS"	"collaborator_participant_id: GTEX-Y111"	"collaborator_participant_id: GTEX-ZVZP"	"collaborator_participant_id: GTEX-ZVZQ"	"collaborator_participant_id: GTEX-11EM3"	"collaborator_participant_id: GTEX-11EMC"	"collaborator_participant_id: GTEX-11GSP"	"collaborator_participant_id: GTEX-11I78"	"collaborator_participant_id: GTEX-11VI4"	"collaborator_participant_id: GTEX-11XUK"	"collaborator_participant_id: GTEX-11ZTS"	"collaborator_participant_id: GTEX-11ZTT"	"collaborator_participant_id: GTEX-12WSD"	"collaborator_participant_id: GTEX-12WSG"	"collaborator_participant_id: GTEX-12WSJ"	"collaborator_participant_id: GTEX-12WSK"	"collaborator_participant_id: GTEX-12ZZX"	"collaborator_participant_id: GTEX-133LE"	"collaborator_participant_id: GTEX-1399U"	"collaborator_participant_id: GTEX-13FTY"	"collaborator_participant_id: GTEX-13N11"	"collaborator_participant_id: GTEX-13O3O"	"collaborator_participant_id: GTEX-13OVJ"	"collaborator_participant_id: GTEX-13PL7"	"collaborator_participant_id: GTEX-13QBU"	"collaborator_participant_id: GTEX-13QIC"	"collaborator_participant_id: GTEX-13QJC"	"collaborator_participant_id: GTEX-13SLX"	"collaborator_participant_id: GTEX-13VXT"	"collaborator_participant_id: GTEX-13X6H"	"collaborator_participant_id: GTEX-145LS"	"collaborator_participant_id: GTEX-145ME"	"collaborator_participant_id: GTEX-146FH"	"collaborator_participant_id: GTEX-14AS3"	"collaborator_participant_id: GTEX-14BIM"	"collaborator_participant_id: GTEX-14BIN"	"collaborator_participant_id: GTEX-14BMU"	"collaborator_participant_id: GTEX-14DAQ"	"collaborator_participant_id: GTEX-14H4A"	"collaborator_participant_id: GTEX-14JG6"	"collaborator_participant_id: GTEX-14LZ3"	"collaborator_participant_id: GTEX-14PHW"	"collaborator_participant_id: GTEX-14PHY"	"collaborator_participant_id: GTEX-14PJ6"	"collaborator_participant_id: GTEX-14PJM"	"collaborator_participant_id: GTEX-14PKU"	"collaborator_participant_id: GTEX-14PN3"	"collaborator_participant_id: GTEX-14PQA"	"collaborator_participant_id: GTEX-15DCD"	"collaborator_participant_id: GTEX-15DDE"	"collaborator_participant_id: GTEX-15DYW"	"collaborator_participant_id: GTEX-15EOM"	"collaborator_participant_id: GTEX-15ER7"	"collaborator_participant_id: GTEX-15ETS"	"collaborator_participant_id: GTEX-15FZZ"	"collaborator_participant_id: GTEX-15SDE"	"collaborator_participant_id: GTEX-15SHU"	"collaborator_participant_id: GTEX-15UF6"	"collaborator_participant_id: GTEX-16MT8"	"collaborator_participant_id: GTEX-16NGA"	"collaborator_participant_id: GTEX-16NPV"	"collaborator_participant_id: GTEX-17F9Y"	"collaborator_participant_id: GTEX-17HG3"	"collaborator_participant_id: GTEX-17JCI"	"collaborator_participant_id: GTEX-183WM"	"collaborator_participant_id: GTEX-18A7A"	"collaborator_participant_id: GTEX-18D9A"	"collaborator_participant_id: GTEX-19HZE"	"collaborator_participant_id: GTEX-1A32A"	"collaborator_participant_id: GTEX-1A3MW"	"collaborator_participant_id: GTEX-1AMEY"	"collaborator_participant_id: GTEX-1AMFI"	"collaborator_participant_id: GTEX-1C475"	"collaborator_participant_id: GTEX-1CAMS"	"collaborator_participant_id: GTEX-1CAV2"	"collaborator_participant_id: GTEX-1CB4H"	"collaborator_participant_id: GTEX-1EWIQ"	"collaborator_participant_id: GTEX-1F48J"	"collaborator_participant_id: GTEX-1F52S"	"collaborator_participant_id: GTEX-1F5PL"	"collaborator_participant_id: GTEX-1F6RS"	"collaborator_participant_id: GTEX-1GN1W"	"collaborator_participant_id: GTEX-1GZHY"	"collaborator_participant_id: GTEX-1H1CY"	"collaborator_participant_id: GTEX-1H1DF"	"collaborator_participant_id: GTEX-1H2FU"	"collaborator_participant_id: GTEX-1HBPH"	"collaborator_participant_id: GTEX-1HCU6"	"collaborator_participant_id: GTEX-1HCU8"	"collaborator_participant_id: GTEX-1HCUA"	"collaborator_participant_id: GTEX-1HSGN"	"collaborator_participant_id: GTEX-1IDJE"	"collaborator_participant_id: GTEX-1IDJI"	"collaborator_participant_id: GTEX-1IDJU"	"collaborator_participant_id: GTEX-1IKOE"	"collaborator_participant_id: GTEX-1J1OQ"	"collaborator_participant_id: GTEX-1J8JJ"	"collaborator_participant_id: GTEX-1J8QM"	"collaborator_participant_id: GTEX-1JMOU"	"collaborator_participant_id: GTEX-1JN1M"	"collaborator_participant_id: GTEX-1JN76"	"collaborator_participant_id: GTEX-1K9T9"	"collaborator_participant_id: GTEX-1KANC"	"collaborator_participant_id: GTEX-1LGOU"	"collaborator_participant_id: GTEX-1LKK1"	"collaborator_participant_id: GTEX-1LVAM"	"collaborator_participant_id: GTEX-1MCC2"	"collaborator_participant_id: GTEX-1MCYP"	"collaborator_participant_id: GTEX-1N7R6"	"collaborator_participant_id: GTEX-1NUQO"	"collaborator_participant_id: GTEX-1NV5F"	"collaborator_participant_id: GTEX-1PBJI"	"collaborator_participant_id: GTEX-1PIEJ"	"collaborator_participant_id: GTEX-1QEPI"	"collaborator_participant_id: GTEX-1QP28"	"collaborator_participant_id: GTEX-1QP67"	"collaborator_participant_id: GTEX-1QPFJ"	"collaborator_participant_id: GTEX-1R46S"	"collaborator_participant_id: GTEX-1R9JW"	"collaborator_participant_id: GTEX-1R9PN"	"collaborator_participant_id: GTEX-1RDX4"	"collaborator_participant_id: GTEX-1RNTQ"	"collaborator_participant_id: GTEX-1S5ZU"	"collaborator_participant_id: GTEX-P4PP"	"collaborator_participant_id: GTEX-POMQ"	"collaborator_participant_id: GTEX-R55G"	"collaborator_participant_id: GTEX-RWS6"	"collaborator_participant_id: GTEX-S341"	"collaborator_participant_id: GTEX-S4P3"	"collaborator_participant_id: GTEX-S4UY"	"collaborator_participant_id: GTEX-S7SF"	"collaborator_participant_id: GTEX-SE5C"	"collaborator_participant_id: GTEX-SN8G"	"collaborator_participant_id: GTEX-T2IS"	"collaborator_participant_id: GTEX-T5JW"	"collaborator_participant_id: GTEX-T6MO"	"collaborator_participant_id: GTEX-TML8"	"collaborator_participant_id: GTEX-TMMY"	"collaborator_participant_id: GTEX-TSE9"	"collaborator_participant_id: GTEX-U3ZN"	"collaborator_participant_id: GTEX-UJHI"	"collaborator_participant_id: GTEX-W5WG"	"collaborator_participant_id: GTEX-WEY5"	"collaborator_participant_id: GTEX-WI4N"	"collaborator_participant_id: GTEX-WRHU"	"collaborator_participant_id: GTEX-WWYW"	"collaborator_participant_id: GTEX-WXYG"	"collaborator_participant_id: GTEX-WYVS"	"collaborator_participant_id: GTEX-X15G"	"collaborator_participant_id: GTEX-X4EP"	"collaborator_participant_id: GTEX-X8HC"	"collaborator_participant_id: GTEX-XMD2"	"collaborator_participant_id: GTEX-XOT4"	"collaborator_participant_id: GTEX-XUJ4"	"collaborator_participant_id: GTEX-XUW1"	"collaborator_participant_id: GTEX-XUZC"	"collaborator_participant_id: GTEX-XYKS"	"collaborator_participant_id: GTEX-Y114"	"collaborator_participant_id: GTEX-YFC4"	"collaborator_participant_id: GTEX-ZAJG"	"collaborator_participant_id: GTEX-ZLWG"	"collaborator_participant_id: GTEX-ZP4G"	"collaborator_participant_id: GTEX-ZPIC"	"collaborator_participant_id: GTEX-ZVT2"	"collaborator_participant_id: GTEX-ZVT3"	"collaborator_participant_id: GTEX-ZYFG"	"collaborator_participant_id: GTEX-ZYWO"	"collaborator_participant_id: GTEX-ZZPU"	"collaborator_participant_id: GTEX-111FC"	"collaborator_participant_id: GTEX-117YW"	"collaborator_participant_id: GTEX-1192X"	"collaborator_participant_id: GTEX-11DYG"	"collaborator_participant_id: GTEX-11NV4"	"collaborator_participant_id: GTEX-11ONC"	"collaborator_participant_id: GTEX-11TT1"	"collaborator_participant_id: GTEX-11UD2"	"collaborator_participant_id: GTEX-11WQC"	"collaborator_participant_id: GTEX-11WQK"	"collaborator_participant_id: GTEX-11ZU8"	"collaborator_participant_id: GTEX-11ZUS"	"collaborator_participant_id: GTEX-12696"	"collaborator_participant_id: GTEX-12KS4"	"collaborator_participant_id: GTEX-12WSA"	"collaborator_participant_id: GTEX-12WSE"	"collaborator_participant_id: GTEX-12WSF"	"collaborator_participant_id: GTEX-12ZZW"	"collaborator_participant_id: GTEX-12ZZY"	"collaborator_participant_id: GTEX-13111"	"collaborator_participant_id: GTEX-13112"	"collaborator_participant_id: GTEX-139TT"	"collaborator_participant_id: GTEX-139YR"	"collaborator_participant_id: GTEX-13FHP"	"collaborator_participant_id: GTEX-13FTW"	"collaborator_participant_id: GTEX-13IVO"	"collaborator_participant_id: GTEX-13N1W"	"collaborator_participant_id: GTEX-13NYS"	"collaborator_participant_id: GTEX-13NZA"	"collaborator_participant_id: GTEX-13OW5"	"collaborator_participant_id: GTEX-13W46"	"collaborator_participant_id: GTEX-13X6I"	"collaborator_participant_id: GTEX-147GR"	"collaborator_participant_id: GTEX-14BMV"	"collaborator_participant_id: GTEX-14C39"	"collaborator_participant_id: GTEX-14JG1"	"collaborator_participant_id: GTEX-14PJO"	"collaborator_participant_id: GTEX-15CHQ"	"collaborator_participant_id: GTEX-15CHR"	"collaborator_participant_id: GTEX-15G1A"	"collaborator_participant_id: GTEX-15SKB"	"collaborator_participant_id: GTEX-15SZO"	"collaborator_participant_id: GTEX-15UKP"	"collaborator_participant_id: GTEX-16YQH"	"collaborator_participant_id: GTEX-17EVQ"	"collaborator_participant_id: GTEX-17HGU"	"collaborator_participant_id: GTEX-1A3MV"	"collaborator_participant_id: GTEX-1B8KE"	"collaborator_participant_id: GTEX-1B98T"	"collaborator_participant_id: GTEX-1CAMQ"	"collaborator_participant_id: GTEX-1E2YA"	"collaborator_participant_id: GTEX-1F5PK"	"collaborator_participant_id: GTEX-1F6IF"	"collaborator_participant_id: GTEX-1F75A"	"collaborator_participant_id: GTEX-1F75W"	"collaborator_participant_id: GTEX-1GL5R"	"collaborator_participant_id: GTEX-1GMR3"	"collaborator_participant_id: GTEX-1GN73"	"collaborator_participant_id: GTEX-1GTWX"	"collaborator_participant_id: GTEX-1GZ2Q"	"collaborator_participant_id: GTEX-1H11D"	"collaborator_participant_id: GTEX-1H1ZS"	"collaborator_participant_id: GTEX-1H3NZ"	"collaborator_participant_id: GTEX-1H3VE"	"collaborator_participant_id: GTEX-1HR9M"	"collaborator_participant_id: GTEX-1HSKV"	"collaborator_participant_id: GTEX-1I6K6"	"collaborator_participant_id: GTEX-1ICLY"	"collaborator_participant_id: GTEX-1IDJH"	"collaborator_participant_id: GTEX-1IGQW"	"collaborator_participant_id: GTEX-1IKJJ"	"collaborator_participant_id: GTEX-1IKK5"	"collaborator_participant_id: GTEX-1IL2U"	"collaborator_participant_id: GTEX-1IY9M"	"collaborator_participant_id: GTEX-1J1R8"	"collaborator_participant_id: GTEX-1J8Q3"	"collaborator_participant_id: GTEX-RUSQ"	"collaborator_participant_id: GTEX-RVPU"	"collaborator_participant_id: GTEX-RWSA"	"collaborator_participant_id: GTEX-S33H"	"collaborator_participant_id: GTEX-S3XE"	"collaborator_participant_id: GTEX-S4Q7"	"collaborator_participant_id: GTEX-S7PM"	"collaborator_participant_id: GTEX-S7SE"	"collaborator_participant_id: GTEX-S95S"	"collaborator_participant_id: GTEX-SIU8"	"collaborator_participant_id: GTEX-SJXC"	"collaborator_participant_id: GTEX-SNMC"	"collaborator_participant_id: GTEX-SNOS"	"collaborator_participant_id: GTEX-SUCS"	"collaborator_participant_id: GTEX-T8EM"	"collaborator_participant_id: GTEX-U3ZH"	"collaborator_participant_id: GTEX-U3ZM"	"collaborator_participant_id: GTEX-U412"	"collaborator_participant_id: GTEX-U8T8"	"collaborator_participant_id: GTEX-UPK5"	"collaborator_participant_id: GTEX-UTHO"	"collaborator_participant_id: GTEX-WFG8"	"collaborator_participant_id: GTEX-WHSE"	"collaborator_participant_id: GTEX-WL46"	"collaborator_participant_id: GTEX-WOFL"	"collaborator_participant_id: GTEX-WQUQ"	"collaborator_participant_id: GTEX-WVLH"	"collaborator_participant_id: GTEX-WY7C"	"collaborator_participant_id: GTEX-WYJK"	"collaborator_participant_id: GTEX-WZTO"	"collaborator_participant_id: GTEX-X261"	"collaborator_participant_id: GTEX-X3Y1"	"collaborator_participant_id: GTEX-X4XY"	"collaborator_participant_id: GTEX-X585"	"collaborator_participant_id: GTEX-X62O"	"collaborator_participant_id: GTEX-XBED"	"collaborator_participant_id: GTEX-XBEW"	"collaborator_participant_id: GTEX-XGQ4"	"collaborator_participant_id: GTEX-XMD1"	"collaborator_participant_id: GTEX-XMK1"	"collaborator_participant_id: GTEX-XPT6"	"collaborator_participant_id: GTEX-XPVG"	"collaborator_participant_id: GTEX-XQ3S"	"collaborator_participant_id: GTEX-Y111"	"collaborator_participant_id: GTEX-YB5E"	"collaborator_participant_id: GTEX-YEC3"	"collaborator_participant_id: GTEX-YJ89"	"collaborator_participant_id: GTEX-111FC"	"collaborator_participant_id: GTEX-1192W"	"collaborator_participant_id: GTEX-11NV4"	"collaborator_participant_id: GTEX-11TT1"	"collaborator_participant_id: GTEX-11UD2"	"collaborator_participant_id: GTEX-11ZUS"	"collaborator_participant_id: GTEX-1212Z"	"collaborator_participant_id: GTEX-12696"	"collaborator_participant_id: GTEX-12KS4"	"collaborator_participant_id: GTEX-12WSA"	"collaborator_participant_id: GTEX-12WSE"	"collaborator_participant_id: GTEX-12ZZW"	"collaborator_participant_id: GTEX-12ZZY"	"collaborator_participant_id: GTEX-13112"	"collaborator_participant_id: GTEX-1399R"	"collaborator_participant_id: GTEX-139YR"	"collaborator_participant_id: GTEX-13FTW"	"collaborator_participant_id: GTEX-13NYS"	"collaborator_participant_id: GTEX-13NZA"	"collaborator_participant_id: GTEX-13O3P"	"collaborator_participant_id: GTEX-13OW5"	"collaborator_participant_id: GTEX-13W46"	"collaborator_participant_id: GTEX-147GR"	"collaborator_participant_id: GTEX-148VJ"	"collaborator_participant_id: GTEX-14C39"	"collaborator_participant_id: GTEX-14E6D"	"collaborator_participant_id: GTEX-15CHQ"	"collaborator_participant_id: GTEX-15D1Q"	"collaborator_participant_id: GTEX-15EU6"	"collaborator_participant_id: GTEX-15G1A"	"collaborator_participant_id: GTEX-18465"	"collaborator_participant_id: GTEX-1A3MV"	"collaborator_participant_id: GTEX-1B98T"	"collaborator_participant_id: GTEX-1C64N"	"collaborator_participant_id: GTEX-1CAMQ"	"collaborator_participant_id: GTEX-1F5PK"	"collaborator_participant_id: GTEX-1F6IF"	"collaborator_participant_id: GTEX-1GL5R"	"collaborator_participant_id: GTEX-1GTWX"	"collaborator_participant_id: GTEX-1H1ZS"	"collaborator_participant_id: GTEX-S33H"	"collaborator_participant_id: GTEX-SIU8"	"collaborator_participant_id: GTEX-SNOS"	"collaborator_participant_id: GTEX-T8EM"	"collaborator_participant_id: GTEX-U3ZH"	"collaborator_participant_id: GTEX-WOFL"	"collaborator_participant_id: GTEX-X261"	"collaborator_participant_id: GTEX-X4XX"	"collaborator_participant_id: GTEX-X585"	"collaborator_participant_id: GTEX-X62O"	"collaborator_participant_id: GTEX-117YW"	"collaborator_participant_id: GTEX-11DYG"	"collaborator_participant_id: GTEX-11EMC"	"collaborator_participant_id: GTEX-11TT1"	"collaborator_participant_id: GTEX-11ZU8"	"collaborator_participant_id: GTEX-11ZUS"	"collaborator_participant_id: GTEX-12KS4"	"collaborator_participant_id: GTEX-12WSA"	"collaborator_participant_id: GTEX-12WSE"	"collaborator_participant_id: GTEX-12WSI"	"collaborator_participant_id: GTEX-12ZZW"	"collaborator_participant_id: GTEX-12ZZY"	"collaborator_participant_id: GTEX-139YR"	"collaborator_participant_id: GTEX-13NYS"	"collaborator_participant_id: GTEX-13NZA"	"collaborator_participant_id: GTEX-13OW5"	"collaborator_participant_id: GTEX-13QIC"	"collaborator_participant_id: GTEX-13SLX"	"collaborator_participant_id: GTEX-14A6H"	"collaborator_participant_id: GTEX-14C39"	"collaborator_participant_id: GTEX-14E6D"	"collaborator_participant_id: GTEX-15CHQ"	"collaborator_participant_id: GTEX-15D1Q"	"collaborator_participant_id: GTEX-15DDE"	"collaborator_participant_id: GTEX-15EU6"	"collaborator_participant_id: GTEX-15SHU"	"collaborator_participant_id: GTEX-1A3MV"	"collaborator_participant_id: GTEX-1B98T"	"collaborator_participant_id: GTEX-1C64N"	"collaborator_participant_id: GTEX-1CAMQ"	"collaborator_participant_id: GTEX-1GMR3"	"collaborator_participant_id: GTEX-1GTWX"	"collaborator_participant_id: GTEX-1H1ZS"	"collaborator_participant_id: GTEX-1H3VE"	"collaborator_participant_id: GTEX-1I6K6"	"collaborator_participant_id: GTEX-1J1R8"	"collaborator_participant_id: GTEX-SNOS"	"collaborator_participant_id: GTEX-U3ZH"	"collaborator_participant_id: GTEX-U3ZM"	"collaborator_participant_id: GTEX-U8XE"	"collaborator_participant_id: GTEX-WFG8"	"collaborator_participant_id: GTEX-WH7G"	"collaborator_participant_id: GTEX-WRHU"	"collaborator_participant_id: GTEX-WWYW"	"collaborator_participant_id: GTEX-X261"	"collaborator_participant_id: GTEX-X4EP"	"collaborator_participant_id: GTEX-X4XX"	"collaborator_participant_id: GTEX-X585"	"collaborator_participant_id: GTEX-X5EB"	"collaborator_participant_id: GTEX-XMK1"	"collaborator_participant_id: GTEX-XPT6"	"collaborator_participant_id: GTEX-YFC4"	"collaborator_participant_id: GTEX-YFCO"	"collaborator_participant_id: GTEX-ZAB4"
!Sample_characteristics_ch1	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 2"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 1"	"Sex: 2"	"Sex: 1"	"Sex: 1"
!Sample_characteristics_ch1	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: None"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Moderate"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: None"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: None"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: None"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: None"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Mild"	"autolysis_score: Severe"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Moderate"	"autolysis_score: Mild"	"autolysis_score: Moderate"	"autolysis_score: Severe"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"	"autolysis_score: NA"
!Sample_characteristics_ch1	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Breast - Mammary Tissue"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Colon - Transverse"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Kidney - Cortex"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Lung"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Muscle - Skeletal"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Ovary"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Prostate"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Testis"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"	"tissue: Whole Blood"
!Sample_characteristics_ch1	"age: 20-29"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 40-49"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 70-79"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 20-29"	"age: 50-59"	"age: 40-49"	"age: 40-49"	"age: 30-39"	"age: 40-49"	"age: 30-39"	"age: 50-59"	"age: 60-69"	"age: 40-49"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 40-49"	"age: 50-59"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 40-49"	"age: 40-49"	"age: 30-39"	"age: 50-59"	"age: 40-49"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 30-39"	"age: 40-49"	"age: 40-49"	"age: 40-49"	"age: 30-39"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 20-29"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 20-29"	"age: 20-29"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 30-39"	"age: 60-69"	"age: 40-49"	"age: 60-69"	"age: 30-39"	"age: 20-29"	"age: 70-79"	"age: 50-59"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 30-39"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 70-79"	"age: 60-69"	"age: 30-39"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 70-79"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 30-39"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 70-79"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 70-79"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 30-39"	"age: 70-79"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 40-49"	"age: 70-79"	"age: 50-59"	"age: 30-39"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 70-79"	"age: 30-39"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 40-49"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 40-49"	"age: 40-49"	"age: 70-79"	"age: 60-69"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 30-39"	"age: 50-59"	"age: 70-79"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 40-49"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 30-39"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 20-29"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 30-39"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 20-29"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 30-39"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 40-49"	"age: 20-29"	"age: 40-49"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 40-49"	"age: 20-29"	"age: 50-59"	"age: 20-29"	"age: 60-69"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 30-39"	"age: 60-69"	"age: 60-69"	"age: 70-79"	"age: 50-59"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 70-79"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 70-79"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 70-79"	"age: 30-39"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 30-39"	"age: 60-69"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 20-29"	"age: 40-49"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 70-79"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 30-39"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 40-49"	"age: 70-79"	"age: 60-69"	"age: 40-49"	"age: 30-39"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 70-79"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 30-39"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 70-79"	"age: 20-29"	"age: 50-59"	"age: 50-59"	"age: 30-39"	"age: 70-79"	"age: 30-39"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 40-49"	"age: 70-79"	"age: 30-39"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 70-79"	"age: 30-39"	"age: 50-59"	"age: 60-69"	"age: 40-49"	"age: 40-49"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 40-49"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 40-49"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 30-39"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 40-49"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 20-29"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 30-39"	"age: 40-49"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 20-29"	"age: 50-59"	"age: 20-29"	"age: 60-69"	"age: 60-69"	"age: 20-29"	"age: 40-49"	"age: 30-39"	"age: 30-39"	"age: 60-69"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 30-39"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 40-49"	"age: 50-59"	"age: 40-49"	"age: 40-49"	"age: 60-69"	"age: 30-39"	"age: 40-49"	"age: 60-69"	"age: 30-39"	"age: 50-59"	"age: 50-59"	"age: 40-49"	"age: 40-49"	"age: 20-29"	"age: 40-49"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 20-29"	"age: 50-59"	"age: 20-29"	"age: 60-69"	"age: 40-49"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 40-49"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 40-49"	"age: 40-49"	"age: 70-79"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 70-79"	"age: 60-69"	"age: 30-39"	"age: 40-49"	"age: 70-79"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 70-79"	"age: 60-69"	"age: 60-69"	"age: 30-39"	"age: 60-69"	"age: 40-49"	"age: 40-49"	"age: 40-49"	"age: 30-39"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 40-49"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 20-29"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 40-49"	"age: 40-49"	"age: 20-29"	"age: 50-59"	"age: 40-49"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 20-29"	"age: 50-59"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 20-29"	"age: 60-69"	"age: 40-49"	"age: 30-39"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 70-79"	"age: 50-59"	"age: 60-69"	"age: 20-29"	"age: 20-29"	"age: 40-49"	"age: 30-39"	"age: 50-59"	"age: 40-49"	"age: 70-79"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 70-79"	"age: 30-39"	"age: 60-69"	"age: 70-79"	"age: 50-59"	"age: 30-39"	"age: 70-79"	"age: 50-59"	"age: 60-69"	"age: 30-39"	"age: 50-59"	"age: 40-49"	"age: 40-49"	"age: 40-49"	"age: 60-69"	"age: 70-79"	"age: 50-59"	"age: 60-69"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 40-49"	"age: 60-69"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 30-39"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 20-29"	"age: 50-59"	"age: 50-59"	"age: 20-29"	"age: 50-59"	"age: 50-59"	"age: 30-39"	"age: 20-29"	"age: 20-29"	"age: 20-29"	"age: 60-69"	"age: 20-29"	"age: 20-29"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 30-39"	"age: 60-69"	"age: 30-39"	"age: 40-49"	"age: 50-59"	"age: 20-29"	"age: 20-29"	"age: 30-39"	"age: 20-29"	"age: 40-49"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 40-49"	"age: 20-29"	"age: 40-49"	"age: 50-59"	"age: 20-29"	"age: 20-29"	"age: 40-49"	"age: 40-49"	"age: 40-49"	"age: 60-69"	"age: 30-39"	"age: 50-59"	"age: 50-59"	"age: 40-49"	"age: 40-49"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 40-49"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 30-39"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 50-59"	"age: 50-59"	"age: 20-29"	"age: 40-49"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 20-29"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 30-39"	"age: 60-69"	"age: 30-39"	"age: 60-69"	"age: 20-29"	"age: 70-79"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 40-49"	"age: 70-79"	"age: 70-79"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 30-39"	"age: 60-69"	"age: 50-59"	"age: 20-29"	"age: 30-39"	"age: 70-79"	"age: 50-59"	"age: 30-39"	"age: 50-59"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 40-49"	"age: 40-49"	"age: 70-79"	"age: 60-69"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 30-39"	"age: 50-59"	"age: 70-79"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 40-49"	"age: 30-39"	"age: 50-59"	"age: 20-29"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 20-29"	"age: 40-49"	"age: 70-79"	"age: 40-49"	"age: 30-39"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 40-49"	"age: 60-69"	"age: 20-29"	"age: 20-29"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 40-49"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 60-69"	"age: 40-49"	"age: 20-29"	"age: 50-59"	"age: 20-29"	"age: 50-59"	"age: 40-49"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 20-29"	"age: 50-59"	"age: 30-39"	"age: 60-69"	"age: 60-69"	"age: 30-39"	"age: 60-69"	"age: 20-29"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 30-39"	"age: 50-59"	"age: 40-49"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 70-79"	"age: 40-49"	"age: 50-59"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 30-39"	"age: 50-59"	"age: 30-39"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 70-79"	"age: 30-39"	"age: 50-59"	"age: 40-49"	"age: 40-49"	"age: 30-39"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 20-29"	"age: 60-69"	"age: 30-39"	"age: 30-39"	"age: 60-69"	"age: 20-29"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 30-39"	"age: 40-49"	"age: 50-59"	"age: 60-69"	"age: 40-49"	"age: 50-59"	"age: 50-59"	"age: 40-49"	"age: 30-39"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 40-49"	"age: 60-69"	"age: 70-79"	"age: 40-49"	"age: 30-39"	"age: 40-49"	"age: 40-49"	"age: 30-39"	"age: 40-49"	"age: 30-39"	"age: 20-29"	"age: 40-49"	"age: 50-59"	"age: 50-59"	"age: 50-59"	"age: 60-69"	"age: 60-69"	"age: 50-59"	"age: 40-49"	"age: 40-49"	"age: 20-29"	"age: 40-49"	"age: 40-49"	"age: 40-49"
!Sample_characteristics_ch1	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: NA"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: NA"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: NA"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Never"	"smoker_status: Former"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Former"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"	"smoker_status: Current"	"smoker_status: Never"	"smoker_status: Current"
!Sample_molecule_ch1	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"	"genomic DNA"
!Sample_extract_protocol_ch1	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."	"DNA samples were extracted from GTEx tissue samples using Qiagen Gentra Puregene method at GTEx Laboratory Data, Analysis and Coordinating Center (LDACC), and sent to the Institute for Population and Precision Health Laboratory on 96-well plates. Tissue types were not batched by plate. Bisulfite conversion was applied to 500 ng of DNA using EZ-96 DNA methylation kit (Zymo Research, Irvine, CA, USA)."
!Sample_label_ch1	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"	"Cy5 and Cy3"
!Sample_label_protocol_ch1	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"	"Standard Illumina Protocol"
!Sample_taxid_ch1	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"	"9606"
!Sample_hyb_protocol	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"	"All samples were  prepared and analyzed in accordance with the manufacturer guidelines and protocol for the Illumina Infinium HumanMethylationEPIC array (Illumina, San Diego, CA, USA). That is, bisulphite converted DNA was amplified, fragmented and hybridised to IIllumina Infinium HumanMethylationEPIC BeadChip using standard Illumina protocol"
!Sample_scan_protocol	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"	"Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting"
!Sample_description	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"	"sample name:"
!Sample_description	"GTEX-11EM3-1326-SM-GW24C"	"GTEX-11EMC-2026-SM-GW242"	"GTEX-11GSP-0926-SM-GW21X"	"GTEX-13D11-1026-SM-GW1D7"	"GTEX-13PL6-2926-SM-GW1SN"	"GTEX-147F3-1626-SM-GW1DU"	"GTEX-14BIL-2526-SM-GW1SZ"	"GTEX-14BIN-1826-SM-GW1X6"	"GTEX-14E6C-1326-SM-GW1D1"	"GTEX-14H4A-2526-SM-GW1GY"	"GTEX-14PHY-1926-SM-GW2A6"	"GTEX-14PJ6-2026-SM-GW1R5"	"GTEX-14PK6-1526-SM-GW21C"	"GTEX-15CHQ-0426-SM-GW1QF"	"GTEX-15CHR-1026-SM-GW218"	"GTEX-15DDE-0726-SM-GW1RC"	"GTEX-15ER7-1626-SM-GW1VP"	"GTEX-15EU6-2426-SM-GW1RL"	"GTEX-15SHU-0826-SM-GW21B"	"GTEX-16NGA-0826-SM-GW1UD"	"GTEX-17HG3-0126-SM-GW1R6"	"GTEX-18D9U-2326-SM-GW1S1"	"GTEX-18QFQ-0826-SM-GW1CA"	"GTEX-1AYD5-2526-SM-GW1DB"	"GTEX-1C6WA-2426-SM-GW1RG"	"GTEX-1F5PL-1026-SM-GW1AX"	"GTEX-1F88E-0326-SM-GW1CC"	"GTEX-1GMR3-2626-SM-GW1E8"	"GTEX-1GN1W-1926-SM-GW1DD"	"GTEX-1GPI6-0626-SM-GW1S3"	"GTEX-1GTWX-2826-SM-GW1E9"	"GTEX-1GZ2Q-2626-SM-GW1PZ"	"GTEX-1GZ4H-0326-SM-GW1RT"	"GTEX-1H3VE-2226-SM-GW1S4"	"GTEX-1IDJE-0826-SM-GW1GS"	"GTEX-1IKOH-2326-SM-GW1T3"	"GTEX-S341-1526-SM-GW24F"	"GTEX-S4P3-1326-SM-GW2AH"	"GTEX-SE5C-2126-SM-GW1G8"	"GTEX-T6MO-0326-SM-GW1ZU"	"GTEX-U3ZN-1926-SM-GW1U4"	"GTEX-UJHI-1426-SM-GW1SO"	"GTEX-WI4N-1426-SM-GW1FZ"	"GTEX-WRHU-0326-SM-GW1U1"	"GTEX-X15G-1626-SM-GW1D9"	"GTEX-X8HC-0826-SM-GW2B2"	"GTEX-XUW1-2326-SM-GW2AA"	"GTEX-XUZC-1626-SM-GW1CI"	"GTEX-XV7Q-2326-SM-GW1VQ"	"GTEX-YFC4-1426-SM-GW1SR"	"GTEX-ZC5H-2626-SM-GW1G6"	"GTEX-ZXES-0826-SM-GW2BT"	"GTEX-1117F-2726-SM-GW1F9"	"GTEX-111FC-2326-SM-GW2AK"	"GTEX-111VG-2226-SM-GW1XW"	"GTEX-111YS-1626-SM-GW23H"	"GTEX-113JC-1826-SM-GW29S"	"GTEX-1192W-1826-SM-GW248"	"GTEX-1192X-2626-SM-GW1EK"	"GTEX-11DXX-1826-SM-GW1UB"	"GTEX-11DXZ-1726-SM-GW1EW"	"GTEX-11EM3-1526-SM-GW249"	"GTEX-11EMC-1526-SM-GW23O"	"GTEX-11GS4-1926-SM-GW2CA"	"GTEX-11I78-1226-SM-GW192"	"GTEX-11ONC-2026-SM-GW1YJ"	"GTEX-11P82-1026-SM-GW1XX"	"GTEX-11TT1-1026-SM-GW1AF"	"GTEX-11TTK-2426-SM-GW24B"	"GTEX-11UD2-2426-SM-GW1BM"	"GTEX-11WQC-2126-SM-GW1Z4"	"GTEX-11ZTS-1726-SM-GW2BJ"	"GTEX-11ZTT-1326-SM-GW19N"	"GTEX-11ZU8-2226-SM-GW2B5"	"GTEX-11ZUS-2226-SM-GW1Z3"	"GTEX-1211K-1726-SM-GW1U8"	"GTEX-12584-2626-SM-GW1ZC"	"GTEX-12696-2126-SM-GW1BJ"	"GTEX-12KS4-2426-SM-GW1BA"	"GTEX-12WSE-2626-SM-GW1VB"	"GTEX-12WSF-2826-SM-GW1FS"	"GTEX-12WSI-1626-SM-GW1AC"	"GTEX-12ZZW-2526-SM-GW1AB"	"GTEX-12ZZX-2626-SM-GW2BU"	"GTEX-12ZZY-2826-SM-GW29L"	"GTEX-12ZZZ-2426-SM-GW24E"	"GTEX-13111-0726-SM-GW1Z8"	"GTEX-13112-1826-SM-GW1TV"	"GTEX-1399R-2226-SM-GW21Z"	"GTEX-139TT-2026-SM-GW1YB"	"GTEX-139YR-2126-SM-GW1G2"	"GTEX-13CF2-1926-SM-GW22O"	"GTEX-13N1W-2326-SM-GW1FV"	"GTEX-13NYS-2726-SM-GW1GE"	"GTEX-13NZB-1826-SM-GW1AH"	"GTEX-13O3P-2326-SM-GW19Y"	"GTEX-13OW5-2626-SM-GW1SS"	"GTEX-13OW7-2426-SM-GW1Z7"	"GTEX-13OW8-2626-SM-GW1R9"	"GTEX-13PL6-1826-SM-GW243"	"GTEX-13QIC-2726-SM-GW2B8"	"GTEX-13QJC-2026-SM-GW23U"	"GTEX-13SLW-2726-SM-GW1FX"	"GTEX-13SLX-2826-SM-GW1YI"	"GTEX-13X6I-2626-SM-GW1U3"	"GTEX-145MH-2526-SM-GW19X"	"GTEX-1477Z-1826-SM-GW1TG"	"GTEX-147GR-2726-SM-GW1TI"	"GTEX-14A5I-2626-SM-GW1R2"	"GTEX-14A6H-1826-SM-GW1RY"	"GTEX-14ABY-2426-SM-GW1UN"	"GTEX-14AS3-1126-SM-GW1UG"	"GTEX-14BIM-2426-SM-GW1QP"	"GTEX-14BIN-3026-SM-GW1QX"	"GTEX-14BMV-2426-SM-GW1RK"	"GTEX-14DAQ-2726-SM-GW1E6"	"GTEX-14DAR-1526-SM-GW1WG"	"GTEX-14E6D-2226-SM-GW1DI"	"GTEX-14E7W-2526-SM-GW1AR"	"GTEX-14H4A-1926-SM-GW1DE"	"GTEX-14LZ3-2726-SM-GW1WK"	"GTEX-14PJ4-1926-SM-GW1DO"	"GTEX-14PJM-2626-SM-GW1RJ"	"GTEX-14PK6-1726-SM-GW1WH"	"GTEX-14PN3-1826-SM-GW1UC"	"GTEX-15CHQ-2526-SM-GW1E3"	"GTEX-15CHR-1426-SM-GW22K"	"GTEX-15D79-2626-SM-GW1RH"	"GTEX-15DDE-2726-SM-GW1TP"	"GTEX-15DYW-2326-SM-GW1RO"	"GTEX-15EO6-2126-SM-GW1DH"	"GTEX-15EU6-1926-SM-GW1D3"	"GTEX-15RIE-1826-SM-GW1EB"	"GTEX-15SDE-1026-SM-GW1E5"	"GTEX-15SHU-2526-SM-GW1EC"	"GTEX-15SHV-1326-SM-GW1DY"	"GTEX-15SHW-2526-SM-GW1QY"	"GTEX-15SKB-2626-SM-GW1DC"	"GTEX-15SZO-2626-SM-GW1CT"	"GTEX-16AAH-1326-SM-GW22B"	"GTEX-16NPV-2626-SM-GW1R1"	"GTEX-16YQH-2526-SM-GW1DF"	"GTEX-17EVQ-1826-SM-GW1Q1"	"GTEX-17HGU-2426-SM-GW1GQ"	"GTEX-18A7A-2226-SM-GW1RX"	"GTEX-18D9B-2526-SM-GW22E"	"GTEX-18D9U-1926-SM-GW1D2"	"GTEX-19HZE-2626-SM-GW1BU"	"GTEX-1A32A-2426-SM-GW1GU"	"GTEX-1A3MV-1126-SM-GW1TJ"	"GTEX-1A3MX-2226-SM-GW1EF"	"GTEX-1AX9I-2626-SM-GW1RQ"	"GTEX-1AYD5-1726-SM-GW1UK"	"GTEX-1B8KE-1926-SM-GW1QT"	"GTEX-1B98T-2826-SM-GW1UE"	"GTEX-1BAJH-2326-SM-GW1RI"	"GTEX-1C4CL-2126-SM-GW21V"	"GTEX-1C64N-2326-SM-GW22X"	"GTEX-1C64O-2326-SM-GW22L"	"GTEX-1C6WA-2726-SM-GW1DK"	"GTEX-1CAMQ-1926-SM-GW1WS"	"GTEX-1CAV2-1826-SM-GW1EG"	"GTEX-1CB4H-2126-SM-GW1QJ"	"GTEX-1E2YA-2626-SM-GW1QZ"	"GTEX-1EN7A-2626-SM-GW1S2"	"GTEX-1F52S-2626-SM-GW1PV"	"GTEX-1F5PK-1926-SM-GW1AY"	"GTEX-1F5PL-2126-SM-GW1TK"	"GTEX-1F6I4-2626-SM-GW1WQ"	"GTEX-1F6IF-1226-SM-GW2A1"	"GTEX-1F6RS-2526-SM-GW1E4"	"GTEX-1F75A-2726-SM-GW1UL"	"GTEX-1F75W-2226-SM-GW1BY"	"GTEX-1F88E-2226-SM-GW1RS"	"GTEX-1GL5R-2426-SM-GW1TE"	"GTEX-1GMR2-1726-SM-GW1DS"	"GTEX-1GMR3-2826-SM-GW1RA"	"GTEX-1GTWX-2326-SM-GW1E2"	"GTEX-1GZ4I-2426-SM-GW1GO"	"GTEX-1GZHY-2626-SM-GW1WJ"	"GTEX-1H11D-2626-SM-GW1WM"	"GTEX-1H1DF-2526-SM-GW1PY"	"GTEX-1H1ZS-2326-SM-GW22W"	"GTEX-1H23P-2426-SM-GW1RE"	"GTEX-1H2FU-2726-SM-GW1TF"	"GTEX-1H3VE-2426-SM-GW1WI"	"GTEX-1H3VY-2426-SM-GW1DQ"	"GTEX-1HB9E-2426-SM-GW1TC"	"GTEX-1HCVE-2526-SM-GW1QI"	"GTEX-1HGF4-2126-SM-GW1GX"	"GTEX-1HSKV-2226-SM-GW1BW"	"GTEX-1I6K6-1826-SM-GW1PW"	"GTEX-1ICLY-2626-SM-GW1RB"	"GTEX-1IDJH-2726-SM-GW1X1"	"GTEX-1IDJI-2326-SM-GW1GZ"	"GTEX-1IDJU-2026-SM-GW1GM"	"GTEX-1IDJV-2726-SM-GW1WP"	"GTEX-1IGQW-2326-SM-GW29Y"	"GTEX-1IKJJ-2426-SM-GW1PX"	"GTEX-1IKK5-2726-SM-GW1C3"	"GTEX-1IY9M-2126-SM-GW1QM"	"GTEX-1J1OQ-2726-SM-GW1QH"	"GTEX-1J1R8-1126-SM-GW1T4"	"GTEX-1J8Q2-2426-SM-GW219"	"GTEX-1J8Q3-2326-SM-GW1BV"	"GTEX-1JK1U-1526-SM-GW2CH"	"GTEX-1JMOU-2426-SM-GW2CD"	"GTEX-1JMPZ-2426-SM-GW177"	"GTEX-1JMQJ-2826-SM-GW1EP"	"GTEX-1JN1M-2626-SM-GW1VZ"	"GTEX-1JN6P-1926-SM-GW1EO"	"GTEX-1JN76-1226-SM-GW211"	"GTEX-RUSQ-1226-SM-GW19J"	"GTEX-RVPU-1626-SM-GW1ZJ"	"GTEX-RVPV-2226-SM-GW23T"	"GTEX-S33H-2126-SM-GW1AJ"	"GTEX-S341-1426-SM-GW1XN"	"GTEX-S4Z8-1526-SM-GW1US"	"GTEX-S7SE-2226-SM-GW19R"	"GTEX-SIU8-2426-SM-GW2BZ"	"GTEX-SJXC-2226-SM-GW23Z"	"GTEX-SN8G-2726-SM-GW1YA"	"GTEX-T2IS-2726-SM-GW1ZR"	"GTEX-T2YK-2126-SM-GW193"	"GTEX-T8EM-1426-SM-GW19O"	"GTEX-TSE9-1826-SM-GW245"	"GTEX-U3ZH-1326-SM-GW1U2"	"GTEX-U3ZM-1126-SM-GW1YU"	"GTEX-U8T8-1326-SM-GW19F"	"GTEX-UJHI-1126-SM-GW1B7"	"GTEX-UPJH-2026-SM-GW1ZF"	"GTEX-UPK5-2226-SM-GW2AP"	"GTEX-UTHO-2526-SM-GW1B2"	"GTEX-W5X1-1726-SM-GW1ZH"	"GTEX-WFG8-1526-SM-GW2C7"	"GTEX-WH7G-1326-SM-GW1H6"	"GTEX-WK11-2326-SM-GW1BH"	"GTEX-WOFL-2626-SM-GW1FR"	"GTEX-WQUQ-2526-SM-GW1YS"	"GTEX-WRHU-2326-SM-GW1ZI"	"GTEX-WVLH-2426-SM-GW1ZT"	"GTEX-WWYW-2326-SM-GW1YR"	"GTEX-WXYG-1826-SM-GW1FQ"	"GTEX-WY7C-1626-SM-GW1WC"	"GTEX-WYBS-2326-SM-GW2AI"	"GTEX-X261-1826-SM-GW1ES"	"GTEX-X4EO-2526-SM-GW22T"	"GTEX-X4EP-2726-SM-GW2AY"	"GTEX-X4XX-2526-SM-GW1CH"	"GTEX-X4XY-2626-SM-GW23M"	"GTEX-X585-2626-SM-GW23A"	"GTEX-X5EB-0926-SM-GW22S"	"GTEX-X62O-2626-SM-GW2BO"	"GTEX-X8HC-2426-SM-GW1BF"	"GTEX-XBEC-2426-SM-GW1EU"	"GTEX-XBED-1526-SM-GW1XS"	"GTEX-XMD2-2526-SM-GW247"	"GTEX-XMK1-1726-SM-GW2AO"	"GTEX-XPT6-1126-SM-GW246"	"GTEX-XPVG-1826-SM-GW2BB"	"GTEX-XQ3S-2626-SM-GW1CK"	"GTEX-XUJ4-2026-SM-GW1WN"	"GTEX-XV7Q-2126-SM-GW1WA"	"GTEX-XYKS-2226-SM-GW1F7"	"GTEX-Y111-1426-SM-GW1YN"	"GTEX-YB5E-1626-SM-GW1B9"	"GTEX-YFCO-1426-SM-GW1A4"	"GTEX-YJ89-2426-SM-GW1Y9"	"GTEX-Z93S-2426-SM-GW1UT"	"GTEX-ZAB4-2226-SM-GW1GJ"	"GTEX-ZDTS-2526-SM-GW1GB"	"GTEX-ZDXO-1826-SM-GW229"	"GTEX-ZVZP-1926-SM-GW1XM"	"GTEX-ZVZQ-2526-SM-GW1UV"	"GTEX-ZYFG-1926-SM-GW23Q"	"GTEX-ZYY3-2026-SM-GW1GL"	"GTEX-117XS-1326-SM-GW22U"	"GTEX-117YW-1226-SM-GW1UU"	"GTEX-1192W-1326-SM-GW1BO"	"GTEX-1192X-2026-SM-GW1GI"	"GTEX-11EMC-1326-SM-GW1UW"	"GTEX-11NV4-1526-SM-GW1YO"	"GTEX-11UD2-2126-SM-GW1YM"	"GTEX-11WQC-1426-SM-GW1EM"	"GTEX-11WQK-1926-SM-GW29M"	"GTEX-11ZU8-1826-SM-GW1BE"	"GTEX-1212Z-1626-SM-GW2AS"	"GTEX-12696-0926-SM-GW2AJ"	"GTEX-12KS4-1826-SM-GW19V"	"GTEX-12WSA-2126-SM-GW23P"	"GTEX-12WSD-2226-SM-GW21W"	"GTEX-12WSF-2126-SM-GW2C8"	"GTEX-12WSI-1826-SM-GW1EH"	"GTEX-12ZZW-2126-SM-GW23V"	"GTEX-12ZZX-2226-SM-GW1BD"	"GTEX-12ZZY-2226-SM-GW1EI"	"GTEX-12ZZZ-1026-SM-GW1F4"	"GTEX-13112-2126-SM-GW2BK"	"GTEX-13N1W-2126-SM-GW1XQ"	"GTEX-13NYS-1426-SM-GW195"	"GTEX-13O3P-1926-SM-GW2C3"	"GTEX-13OW5-2026-SM-GW23Y"	"GTEX-13QJC-1226-SM-GW1H7"	"GTEX-13SLX-1526-SM-GW29U"	"GTEX-13W46-2326-SM-GW1ZG"	"GTEX-148VJ-1926-SM-GW22I"	"GTEX-14A5H-2526-SM-GW22F"	"GTEX-14C39-2126-SM-GW22J"	"GTEX-15DDE-2126-SM-GW1SW"	"GTEX-15SHU-2026-SM-GW22D"	"GTEX-1B98T-2526-SM-GW1SX"	"GTEX-1F6IF-1626-SM-GW1TL"	"GTEX-1GTWX-1826-SM-GW2A3"	"GTEX-1H1ZS-2026-SM-GW22H"	"GTEX-S33H-1426-SM-GW22P"	"GTEX-SIU8-1826-SM-GW1AO"	"GTEX-UTHO-2326-SM-GW1FP"	"GTEX-WOFL-1826-SM-GW1ZV"	"GTEX-WRHU-0526-SM-GW196"	"GTEX-WWYW-2226-SM-GW1YQ"	"GTEX-X261-1126-SM-GW1YZ"	"GTEX-X4EP-1926-SM-GW2AD"	"GTEX-X4XX-2326-SM-GW1CN"	"GTEX-X585-2126-SM-GW23B"	"GTEX-X62O-1926-SM-GW19P"	"GTEX-YFC4-1926-SM-GW244"	"GTEX-1117F-1026-SM-GW2CO"	"GTEX-113JC-1326-SM-GW1F2"	"GTEX-1192W-0626-SM-GW224"	"GTEX-1192X-1326-SM-GW191"	"GTEX-11DXZ-0726-SM-GW23R"	"GTEX-11DYG-0626-SM-GW1XU"	"GTEX-11GSP-0726-SM-GW2CL"	"GTEX-11I78-0126-SM-GW226"	"GTEX-11NV4-1126-SM-GW17Z"	"GTEX-11TTK-0926-SM-GW19B"	"GTEX-11WQK-1226-SM-GW2CV"	"GTEX-11XUK-0326-SM-GW19G"	"GTEX-11ZTS-1226-SM-GW1A7"	"GTEX-11ZUS-0126-SM-GW2BW"	"GTEX-1212Z-1026-SM-GW1UX"	"GTEX-12584-1426-SM-GW1UR"	"GTEX-12WSA-1026-SM-GW18E"	"GTEX-12WSD-0826-SM-GW21I"	"GTEX-12WSE-0826-SM-GW22V"	"GTEX-12ZZX-0926-SM-GW18L"	"GTEX-13111-0426-SM-GW1YH"	"GTEX-13112-0826-SM-GW1ST"	"GTEX-139TT-0726-SM-GW1XV"	"GTEX-139YR-0926-SM-GW1FL"	"GTEX-13CF2-0726-SM-GW1FT"	"GTEX-13FXS-0826-SM-GW2AX"	"GTEX-13IVO-1026-SM-GW1EL"	"GTEX-13NYS-1626-SM-GW1VT"	"GTEX-13NZA-1426-SM-GW1VS"	"GTEX-13O3P-1026-SM-GW1UY"	"GTEX-13OVK-0126-SM-GW1XG"	"GTEX-13OW5-0726-SM-GW1V7"	"GTEX-13OW8-1726-SM-GW1U6"	"GTEX-13PL6-2426-SM-GW1UQ"	"GTEX-13QIC-0326-SM-GW1TX"	"GTEX-13RTJ-1126-SM-GW18K"	"GTEX-13W46-1426-SM-GW1AA"	"GTEX-145MH-0626-SM-GW1ZB"	"GTEX-146FH-1226-SM-GW1RN"	"GTEX-14753-0826-SM-GW1E7"	"GTEX-1477Z-0626-SM-GW1RM"	"GTEX-14A5I-0926-SM-GW2DC"	"GTEX-14A6H-0526-SM-GW1DA"	"GTEX-14AS3-0926-SM-GW1X7"	"GTEX-14BIM-0726-SM-GW18T"	"GTEX-14BIN-0226-SM-GW188"	"GTEX-14BMV-0826-SM-GW1QQ"	"GTEX-14DAR-0226-SM-GW1WU"	"GTEX-14E6C-1426-SM-GW1CP"	"GTEX-14E7W-1326-SM-GW217"	"GTEX-14JFF-1126-SM-GW1CX"	"GTEX-14JG1-0926-SM-GW1CZ"	"GTEX-14JG6-0326-SM-GW1ED"	"GTEX-14LZ3-0726-SM-GW18U"	"GTEX-14PJ4-0626-SM-GW1QR"	"GTEX-14PJ6-0426-SM-GW1C8"	"GTEX-14PJM-0926-SM-GW2CR"	"GTEX-14PJO-0926-SM-GW1RZ"	"GTEX-14PK6-0326-SM-GW1C7"	"GTEX-14PN3-0926-SM-GW1DX"	"GTEX-15CHR-0726-SM-GW1RR"	"GTEX-15D1Q-0526-SM-GW2DA"	"GTEX-15D79-1026-SM-GW1CY"	"GTEX-15DDE-0826-SM-GW21H"	"GTEX-15EO6-0326-SM-GW1T5"	"GTEX-15EU6-1226-SM-GW17S"	"GTEX-15G1A-0426-SM-GW1BS"	"GTEX-15RIE-0326-SM-GW1GV"	"GTEX-15RJE-1026-SM-GW2CM"	"GTEX-15SDE-0226-SM-GW1S7"	"GTEX-15SHV-0326-SM-GW1QS"	"GTEX-15SHW-0926-SM-GW1RW"	"GTEX-15SKB-0826-SM-GW1S9"	"GTEX-15SZO-0926-SM-GW2DF"	"GTEX-15UF6-1226-SM-GW1WV"	"GTEX-15UKP-1926-SM-GW22M"	"GTEX-16AAH-0426-SM-GW1DR"	"GTEX-16NPV-0726-SM-GW2DE"	"GTEX-16YQH-1626-SM-GW17E"	"GTEX-17EVQ-1526-SM-GW1R3"	"GTEX-17HG3-0326-SM-GW231"	"GTEX-18465-0626-SM-GW1C9"	"GTEX-18A66-0926-SM-GW29X"	"GTEX-18D9B-1026-SM-GW1QG"	"GTEX-18D9U-0526-SM-GW1XD"	"GTEX-19HZE-0526-SM-GW1RP"	"GTEX-1A3MV-0526-SM-GW2DB"	"GTEX-1A3MX-0726-SM-GW1DP"	"GTEX-1AX9I-0826-SM-GW1R7"	"GTEX-1AYD5-1226-SM-GW1EA"	"GTEX-1B98T-1226-SM-GW1S5"	"GTEX-1BAJH-1326-SM-GW1FE"	"GTEX-1C4CL-0826-SM-GW1D4"	"GTEX-1C64N-1126-SM-GW1CB"	"GTEX-1C64O-1226-SM-GW1TA"	"GTEX-1CAMQ-1026-SM-GW1QU"	"GTEX-1CAV2-0626-SM-GW29Z"	"GTEX-1E1VI-0926-SM-GW1DZ"	"GTEX-1EN7A-0826-SM-GW1R8"	"GTEX-1F52S-0726-SM-GW1QO"	"GTEX-1F5PK-0526-SM-GW189"	"GTEX-1F6I4-1026-SM-GW1WX"	"GTEX-1F6IF-1826-SM-GW1EE"	"GTEX-1F75B-1026-SM-GW2D8"	"GTEX-1F75W-0626-SM-GW2D9"	"GTEX-1F88E-0226-SM-GW1TM"	"GTEX-1GL5R-0526-SM-GW1DT"	"GTEX-1GMR2-0126-SM-GW1WR"	"GTEX-1GMR3-0226-SM-GW1C2"	"GTEX-1GN1W-1026-SM-GW17F"	"GTEX-1GPI6-0726-SM-GW2D7"	"GTEX-1GTWX-0626-SM-GW1S8"	"GTEX-1GZHY-0826-SM-GW1RD"	"GTEX-1H11D-0726-SM-GW1XA"	"GTEX-1H1DF-1226-SM-GW1D5"	"GTEX-1H23P-1026-SM-GW1WW"	"GTEX-1H3VE-1026-SM-GW2CS"	"GTEX-1H3VY-1426-SM-GW2CN"	"GTEX-1HB9E-0726-SM-GW1XB"	"GTEX-1HCVE-0626-SM-GW1CF"	"GTEX-1HR9M-0826-SM-GW18A"	"GTEX-1I6K6-0926-SM-GW2CT"	"GTEX-1IDJI-0626-SM-GW1WO"	"GTEX-1IDJU-0226-SM-GW1T6"	"GTEX-1IGQW-0726-SM-GW1CE"	"GTEX-1IKJJ-0926-SM-GW1DJ"	"GTEX-1IKK5-1926-SM-GW1QN"	"GTEX-1IL2U-0926-SM-GW1DV"	"GTEX-1J1OQ-0926-SM-GW21Y"	"GTEX-1J1R8-0226-SM-GW1C1"	"GTEX-1J8JJ-1126-SM-GW1Q2"	"GTEX-1J8Q3-0826-SM-GW1TO"	"GTEX-1JK1U-1126-SM-GW1VL"	"GTEX-1JMOU-0526-SM-GW2CI"	"GTEX-1JMQJ-2126-SM-GW2D5"	"GTEX-1JN76-0826-SM-GW1SB"	"GTEX-1KXAM-0426-SM-GW2CW"	"GTEX-1L5NE-0726-SM-GW17C"	"GTEX-1LC47-1126-SM-GW2CJ"	"GTEX-1LG7Y-0826-SM-GW2D2"	"GTEX-1LSNL-1126-SM-GW2D6"	"GTEX-1LSVX-0626-SM-GW2CX"	"GTEX-1LVA9-1126-SM-GW2D1"	"GTEX-1LVAO-1226-SM-GW2D4"	"GTEX-1MCC2-0726-SM-GW2CC"	"GTEX-1MGNQ-0826-SM-GW2D3"	"GTEX-1MJK2-1126-SM-GW179"	"GTEX-1N2EE-1626-SM-GW17A"	"GTEX-1N5O9-1226-SM-GW17M"	"GTEX-1N7R6-0726-SM-GW1W9"	"GTEX-1NHNU-0426-SM-GW1ZY"	"GTEX-1NUQO-1026-SM-GW2CK"	"GTEX-1O97I-1526-SM-GW2CY"	"GTEX-1OFPY-0226-SM-GW2CZ"	"GTEX-1OJC3-0726-SM-GW1W7"	"GTEX-1OZHM-0826-SM-GW18Y"	"GTEX-1PBJJ-1326-SM-GW1VU"	"GTEX-1QCLY-1026-SM-GW2CF"	"GTEX-1QMI2-0926-SM-GW178"	"GTEX-1R46S-1226-SM-GW2CU"	"GTEX-1RAZR-0726-SM-GW1VY"	"GTEX-RUSQ-0626-SM-GW19E"	"GTEX-RVPU-0526-SM-GW19H"	"GTEX-RVPV-1726-SM-GW1XI"	"GTEX-S33H-0626-SM-GW1ZK"	"GTEX-S341-0326-SM-GW23W"	"GTEX-S4Z8-0426-SM-GW2DD"	"GTEX-S7SE-0926-SM-GW181"	"GTEX-SIU8-0926-SM-GW2A7"	"GTEX-SN8G-0926-SM-GW23D"	"GTEX-SNOS-0426-SM-GW1SU"	"GTEX-T2YK-0826-SM-GW1A9"	"GTEX-T6MO-0426-SM-GW1GH"	"GTEX-T8EM-0326-SM-GW1ZN"	"GTEX-TSE9-0726-SM-GW1WE"	"GTEX-U3ZH-0526-SM-GW19I"	"GTEX-U3ZM-0426-SM-GW2BF"	"GTEX-U8T8-2226-SM-GW17X"	"GTEX-U8XE-1426-SM-GW1VC"	"GTEX-UJHI-0726-SM-GW1W5"	"GTEX-UPJH-0826-SM-GW19D"	"GTEX-UPK5-1126-SM-GW2BY"	"GTEX-W5X1-0526-SM-GW241"	"GTEX-WFG8-0926-SM-GW18N"	"GTEX-WH7G-0726-SM-GW18W"	"GTEX-WHWD-0626-SM-GW1B4"	"GTEX-WK11-0526-SM-GW18G"	"GTEX-WOFL-1126-SM-GW29K"	"GTEX-WQUQ-1126-SM-GW184"	"GTEX-WRHU-0226-SM-GW18F"	"GTEX-WVLH-0826-SM-GW182"	"GTEX-WWYW-0926-SM-GW186"	"GTEX-WXYG-0726-SM-GW18D"	"GTEX-WY7C-0426-SM-GW1VR"	"GTEX-WYBS-1126-SM-GW1Z1"	"GTEX-WZTO-0426-SM-GW1TS"	"GTEX-X261-1026-SM-GW18Q"	"GTEX-X4EO-0926-SM-GW1Z5"	"GTEX-X4EP-0526-SM-GW18O"	"GTEX-X4XY-1026-SM-GW18J"	"GTEX-X5EB-0426-SM-GW18S"	"GTEX-X62O-0726-SM-GW1ER"	"GTEX-X8HC-0926-SM-GW183"	"GTEX-XBEC-1026-SM-GW18I"	"GTEX-XBED-0826-SM-GW17W"	"GTEX-XMD1-1026-SM-GW1VA"	"GTEX-XPT6-1226-SM-GW2AZ"	"GTEX-XPVG-1026-SM-GW1B6"	"GTEX-XQ3S-0926-SM-GW1CL"	"GTEX-XUJ4-1426-SM-GW22Z"	"GTEX-XV7Q-0426-SM-GW1TT"	"GTEX-XYKS-0526-SM-GW18H"	"GTEX-YB5E-0726-SM-GW2CQ"	"GTEX-YEC3-0226-SM-GW17H"	"GTEX-YFC4-1126-SM-GW2BS"	"GTEX-YFCO-0426-SM-GW1FK"	"GTEX-YJ89-0826-SM-GW1FD"	"GTEX-Z93S-0626-SM-GW18C"	"GTEX-ZAB4-0626-SM-GW1G5"	"GTEX-ZDTS-1026-SM-GW23S"	"GTEX-ZDXO-1326-SM-GW21U"	"GTEX-ZYFG-0226-SM-GW1G9"	"GTEX-ZYY3-0926-SM-GW1XT"	"GTEX-11XUK-2226-SM-GW2AB"	"GTEX-12584-0526-SM-GW1W4"	"GTEX-12WSF-0926-SM-GW2AE"	"GTEX-13RTJ-2726-SM-GW22R"	"GTEX-13SLX-0326-SM-GW1V9"	"GTEX-13X6I-0526-SM-GW1GF"	"GTEX-13X6K-0326-SM-GW1AG"	"GTEX-14753-0526-SM-GW1QL"	"GTEX-147GR-0126-SM-GW1T2"	"GTEX-148VJ-0326-SM-GW1GP"	"GTEX-14A5H-0326-SM-GW1T1"	"GTEX-14B4R-1726-SM-GW1AZ"	"GTEX-15D1Q-0926-SM-GW1S6"	"GTEX-15DCD-0626-SM-GW1R4"	"GTEX-15SHU-0626-SM-GW1RF"	"GTEX-1F6IF-0226-SM-GW1QW"	"GTEX-1F75B-0526-SM-GW1CD"	"GTEX-1F88E-1826-SM-GW1QK"	"GTEX-1GPI6-0326-SM-GW1QV"	"GTEX-1H1ZS-0626-SM-GW1DG"	"GTEX-1H3NZ-0326-SM-GW1D6"	"GTEX-1H3O1-0626-SM-GW1RV"	"GTEX-1IKOE-0326-SM-GW1E1"	"GTEX-1J8QM-2226-SM-GW1GN"	"GTEX-SNOS-1526-SM-GW24A"	"GTEX-T6MO-1826-SM-GW1Y2"	"GTEX-T8EM-1326-SM-GW2BQ"	"GTEX-U3ZH-1926-SM-GW1XZ"	"GTEX-W5WG-1926-SM-GW2AV"	"GTEX-W5X1-2726-SM-GW19S"	"GTEX-WOFL-0626-SM-GW1G1"	"GTEX-WWYW-0526-SM-GW194"	"GTEX-WYBS-0526-SM-GW1Y3"	"GTEX-X4EO-0526-SM-GW1XH"	"GTEX-X4EP-0926-SM-GW1XJ"	"GTEX-X4XY-0626-SM-GW1XO"	"GTEX-X585-0626-SM-GW227"	"GTEX-X5EB-2326-SM-GW1TW"	"GTEX-X62O-1226-SM-GW1ZE"	"GTEX-XMD1-0626-SM-GW19T"	"GTEX-XMD2-0526-SM-GW1Y1"	"GTEX-XMK1-2326-SM-GW1SM"	"GTEX-XV7Q-2926-SM-GW1TR"	"GTEX-XYKS-2426-SM-GW1W1"	"GTEX-Y111-0326-SM-GW1Z6"	"GTEX-ZVZP-2526-SM-GW1EJ"	"GTEX-ZVZQ-0526-SM-GW2A9"	"GTEX-11EM3-1726-SM-GW199"	"GTEX-11EMC-1726-SM-GW2AF"	"GTEX-11GSP-0226-SM-GW1Q3"	"GTEX-11I78-1926-SM-GW2BI"	"GTEX-11VI4-1026-SM-GW223"	"GTEX-11XUK-1626-SM-GW1YD"	"GTEX-11ZTS-1926-SM-GW1GA"	"GTEX-11ZTT-1826-SM-GW1BG"	"GTEX-12WSD-2726-SM-GW1UA"	"GTEX-12WSG-1426-SM-GW1FC"	"GTEX-12WSJ-1226-SM-GW2BN"	"GTEX-12WSK-1926-SM-GW1AP"	"GTEX-12ZZX-2026-SM-GW222"	"GTEX-133LE-1226-SM-GW1A3"	"GTEX-1399U-1726-SM-GW1CW"	"GTEX-13FTY-1826-SM-GW23X"	"GTEX-13N11-0526-SM-GW1A6"	"GTEX-13O3O-2726-SM-GW29N"	"GTEX-13OVJ-2426-SM-GW2BA"	"GTEX-13PL7-2326-SM-GW1Z9"	"GTEX-13QBU-1526-SM-GW1YG"	"GTEX-13QIC-1526-SM-GW1D8"	"GTEX-13QJC-1526-SM-GW29O"	"GTEX-13SLX-2426-SM-GW1EY"	"GTEX-13VXT-1526-SM-GW1ZA"	"GTEX-13X6H-1026-SM-GW24H"	"GTEX-145LS-2326-SM-GW16E"	"GTEX-145ME-1226-SM-GW1CQ"	"GTEX-146FH-2526-SM-GW1H1"	"GTEX-14AS3-1326-SM-GW16Q"	"GTEX-14BIM-2026-SM-GW16J"	"GTEX-14BIN-1426-SM-GW234"	"GTEX-14BMU-1726-SM-GW16P"	"GTEX-14DAQ-2226-SM-GW21P"	"GTEX-14H4A-2226-SM-GW16W"	"GTEX-14JG6-0626-SM-GW16R"	"GTEX-14LZ3-2326-SM-GW1VH"	"GTEX-14PHW-2226-SM-GW16D"	"GTEX-14PHY-1626-SM-GW237"	"GTEX-14PJ6-1426-SM-GW16N"	"GTEX-14PJM-2426-SM-GW174"	"GTEX-14PKU-1226-SM-GW233"	"GTEX-14PN3-1526-SM-GW1UZ"	"GTEX-14PQA-2626-SM-GW16M"	"GTEX-15DCD-2126-SM-GW16C"	"GTEX-15DDE-2326-SM-GW1VI"	"GTEX-15DYW-2626-SM-GW16A"	"GTEX-15EOM-1526-SM-GW16Z"	"GTEX-15ER7-2326-SM-GW1VO"	"GTEX-15ETS-1426-SM-GW175"	"GTEX-15FZZ-0826-SM-GW1VD"	"GTEX-15SDE-0926-SM-GW16H"	"GTEX-15SHU-2726-SM-GW16S"	"GTEX-15UF6-2026-SM-GW21M"	"GTEX-16MT8-2226-SM-GW21N"	"GTEX-16NGA-0426-SM-GW16O"	"GTEX-16NPV-2326-SM-GW1V1"	"GTEX-17F9Y-2226-SM-GW239"	"GTEX-17HG3-1826-SM-GW238"	"GTEX-17JCI-2326-SM-GW232"	"GTEX-183WM-1926-SM-GW16G"	"GTEX-18A7A-2626-SM-GW16T"	"GTEX-18D9A-0826-SM-GW171"	"GTEX-19HZE-2226-SM-GW16V"	"GTEX-1A32A-2726-SM-GW1V2"	"GTEX-1A3MW-2726-SM-GW172"	"GTEX-1AMEY-0926-SM-GW16U"	"GTEX-1AMFI-1426-SM-GW173"	"GTEX-1C475-0426-SM-GW176"	"GTEX-1CAMS-2126-SM-GW21Q"	"GTEX-1CAV2-1526-SM-GW1VG"	"GTEX-1CB4H-2526-SM-GW1GW"	"GTEX-1EWIQ-2226-SM-GW16Y"	"GTEX-1F48J-2326-SM-GW16X"	"GTEX-1F52S-2226-SM-GW1QC"	"GTEX-1F5PL-1626-SM-GW1QA"	"GTEX-1F6RS-2726-SM-GW1QD"	"GTEX-1GN1W-1426-SM-GW1Q9"	"GTEX-1GZHY-2426-SM-GW1Q8"	"GTEX-1H1CY-1926-SM-GW1Q5"	"GTEX-1H1DF-2326-SM-GW1C6"	"GTEX-1H2FU-2326-SM-GW1QE"	"GTEX-1HBPH-2726-SM-GW169"	"GTEX-1HCU6-2226-SM-GW236"	"GTEX-1HCU8-2126-SM-GW1EN"	"GTEX-1HCUA-1326-SM-GW235"	"GTEX-1HSGN-2426-SM-GW1Q6"	"GTEX-1IDJE-1126-SM-GW1QB"	"GTEX-1IDJI-1526-SM-GW1Q4"	"GTEX-1IDJU-1126-SM-GW1VJ"	"GTEX-1IKOE-2326-SM-GW21T"	"GTEX-1J1OQ-1626-SM-GW1Q7"	"GTEX-1J8JJ-0826-SM-GW16I"	"GTEX-1J8QM-1326-SM-GW21O"	"GTEX-1JMOU-1626-SM-GW1W6"	"GTEX-1JN1M-2126-SM-GW212"	"GTEX-1JN76-1426-SM-GW215"	"GTEX-1K9T9-2426-SM-GW1SD"	"GTEX-1KANC-1026-SM-GW1SK"	"GTEX-1LGOU-1026-SM-GW1SC"	"GTEX-1LKK1-1626-SM-GW1SI"	"GTEX-1LVAM-1826-SM-GW1SL"	"GTEX-1MCC2-1026-SM-GW1SA"	"GTEX-1MCYP-1426-SM-GW1SJ"	"GTEX-1N7R6-1826-SM-GW1VV"	"GTEX-1NUQO-1726-SM-GW1SE"	"GTEX-1NV5F-1626-SM-GW2CG"	"GTEX-1PBJI-2026-SM-GW1SF"	"GTEX-1PIEJ-1626-SM-GW1VX"	"GTEX-1QEPI-2726-SM-GW216"	"GTEX-1QP28-1326-SM-GW1W8"	"GTEX-1QP67-1526-SM-GW2CB"	"GTEX-1QPFJ-1726-SM-GW213"	"GTEX-1R46S-1826-SM-GW2CE"	"GTEX-1R9JW-1226-SM-GW214"	"GTEX-1R9PN-0626-SM-GW1SG"	"GTEX-1RDX4-0826-SM-GW1VW"	"GTEX-1RNTQ-1726-SM-GW1SH"	"GTEX-1S5ZU-2326-SM-GW1ZZ"	"GTEX-P4PP-2426-SM-GW23I"	"GTEX-POMQ-1426-SM-GW1ZQ"	"GTEX-R55G-1526-SM-GW1Y7"	"GTEX-RWS6-1026-SM-GW1A1"	"GTEX-S341-0726-SM-GW1Y6"	"GTEX-S4P3-0926-SM-GW1YV"	"GTEX-S4UY-1026-SM-GW23C"	"GTEX-S7SF-1326-SM-GW2BM"	"GTEX-SE5C-0826-SM-GW1GG"	"GTEX-SN8G-2426-SM-GW1GD"	"GTEX-T2IS-2026-SM-GW1ZS"	"GTEX-T5JW-0426-SM-GW1BB"	"GTEX-T6MO-1126-SM-GW18Z"	"GTEX-TML8-0926-SM-GW2AN"	"GTEX-TMMY-1726-SM-GW2C9"	"GTEX-TSE9-2226-SM-GW1VN"	"GTEX-U3ZN-1026-SM-GW1U5"	"GTEX-UJHI-1226-SM-GW1ZL"	"GTEX-W5WG-0926-SM-GW1YX"	"GTEX-WEY5-0626-SM-GW1FH"	"GTEX-WI4N-2526-SM-GW1AM"	"GTEX-WRHU-2026-SM-GW2BC"	"GTEX-WWYW-2726-SM-GW1BC"	"GTEX-WXYG-1426-SM-GW1H5"	"GTEX-WYVS-1526-SM-GW1VM"	"GTEX-X15G-1726-SM-GW1F5"	"GTEX-X4EP-2426-SM-GW23J"	"GTEX-X8HC-2726-SM-GW2AL"	"GTEX-XMD2-2726-SM-GW1ET"	"GTEX-XOT4-2726-SM-GW2B4"	"GTEX-XUJ4-1326-SM-GW1U9"	"GTEX-XUW1-0126-SM-GW29T"	"GTEX-XUZC-1026-SM-GW1CO"	"GTEX-XYKS-1726-SM-GW1Y5"	"GTEX-Y114-1726-SM-GW2BE"	"GTEX-YFC4-2726-SM-GW2C1"	"GTEX-ZAJG-2726-SM-GW1Z2"	"GTEX-ZLWG-0926-SM-GW1GK"	"GTEX-ZP4G-0626-SM-GW1H3"	"GTEX-ZPIC-1426-SM-GW2B6"	"GTEX-ZVT2-0326-SM-GW1B8"	"GTEX-ZVT3-2626-SM-GW1FA"	"GTEX-ZYFG-1726-SM-GW29P"	"GTEX-ZYWO-1926-SM-GW1BL"	"GTEX-ZZPU-2126-SM-GW1YK"	"GTEX-111FC-2026-SM-GW2C2"	"GTEX-117YW-1426-SM-GW24I"	"GTEX-1192X-2126-SM-GW1EQ"	"GTEX-11DYG-2526-SM-GW197"	"GTEX-11NV4-1826-SM-GW29Q"	"GTEX-11ONC-0626-SM-GW1BN"	"GTEX-11TT1-2026-SM-GW1A8"	"GTEX-11UD2-2626-SM-GW2BV"	"GTEX-11WQC-1926-SM-GW1FO"	"GTEX-11WQK-2726-SM-GW1XL"	"GTEX-11ZU8-0526-SM-GW1AE"	"GTEX-11ZUS-2126-SM-GW1ZD"	"GTEX-12696-2226-SM-GW2AG"	"GTEX-12KS4-2526-SM-GW1AD"	"GTEX-12WSA-2426-SM-GW1XF"	"GTEX-12WSE-2526-SM-GW1B5"	"GTEX-12WSF-2526-SM-GW2AW"	"GTEX-12ZZW-2626-SM-GW1A2"	"GTEX-12ZZY-2526-SM-GW1ZO"	"GTEX-13111-1326-SM-GW1V5"	"GTEX-13112-2226-SM-GW1FY"	"GTEX-139TT-1726-SM-GW1G3"	"GTEX-139YR-1326-SM-GW1XY"	"GTEX-13FHP-2726-SM-GW2A8"	"GTEX-13FTW-1226-SM-GW21A"	"GTEX-13IVO-1326-SM-GW19W"	"GTEX-13N1W-2526-SM-GW1FU"	"GTEX-13NYS-1026-SM-GW19Z"	"GTEX-13NZA-2226-SM-GW1FG"	"GTEX-13OW5-2426-SM-GW1AL"	"GTEX-13W46-2826-SM-GW19U"	"GTEX-13X6I-2226-SM-GW2AR"	"GTEX-147GR-2526-SM-GW1AW"	"GTEX-14BMV-2326-SM-GW1T8"	"GTEX-14C39-2226-SM-GW1T7"	"GTEX-14JG1-2426-SM-GW22A"	"GTEX-14PJO-2826-SM-GW1BR"	"GTEX-15CHQ-2826-SM-GW1AQ"	"GTEX-15CHR-1226-SM-GW1AU"	"GTEX-15G1A-1326-SM-GW1TB"	"GTEX-15SKB-2226-SM-GW1BT"	"GTEX-15SZO-2126-SM-GW1AS"	"GTEX-15UKP-0626-SM-GW1SV"	"GTEX-16YQH-2326-SM-GW1UM"	"GTEX-17EVQ-2626-SM-GW1WT"	"GTEX-17HGU-2226-SM-GW22C"	"GTEX-1A3MV-0826-SM-GW1X5"	"GTEX-1B8KE-1026-SM-GW1UF"	"GTEX-1B98T-2626-SM-GW29W"	"GTEX-1CAMQ-2226-SM-GW1T9"	"GTEX-1E2YA-2226-SM-GW1XE"	"GTEX-1F5PK-1126-SM-GW2A4"	"GTEX-1F6IF-0326-SM-GW1BZ"	"GTEX-1F75A-2226-SM-GW1WY"	"GTEX-1F75W-2526-SM-GW1UO"	"GTEX-1GL5R-1226-SM-GW1X2"	"GTEX-1GMR3-1826-SM-GW1BX"	"GTEX-1GN73-1626-SM-GW22G"	"GTEX-1GTWX-2126-SM-GW2A5"	"GTEX-1GZ2Q-2426-SM-GW1WZ"	"GTEX-1H11D-1726-SM-GW24G"	"GTEX-1H1ZS-2226-SM-GW1TQ"	"GTEX-1H3NZ-2826-SM-GW1WL"	"GTEX-1H3VE-2126-SM-GW1UI"	"GTEX-1HR9M-2026-SM-GW1X8"	"GTEX-1HSKV-1726-SM-GW1X4"	"GTEX-1I6K6-2126-SM-GW1X3"	"GTEX-1ICLY-2826-SM-GW1UJ"	"GTEX-1IDJH-2426-SM-GW1AV"	"GTEX-1IGQW-2226-SM-GW1TH"	"GTEX-1IKJJ-2026-SM-GW1TD"	"GTEX-1IKK5-2326-SM-GW2A2"	"GTEX-1IL2U-2826-SM-GW1TN"	"GTEX-1IY9M-2426-SM-GW22N"	"GTEX-1J1R8-0726-SM-GW1UH"	"GTEX-1J8Q3-0926-SM-GW1X9"	"GTEX-RUSQ-1426-SM-GW1YP"	"GTEX-RVPU-1826-SM-GW1XP"	"GTEX-RWSA-2026-SM-GW2BR"	"GTEX-S33H-1826-SM-GW1Y8"	"GTEX-S3XE-1326-SM-GW1W3"	"GTEX-S4Q7-1026-SM-GW1YE"	"GTEX-S7PM-2426-SM-GW29V"	"GTEX-S7SE-2426-SM-GW2BP"	"GTEX-S95S-1026-SM-GW1A5"	"GTEX-SIU8-2226-SM-GW1BI"	"GTEX-SJXC-2026-SM-GW19M"	"GTEX-SNMC-0926-SM-GW1EX"	"GTEX-SNOS-1026-SM-GW22Q"	"GTEX-SUCS-1126-SM-GW1SP"	"GTEX-T8EM-1826-SM-GW2BH"	"GTEX-U3ZH-0926-SM-GW1TY"	"GTEX-U3ZM-0926-SM-GW1ZM"	"GTEX-U412-2026-SM-GW1AI"	"GTEX-U8T8-2126-SM-GW2C6"	"GTEX-UPK5-2526-SM-GW2C4"	"GTEX-UTHO-2726-SM-GW1B3"	"GTEX-WFG8-1826-SM-GW2B1"	"GTEX-WHSE-2826-SM-GW1CM"	"GTEX-WL46-2126-SM-GW1GC"	"GTEX-WOFL-2126-SM-GW1H4"	"GTEX-WQUQ-2726-SM-GW1YT"	"GTEX-WVLH-2826-SM-GW19C"	"GTEX-WY7C-2026-SM-GW1WF"	"GTEX-WYJK-0626-SM-GW1WD"	"GTEX-WZTO-0926-SM-GW1WB"	"GTEX-X261-2226-SM-GW1F6"	"GTEX-X3Y1-1026-SM-GW1UP"	"GTEX-X4XY-2826-SM-GW1FB"	"GTEX-X585-2726-SM-GW19Q"	"GTEX-X62O-2726-SM-GW1EV"	"GTEX-XBED-1826-SM-GW1F8"	"GTEX-XBEW-2226-SM-GW2BG"	"GTEX-XGQ4-1826-SM-GW1BK"	"GTEX-XMD1-2626-SM-GW2BD"	"GTEX-XMK1-1026-SM-GW1G4"	"GTEX-XPT6-1526-SM-GW1W2"	"GTEX-XPVG-2026-SM-GW2AQ"	"GTEX-XQ3S-2526-SM-GW1CJ"	"GTEX-Y111-2326-SM-GW1FN"	"GTEX-YB5E-1826-SM-GW2AC"	"GTEX-YEC3-2226-SM-GW2B9"	"GTEX-YJ89-2726-SM-GW198"	"GTEX-111FC-1926-SM-GW23G"	"GTEX-1192W-2326-SM-GW2AU"	"GTEX-11NV4-1726-SM-GW1ZP"	"GTEX-11TT1-2226-SM-GW2BX"	"GTEX-11UD2-2826-SM-GW23F"	"GTEX-11ZUS-2726-SM-GW1TZ"	"GTEX-1212Z-0326-SM-GW2C5"	"GTEX-12696-0226-SM-GW1XR"	"GTEX-12KS4-0226-SM-GW2AT"	"GTEX-12WSA-0126-SM-GW1YY"	"GTEX-12WSE-0126-SM-GW23K"	"GTEX-12ZZW-0626-SM-GW1F1"	"GTEX-12ZZY-0126-SM-GW1SQ"	"GTEX-13112-0226-SM-GW2AM"	"GTEX-1399R-1626-SM-GW1U7"	"GTEX-139YR-1426-SM-GW1XK"	"GTEX-13FTW-1326-SM-GW1RU"	"GTEX-13NYS-1126-SM-GW1Y4"	"GTEX-13NZA-2526-SM-GW23E"	"GTEX-13O3P-2526-SM-GW1V8"	"GTEX-13OW5-2526-SM-GW19A"	"GTEX-13W46-0126-SM-GW1AN"	"GTEX-147GR-0626-SM-GW1CU"	"GTEX-148VJ-2526-SM-GW1VF"	"GTEX-14C39-0526-SM-GW16B"	"GTEX-14E6D-1226-SM-GW1CS"	"GTEX-15CHQ-2726-SM-GW1VK"	"GTEX-15D1Q-2326-SM-GW21J"	"GTEX-15EU6-2326-SM-GW16L"	"GTEX-15G1A-1526-SM-GW21L"	"GTEX-18465-1526-SM-GW1GT"	"GTEX-1A3MV-0726-SM-GW1V4"	"GTEX-1B98T-0626-SM-GW21S"	"GTEX-1C64N-2826-SM-GW21K"	"GTEX-1CAMQ-2326-SM-GW21R"	"GTEX-1F5PK-1226-SM-GW1V3"	"GTEX-1F6IF-0526-SM-GW1C5"	"GTEX-1GL5R-0826-SM-GW1H2"	"GTEX-1GTWX-2226-SM-GW16F"	"GTEX-1H1ZS-2826-SM-GW1VE"	"GTEX-S33H-0126-SM-GW1ZW"	"GTEX-SIU8-2326-SM-GW1FW"	"GTEX-SNOS-1126-SM-GW1TU"	"GTEX-T8EM-0126-SM-GW23L"	"GTEX-U3ZH-1526-SM-GW1YW"	"GTEX-WOFL-0526-SM-GW221"	"GTEX-X261-2326-SM-GW24K"	"GTEX-X4XX-0726-SM-GW1CG"	"GTEX-X585-0126-SM-GW1EZ"	"GTEX-X62O-0326-SM-GW228"	"GTEX-117YW-0003-SM-GW185"	"GTEX-11DYG-0004-SM-GW225"	"GTEX-11EMC-0004-SM-GW1YF"	"GTEX-11TT1-0001-SM-GW21F"	"GTEX-11ZU8-0002-SM-GW18V"	"GTEX-11ZUS-0003-SM-GW1V6"	"GTEX-12KS4-0003-SM-GW1BP"	"GTEX-12WSA-0001-SM-GW187"	"GTEX-12WSE-0002-SM-GW19L"	"GTEX-12WSI-0004-SM-GW2CP"	"GTEX-12ZZW-0003-SM-GW18R"	"GTEX-12ZZY-0004-SM-GW19K"	"GTEX-139YR-0004-SM-GW1DM"	"GTEX-13NYS-0003-SM-GW1FJ"	"GTEX-13NZA-0003-SM-GW1F3"	"GTEX-13OW5-0003-SM-GW2B3"	"GTEX-13QIC-0004-SM-GW2BL"	"GTEX-13SLX-0003-SM-GW18M"	"GTEX-14A6H-0003-SM-GW21E"	"GTEX-14C39-0004-SM-GW17K"	"GTEX-14E6D-0002-SM-GW17I"	"GTEX-15CHQ-0002-SM-GW21D"	"GTEX-15D1Q-0004-SM-GW17J"	"GTEX-15DDE-0001-SM-GW17D"	"GTEX-15EU6-0003-SM-GW17V"	"GTEX-15SHU-0001-SM-GW17T"	"GTEX-1A3MV-0002-SM-GW17U"	"GTEX-1B98T-0003-SM-GW1CR"	"GTEX-1C64N-0003-SM-GW1CV"	"GTEX-1CAMQ-0003-SM-GW1ZX"	"GTEX-1GMR3-0001-SM-GW1BQ"	"GTEX-1GTWX-0001-SM-GW1GR"	"GTEX-1H1ZS-0002-SM-GW1AK"	"GTEX-1H3VE-0001-SM-GW18P"	"GTEX-1I6K6-0004-SM-GW1DL"	"GTEX-1J1R8-0004-SM-GW22Y"	"GTEX-SNOS-0004-SM-GW1FF"	"GTEX-U3ZH-0003-SM-GW1FM"	"GTEX-U3ZM-0004-SM-GW1C4"	"GTEX-U8XE-0004-SM-GW1FI"	"GTEX-WFG8-0004-SM-GW21G"	"GTEX-WH7G-0004-SM-GW17G"	"GTEX-WRHU-0003-SM-GW18B"	"GTEX-WWYW-0004-SM-GW17Q"	"GTEX-X261-0002-SM-GW17B"	"GTEX-X4EP-0002-SM-GW17R"	"GTEX-X4XX-0004-SM-GW17N"	"GTEX-X585-0003-SM-GW17P"	"GTEX-X5EB-0001-SM-GW17Y"	"GTEX-XMK1-0003-SM-GW2B7"	"GTEX-XPT6-0004-SM-GW1DN"	"GTEX-YFC4-0001-SM-GW1YL"	"GTEX-YFCO-0001-SM-GW29R"	"GTEX-ZAB4-0001-SM-GW24D"
!Sample_data_processing	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."	"Raw DNAm data was processed with ChAMP software. For sample quality control (QC), we excluded (1) 3 samples with undetectable or missing methylation values (detection P>0.01) in  5% of CpGs and (2) 6 samples with mismatched sex. For CpG QC, we excluded (1) CpGs that had detection P>0.01 in  1 samples (N = 44,135) and that had a beadcount < 3 in  5% samples (N = 660), (2) cross-reactive CpGs (N = 40,812), (3) variant-overlapping CpGs or within a single base pair extension (N = 7,708) and (4) CpGs mapping to sex chromosomes. For filters (2) and (3), we selected CpG probes overlapping variants defined at MAF > 5% in 1000G. A total of 754,054 CpGs passed QC, could be mapped and lifted over from GRCh37 to GRCh38 human genome build and were retained for further analysis.Raw DNAm values were background-adjusted using the single sample normal-exponential out-of-band (ssnoob) method with dye bias correction. DNAm  values were normalized using the beta mixture quantile (BMIQ) method, adjusting for type I/II probe bias; output  values for each CpG were used in downstream analysis. After normalization, we removed one additional sample with array-derived genotype profile not matching the WGS-derived one. Principal component analysis (PCA) was conducted on DNAm  values within each tissue type, and 3 samples were removed for being outliers with respect to the top 5 principal components (PCs) of the corresponding tissue. A total of 987 samples passed final QC and were retained for further analysis."
!Sample_data_processing	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"	"Processed data file contains: Normalized Average Beta"
!Sample_platform_id	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"	"GPL21145"
!Sample_contact_name	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"	"Meritxell,,Oliva"
!Sample_contact_email	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"	"meritxellop@gmail.com"
!Sample_contact_laboratory	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"	"Brandon Pierce & Lin Chen"
!Sample_contact_department	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"	"Public Health Sciences"
!Sample_contact_institute	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"	"University of Chicago"
!Sample_contact_address	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"	"5841 S. Maryland Ave"
!Sample_contact_city	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"	"Chicago"
!Sample_contact_state	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"	"Illinois"
!Sample_contact_zip/postal_code	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"	"60637"
!Sample_contact_country	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"	"USA"
!Sample_supplementary_file	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"	"NONE"
!Sample_data_row_count	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"	"0"
!series_matrix_table_begin
"ID_REF"	"GSM6586938"	"GSM6586939"	"GSM6586940"	"GSM6586941"	"GSM6586942"	"GSM6586943"	"GSM6586944"	"GSM6586945"	"GSM6586946"	"GSM6586947"	"GSM6586948"	"GSM6586949"	"GSM6586950"	"GSM6586951"	"GSM6586952"	"GSM6586953"	"GSM6586954"	"GSM6586955"	"GSM6586956"	"GSM6586957"	"GSM6586958"	"GSM6586959"	"GSM6586960"	"GSM6586961"	"GSM6586962"	"GSM6586963"	"GSM6586964"	"GSM6586965"	"GSM6586966"	"GSM6586967"	"GSM6586968"	"GSM6586969"	"GSM6586970"	"GSM6586971"	"GSM6586972"	"GSM6586973"	"GSM6586974"	"GSM6586975"	"GSM6586976"	"GSM6586977"	"GSM6586978"	"GSM6586979"	"GSM6586980"	"GSM6586981"	"GSM6586982"	"GSM6586983"	"GSM6586984"	"GSM6586985"	"GSM6586986"	"GSM6586987"	"GSM6586988"	"GSM6586989"	"GSM6586990"	"GSM6586991"	"GSM6586992"	"GSM6586993"	"GSM6586994"	"GSM6586995"	"GSM6586996"	"GSM6586997"	"GSM6586998"	"GSM6586999"	"GSM6587000"	"GSM6587001"	"GSM6587002"	"GSM6587003"	"GSM6587004"	"GSM6587005"	"GSM6587006"	"GSM6587007"	"GSM6587008"	"GSM6587009"	"GSM6587010"	"GSM6587011"	"GSM6587012"	"GSM6587013"	"GSM6587014"	"GSM6587015"	"GSM6587016"	"GSM6587017"	"GSM6587018"	"GSM6587019"	"GSM6587020"	"GSM6587021"	"GSM6587022"	"GSM6587023"	"GSM6587024"	"GSM6587025"	"GSM6587026"	"GSM6587027"	"GSM6587028"	"GSM6587029"	"GSM6587030"	"GSM6587031"	"GSM6587032"	"GSM6587033"	"GSM6587034"	"GSM6587035"	"GSM6587036"	"GSM6587037"	"GSM6587038"	"GSM6587039"	"GSM6587040"	"GSM6587041"	"GSM6587042"	"GSM6587043"	"GSM6587044"	"GSM6587045"	"GSM6587046"	"GSM6587047"	"GSM6587048"	"GSM6587049"	"GSM6587050"	"GSM6587051"	"GSM6587052"	"GSM6587053"	"GSM6587054"	"GSM6587055"	"GSM6587056"	"GSM6587057"	"GSM6587058"	"GSM6587059"	"GSM6587060"	"GSM6587061"	"GSM6587062"	"GSM6587063"	"GSM6587064"	"GSM6587065"	"GSM6587066"	"GSM6587067"	"GSM6587068"	"GSM6587069"	"GSM6587070"	"GSM6587071"	"GSM6587072"	"GSM6587073"	"GSM6587074"	"GSM6587075"	"GSM6587076"	"GSM6587077"	"GSM6587078"	"GSM6587079"	"GSM6587080"	"GSM6587081"	"GSM6587082"	"GSM6587083"	"GSM6587084"	"GSM6587085"	"GSM6587086"	"GSM6587087"	"GSM6587088"	"GSM6587089"	"GSM6587090"	"GSM6587091"	"GSM6587092"	"GSM6587093"	"GSM6587094"	"GSM6587095"	"GSM6587096"	"GSM6587097"	"GSM6587098"	"GSM6587099"	"GSM6587100"	"GSM6587101"	"GSM6587102"	"GSM6587103"	"GSM6587104"	"GSM6587105"	"GSM6587106"	"GSM6587107"	"GSM6587108"	"GSM6587109"	"GSM6587110"	"GSM6587111"	"GSM6587112"	"GSM6587113"	"GSM6587114"	"GSM6587115"	"GSM6587116"	"GSM6587117"	"GSM6587118"	"GSM6587119"	"GSM6587120"	"GSM6587121"	"GSM6587122"	"GSM6587123"	"GSM6587124"	"GSM6587125"	"GSM6587126"	"GSM6587127"	"GSM6587128"	"GSM6587129"	"GSM6587130"	"GSM6587131"	"GSM6587132"	"GSM6587133"	"GSM6587134"	"GSM6587135"	"GSM6587136"	"GSM6587137"	"GSM6587138"	"GSM6587139"	"GSM6587140"	"GSM6587141"	"GSM6587142"	"GSM6587143"	"GSM6587144"	"GSM6587145"	"GSM6587146"	"GSM6587147"	"GSM6587148"	"GSM6587149"	"GSM6587150"	"GSM6587151"	"GSM6587152"	"GSM6587153"	"GSM6587154"	"GSM6587155"	"GSM6587156"	"GSM6587157"	"GSM6587158"	"GSM6587159"	"GSM6587160"	"GSM6587161"	"GSM6587162"	"GSM6587163"	"GSM6587164"	"GSM6587165"	"GSM6587166"	"GSM6587167"	"GSM6587168"	"GSM6587169"	"GSM6587170"	"GSM6587171"	"GSM6587172"	"GSM6587173"	"GSM6587174"	"GSM6587175"	"GSM6587176"	"GSM6587177"	"GSM6587178"	"GSM6587179"	"GSM6587180"	"GSM6587181"	"GSM6587182"	"GSM6587183"	"GSM6587184"	"GSM6587185"	"GSM6587186"	"GSM6587187"	"GSM6587188"	"GSM6587189"	"GSM6587190"	"GSM6587191"	"GSM6587192"	"GSM6587193"	"GSM6587194"	"GSM6587195"	"GSM6587196"	"GSM6587197"	"GSM6587198"	"GSM6587199"	"GSM6587200"	"GSM6587201"	"GSM6587202"	"GSM6587203"	"GSM6587204"	"GSM6587205"	"GSM6587206"	"GSM6587207"	"GSM6587208"	"GSM6587209"	"GSM6587210"	"GSM6587211"	"GSM6587212"	"GSM6587213"	"GSM6587214"	"GSM6587215"	"GSM6587216"	"GSM6587217"	"GSM6587218"	"GSM6587219"	"GSM6587220"	"GSM6587221"	"GSM6587222"	"GSM6587223"	"GSM6587224"	"GSM6587225"	"GSM6587226"	"GSM6587227"	"GSM6587228"	"GSM6587229"	"GSM6587230"	"GSM6587231"	"GSM6587232"	"GSM6587233"	"GSM6587234"	"GSM6587235"	"GSM6587236"	"GSM6587237"	"GSM6587238"	"GSM6587239"	"GSM6587240"	"GSM6587241"	"GSM6587242"	"GSM6587243"	"GSM6587244"	"GSM6587245"	"GSM6587246"	"GSM6587247"	"GSM6587248"	"GSM6587249"	"GSM6587250"	"GSM6587251"	"GSM6587252"	"GSM6587253"	"GSM6587254"	"GSM6587255"	"GSM6587256"	"GSM6587257"	"GSM6587258"	"GSM6587259"	"GSM6587260"	"GSM6587261"	"GSM6587262"	"GSM6587263"	"GSM6587264"	"GSM6587265"	"GSM6587266"	"GSM6587267"	"GSM6587268"	"GSM6587269"	"GSM6587270"	"GSM6587271"	"GSM6587272"	"GSM6587273"	"GSM6587274"	"GSM6587275"	"GSM6587276"	"GSM6587277"	"GSM6587278"	"GSM6587279"	"GSM6587280"	"GSM6587281"	"GSM6587282"	"GSM6587283"	"GSM6587284"	"GSM6587285"	"GSM6587286"	"GSM6587287"	"GSM6587288"	"GSM6587289"	"GSM6587290"	"GSM6587291"	"GSM6587292"	"GSM6587293"	"GSM6587294"	"GSM6587295"	"GSM6587296"	"GSM6587297"	"GSM6587298"	"GSM6587299"	"GSM6587300"	"GSM6587301"	"GSM6587302"	"GSM6587303"	"GSM6587304"	"GSM6587305"	"GSM6587306"	"GSM6587307"	"GSM6587308"	"GSM6587309"	"GSM6587310"	"GSM6587311"	"GSM6587312"	"GSM6587313"	"GSM6587314"	"GSM6587315"	"GSM6587316"	"GSM6587317"	"GSM6587318"	"GSM6587319"	"GSM6587320"	"GSM6587321"	"GSM6587322"	"GSM6587323"	"GSM6587324"	"GSM6587325"	"GSM6587326"	"GSM6587327"	"GSM6587328"	"GSM6587329"	"GSM6587330"	"GSM6587331"	"GSM6587332"	"GSM6587333"	"GSM6587334"	"GSM6587335"	"GSM6587336"	"GSM6587337"	"GSM6587338"	"GSM6587339"	"GSM6587340"	"GSM6587341"	"GSM6587342"	"GSM6587343"	"GSM6587344"	"GSM6587345"	"GSM6587346"	"GSM6587347"	"GSM6587348"	"GSM6587349"	"GSM6587350"	"GSM6587351"	"GSM6587352"	"GSM6587353"	"GSM6587354"	"GSM6587355"	"GSM6587356"	"GSM6587357"	"GSM6587358"	"GSM6587359"	"GSM6587360"	"GSM6587361"	"GSM6587362"	"GSM6587363"	"GSM6587364"	"GSM6587365"	"GSM6587366"	"GSM6587367"	"GSM6587368"	"GSM6587369"	"GSM6587370"	"GSM6587371"	"GSM6587372"	"GSM6587373"	"GSM6587374"	"GSM6587375"	"GSM6587376"	"GSM6587377"	"GSM6587378"	"GSM6587379"	"GSM6587380"	"GSM6587381"	"GSM6587382"	"GSM6587383"	"GSM6587384"	"GSM6587385"	"GSM6587386"	"GSM6587387"	"GSM6587388"	"GSM6587389"	"GSM6587390"	"GSM6587391"	"GSM6587392"	"GSM6587393"	"GSM6587394"	"GSM6587395"	"GSM6587396"	"GSM6587397"	"GSM6587398"	"GSM6587399"	"GSM6587400"	"GSM6587401"	"GSM6587402"	"GSM6587403"	"GSM6587404"	"GSM6587405"	"GSM6587406"	"GSM6587407"	"GSM6587408"	"GSM6587409"	"GSM6587410"	"GSM6587411"	"GSM6587412"	"GSM6587413"	"GSM6587414"	"GSM6587415"	"GSM6587416"	"GSM6587417"	"GSM6587418"	"GSM6587419"	"GSM6587420"	"GSM6587421"	"GSM6587422"	"GSM6587423"	"GSM6587424"	"GSM6587425"	"GSM6587426"	"GSM6587427"	"GSM6587428"	"GSM6587429"	"GSM6587430"	"GSM6587431"	"GSM6587432"	"GSM6587433"	"GSM6587434"	"GSM6587435"	"GSM6587436"	"GSM6587437"	"GSM6587438"	"GSM6587439"	"GSM6587440"	"GSM6587441"	"GSM6587442"	"GSM6587443"	"GSM6587444"	"GSM6587445"	"GSM6587446"	"GSM6587447"	"GSM6587448"	"GSM6587449"	"GSM6587450"	"GSM6587451"	"GSM6587452"	"GSM6587453"	"GSM6587454"	"GSM6587455"	"GSM6587456"	"GSM6587457"	"GSM6587458"	"GSM6587459"	"GSM6587460"	"GSM6587461"	"GSM6587462"	"GSM6587463"	"GSM6587464"	"GSM6587465"	"GSM6587466"	"GSM6587467"	"GSM6587468"	"GSM6587469"	"GSM6587470"	"GSM6587471"	"GSM6587472"	"GSM6587473"	"GSM6587474"	"GSM6587475"	"GSM6587476"	"GSM6587477"	"GSM6587478"	"GSM6587479"	"GSM6587480"	"GSM6587481"	"GSM6587482"	"GSM6587483"	"GSM6587484"	"GSM6587485"	"GSM6587486"	"GSM6587487"	"GSM6587488"	"GSM6587489"	"GSM6587490"	"GSM6587491"	"GSM6587492"	"GSM6587493"	"GSM6587494"	"GSM6587495"	"GSM6587496"	"GSM6587497"	"GSM6587498"	"GSM6587499"	"GSM6587500"	"GSM6587501"	"GSM6587502"	"GSM6587503"	"GSM6587504"	"GSM6587505"	"GSM6587506"	"GSM6587507"	"GSM6587508"	"GSM6587509"	"GSM6587510"	"GSM6587511"	"GSM6587512"	"GSM6587513"	"GSM6587514"	"GSM6587515"	"GSM6587516"	"GSM6587517"	"GSM6587518"	"GSM6587519"	"GSM6587520"	"GSM6587521"	"GSM6587522"	"GSM6587523"	"GSM6587524"	"GSM6587525"	"GSM6587526"	"GSM6587527"	"GSM6587528"	"GSM6587529"	"GSM6587530"	"GSM6587531"	"GSM6587532"	"GSM6587533"	"GSM6587534"	"GSM6587535"	"GSM6587536"	"GSM6587537"	"GSM6587538"	"GSM6587539"	"GSM6587540"	"GSM6587541"	"GSM6587542"	"GSM6587543"	"GSM6587544"	"GSM6587545"	"GSM6587546"	"GSM6587547"	"GSM6587548"	"GSM6587549"	"GSM6587550"	"GSM6587551"	"GSM6587552"	"GSM6587553"	"GSM6587554"	"GSM6587555"	"GSM6587556"	"GSM6587557"	"GSM6587558"	"GSM6587559"	"GSM6587560"	"GSM6587561"	"GSM6587562"	"GSM6587563"	"GSM6587564"	"GSM6587565"	"GSM6587566"	"GSM6587567"	"GSM6587568"	"GSM6587569"	"GSM6587570"	"GSM6587571"	"GSM6587572"	"GSM6587573"	"GSM6587574"	"GSM6587575"	"GSM6587576"	"GSM6587577"	"GSM6587578"	"GSM6587579"	"GSM6587580"	"GSM6587581"	"GSM6587582"	"GSM6587583"	"GSM6587584"	"GSM6587585"	"GSM6587586"	"GSM6587587"	"GSM6587588"	"GSM6587589"	"GSM6587590"	"GSM6587591"	"GSM6587592"	"GSM6587593"	"GSM6587594"	"GSM6587595"	"GSM6587596"	"GSM6587597"	"GSM6587598"	"GSM6587599"	"GSM6587600"	"GSM6587601"	"GSM6587602"	"GSM6587603"	"GSM6587604"	"GSM6587605"	"GSM6587606"	"GSM6587607"	"GSM6587608"	"GSM6587609"	"GSM6587610"	"GSM6587611"	"GSM6587612"	"GSM6587613"	"GSM6587614"	"GSM6587615"	"GSM6587616"	"GSM6587617"	"GSM6587618"	"GSM6587619"	"GSM6587620"	"GSM6587621"	"GSM6587622"	"GSM6587623"	"GSM6587624"	"GSM6587625"	"GSM6587626"	"GSM6587627"	"GSM6587628"	"GSM6587629"	"GSM6587630"	"GSM6587631"	"GSM6587632"	"GSM6587633"	"GSM6587634"	"GSM6587635"	"GSM6587636"	"GSM6587637"	"GSM6587638"	"GSM6587639"	"GSM6587640"	"GSM6587641"	"GSM6587642"	"GSM6587643"	"GSM6587644"	"GSM6587645"	"GSM6587646"	"GSM6587647"	"GSM6587648"	"GSM6587649"	"GSM6587650"	"GSM6587651"	"GSM6587652"	"GSM6587653"	"GSM6587654"	"GSM6587655"	"GSM6587656"	"GSM6587657"	"GSM6587658"	"GSM6587659"	"GSM6587660"	"GSM6587661"	"GSM6587662"	"GSM6587663"	"GSM6587664"	"GSM6587665"	"GSM6587666"	"GSM6587667"	"GSM6587668"	"GSM6587669"	"GSM6587670"	"GSM6587671"	"GSM6587672"	"GSM6587673"	"GSM6587674"	"GSM6587675"	"GSM6587676"	"GSM6587677"	"GSM6587678"	"GSM6587679"	"GSM6587680"	"GSM6587681"	"GSM6587682"	"GSM6587683"	"GSM6587684"	"GSM6587685"	"GSM6587686"	"GSM6587687"	"GSM6587688"	"GSM6587689"	"GSM6587690"	"GSM6587691"	"GSM6587692"	"GSM6587693"	"GSM6587694"	"GSM6587695"	"GSM6587696"	"GSM6587697"	"GSM6587698"	"GSM6587699"	"GSM6587700"	"GSM6587701"	"GSM6587702"	"GSM6587703"	"GSM6587704"	"GSM6587705"	"GSM6587706"	"GSM6587707"	"GSM6587708"	"GSM6587709"	"GSM6587710"	"GSM6587711"	"GSM6587712"	"GSM6587713"	"GSM6587714"	"GSM6587715"	"GSM6587716"	"GSM6587717"	"GSM6587718"	"GSM6587719"	"GSM6587720"	"GSM6587721"	"GSM6587722"	"GSM6587723"	"GSM6587724"	"GSM6587725"	"GSM6587726"	"GSM6587727"	"GSM6587728"	"GSM6587729"	"GSM6587730"	"GSM6587731"	"GSM6587732"	"GSM6587733"	"GSM6587734"	"GSM6587735"	"GSM6587736"	"GSM6587737"	"GSM6587738"	"GSM6587739"	"GSM6587740"	"GSM6587741"	"GSM6587742"	"GSM6587743"	"GSM6587744"	"GSM6587745"	"GSM6587746"	"GSM6587747"	"GSM6587748"	"GSM6587749"	"GSM6587750"	"GSM6587751"	"GSM6587752"	"GSM6587753"	"GSM6587754"	"GSM6587755"	"GSM6587756"	"GSM6587757"	"GSM6587758"	"GSM6587759"	"GSM6587760"	"GSM6587761"	"GSM6587762"	"GSM6587763"	"GSM6587764"	"GSM6587765"	"GSM6587766"	"GSM6587767"	"GSM6587768"	"GSM6587769"	"GSM6587770"	"GSM6587771"	"GSM6587772"	"GSM6587773"	"GSM6587774"	"GSM6587775"	"GSM6587776"	"GSM6587777"	"GSM6587778"	"GSM6587779"	"GSM6587780"	"GSM6587781"	"GSM6587782"	"GSM6587783"	"GSM6587784"	"GSM6587785"	"GSM6587786"	"GSM6587787"	"GSM6587788"	"GSM6587789"	"GSM6587790"	"GSM6587791"	"GSM6587792"	"GSM6587793"	"GSM6587794"	"GSM6587795"	"GSM6587796"	"GSM6587797"	"GSM6587798"	"GSM6587799"	"GSM6587800"	"GSM6587801"	"GSM6587802"	"GSM6587803"	"GSM6587804"	"GSM6587805"	"GSM6587806"	"GSM6587807"	"GSM6587808"	"GSM6587809"	"GSM6587810"	"GSM6587811"	"GSM6587812"	"GSM6587813"	"GSM6587814"	"GSM6587815"	"GSM6587816"	"GSM6587817"	"GSM6587818"	"GSM6587819"	"GSM6587820"	"GSM6587821"	"GSM6587822"	"GSM6587823"	"GSM6587824"	"GSM6587825"	"GSM6587826"	"GSM6587827"	"GSM6587828"	"GSM6587829"	"GSM6587830"	"GSM6587831"	"GSM6587832"	"GSM6587833"	"GSM6587834"	"GSM6587835"	"GSM6587836"	"GSM6587837"	"GSM6587838"	"GSM6587839"	"GSM6587840"	"GSM6587841"	"GSM6587842"	"GSM6587843"	"GSM6587844"	"GSM6587845"	"GSM6587846"	"GSM6587847"	"GSM6587848"	"GSM6587849"	"GSM6587850"	"GSM6587851"	"GSM6587852"	"GSM6587853"	"GSM6587854"	"GSM6587855"	"GSM6587856"	"GSM6587857"	"GSM6587858"	"GSM6587859"	"GSM6587860"	"GSM6587861"	"GSM6587862"	"GSM6587863"	"GSM6587864"	"GSM6587865"	"GSM6587866"	"GSM6587867"	"GSM6587868"	"GSM6587869"	"GSM6587870"	"GSM6587871"	"GSM6587872"	"GSM6587873"	"GSM6587874"	"GSM6587875"	"GSM6587876"	"GSM6587877"	"GSM6587878"	"GSM6587879"	"GSM6587880"	"GSM6587881"	"GSM6587882"	"GSM6587883"	"GSM6587884"	"GSM6587885"	"GSM6587886"	"GSM6587887"	"GSM6587888"	"GSM6587889"	"GSM6587890"	"GSM6587891"	"GSM6587892"	"GSM6587893"	"GSM6587894"	"GSM6587895"	"GSM6587896"	"GSM6587897"	"GSM6587898"	"GSM6587899"	"GSM6587900"	"GSM6587901"	"GSM6587902"	"GSM6587903"	"GSM6587904"	"GSM6587905"	"GSM6587906"	"GSM6587907"	"GSM6587908"	"GSM6587909"	"GSM6587910"	"GSM6587911"	"GSM6587912"	"GSM6587913"	"GSM6587914"	"GSM6587915"	"GSM6587916"	"GSM6587917"	"GSM6587918"	"GSM6587919"	"GSM6587920"	"GSM6587921"	"GSM6587922"	"GSM6587923"	"GSM6587924"
!series_matrix_table_end
